id	sid	tid	token	lemma	pos
dpc-1881	1	1	melanoma	melanoma	NOUN
dpc-1881	1	2	today	today	NOUN
dpc-1881	1	3	dpc	dpc	PROPN
dpc-1881	1	4	journal	journal	PROPN
dpc-1881	1	5	special	special	ADJ
dpc-1881	1	6	issue	issue	NOUN
dpc-1881	1	7	table	table	NOUN
dpc-1881	1	8	of	of	ADP
dpc-1881	1	9	contents	content	NOUN
dpc-1881	1	10	epidemiology	epidemiology	NOUN
dpc-1881	1	11	and	and	CCONJ
dpc-1881	1	12	risk	risk	NOUN
dpc-1881	1	13	factors	factor	NOUN
dpc-1881	1	14	of	of	ADP
dpc-1881	1	15	melanoma	melanoma	NOUN
dpc-1881	1	16	:	:	PUNCT
dpc-1881	1	17	a	a	DET
dpc-1881	1	18	review	review	NOUN
dpc-1881	1	19	claudio	claudio	PROPN
dpc-1881	1	20	conforti	conforti	PROPN
dpc-1881	1	21	,	,	PUNCT
dpc-1881	1	22	iris	iris	NOUN
dpc-1881	1	23	zalaudek	zalaudek	PROPN
dpc-1881	1	24	evolution	evolution	NOUN
dpc-1881	1	25	of	of	ADP
dpc-1881	1	26	the	the	DET
dpc-1881	1	27	clinical	clinical	ADJ
dpc-1881	1	28	,	,	PUNCT
dpc-1881	1	29	dermoscopic	dermoscopic	ADJ
dpc-1881	1	30	and	and	CCONJ
dpc-1881	1	31	pathologic	pathologic	ADJ
dpc-1881	1	32	diagnosis	diagnosis	NOUN
dpc-1881	1	33	of	of	ADP
dpc-1881	1	34	melanoma	melanoma	NOUN
dpc-1881	1	35	harald	harald	PROPN
dpc-1881	1	36	kittler	kittler	PROPN
dpc-1881	1	37	melanoma	melanoma	NOUN
dpc-1881	1	38	:	:	PUNCT
dpc-1881	1	39	staging	staging	NOUN
dpc-1881	1	40	and	and	CCONJ
dpc-1881	1	41	follow	follow	VERB
dpc-1881	1	42	-	-	PUNCT
dpc-1881	1	43	up	up	ADP
dpc-1881	1	44	chryssoula	chryssoula	PROPN
dpc-1881	1	45	papageorgiou	papageorgiou	NOUN
dpc-1881	1	46	,	,	PUNCT
dpc-1881	1	47	zoe	zoe	PROPN
dpc-1881	1	48	apalla	apalla	PROPN
dpc-1881	1	49	,	,	PUNCT
dpc-1881	1	50	sofia	sofia	NOUN
dpc-1881	1	51	-	-	PUNCT
dpc-1881	1	52	magdalini	magdalini	PROPN
dpc-1881	1	53	manoli	manoli	PROPN
dpc-1881	1	54	,	,	PUNCT
dpc-1881	1	55	konstantinos	konstantinos	PROPN
dpc-1881	1	56	lallas	lallas	PROPN
dpc-1881	1	57	,	,	PUNCT
dpc-1881	1	58	efstratios	efstratio	NOUN
dpc-1881	1	59	vakirlis	vakirli	NOUN
dpc-1881	1	60	,	,	PUNCT
dpc-1881	1	61	aimilios	aimilios	PROPN
dpc-1881	1	62	lallas	lalla	NOUN
dpc-1881	1	63	current	current	ADJ
dpc-1881	1	64	landscape	landscape	NOUN
dpc-1881	1	65	and	and	CCONJ
dpc-1881	1	66	open	open	ADJ
dpc-1881	1	67	questions	question	NOUN
dpc-1881	1	68	on	on	ADP
dpc-1881	1	69	adjuvant	adjuvant	ADJ
dpc-1881	1	70	therapies	therapy	NOUN
dpc-1881	1	71	in	in	ADP
dpc-1881	1	72	melanoma	melanoma	PROPN
dpc-1881	1	73	vincenzo	vincenzo	PROPN
dpc-1881	1	74	de	de	PROPN
dpc-1881	1	75	falco	falco	PROPN
dpc-1881	1	76	,	,	PUNCT
dpc-1881	1	77	stefania	stefania	PROPN
dpc-1881	1	78	napolitano	napolitano	PROPN
dpc-1881	1	79	,	,	PUNCT
dpc-1881	1	80	luigi	luigi	PROPN
dpc-1881	1	81	pio	pio	PROPN
dpc-1881	1	82	guerrera	guerrera	PROPN
dpc-1881	1	83	,	,	PUNCT
dpc-1881	1	84	teresa	teresa	PROPN
dpc-1881	1	85	troiani	troiani	ADJ
dpc-1881	1	86	treatment	treatment	NOUN
dpc-1881	1	87	of	of	ADP
dpc-1881	1	88	advanced	advanced	ADJ
dpc-1881	1	89	metastatic	metastatic	ADJ
dpc-1881	1	90	melanoma	melanoma	NOUN
dpc-1881	1	91	pietro	pietro	NOUN
dpc-1881	1	92	quaglino	quaglino	PROPN
dpc-1881	1	93	,	,	PUNCT
dpc-1881	1	94	paolo	paolo	PROPN
dpc-1881	1	95	fava	fava	NOUN
dpc-1881	1	96	,	,	PUNCT
dpc-1881	1	97	luca	luca	PROPN
dpc-1881	1	98	tonella	tonella	PROPN
dpc-1881	1	99	,	,	PUNCT
dpc-1881	1	100	marco	marco	PROPN
dpc-1881	1	101	rubatto	rubatto	NOUN
dpc-1881	1	102	,	,	PUNCT
dpc-1881	1	103	simone	simone	NOUN
dpc-1881	1	104	ribero	ribero	PROPN
dpc-1881	1	105	,	,	PUNCT
dpc-1881	1	106	maria	maria	PROPN
dpc-1881	1	107	teresa	teresa	PROPN
dpc-1881	1	108	fierro	fierro	PROPN
dpc-1881	1	109	mattioli	mattioli	PROPN
dpc-1881	1	110	1885	1885	NUM
dpc-1881	1	111	www.mattioli1885.com	www.mattioli1885.com	NOUN
dpc-1881	1	112	chief	chief	ADJ
dpc-1881	1	113	editor	editor	NOUN
dpc-1881	1	114	prof	prof	NOUN
dpc-1881	1	115	.	.	PUNCT
dpc-1881	2	1	giuseppe	giuseppe	PROPN
dpc-1881	2	2	argenziano	argenziano	PROPN
dpc-1881	2	3	,	,	PUNCT
dpc-1881	2	4	md	md	PROPN
dpc-1881	2	5	dermatology	dermatology	NOUN
dpc-1881	2	6	unit	unit	NOUN
dpc-1881	2	7	,	,	PUNCT
dpc-1881	2	8	university	university	PROPN
dpc-1881	2	9	of	of	ADP
dpc-1881	2	10	campania	campania	PROPN
dpc-1881	2	11	luigi	luigi	PROPN
dpc-1881	2	12	vanvitelli	vanvitelli	PROPN
dpc-1881	2	13	,	,	PUNCT
dpc-1881	2	14	naples	naples	PROPN
dpc-1881	2	15	guest	guest	PROPN
dpc-1881	2	16	editors	editor	NOUN
dpc-1881	2	17	prof	prof	PROPN
dpc-1881	2	18	.	.	PUNCT
dpc-1881	3	1	h.	h.	PROPN
dpc-1881	3	2	peter	peter	PROPN
dpc-1881	3	3	soyer	soyer	PROPN
dpc-1881	3	4	,	,	PUNCT
dpc-1881	3	5	md	md	PROPN
dpc-1881	3	6	,	,	PUNCT
dpc-1881	3	7	facd	facd	NOUN
dpc-1881	3	8	,	,	PUNCT
dpc-1881	3	9	fahms	fahm	NOUN
dpc-1881	3	10	chair	chair	NOUN
dpc-1881	3	11	in	in	ADP
dpc-1881	3	12	dermatology	dermatology	NOUN
dpc-1881	3	13	.	.	PUNCT
dpc-1881	4	1	director	director	NOUN
dpc-1881	4	2	,	,	PUNCT
dpc-1881	4	3	dermatology	dermatology	NOUN
dpc-1881	4	4	research	research	NOUN
dpc-1881	4	5	centre	centre	NOUN
dpc-1881	4	6	,	,	PUNCT
dpc-1881	4	7	the	the	DET
dpc-1881	4	8	university	university	PROPN
dpc-1881	4	9	of	of	ADP
dpc-1881	4	10	queensland	queensland	PROPN
dpc-1881	4	11	diamantina	diamantina	PROPN
dpc-1881	4	12	institute	institute	PROPN
dpc-1881	4	13	;	;	PUNCT
dpc-1881	4	14	director	director	NOUN
dpc-1881	4	15	,	,	PUNCT
dpc-1881	4	16	dermatology	dermatology	NOUN
dpc-1881	4	17	department	department	NOUN
dpc-1881	4	18	,	,	PUNCT
dpc-1881	4	19	princess	princess	NOUN
dpc-1881	4	20	alexandra	alexandra	PROPN
dpc-1881	4	21	hospital	hospital	PROPN
dpc-1881	4	22	prof	prof	PROPN
dpc-1881	4	23	.	.	PUNCT
dpc-1881	5	1	paola	paola	PROPN
dpc-1881	5	2	queirolo	queirolo	PROPN
dpc-1881	5	3	,	,	PUNCT
dpc-1881	5	4	md	md	PROPN
dpc-1881	5	5	director	director	NOUN
dpc-1881	5	6	of	of	ADP
dpc-1881	5	7	the	the	DET
dpc-1881	5	8	“	"	PUNCT
dpc-1881	5	9	divisione	divisione	X
dpc-1881	5	10	di	di	X
dpc-1881	5	11	oncologia	oncologia	PROPN
dpc-1881	5	12	medica	medica	PROPN
dpc-1881	5	13	del	del	PROPN
dpc-1881	5	14	melanoma	melanoma	PROPN
dpc-1881	5	15	,	,	PUNCT
dpc-1881	5	16	sarcoma	sarcoma	PROPN
dpc-1881	5	17	e	e	PROPN
dpc-1881	5	18	tumori	tumori	PROPN
dpc-1881	5	19	rari	rari	PROPN
dpc-1881	5	20	”	"	PUNCT
dpc-1881	5	21	istituto	istituto	PROPN
dpc-1881	5	22	europeo	europeo	PROPN
dpc-1881	5	23	di	di	PROPN
dpc-1881	5	24	oncologia	oncologia	PROPN
dpc-1881	5	25	,	,	PUNCT
dpc-1881	5	26	ieo	ieo	PROPN
dpc-1881	5	27	grazie	grazie	PROPN
dpc-1881	5	28	al	al	PROPN
dpc-1881	5	29	contributo	contributo	PROPN
dpc-1881	5	30	di	di	X
dpc-1881	5	31	melanoma	melanoma	PROPN
dpc-1881	5	32	today	today	NOUN
dpc-1881	5	33	dpc	dpc	PROPN
dpc-1881	5	34	journal	journal	PROPN
dpc-1881	5	35	special	special	ADJ
dpc-1881	5	36	issue	issue	NOUN
dpc-1881	5	37	table	table	NOUN
dpc-1881	5	38	of	of	ADP
dpc-1881	5	39	contents	content	NOUN
dpc-1881	5	40	epidemiology	epidemiology	NOUN
dpc-1881	5	41	and	and	CCONJ
dpc-1881	5	42	risk	risk	NOUN
dpc-1881	5	43	factors	factor	NOUN
dpc-1881	5	44	of	of	ADP
dpc-1881	5	45	melanoma	melanoma	NOUN
dpc-1881	5	46	:	:	PUNCT
dpc-1881	5	47	a	a	DET
dpc-1881	5	48	review	review	NOUN
dpc-1881	5	49	claudio	claudio	PROPN
dpc-1881	5	50	conforti	conforti	PROPN
dpc-1881	5	51	,	,	PUNCT
dpc-1881	5	52	iris	iris	NOUN
dpc-1881	5	53	zalaudek	zalaudek	PROPN
dpc-1881	5	54	the	the	DET
dpc-1881	5	55	evolution	evolution	NOUN
dpc-1881	5	56	of	of	ADP
dpc-1881	5	57	the	the	DET
dpc-1881	5	58	clinical	clinical	ADJ
dpc-1881	5	59	,	,	PUNCT
dpc-1881	5	60	dermoscopic	dermoscopic	ADJ
dpc-1881	5	61	and	and	CCONJ
dpc-1881	5	62	pathologic	pathologic	ADJ
dpc-1881	5	63	diagnosis	diagnosis	NOUN
dpc-1881	5	64	of	of	ADP
dpc-1881	5	65	melanoma	melanoma	NOUN
dpc-1881	5	66	harald	harald	PROPN
dpc-1881	5	67	kittler	kittler	PROPN
dpc-1881	5	68	melanoma	melanoma	NOUN
dpc-1881	5	69	:	:	PUNCT
dpc-1881	5	70	staging	staging	NOUN
dpc-1881	5	71	and	and	CCONJ
dpc-1881	5	72	follow	follow	VERB
dpc-1881	5	73	-	-	PUNCT
dpc-1881	5	74	up	up	ADP
dpc-1881	5	75	chryssoula	chryssoula	PROPN
dpc-1881	5	76	papageorgiou	papageorgiou	NOUN
dpc-1881	5	77	,	,	PUNCT
dpc-1881	5	78	zoe	zoe	PROPN
dpc-1881	5	79	apalla	apalla	PROPN
dpc-1881	5	80	,	,	PUNCT
dpc-1881	5	81	sofia	sofia	NOUN
dpc-1881	5	82	-	-	PUNCT
dpc-1881	5	83	magdalini	magdalini	PROPN
dpc-1881	5	84	manoli	manoli	PROPN
dpc-1881	5	85	,	,	PUNCT
dpc-1881	5	86	konstantinos	konstantinos	PROPN
dpc-1881	5	87	lallas	lallas	PROPN
dpc-1881	5	88	,	,	PUNCT
dpc-1881	5	89	efstratios	efstratio	NOUN
dpc-1881	5	90	vakirlis	vakirli	NOUN
dpc-1881	5	91	,	,	PUNCT
dpc-1881	5	92	aimilios	aimilios	PROPN
dpc-1881	5	93	lallas	lalla	NOUN
dpc-1881	5	94	current	current	ADJ
dpc-1881	5	95	landscape	landscape	NOUN
dpc-1881	5	96	and	and	CCONJ
dpc-1881	5	97	open	open	ADJ
dpc-1881	5	98	questions	question	NOUN
dpc-1881	5	99	on	on	ADP
dpc-1881	5	100	adjuvant	adjuvant	ADJ
dpc-1881	5	101	therapies	therapy	NOUN
dpc-1881	5	102	in	in	ADP
dpc-1881	5	103	melanoma	melanoma	PROPN
dpc-1881	5	104	vincenzo	vincenzo	PROPN
dpc-1881	5	105	de	de	PROPN
dpc-1881	5	106	falco	falco	PROPN
dpc-1881	5	107	,	,	PUNCT
dpc-1881	5	108	stefania	stefania	PROPN
dpc-1881	5	109	napolitano	napolitano	PROPN
dpc-1881	5	110	,	,	PUNCT
dpc-1881	5	111	luigi	luigi	PROPN
dpc-1881	5	112	pio	pio	PROPN
dpc-1881	5	113	guerrera	guerrera	PROPN
dpc-1881	5	114	,	,	PUNCT
dpc-1881	5	115	teresa	teresa	PROPN
dpc-1881	5	116	troiani	troiani	ADJ
dpc-1881	5	117	treatment	treatment	NOUN
dpc-1881	5	118	of	of	ADP
dpc-1881	5	119	advanced	advanced	ADJ
dpc-1881	5	120	metastatic	metastatic	ADJ
dpc-1881	5	121	melanoma	melanoma	NOUN
dpc-1881	5	122	pietro	pietro	NOUN
dpc-1881	5	123	quaglino	quaglino	PROPN
dpc-1881	5	124	,	,	PUNCT
dpc-1881	5	125	paolo	paolo	PROPN
dpc-1881	5	126	fava	fava	NOUN
dpc-1881	5	127	,	,	PUNCT
dpc-1881	5	128	luca	luca	PROPN
dpc-1881	5	129	tonella	tonella	PROPN
dpc-1881	5	130	,	,	PUNCT
dpc-1881	5	131	marco	marco	PROPN
dpc-1881	5	132	rubatto	rubatto	NOUN
dpc-1881	5	133	,	,	PUNCT
dpc-1881	5	134	simone	simone	NOUN
dpc-1881	5	135	ribero	ribero	PROPN
dpc-1881	5	136	,	,	PUNCT
dpc-1881	5	137	maria	maria	PROPN
dpc-1881	5	138	teresa	teresa	PROPN
dpc-1881	5	139	fierro	fierro	PROPN
dpc-1881	5	140	mattioli	mattioli	PROPN
dpc-1881	5	141	1885	1885	NUM
dpc-1881	5	142	www.mattioli1885.com	www.mattioli1885.com	NOUN
dpc-1881	5	143	chief	chief	ADJ
dpc-1881	5	144	editor	editor	NOUN
dpc-1881	5	145	prof	prof	NOUN
dpc-1881	5	146	.	.	PUNCT
dpc-1881	6	1	giuseppe	giuseppe	PROPN
dpc-1881	6	2	argenziano	argenziano	PROPN
dpc-1881	6	3	,	,	PUNCT
dpc-1881	6	4	md	md	PROPN
dpc-1881	6	5	dermatology	dermatology	NOUN
dpc-1881	6	6	unit	unit	NOUN
dpc-1881	6	7	,	,	PUNCT
dpc-1881	6	8	university	university	PROPN
dpc-1881	6	9	of	of	ADP
dpc-1881	6	10	campania	campania	PROPN
dpc-1881	6	11	luigi	luigi	PROPN
dpc-1881	6	12	vanvitelli	vanvitelli	PROPN
dpc-1881	6	13	,	,	PUNCT
dpc-1881	6	14	naples	naples	PROPN
dpc-1881	6	15	guest	guest	PROPN
dpc-1881	6	16	editors	editor	NOUN
dpc-1881	6	17	prof	prof	PROPN
dpc-1881	6	18	.	.	PUNCT
dpc-1881	7	1	h.	h.	PROPN
dpc-1881	7	2	peter	peter	PROPN
dpc-1881	7	3	soyer	soyer	PROPN
dpc-1881	7	4	,	,	PUNCT
dpc-1881	7	5	md	md	PROPN
dpc-1881	7	6	,	,	PUNCT
dpc-1881	7	7	facd	facd	NOUN
dpc-1881	7	8	,	,	PUNCT
dpc-1881	7	9	fahms	fahm	NOUN
dpc-1881	7	10	chair	chair	NOUN
dpc-1881	7	11	in	in	ADP
dpc-1881	7	12	dermatology	dermatology	NOUN
dpc-1881	7	13	.	.	PUNCT
dpc-1881	8	1	director	director	NOUN
dpc-1881	8	2	,	,	PUNCT
dpc-1881	8	3	dermatology	dermatology	NOUN
dpc-1881	8	4	research	research	NOUN
dpc-1881	8	5	centre	centre	NOUN
dpc-1881	8	6	,	,	PUNCT
dpc-1881	8	7	the	the	DET
dpc-1881	8	8	university	university	PROPN
dpc-1881	8	9	of	of	ADP
dpc-1881	8	10	queensland	queensland	PROPN
dpc-1881	8	11	diamantina	diamantina	PROPN
dpc-1881	8	12	institute	institute	PROPN
dpc-1881	8	13	;	;	PUNCT
dpc-1881	8	14	director	director	NOUN
dpc-1881	8	15	,	,	PUNCT
dpc-1881	8	16	dermatology	dermatology	NOUN
dpc-1881	8	17	department	department	NOUN
dpc-1881	8	18	,	,	PUNCT
dpc-1881	8	19	princess	princess	NOUN
dpc-1881	8	20	alexandra	alexandra	PROPN
dpc-1881	8	21	hospital	hospital	PROPN
dpc-1881	8	22	prof	prof	PROPN
dpc-1881	8	23	.	.	PUNCT
dpc-1881	9	1	paola	paola	PROPN
dpc-1881	9	2	queirolo	queirolo	PROPN
dpc-1881	9	3	,	,	PUNCT
dpc-1881	9	4	md	md	PROPN
dpc-1881	9	5	director	director	NOUN
dpc-1881	9	6	of	of	ADP
dpc-1881	9	7	the	the	DET
dpc-1881	9	8	“	"	PUNCT
dpc-1881	9	9	divisione	divisione	X
dpc-1881	9	10	di	di	X
dpc-1881	9	11	oncologia	oncologia	PROPN
dpc-1881	9	12	medica	medica	PROPN
dpc-1881	9	13	del	del	PROPN
dpc-1881	9	14	melanoma	melanoma	PROPN
dpc-1881	9	15	,	,	PUNCT
dpc-1881	9	16	sarcoma	sarcoma	PROPN
dpc-1881	9	17	e	e	PROPN
dpc-1881	9	18	tumori	tumori	PROPN
dpc-1881	9	19	rari	rari	PROPN
dpc-1881	9	20	”	"	PUNCT
dpc-1881	9	21	istituto	istituto	PROPN
dpc-1881	9	22	europeo	europeo	PROPN
dpc-1881	9	23	di	di	PROPN
dpc-1881	9	24	oncologia	oncologia	PROPN
dpc-1881	9	25	,	,	PUNCT
dpc-1881	9	26	ieo	ieo	PROPN
dpc-1881	9	27	grazie	grazie	PROPN
dpc-1881	9	28	al	al	PROPN
dpc-1881	9	29	contributo	contributo	PROPN
dpc-1881	9	30	di	di	X
dpc-1881	9	31	melanoma	melanoma	PROPN
dpc-1881	9	32	today	today	NOUN
dpc-1881	9	33	dpc	dpc	PROPN
dpc-1881	9	34	journal	journal	PROPN
dpc-1881	9	35	special	special	ADJ
dpc-1881	9	36	issue	issue	NOUN
dpc-1881	9	37	table	table	NOUN
dpc-1881	9	38	of	of	ADP
dpc-1881	9	39	contents	content	NOUN
dpc-1881	9	40	epidemiology	epidemiology	NOUN
dpc-1881	9	41	and	and	CCONJ
dpc-1881	9	42	risk	risk	NOUN
dpc-1881	9	43	factors	factor	NOUN
dpc-1881	9	44	of	of	ADP
dpc-1881	9	45	melanoma	melanoma	NOUN
dpc-1881	9	46	:	:	PUNCT
dpc-1881	9	47	a	a	DET
dpc-1881	9	48	review	review	NOUN
dpc-1881	9	49	claudio	claudio	PROPN
dpc-1881	9	50	conforti	conforti	PROPN
dpc-1881	9	51	,	,	PUNCT
dpc-1881	9	52	iris	iris	NOUN
dpc-1881	9	53	zalaudek	zalaudek	PROPN
dpc-1881	9	54	the	the	DET
dpc-1881	9	55	evolution	evolution	NOUN
dpc-1881	9	56	of	of	ADP
dpc-1881	9	57	the	the	DET
dpc-1881	9	58	clinical	clinical	ADJ
dpc-1881	9	59	,	,	PUNCT
dpc-1881	9	60	dermoscopic	dermoscopic	ADJ
dpc-1881	9	61	and	and	CCONJ
dpc-1881	9	62	pathologic	pathologic	ADJ
dpc-1881	9	63	diagnosis	diagnosis	NOUN
dpc-1881	9	64	of	of	ADP
dpc-1881	9	65	melanoma	melanoma	NOUN
dpc-1881	9	66	harald	harald	PROPN
dpc-1881	9	67	kittler	kittler	PROPN
dpc-1881	9	68	melanoma	melanoma	NOUN
dpc-1881	9	69	:	:	PUNCT
dpc-1881	9	70	staging	staging	NOUN
dpc-1881	9	71	and	and	CCONJ
dpc-1881	9	72	follow	follow	VERB
dpc-1881	9	73	-	-	PUNCT
dpc-1881	9	74	up	up	ADP
dpc-1881	9	75	chryssoula	chryssoula	PROPN
dpc-1881	9	76	papageorgiou	papageorgiou	NOUN
dpc-1881	9	77	,	,	PUNCT
dpc-1881	9	78	zoe	zoe	PROPN
dpc-1881	9	79	apalla	apalla	PROPN
dpc-1881	9	80	,	,	PUNCT
dpc-1881	9	81	sofia	sofia	NOUN
dpc-1881	9	82	-	-	PUNCT
dpc-1881	9	83	magdalini	magdalini	PROPN
dpc-1881	9	84	manoli	manoli	PROPN
dpc-1881	9	85	,	,	PUNCT
dpc-1881	9	86	konstantinos	konstantinos	PROPN
dpc-1881	9	87	lallas	lallas	PROPN
dpc-1881	9	88	,	,	PUNCT
dpc-1881	9	89	efstratios	efstratio	NOUN
dpc-1881	9	90	vakirlis	vakirli	NOUN
dpc-1881	9	91	,	,	PUNCT
dpc-1881	9	92	aimilios	aimilios	PROPN
dpc-1881	9	93	lallas	lalla	NOUN
dpc-1881	9	94	current	current	ADJ
dpc-1881	9	95	landscape	landscape	NOUN
dpc-1881	9	96	and	and	CCONJ
dpc-1881	9	97	open	open	ADJ
dpc-1881	9	98	questions	question	NOUN
dpc-1881	9	99	on	on	ADP
dpc-1881	9	100	adjuvant	adjuvant	ADJ
dpc-1881	9	101	therapies	therapy	NOUN
dpc-1881	9	102	in	in	ADP
dpc-1881	9	103	melanoma	melanoma	PROPN
dpc-1881	9	104	vincenzo	vincenzo	PROPN
dpc-1881	9	105	de	de	PROPN
dpc-1881	9	106	falco	falco	PROPN
dpc-1881	9	107	,	,	PUNCT
dpc-1881	9	108	stefania	stefania	PROPN
dpc-1881	9	109	napolitano	napolitano	PROPN
dpc-1881	9	110	,	,	PUNCT
dpc-1881	9	111	luigi	luigi	PROPN
dpc-1881	9	112	pio	pio	PROPN
dpc-1881	9	113	guerrera	guerrera	PROPN
dpc-1881	9	114	,	,	PUNCT
dpc-1881	9	115	teresa	teresa	PROPN
dpc-1881	9	116	troiani	troiani	ADJ
dpc-1881	9	117	treatment	treatment	NOUN
dpc-1881	9	118	of	of	ADP
dpc-1881	9	119	advanced	advanced	ADJ
dpc-1881	9	120	metastatic	metastatic	ADJ
dpc-1881	9	121	melanoma	melanoma	NOUN
dpc-1881	9	122	pietro	pietro	NOUN
dpc-1881	9	123	quaglino	quaglino	PROPN
dpc-1881	9	124	,	,	PUNCT
dpc-1881	9	125	paolo	paolo	PROPN
dpc-1881	9	126	fava	fava	NOUN
dpc-1881	9	127	,	,	PUNCT
dpc-1881	9	128	luca	luca	PROPN
dpc-1881	9	129	tonella	tonella	PROPN
dpc-1881	9	130	,	,	PUNCT
dpc-1881	9	131	marco	marco	PROPN
dpc-1881	9	132	rubatto	rubatto	NOUN
dpc-1881	9	133	,	,	PUNCT
dpc-1881	9	134	simone	simone	NOUN
dpc-1881	9	135	ribero	ribero	PROPN
dpc-1881	9	136	,	,	PUNCT
dpc-1881	9	137	maria	maria	PROPN
dpc-1881	9	138	teresa	teresa	PROPN
dpc-1881	9	139	fierro	fierro	PROPN
dpc-1881	9	140	guest	guest	PROPN
dpc-1881	9	141	editors	editor	NOUN
dpc-1881	9	142	prof	prof	PROPN
dpc-1881	9	143	.	.	PUNCT
dpc-1881	10	1	h.	h.	PROPN
dpc-1881	10	2	peter	peter	PROPN
dpc-1881	10	3	soyer	soyer	PROPN
dpc-1881	10	4	,	,	PUNCT
dpc-1881	10	5	md	md	PROPN
dpc-1881	10	6	,	,	PUNCT
dpc-1881	10	7	facd	facd	NOUN
dpc-1881	10	8	,	,	PUNCT
dpc-1881	10	9	fahms	fahm	NOUN
dpc-1881	10	10	chair	chair	NOUN
dpc-1881	10	11	in	in	ADP
dpc-1881	10	12	dermatology	dermatology	NOUN
dpc-1881	10	13	.	.	PUNCT
dpc-1881	11	1	director	director	NOUN
dpc-1881	11	2	,	,	PUNCT
dpc-1881	11	3	dermatology	dermatology	NOUN
dpc-1881	11	4	research	research	NOUN
dpc-1881	11	5	centre	centre	NOUN
dpc-1881	11	6	,	,	PUNCT
dpc-1881	11	7	the	the	DET
dpc-1881	11	8	university	university	PROPN
dpc-1881	11	9	of	of	ADP
dpc-1881	11	10	queensland	queensland	PROPN
dpc-1881	11	11	diamantina	diamantina	PROPN
dpc-1881	11	12	institute	institute	PROPN
dpc-1881	11	13	;	;	PUNCT
dpc-1881	11	14	director	director	NOUN
dpc-1881	11	15	,	,	PUNCT
dpc-1881	11	16	dermatology	dermatology	NOUN
dpc-1881	11	17	department	department	NOUN
dpc-1881	11	18	,	,	PUNCT
dpc-1881	11	19	princess	princess	NOUN
dpc-1881	11	20	alexandra	alexandra	PROPN
dpc-1881	11	21	hospital	hospital	PROPN
dpc-1881	11	22	prof	prof	PROPN
dpc-1881	11	23	.	.	PUNCT
dpc-1881	12	1	paola	paola	PROPN
dpc-1881	12	2	queirolo	queirolo	PROPN
dpc-1881	12	3	,	,	PUNCT
dpc-1881	12	4	md	md	PROPN
dpc-1881	12	5	director	director	NOUN
dpc-1881	12	6	of	of	ADP
dpc-1881	12	7	the	the	DET
dpc-1881	12	8	“	"	PUNCT
dpc-1881	12	9	divisione	divisione	X
dpc-1881	12	10	di	di	X
dpc-1881	12	11	oncologia	oncologia	PROPN
dpc-1881	12	12	medica	medica	PROPN
dpc-1881	12	13	del	del	PROPN
dpc-1881	12	14	melanoma	melanoma	PROPN
dpc-1881	12	15	,	,	PUNCT
dpc-1881	12	16	sarcoma	sarcoma	PROPN
dpc-1881	12	17	e	e	PROPN
dpc-1881	12	18	tumori	tumori	PROPN
dpc-1881	12	19	rari	rari	PROPN
dpc-1881	12	20	”	"	PUNCT
dpc-1881	12	21	istituto	istituto	PROPN
dpc-1881	12	22	europeo	europeo	PROPN
dpc-1881	12	23	di	di	PROPN
dpc-1881	12	24	oncologia	oncologia	PROPN
dpc-1881	12	25	,	,	PUNCT
dpc-1881	12	26	ieo	ieo	NOUN
dpc-1881	12	27	.	.	PROPN
dpc-1881	13	1	thanks	thank	NOUN
dpc-1881	13	2	to	to	ADP
dpc-1881	13	3	dermatology	dermatology	NOUN
dpc-1881	13	4	practical	practical	ADJ
dpc-1881	13	5	&	&	CCONJ
dpc-1881	13	6	conceptual	conceptual	ADJ
dpc-1881	13	7	review	review	NOUN
dpc-1881	13	8	|	|	ADV
dpc-1881	13	9	dermatol	dermatol	ADJ
dpc-1881	13	10	pract	pract	NOUN
dpc-1881	13	11	concept	concept	NOUN
dpc-1881	13	12	.	.	PUNCT
dpc-1881	14	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	14	2	):	):	PUNCT
dpc-1881	14	3	e2021164s	e2021164s	PROPN
dpc-1881	14	4	1	1	NUM
dpc-1881	14	5	treatment	treatment	NOUN
dpc-1881	14	6	of	of	ADP
dpc-1881	14	7	advanced	advanced	ADJ
dpc-1881	14	8	metastatic	metastatic	ADJ
dpc-1881	14	9	melanoma	melanoma	NOUN
dpc-1881	14	10	pietro	pietro	NOUN
dpc-1881	14	11	quaglino	quaglino	PROPN
dpc-1881	14	12	,	,	PUNCT
dpc-1881	14	13	paolo	paolo	PROPN
dpc-1881	14	14	fava	fava	NOUN
dpc-1881	14	15	,	,	PUNCT
dpc-1881	14	16	luca	luca	PROPN
dpc-1881	14	17	tonella	tonella	PROPN
dpc-1881	14	18	,	,	PUNCT
dpc-1881	14	19	marco	marco	PROPN
dpc-1881	14	20	rubatto	rubatto	NOUN
dpc-1881	14	21	,	,	PUNCT
dpc-1881	14	22	simone	simone	NOUN
dpc-1881	14	23	ribero	ribero	PROPN
dpc-1881	14	24	,	,	PUNCT
dpc-1881	14	25	maria	maria	PROPN
dpc-1881	14	26	teresa	teresa	PROPN
dpc-1881	14	27	fierro	fierro	ADJ
dpc-1881	14	28	dermatologic	dermatologic	ADJ
dpc-1881	14	29	clinic	clinic	NOUN
dpc-1881	14	30	,	,	PUNCT
dpc-1881	14	31	university	university	PROPN
dpc-1881	14	32	of	of	ADP
dpc-1881	14	33	turin	turin	PROPN
dpc-1881	14	34	medical	medical	PROPN
dpc-1881	14	35	school	school	PROPN
dpc-1881	14	36	,	,	PUNCT
dpc-1881	14	37	turin	turin	PROPN
dpc-1881	14	38	,	,	PUNCT
dpc-1881	14	39	italy	italy	PROPN
dpc-1881	14	40	key	key	ADJ
dpc-1881	14	41	words	word	NOUN
dpc-1881	14	42	:	:	PUNCT
dpc-1881	14	43	metastatic	metastatic	ADJ
dpc-1881	14	44	melanoma	melanoma	NOUN
dpc-1881	14	45	treatment	treatment	NOUN
dpc-1881	14	46	,	,	PUNCT
dpc-1881	14	47	anti	anti	ADJ
dpc-1881	14	48	-	-	ADJ
dpc-1881	14	49	pd1	pd1	NOUN
dpc-1881	14	50	,	,	PUNCT
dpc-1881	14	51	target	target	NOUN
dpc-1881	14	52	therapy	therapy	NOUN
dpc-1881	14	53	,	,	PUNCT
dpc-1881	14	54	metastatic	metastatic	ADJ
dpc-1881	14	55	melanoma	melanoma	NOUN
dpc-1881	14	56	survival	survival	NOUN
dpc-1881	14	57	,	,	PUNCT
dpc-1881	14	58	response	response	NOUN
dpc-1881	14	59	rate	rate	NOUN
dpc-1881	14	60	citation	citation	NOUN
dpc-1881	14	61	:	:	PUNCT
dpc-1881	14	62	quaglino	quaglino	PROPN
dpc-1881	14	63	p	p	X
dpc-1881	14	64	,	,	PUNCT
dpc-1881	14	65	fava	fava	NOUN
dpc-1881	14	66	p	p	NOUN
dpc-1881	14	67	,	,	PUNCT
dpc-1881	14	68	tonella	tonella	NOUN
dpc-1881	14	69	l	l	NOUN
dpc-1881	14	70	,	,	PUNCT
dpc-1881	14	71	rubatto	rubatto	NOUN
dpc-1881	14	72	m	m	PROPN
dpc-1881	14	73	,	,	PUNCT
dpc-1881	14	74	ribero	ribero	PROPN
dpc-1881	14	75	s	s	PROPN
dpc-1881	14	76	,	,	PUNCT
dpc-1881	15	1	fierro	fierro	PROPN
dpc-1881	15	2	mt	mt	PROPN
dpc-1881	15	3	.	.	PROPN
dpc-1881	15	4	treatment	treatment	NOUN
dpc-1881	15	5	of	of	ADP
dpc-1881	15	6	advanced	advanced	ADJ
dpc-1881	15	7	metastatic	metastatic	ADJ
dpc-1881	15	8	melanoma	melanoma	NOUN
dpc-1881	15	9	.	.	PUNCT
dpc-1881	16	1	dermatol	dermatol	NOUN
dpc-1881	16	2	pract	pract	PROPN
dpc-1881	16	3	concept	concept	NOUN
dpc-1881	16	4	.	.	PUNCT
dpc-1881	17	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	17	2	):	):	PUNCT
dpc-1881	17	3	e2021164s	e2021164s	PROPN
dpc-1881	17	4	.	.	PUNCT
dpc-1881	17	5	doi	doi	PROPN
dpc-1881	17	6	:	:	PUNCT
dpc-1881	17	7	https://doi.org/10.5826/dpc.11s1a164s	https://doi.org/10.5826/dpc.11s1a164s	X
dpc-1881	17	8	accepted	accept	VERB
dpc-1881	17	9	:	:	PUNCT
dpc-1881	17	10	july	july	PROPN
dpc-1881	17	11	10	10	NUM
dpc-1881	17	12	,	,	PUNCT
dpc-1881	17	13	2021	2021	NUM
dpc-1881	17	14	;	;	PUNCT
dpc-1881	17	15	published	publish	VERB
dpc-1881	17	16	:	:	PUNCT
dpc-1881	18	1	july	july	PROPN
dpc-1881	18	2	2021	2021	NUM
dpc-1881	18	3	copyright	copyright	NOUN
dpc-1881	18	4	:	:	PUNCT
dpc-1881	18	5	©	©	PROPN
dpc-1881	18	6	2021	2021	NUM
dpc-1881	18	7	quaglino	quaglino	NOUN
dpc-1881	18	8	et	et	PROPN
dpc-1881	18	9	al	al	PROPN
dpc-1881	18	10	.	.	PUNCT
dpc-1881	19	1	this	this	PRON
dpc-1881	19	2	is	be	AUX
dpc-1881	19	3	an	an	DET
dpc-1881	19	4	open	open	ADJ
dpc-1881	19	5	-	-	PUNCT
dpc-1881	19	6	access	access	NOUN
dpc-1881	19	7	article	article	NOUN
dpc-1881	19	8	distributed	distribute	VERB
dpc-1881	19	9	under	under	ADP
dpc-1881	19	10	the	the	DET
dpc-1881	19	11	terms	term	NOUN
dpc-1881	19	12	of	of	ADP
dpc-1881	19	13	the	the	DET
dpc-1881	19	14	creative	creative	ADJ
dpc-1881	19	15	commons	common	NOUN
dpc-1881	19	16	attribution	attribution	NOUN
dpc-1881	19	17	license	license	NOUN
dpc-1881	19	18	by	by	ADP
dpc-1881	19	19	-	-	PUNCT
dpc-1881	19	20	nc-4.0	nc-4.0	NOUN
dpc-1881	19	21	,	,	PUNCT
dpc-1881	19	22	which	which	PRON
dpc-1881	19	23	permits	permit	VERB
dpc-1881	19	24	unrestricted	unrestricted	ADJ
dpc-1881	19	25	noncommercial	noncommercial	ADJ
dpc-1881	19	26	use	use	NOUN
dpc-1881	19	27	,	,	PUNCT
dpc-1881	19	28	distribution	distribution	NOUN
dpc-1881	19	29	,	,	PUNCT
dpc-1881	19	30	and	and	CCONJ
dpc-1881	19	31	reproduction	reproduction	NOUN
dpc-1881	19	32	in	in	ADP
dpc-1881	19	33	any	any	DET
dpc-1881	19	34	medium	medium	NOUN
dpc-1881	19	35	,	,	PUNCT
dpc-1881	19	36	provided	provide	VERB
dpc-1881	19	37	the	the	DET
dpc-1881	19	38	original	original	ADJ
dpc-1881	19	39	authors	author	NOUN
dpc-1881	19	40	and	and	CCONJ
dpc-1881	19	41	source	source	NOUN
dpc-1881	19	42	are	be	AUX
dpc-1881	19	43	credited	credit	VERB
dpc-1881	19	44	.	.	PUNCT
dpc-1881	20	1	funding	funding	NOUN
dpc-1881	20	2	:	:	PUNCT
dpc-1881	20	3	this	this	DET
dpc-1881	20	4	work	work	NOUN
dpc-1881	20	5	was	be	AUX
dpc-1881	20	6	partially	partially	ADV
dpc-1881	20	7	funded	fund	VERB
dpc-1881	20	8	with	with	ADP
dpc-1881	20	9	the	the	DET
dpc-1881	20	10	teseo	teseo	NOUN
dpc-1881	20	11	project	project	NOUN
dpc-1881	20	12	medicina	medicina	PROPN
dpc-1881	20	13	di	di	PROPN
dpc-1881	20	14	precisione	precisione	PROPN
dpc-1881	20	15	nelle	nelle	PROPN
dpc-1881	20	16	neoplasie	neoplasie	PROPN
dpc-1881	20	17	mediante	mediante	PROPN
dpc-1881	20	18	omica	omica	PROPN
dpc-1881	20	19	e	e	PROPN
dpc-1881	20	20	big	big	ADJ
dpc-1881	20	21	data	datum	NOUN
dpc-1881	20	22	,	,	PUNCT
dpc-1881	20	23	progetto	progetto	NOUN
dpc-1881	20	24	strategico	strategico	ADP
dpc-1881	20	25	di	di	X
dpc-1881	20	26	eccellenza	eccellenza	PROPN
dpc-1881	20	27	dipartimentale	dipartimentale	PROPN
dpc-1881	20	28	,	,	PUNCT
dpc-1881	20	29	department	department	NOUN
dpc-1881	20	30	of	of	ADP
dpc-1881	20	31	medical	medical	ADJ
dpc-1881	20	32	sciences	sciences	PROPN
dpc-1881	20	33	,	,	PUNCT
dpc-1881	20	34	university	university	PROPN
dpc-1881	20	35	of	of	ADP
dpc-1881	20	36	turin	turin	PROPN
dpc-1881	20	37	.	.	PUNCT
dpc-1881	21	1	competing	compete	VERB
dpc-1881	21	2	interests	interest	NOUN
dpc-1881	21	3	:	:	PUNCT
dpc-1881	21	4	the	the	DET
dpc-1881	21	5	authors	author	NOUN
dpc-1881	21	6	have	have	VERB
dpc-1881	21	7	no	no	DET
dpc-1881	21	8	conflicts	conflict	NOUN
dpc-1881	21	9	of	of	ADP
dpc-1881	21	10	interest	interest	NOUN
dpc-1881	21	11	to	to	PART
dpc-1881	21	12	disclose	disclose	VERB
dpc-1881	21	13	.	.	PUNCT
dpc-1881	22	1	authorship	authorship	NOUN
dpc-1881	22	2	:	:	PUNCT
dpc-1881	23	1	p.q	p.q	PROPN
dpc-1881	23	2	.	.	PROPN
dpc-1881	23	3	and	and	CCONJ
dpc-1881	23	4	p.f	p.f	PROPN
dpc-1881	23	5	.	.	PROPN
dpc-1881	23	6	have	have	AUX
dpc-1881	23	7	contributed	contribute	VERB
dpc-1881	23	8	equally	equally	ADV
dpc-1881	23	9	to	to	ADP
dpc-1881	23	10	the	the	DET
dpc-1881	23	11	article	article	NOUN
dpc-1881	23	12	.	.	PUNCT
dpc-1881	24	1	s.r	s.r	ADJ
dpc-1881	24	2	and	and	CCONJ
dpc-1881	24	3	m.t.f	m.t.f	ADV
dpc-1881	24	4	have	have	VERB
dpc-1881	24	5	equal	equal	ADJ
dpc-1881	24	6	seniorship	seniorship	NOUN
dpc-1881	24	7	.	.	PUNCT
dpc-1881	25	1	corresponding	correspond	VERB
dpc-1881	25	2	author	author	NOUN
dpc-1881	25	3	:	:	PUNCT
dpc-1881	25	4	pietro	pietro	PROPN
dpc-1881	25	5	quaglino	quaglino	PROPN
dpc-1881	25	6	md	md	PROPN
dpc-1881	25	7	,	,	PUNCT
dpc-1881	25	8	dermatologic	dermatologic	ADJ
dpc-1881	25	9	clinic	clinic	NOUN
dpc-1881	25	10	,	,	PUNCT
dpc-1881	25	11	via	via	ADP
dpc-1881	25	12	cherasco	cherasco	ADJ
dpc-1881	25	13	23	23	NUM
dpc-1881	25	14	,	,	PUNCT
dpc-1881	25	15	10126	10126	NUM
dpc-1881	25	16	,	,	PUNCT
dpc-1881	25	17	torino	torino	NOUN
dpc-1881	25	18	.	.	PUNCT
dpc-1881	25	19	email	email	NOUN
dpc-1881	25	20	:	:	PUNCT
dpc-1881	25	21	pietro.quaglino@unito.it	pietro.quaglino@unito.it	VERB
dpc-1881	25	22	the	the	DET
dpc-1881	25	23	introduction	introduction	NOUN
dpc-1881	25	24	in	in	ADP
dpc-1881	25	25	clinical	clinical	ADJ
dpc-1881	25	26	practice	practice	NOUN
dpc-1881	25	27	of	of	ADP
dpc-1881	25	28	new	new	ADJ
dpc-1881	25	29	drug	drug	NOUN
dpc-1881	25	30	compounds	compound	NOUN
dpc-1881	25	31	both	both	DET
dpc-1881	25	32	targeted	target	VERB
dpc-1881	25	33	therapies	therapy	NOUN
dpc-1881	25	34	anti	anti	ADJ
dpc-1881	25	35	-	-	ADJ
dpc-1881	25	36	braf	braf	ADJ
dpc-1881	25	37	and	and	CCONJ
dpc-1881	25	38	checkpoint	checkpoint	NOUN
dpc-1881	25	39	inhibitors	inhibitor	NOUN
dpc-1881	25	40	have	have	AUX
dpc-1881	25	41	largely	largely	ADV
dpc-1881	25	42	improved	improve	VERB
dpc-1881	25	43	our	our	PRON
dpc-1881	25	44	potential	potential	NOUN
dpc-1881	25	45	to	to	PART
dpc-1881	25	46	manage	manage	VERB
dpc-1881	25	47	advanced	advanced	ADJ
dpc-1881	25	48	metastatic	metastatic	ADJ
dpc-1881	25	49	melanoma	melanoma	NOUN
dpc-1881	25	50	patients	patient	NOUN
dpc-1881	25	51	.	.	PUNCT
dpc-1881	26	1	this	this	PRON
dpc-1881	26	2	has	have	AUX
dpc-1881	26	3	led	lead	VERB
dpc-1881	26	4	to	to	ADP
dpc-1881	26	5	a	a	DET
dpc-1881	26	6	significant	significant	ADJ
dpc-1881	26	7	improvement	improvement	NOUN
dpc-1881	26	8	in	in	ADP
dpc-1881	26	9	terms	term	NOUN
dpc-1881	26	10	of	of	ADP
dpc-1881	26	11	response	response	NOUN
dpc-1881	26	12	rates	rate	NOUN
dpc-1881	26	13	and	and	CCONJ
dpc-1881	26	14	particularly	particularly	ADV
dpc-1881	26	15	in	in	ADP
dpc-1881	26	16	the	the	DET
dpc-1881	26	17	overall	overall	ADJ
dpc-1881	26	18	survival	survival	NOUN
dpc-1881	26	19	(	(	PUNCT
dpc-1881	26	20	os	os	NOUN
dpc-1881	26	21	)	)	PUNCT
dpc-1881	26	22	.	.	PUNCT
dpc-1881	27	1	the	the	DET
dpc-1881	27	2	long	long	ADJ
dpc-1881	27	3	-	-	PUNCT
dpc-1881	27	4	term	term	NOUN
dpc-1881	27	5	results	result	NOUN
dpc-1881	27	6	of	of	ADP
dpc-1881	27	7	trials	trial	NOUN
dpc-1881	27	8	with	with	ADP
dpc-1881	27	9	follow	follow	VERB
dpc-1881	27	10	-	-	PUNCT
dpc-1881	27	11	up	up	ADP
dpc-1881	27	12	data	datum	NOUN
dpc-1881	27	13	of	of	ADP
dpc-1881	27	14	patients	patient	NOUN
dpc-1881	27	15	treated	treat	VERB
dpc-1881	27	16	with	with	ADP
dpc-1881	27	17	targeted	target	VERB
dpc-1881	27	18	or	or	CCONJ
dpc-1881	27	19	immunotherapies	immunotherapy	NOUN
dpc-1881	27	20	reported	report	VERB
dpc-1881	27	21	median	median	ADJ
dpc-1881	27	22	os	os	NOUN
dpc-1881	27	23	rates	rate	NOUN
dpc-1881	27	24	around	around	ADP
dpc-1881	27	25	24	24	NUM
dpc-1881	27	26	months	month	NOUN
dpc-1881	27	27	,	,	PUNCT
dpc-1881	27	28	with	with	ADP
dpc-1881	27	29	5	5	NUM
dpc-1881	27	30	-	-	PUNCT
dpc-1881	27	31	year	year	NOUN
dpc-1881	27	32	survival	survival	NOUN
dpc-1881	27	33	rates	rate	NOUN
dpc-1881	27	34	around	around	ADP
dpc-1881	27	35	35	35	NUM
dpc-1881	27	36	-	-	SYM
dpc-1881	27	37	40	40	NUM
dpc-1881	27	38	%	%	NOUN
dpc-1881	27	39	.	.	PUNCT
dpc-1881	28	1	as	as	ADP
dpc-1881	28	2	to	to	ADP
dpc-1881	28	3	the	the	DET
dpc-1881	28	4	drugs	drug	NOUN
dpc-1881	28	5	currently	currently	ADV
dpc-1881	28	6	available	available	ADJ
dpc-1881	28	7	and	and	CCONJ
dpc-1881	28	8	reimbursed	reimburse	VERB
dpc-1881	28	9	by	by	ADP
dpc-1881	28	10	the	the	DET
dpc-1881	28	11	italian	italian	ADJ
dpc-1881	28	12	national	national	ADJ
dpc-1881	28	13	health	health	NOUN
dpc-1881	28	14	system	system	NOUN
dpc-1881	28	15	,	,	PUNCT
dpc-1881	28	16	3	3	NUM
dpc-1881	28	17	combinations	combination	NOUN
dpc-1881	28	18	of	of	ADP
dpc-1881	28	19	anti	anti	ADJ
dpc-1881	28	20	-	-	ADJ
dpc-1881	28	21	braf	braf	ADJ
dpc-1881	28	22	/	/	SYM
dpc-1881	28	23	anti	anti	ADJ
dpc-1881	28	24	-	-	ADJ
dpc-1881	28	25	mek	mek	ADJ
dpc-1881	28	26	inhibitors	inhibitor	NOUN
dpc-1881	28	27	are	be	AUX
dpc-1881	28	28	available	available	ADJ
dpc-1881	28	29	(	(	PUNCT
dpc-1881	28	30	dabrafenib	dabrafenib	NOUN
dpc-1881	28	31	/	/	SYM
dpc-1881	28	32	trametinib	trametinib	NOUN
dpc-1881	28	33	,	,	PUNCT
dpc-1881	28	34	vemurafenib/	vemurafenib/	NUM
dpc-1881	28	35	cobimetinib	cobimetinib	NOUN
dpc-1881	28	36	and	and	CCONJ
dpc-1881	28	37	the	the	DET
dpc-1881	28	38	most	most	ADV
dpc-1881	28	39	recently	recently	ADV
dpc-1881	28	40	introduced	introduce	VERB
dpc-1881	28	41	encorafenib	encorafenib	NOUN
dpc-1881	28	42	/	/	SYM
dpc-1881	28	43	binimetinib	binimetinib	PROPN
dpc-1881	28	44	)	)	PUNCT
dpc-1881	28	45	.	.	PUNCT
dpc-1881	29	1	as	as	ADP
dpc-1881	29	2	for	for	ADP
dpc-1881	29	3	checkpoint	checkpoint	NOUN
dpc-1881	29	4	inhibitors	inhibitor	NOUN
dpc-1881	29	5	,	,	PUNCT
dpc-1881	29	6	first	first	ADJ
dpc-1881	29	7	line	line	NOUN
dpc-1881	29	8	immunotherapy	immunotherapy	NOUN
dpc-1881	29	9	is	be	AUX
dpc-1881	29	10	represented	represent	VERB
dpc-1881	29	11	by	by	ADP
dpc-1881	29	12	anti	anti	ADJ
dpc-1881	29	13	-	-	ADJ
dpc-1881	29	14	pd1	pd1	ADJ
dpc-1881	29	15	blockers	blocker	NOUN
dpc-1881	29	16	(	(	PUNCT
dpc-1881	29	17	nivolumab	nivolumab	NOUN
dpc-1881	29	18	and	and	CCONJ
dpc-1881	29	19	pembrolizumab	pembrolizumab	NOUN
dpc-1881	29	20	)	)	PUNCT
dpc-1881	29	21	,	,	PUNCT
dpc-1881	29	22	whilst	whilst	SCONJ
dpc-1881	29	23	the	the	DET
dpc-1881	29	24	anti	anti	ADJ
dpc-1881	29	25	-	-	ADJ
dpc-1881	29	26	ctla-4	ctla-4	ADJ
dpc-1881	29	27	ipilimumab	ipilimumab	NOUN
dpc-1881	29	28	can	can	AUX
dpc-1881	29	29	be	be	AUX
dpc-1881	29	30	used	use	VERB
dpc-1881	29	31	as	as	ADP
dpc-1881	29	32	second	second	ADJ
dpc-1881	29	33	line	line	NOUN
dpc-1881	29	34	immunotherapy	immunotherapy	NOUN
dpc-1881	29	35	.	.	PUNCT
dpc-1881	30	1	abstract	abstract	ADJ
dpc-1881	30	2	this	this	DET
dpc-1881	30	3	article	article	NOUN
dpc-1881	30	4	is	be	AUX
dpc-1881	30	5	part	part	NOUN
dpc-1881	30	6	of	of	ADP
dpc-1881	30	7	the	the	DET
dpc-1881	30	8	dpc	dpc	PROPN
dpc-1881	30	9	journal	journal	PROPN
dpc-1881	30	10	special	special	ADJ
dpc-1881	30	11	issue	issue	NOUN
dpc-1881	30	12	melanoma	melanoma	NOUN
dpc-1881	30	13	today	today	NOUN
dpc-1881	30	14	guest	guest	PROPN
dpc-1881	30	15	editors	editor	NOUN
dpc-1881	30	16	prof	prof	PROPN
dpc-1881	30	17	.	.	PUNCT
dpc-1881	31	1	h.	h.	PROPN
dpc-1881	31	2	peter	peter	PROPN
dpc-1881	31	3	soyer	soyer	PROPN
dpc-1881	31	4	,	,	PUNCT
dpc-1881	31	5	md	md	PROPN
dpc-1881	31	6	,	,	PUNCT
dpc-1881	31	7	facd	facd	NOUN
dpc-1881	31	8	,	,	PUNCT
dpc-1881	31	9	fahms	fahm	NOUN
dpc-1881	31	10	chair	chair	NOUN
dpc-1881	31	11	in	in	ADP
dpc-1881	31	12	dermatology	dermatology	NOUN
dpc-1881	31	13	.	.	PUNCT
dpc-1881	32	1	director	director	NOUN
dpc-1881	32	2	,	,	PUNCT
dpc-1881	32	3	dermatology	dermatology	NOUN
dpc-1881	32	4	research	research	NOUN
dpc-1881	32	5	centre	centre	NOUN
dpc-1881	32	6	,	,	PUNCT
dpc-1881	32	7	the	the	DET
dpc-1881	32	8	university	university	PROPN
dpc-1881	32	9	of	of	ADP
dpc-1881	32	10	queensland	queensland	PROPN
dpc-1881	32	11	diamantina	diamantina	PROPN
dpc-1881	32	12	institute	institute	PROPN
dpc-1881	32	13	;	;	PUNCT
dpc-1881	32	14	director	director	NOUN
dpc-1881	32	15	,	,	PUNCT
dpc-1881	32	16	dermatology	dermatology	NOUN
dpc-1881	32	17	department	department	NOUN
dpc-1881	32	18	,	,	PUNCT
dpc-1881	32	19	princess	princess	NOUN
dpc-1881	32	20	alexandra	alexandra	PROPN
dpc-1881	32	21	hospital	hospital	PROPN
dpc-1881	32	22	prof	prof	PROPN
dpc-1881	32	23	.	.	PUNCT
dpc-1881	33	1	paola	paola	PROPN
dpc-1881	33	2	queirolo	queirolo	PROPN
dpc-1881	33	3	,	,	PUNCT
dpc-1881	33	4	md	md	PROPN
dpc-1881	33	5	director	director	NOUN
dpc-1881	33	6	of	of	ADP
dpc-1881	33	7	the	the	DET
dpc-1881	33	8	“	"	PUNCT
dpc-1881	33	9	divisione	divisione	X
dpc-1881	33	10	di	di	X
dpc-1881	33	11	oncologia	oncologia	PROPN
dpc-1881	33	12	medica	medica	PROPN
dpc-1881	33	13	del	del	PROPN
dpc-1881	33	14	melanoma	melanoma	PROPN
dpc-1881	33	15	,	,	PUNCT
dpc-1881	33	16	sarcoma	sarcoma	PROPN
dpc-1881	33	17	e	e	PROPN
dpc-1881	33	18	tumori	tumori	PROPN
dpc-1881	33	19	rari	rari	PROPN
dpc-1881	33	20	”	"	PUNCT
dpc-1881	33	21	istituto	istituto	PROPN
dpc-1881	33	22	europeo	europeo	PROPN
dpc-1881	33	23	di	di	PROPN
dpc-1881	33	24	oncologia	oncologia	PROPN
dpc-1881	33	25	,	,	PUNCT
dpc-1881	33	26	ieo	ieo	NOUN
dpc-1881	33	27	.	.	PROPN
dpc-1881	33	28	2	2	NUM
dpc-1881	33	29	review	review	NOUN
dpc-1881	33	30	|	|	ADV
dpc-1881	33	31	dermatol	dermatol	ADJ
dpc-1881	33	32	pract	pract	NOUN
dpc-1881	33	33	concept	concept	NOUN
dpc-1881	33	34	.	.	PUNCT
dpc-1881	34	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	34	2	):	):	PUNCT
dpc-1881	34	3	e2021164s	e2021164	VERB
dpc-1881	34	4	introduction	introduction	NOUN
dpc-1881	34	5	the	the	DET
dpc-1881	34	6	presence	presence	NOUN
dpc-1881	34	7	of	of	ADP
dpc-1881	34	8	distant	distant	ADJ
dpc-1881	34	9	metastases	metastasis	NOUN
dpc-1881	34	10	with	with	ADP
dpc-1881	34	11	soft	soft	ADJ
dpc-1881	34	12	tissues	tissue	NOUN
dpc-1881	34	13	or	or	CCONJ
dpc-1881	34	14	internal	internal	ADJ
dpc-1881	34	15	organs	organ	NOUN
dpc-1881	34	16	’	'	PUNCT
dpc-1881	34	17	involvement	involvement	NOUN
dpc-1881	34	18	is	be	AUX
dpc-1881	34	19	classified	classify	VERB
dpc-1881	34	20	as	as	ADP
dpc-1881	34	21	stage	stage	NOUN
dpc-1881	34	22	iv	iv	NUM
dpc-1881	34	23	metastatic	metastatic	ADJ
dpc-1881	34	24	melanoma	melanoma	NOUN
dpc-1881	34	25	.	.	PUNCT
dpc-1881	35	1	according	accord	VERB
dpc-1881	35	2	to	to	ADP
dpc-1881	35	3	the	the	DET
dpc-1881	35	4	8th	8th	ADJ
dpc-1881	35	5	edition	edition	NOUN
dpc-1881	35	6	american	american	PROPN
dpc-1881	35	7	joint	joint	PROPN
dpc-1881	35	8	committee	committee	PROPN
dpc-1881	35	9	on	on	ADP
dpc-1881	35	10	cancer	cancer	NOUN
dpc-1881	35	11	(	(	PUNCT
dpc-1881	35	12	ajcc	ajcc	PROPN
dpc-1881	35	13	)	)	PUNCT
dpc-1881	35	14	2018	2018	NUM
dpc-1881	35	15	,	,	PUNCT
dpc-1881	35	16	m1	m1	PROPN
dpc-1881	35	17	is	be	AUX
dpc-1881	35	18	defined	define	VERB
dpc-1881	35	19	by	by	ADP
dpc-1881	35	20	both	both	CCONJ
dpc-1881	35	21	the	the	DET
dpc-1881	35	22	anatomic	anatomic	ADJ
dpc-1881	35	23	site	site	NOUN
dpc-1881	35	24	of	of	ADP
dpc-1881	35	25	distant	distant	ADJ
dpc-1881	35	26	metastatic	metastatic	ADJ
dpc-1881	35	27	disease	disease	NOUN
dpc-1881	35	28	(	(	PUNCT
dpc-1881	35	29	“	"	PUNCT
dpc-1881	35	30	a	a	X
dpc-1881	35	31	”	"	PUNCT
dpc-1881	35	32	for	for	ADP
dpc-1881	35	33	soft	soft	ADJ
dpc-1881	35	34	tissue	tissue	NOUN
dpc-1881	35	35	,	,	PUNCT
dpc-1881	35	36	“	"	PUNCT
dpc-1881	35	37	b	b	NOUN
dpc-1881	35	38	”	"	PUNCT
dpc-1881	35	39	for	for	ADP
dpc-1881	35	40	lung	lung	NOUN
dpc-1881	35	41	,	,	PUNCT
dpc-1881	35	42	“	"	PUNCT
dpc-1881	35	43	c	c	NOUN
dpc-1881	35	44	”	"	PUNCT
dpc-1881	35	45	for	for	ADP
dpc-1881	35	46	other	other	ADJ
dpc-1881	35	47	sites	site	NOUN
dpc-1881	35	48	,	,	PUNCT
dpc-1881	35	49	and	and	CCONJ
dpc-1881	35	50	the	the	DET
dpc-1881	35	51	new	new	ADJ
dpc-1881	35	52	“	"	PUNCT
dpc-1881	35	53	d	d	ADJ
dpc-1881	35	54	”	"	PUNCT
dpc-1881	35	55	designation	designation	NOUN
dpc-1881	35	56	added	add	VERB
dpc-1881	35	57	to	to	PART
dpc-1881	35	58	include	include	VERB
dpc-1881	35	59	distant	distant	ADJ
dpc-1881	35	60	metastasis	metastasis	NOUN
dpc-1881	35	61	to	to	ADP
dpc-1881	35	62	the	the	DET
dpc-1881	35	63	central	central	ADJ
dpc-1881	35	64	nervous	nervous	ADJ
dpc-1881	35	65	system	system	NOUN
dpc-1881	35	66	)	)	PUNCT
dpc-1881	35	67	,	,	PUNCT
dpc-1881	35	68	and	and	CCONJ
dpc-1881	35	69	serum	serum	NOUN
dpc-1881	35	70	lactate	lactate	PROPN
dpc-1881	35	71	dehydrogenase	dehydrogenase	NOUN
dpc-1881	35	72	(	(	PUNCT
dpc-1881	35	73	ldh	ldh	NOUN
dpc-1881	35	74	)	)	PUNCT
dpc-1881	35	75	values	value	NOUN
dpc-1881	35	76	(	(	PUNCT
dpc-1881	35	77	designated	designate	VERB
dpc-1881	35	78	as	as	ADP
dpc-1881	35	79	“	"	PUNCT
dpc-1881	35	80	0	0	NUM
dpc-1881	35	81	”	"	PUNCT
dpc-1881	35	82	for	for	ADP
dpc-1881	35	83	not	not	PART
dpc-1881	35	84	elevated	elevated	ADJ
dpc-1881	35	85	and	and	CCONJ
dpc-1881	35	86	“	"	PUNCT
dpc-1881	35	87	1	1	NUM
dpc-1881	35	88	”	"	PUNCT
dpc-1881	35	89	for	for	ADP
dpc-1881	35	90	elevated	elevated	ADJ
dpc-1881	35	91	[	[	X
dpc-1881	35	92	1	1	NUM
dpc-1881	35	93	]	]	PUNCT
dpc-1881	35	94	.	.	PUNCT
dpc-1881	36	1	only	only	ADV
dpc-1881	36	2	a	a	DET
dpc-1881	36	3	minority	minority	NOUN
dpc-1881	36	4	of	of	ADP
dpc-1881	36	5	melanoma	melanoma	NOUN
dpc-1881	36	6	patients	patient	NOUN
dpc-1881	36	7	develop	develop	VERB
dpc-1881	36	8	distant	distant	ADJ
dpc-1881	36	9	metastases	metastasis	NOUN
dpc-1881	36	10	during	during	ADP
dpc-1881	36	11	the	the	DET
dpc-1881	36	12	course	course	NOUN
dpc-1881	36	13	of	of	ADP
dpc-1881	36	14	their	their	PRON
dpc-1881	36	15	disease	disease	NOUN
dpc-1881	36	16	,	,	PUNCT
dpc-1881	36	17	thanks	thank	NOUN
dpc-1881	36	18	to	to	ADP
dpc-1881	36	19	early	early	ADJ
dpc-1881	36	20	diagnosis	diagnosis	NOUN
dpc-1881	36	21	.	.	PUNCT
dpc-1881	37	1	even	even	ADV
dpc-1881	37	2	if	if	SCONJ
dpc-1881	37	3	the	the	DET
dpc-1881	37	4	prognosis	prognosis	NOUN
dpc-1881	37	5	for	for	ADP
dpc-1881	37	6	stage	stage	NOUN
dpc-1881	37	7	iv	iv	NUM
dpc-1881	37	8	patients	patient	NOUN
dpc-1881	37	9	is	be	AUX
dpc-1881	37	10	still	still	ADV
dpc-1881	37	11	severe	severe	ADJ
dpc-1881	37	12	,	,	PUNCT
dpc-1881	37	13	the	the	DET
dpc-1881	37	14	introduction	introduction	NOUN
dpc-1881	37	15	of	of	ADP
dpc-1881	37	16	the	the	DET
dpc-1881	37	17	new	new	ADJ
dpc-1881	37	18	drug	drug	NOUN
dpc-1881	37	19	compounds	compound	NOUN
dpc-1881	37	20	,	,	PUNCT
dpc-1881	37	21	both	both	DET
dpc-1881	37	22	targeted	target	VERB
dpc-1881	37	23	therapies	therapy	NOUN
dpc-1881	37	24	anti	anti	ADJ
dpc-1881	37	25	-	-	ADJ
dpc-1881	37	26	braf	braf	ADJ
dpc-1881	37	27	and	and	CCONJ
dpc-1881	37	28	checkpoint	checkpoint	NOUN
dpc-1881	37	29	inhibitors	inhibitor	NOUN
dpc-1881	37	30	,	,	PUNCT
dpc-1881	37	31	have	have	AUX
dpc-1881	37	32	largely	largely	ADV
dpc-1881	37	33	improved	improve	VERB
dpc-1881	37	34	our	our	PRON
dpc-1881	37	35	potential	potential	NOUN
dpc-1881	37	36	to	to	PART
dpc-1881	37	37	manage	manage	VERB
dpc-1881	37	38	these	these	DET
dpc-1881	37	39	patients	patient	NOUN
dpc-1881	37	40	inducing	induce	VERB
dpc-1881	37	41	a	a	DET
dpc-1881	37	42	significant	significant	ADJ
dpc-1881	37	43	improvement	improvement	NOUN
dpc-1881	37	44	in	in	ADP
dpc-1881	37	45	terms	term	NOUN
dpc-1881	37	46	of	of	ADP
dpc-1881	37	47	response	response	NOUN
dpc-1881	37	48	rates	rate	NOUN
dpc-1881	37	49	(	(	PUNCT
dpc-1881	37	50	rr	rr	NOUN
dpc-1881	37	51	)	)	PUNCT
dpc-1881	37	52	and	and	CCONJ
dpc-1881	37	53	particularly	particularly	ADV
dpc-1881	37	54	overall	overall	ADJ
dpc-1881	37	55	survival	survival	NOUN
dpc-1881	37	56	(	(	PUNCT
dpc-1881	37	57	os	os	NOUN
dpc-1881	37	58	)	)	PUNCT
dpc-1881	37	59	.	.	PUNCT
dpc-1881	38	1	the	the	DET
dpc-1881	38	2	unsatisfactory	unsatisfactory	ADJ
dpc-1881	38	3	results	result	NOUN
dpc-1881	38	4	obtained	obtain	VERB
dpc-1881	38	5	by	by	ADP
dpc-1881	38	6	(	(	PUNCT
dpc-1881	38	7	bio)-chemotherapy	bio)-chemotherapy	NOUN
dpc-1881	38	8	were	be	AUX
dpc-1881	38	9	clearly	clearly	ADV
dpc-1881	38	10	summarized	summarize	VERB
dpc-1881	38	11	in	in	ADP
dpc-1881	38	12	a	a	DET
dpc-1881	38	13	review	review	NOUN
dpc-1881	38	14	study	study	NOUN
dpc-1881	38	15	by	by	ADP
dpc-1881	38	16	korn	korn	PROPN
dpc-1881	38	17	et	et	PROPN
dpc-1881	38	18	al	al	PROPN
dpc-1881	39	1	[	[	X
dpc-1881	39	2	2	2	NUM
dpc-1881	39	3	]	]	PUNCT
dpc-1881	39	4	,	,	PUNCT
dpc-1881	39	5	which	which	PRON
dpc-1881	39	6	analyzed	analyze	VERB
dpc-1881	39	7	clinical	clinical	ADJ
dpc-1881	39	8	data	datum	NOUN
dpc-1881	39	9	obtained	obtain	VERB
dpc-1881	39	10	from	from	ADP
dpc-1881	39	11	more	more	ADJ
dpc-1881	39	12	than	than	ADP
dpc-1881	39	13	2,000	2,000	NUM
dpc-1881	39	14	patients	patient	NOUN
dpc-1881	39	15	enrolled	enrol	VERB
dpc-1881	39	16	since	since	SCONJ
dpc-1881	39	17	1975	1975	NUM
dpc-1881	39	18	in	in	ADP
dpc-1881	39	19	42	42	NUM
dpc-1881	39	20	phase	phase	NOUN
dpc-1881	39	21	ii	ii	NOUN
dpc-1881	39	22	trials	trial	NOUN
dpc-1881	39	23	.	.	PUNCT
dpc-1881	40	1	an	an	DET
dpc-1881	40	2	overall	overall	ADJ
dpc-1881	40	3	1	1	NUM
dpc-1881	40	4	-	-	PUNCT
dpc-1881	40	5	year	year	NOUN
dpc-1881	40	6	survival	survival	NOUN
dpc-1881	40	7	rate	rate	NOUN
dpc-1881	40	8	of	of	ADP
dpc-1881	40	9	25.5	25.5	NUM
dpc-1881	40	10	%	%	NOUN
dpc-1881	40	11	and	and	CCONJ
dpc-1881	40	12	a	a	DET
dpc-1881	40	13	median	median	ADJ
dpc-1881	40	14	os	os	NOUN
dpc-1881	40	15	of	of	ADP
dpc-1881	40	16	6.2	6.2	NUM
dpc-1881	40	17	months	month	NOUN
dpc-1881	40	18	were	be	AUX
dpc-1881	40	19	achieved	achieve	VERB
dpc-1881	40	20	,	,	PUNCT
dpc-1881	40	21	with	with	ADP
dpc-1881	40	22	no	no	DET
dpc-1881	40	23	significant	significant	ADJ
dpc-1881	40	24	improvement	improvement	NOUN
dpc-1881	40	25	during	during	ADP
dpc-1881	40	26	the	the	DET
dpc-1881	40	27	last	last	ADJ
dpc-1881	40	28	30	30	NUM
dpc-1881	40	29	years	year	NOUN
dpc-1881	40	30	.	.	PUNCT
dpc-1881	41	1	the	the	DET
dpc-1881	41	2	long	long	ADJ
dpc-1881	41	3	-	-	PUNCT
dpc-1881	41	4	term	term	NOUN
dpc-1881	41	5	results	result	NOUN
dpc-1881	41	6	of	of	ADP
dpc-1881	41	7	the	the	DET
dpc-1881	41	8	trials	trial	NOUN
dpc-1881	41	9	with	with	ADP
dpc-1881	41	10	follow	follow	VERB
dpc-1881	41	11	-	-	PUNCT
dpc-1881	41	12	up	up	ADP
dpc-1881	41	13	data	datum	NOUN
dpc-1881	41	14	of	of	ADP
dpc-1881	41	15	patients	patient	NOUN
dpc-1881	41	16	treated	treat	VERB
dpc-1881	41	17	with	with	ADP
dpc-1881	41	18	targeted	target	VERB
dpc-1881	41	19	or	or	CCONJ
dpc-1881	41	20	immunotherapies	immunotherapy	NOUN
dpc-1881	41	21	reported	report	VERB
dpc-1881	41	22	median	median	ADJ
dpc-1881	41	23	os	os	NOUN
dpc-1881	41	24	rates	rate	NOUN
dpc-1881	41	25	around	around	ADP
dpc-1881	41	26	24	24	NUM
dpc-1881	41	27	months	month	NOUN
dpc-1881	41	28	,	,	PUNCT
dpc-1881	41	29	with	with	ADP
dpc-1881	41	30	5	5	NUM
dpc-1881	41	31	-	-	PUNCT
dpc-1881	41	32	year	year	NOUN
dpc-1881	41	33	survival	survival	NOUN
dpc-1881	41	34	rates	rate	NOUN
dpc-1881	41	35	around	around	ADP
dpc-1881	41	36	35	35	NUM
dpc-1881	41	37	-	-	SYM
dpc-1881	41	38	40	40	NUM
dpc-1881	41	39	%	%	NOUN
dpc-1881	41	40	[	[	X
dpc-1881	41	41	3	3	NUM
dpc-1881	41	42	]	]	PUNCT
dpc-1881	41	43	.	.	PUNCT
dpc-1881	42	1	currently	currently	ADV
dpc-1881	42	2	,	,	PUNCT
dpc-1881	42	3	the	the	DET
dpc-1881	42	4	main	main	ADJ
dpc-1881	42	5	criterion	criterion	NOUN
dpc-1881	42	6	adopted	adopt	VERB
dpc-1881	42	7	to	to	PART
dpc-1881	42	8	decide	decide	VERB
dpc-1881	42	9	the	the	DET
dpc-1881	42	10	best	good	ADJ
dpc-1881	42	11	therapeutic	therapeutic	ADJ
dpc-1881	42	12	option	option	NOUN
dpc-1881	42	13	for	for	ADP
dpc-1881	42	14	an	an	DET
dpc-1881	42	15	advanced	advanced	ADJ
dpc-1881	42	16	patient	patient	NOUN
dpc-1881	42	17	is	be	AUX
dpc-1881	42	18	the	the	DET
dpc-1881	42	19	presence	presence	NOUN
dpc-1881	42	20	or	or	CCONJ
dpc-1881	42	21	absence	absence	NOUN
dpc-1881	42	22	of	of	ADP
dpc-1881	42	23	the	the	DET
dpc-1881	42	24	braf	braf	NOUN
dpc-1881	42	25	gene	gene	NOUN
dpc-1881	42	26	mutation	mutation	NOUN
dpc-1881	42	27	.	.	PUNCT
dpc-1881	43	1	the	the	DET
dpc-1881	43	2	braf	braf	NOUN
dpc-1881	43	3	mutation	mutation	NOUN
dpc-1881	43	4	is	be	AUX
dpc-1881	43	5	harbored	harbor	VERB
dpc-1881	43	6	by	by	ADP
dpc-1881	43	7	approximately	approximately	ADV
dpc-1881	43	8	50	50	NUM
dpc-1881	43	9	%	%	NOUN
dpc-1881	43	10	of	of	ADP
dpc-1881	43	11	melanomas	melanomas	NOUN
dpc-1881	43	12	.	.	PUNCT
dpc-1881	44	1	more	more	ADV
dpc-1881	44	2	frequently	frequently	ADV
dpc-1881	44	3	,	,	PUNCT
dpc-1881	44	4	those	those	PRON
dpc-1881	44	5	arising	arise	VERB
dpc-1881	44	6	without	without	ADP
dpc-1881	44	7	chronic	chronic	ADJ
dpc-1881	44	8	sun	sun	NOUN
dpc-1881	44	9	-	-	PUNCT
dpc-1881	44	10	induced	induce	VERB
dpc-1881	44	11	damage	damage	NOUN
dpc-1881	44	12	,	,	PUNCT
dpc-1881	44	13	induce	induce	VERB
dpc-1881	44	14	the	the	DET
dpc-1881	44	15	hyperactivation	hyperactivation	NOUN
dpc-1881	44	16	of	of	ADP
dpc-1881	44	17	the	the	DET
dpc-1881	44	18	map	map	NOUN
dpc-1881	44	19	-	-	PUNCT
dpc-1881	44	20	kinase	kinase	ADJ
dpc-1881	44	21	molecular	molecular	ADJ
dpc-1881	44	22	cascade	cascade	NOUN
dpc-1881	44	23	,	,	PUNCT
dpc-1881	44	24	leading	lead	VERB
dpc-1881	44	25	to	to	ADP
dpc-1881	44	26	an	an	DET
dpc-1881	44	27	uncontrolled	uncontrolled	ADJ
dpc-1881	44	28	proliferation	proliferation	NOUN
dpc-1881	44	29	of	of	ADP
dpc-1881	44	30	cancer	cancer	NOUN
dpc-1881	44	31	cells	cell	NOUN
dpc-1881	44	32	[	[	X
dpc-1881	44	33	4	4	NUM
dpc-1881	44	34	]	]	PUNCT
dpc-1881	44	35	.	.	PUNCT
dpc-1881	45	1	in	in	ADP
dpc-1881	45	2	the	the	DET
dpc-1881	45	3	presence	presence	NOUN
dpc-1881	45	4	of	of	ADP
dpc-1881	45	5	braf	braf	NOUN
dpc-1881	45	6	mutation	mutation	NOUN
dpc-1881	45	7	,	,	PUNCT
dpc-1881	45	8	both	both	CCONJ
dpc-1881	45	9	anti	anti	ADJ
dpc-1881	45	10	-	-	ADJ
dpc-1881	45	11	braf	braf	ADJ
dpc-1881	45	12	targeted	target	VERB
dpc-1881	45	13	therapies	therapy	NOUN
dpc-1881	45	14	and	and	CCONJ
dpc-1881	45	15	checkpoint	checkpoint	NOUN
dpc-1881	45	16	inhibitors	inhibitor	NOUN
dpc-1881	45	17	can	can	AUX
dpc-1881	45	18	be	be	AUX
dpc-1881	45	19	used	use	VERB
dpc-1881	45	20	,	,	PUNCT
dpc-1881	45	21	whilst	whilst	SCONJ
dpc-1881	45	22	in	in	ADP
dpc-1881	45	23	the	the	DET
dpc-1881	45	24	presence	presence	NOUN
dpc-1881	45	25	of	of	ADP
dpc-1881	45	26	a	a	DET
dpc-1881	45	27	braf	braf	NOUN
dpc-1881	45	28	wild	wild	ADJ
dpc-1881	45	29	pattern	pattern	NOUN
dpc-1881	45	30	,	,	PUNCT
dpc-1881	45	31	only	only	ADV
dpc-1881	45	32	immunotherapy	immunotherapy	NOUN
dpc-1881	45	33	can	can	AUX
dpc-1881	45	34	be	be	AUX
dpc-1881	45	35	prescribed	prescribe	VERB
dpc-1881	45	36	[	[	X
dpc-1881	45	37	5	5	NUM
dpc-1881	45	38	]	]	PUNCT
dpc-1881	45	39	.	.	PUNCT
dpc-1881	46	1	as	as	ADP
dpc-1881	46	2	to	to	ADP
dpc-1881	46	3	the	the	DET
dpc-1881	46	4	drugs	drug	NOUN
dpc-1881	46	5	currently	currently	ADV
dpc-1881	46	6	available	available	ADJ
dpc-1881	46	7	and	and	CCONJ
dpc-1881	46	8	reimbursed	reimburse	VERB
dpc-1881	46	9	by	by	ADP
dpc-1881	46	10	the	the	DET
dpc-1881	46	11	italian	italian	ADJ
dpc-1881	46	12	national	national	ADJ
dpc-1881	46	13	health	health	NOUN
dpc-1881	46	14	system	system	NOUN
dpc-1881	46	15	,	,	PUNCT
dpc-1881	46	16	3	3	NUM
dpc-1881	46	17	combinations	combination	NOUN
dpc-1881	46	18	of	of	ADP
dpc-1881	46	19	anti	anti	ADJ
dpc-1881	46	20	-	-	ADJ
dpc-1881	46	21	braf	braf	ADJ
dpc-1881	46	22	/	/	SYM
dpc-1881	46	23	anti	anti	ADJ
dpc-1881	46	24	-	-	ADJ
dpc-1881	46	25	mek	mek	ADJ
dpc-1881	46	26	inhibitors	inhibitor	NOUN
dpc-1881	46	27	are	be	AUX
dpc-1881	46	28	available	available	ADJ
dpc-1881	46	29	(	(	PUNCT
dpc-1881	46	30	dabrafenib	dabrafenib	NOUN
dpc-1881	46	31	/	/	SYM
dpc-1881	46	32	trametinib	trametinib	NOUN
dpc-1881	46	33	,	,	PUNCT
dpc-1881	46	34	vemurafenib	vemurafenib	NOUN
dpc-1881	46	35	/	/	SYM
dpc-1881	46	36	cobimetinib	cobimetinib	PROPN
dpc-1881	46	37	and	and	CCONJ
dpc-1881	46	38	the	the	DET
dpc-1881	46	39	most	most	ADV
dpc-1881	46	40	recently	recently	ADV
dpc-1881	46	41	introduced	introduce	VERB
dpc-1881	46	42	encorafenib	encorafenib	NOUN
dpc-1881	46	43	/	/	SYM
dpc-1881	46	44	binimetinib	binimetinib	PROPN
dpc-1881	46	45	)	)	PUNCT
dpc-1881	46	46	.	.	PUNCT
dpc-1881	47	1	as	as	SCONJ
dpc-1881	47	2	to	to	PART
dpc-1881	47	3	checkpoint	checkpoint	VERB
dpc-1881	47	4	inhibitors	inhibitor	NOUN
dpc-1881	47	5	,	,	PUNCT
dpc-1881	47	6	first	first	ADJ
dpc-1881	47	7	line	line	NOUN
dpc-1881	47	8	immunotherapy	immunotherapy	NOUN
dpc-1881	47	9	is	be	AUX
dpc-1881	47	10	represented	represent	VERB
dpc-1881	47	11	by	by	ADP
dpc-1881	47	12	anti	anti	ADJ
dpc-1881	47	13	-	-	ADJ
dpc-1881	47	14	pd1	pd1	ADJ
dpc-1881	47	15	blockers	blocker	NOUN
dpc-1881	47	16	(	(	PUNCT
dpc-1881	47	17	nivolumab	nivolumab	NOUN
dpc-1881	47	18	and	and	CCONJ
dpc-1881	47	19	pembrolizumab	pembrolizumab	NOUN
dpc-1881	47	20	)	)	PUNCT
dpc-1881	47	21	,	,	PUNCT
dpc-1881	47	22	whilst	whilst	SCONJ
dpc-1881	47	23	the	the	DET
dpc-1881	47	24	anti	anti	ADJ
dpc-1881	47	25	-	-	ADJ
dpc-1881	47	26	ctla-4	ctla-4	ADJ
dpc-1881	47	27	ipilimumab	ipilimumab	NOUN
dpc-1881	47	28	can	can	AUX
dpc-1881	47	29	be	be	AUX
dpc-1881	47	30	used	use	VERB
dpc-1881	47	31	as	as	ADP
dpc-1881	47	32	second	second	ADJ
dpc-1881	47	33	line	line	NOUN
dpc-1881	47	34	.	.	PUNCT
dpc-1881	48	1	the	the	DET
dpc-1881	48	2	decision	decision	NOUN
dpc-1881	48	3	-	-	PUNCT
dpc-1881	48	4	making	make	VERB
dpc-1881	48	5	factors	factor	NOUN
dpc-1881	48	6	defining	define	VERB
dpc-1881	48	7	the	the	DET
dpc-1881	48	8	best	good	ADJ
dpc-1881	48	9	treatment	treatment	NOUN
dpc-1881	48	10	option	option	NOUN
dpc-1881	48	11	in	in	ADP
dpc-1881	48	12	a	a	DET
dpc-1881	48	13	stage	stage	NOUN
dpc-1881	48	14	iv	iv	NUM
dpc-1881	48	15	metastatic	metastatic	ADJ
dpc-1881	48	16	melanoma	melanoma	NOUN
dpc-1881	48	17	patient	patient	NOUN
dpc-1881	48	18	are	be	AUX
dpc-1881	48	19	represented	represent	VERB
dpc-1881	48	20	by	by	ADP
dpc-1881	48	21	:	:	PUNCT
dpc-1881	48	22	mutation	mutation	NOUN
dpc-1881	48	23	pattern	pattern	NOUN
dpc-1881	48	24	,	,	PUNCT
dpc-1881	48	25	performance	performance	NOUN
dpc-1881	48	26	status	status	NOUN
dpc-1881	48	27	,	,	PUNCT
dpc-1881	48	28	high	high	ADJ
dpc-1881	48	29	/	/	SYM
dpc-1881	48	30	low	low	ADJ
dpc-1881	48	31	tumor	tumor	NOUN
dpc-1881	48	32	load	load	NOUN
dpc-1881	48	33	,	,	PUNCT
dpc-1881	48	34	brain	brain	NOUN
dpc-1881	48	35	metastases	metastasis	NOUN
dpc-1881	48	36	,	,	PUNCT
dpc-1881	48	37	progression	progression	NOUN
dpc-1881	48	38	pattern	pattern	NOUN
dpc-1881	48	39	(	(	PUNCT
dpc-1881	48	40	low	low	ADJ
dpc-1881	48	41	/	/	SYM
dpc-1881	48	42	fast	fast	ADJ
dpc-1881	48	43	)	)	PUNCT
dpc-1881	48	44	,	,	PUNCT
dpc-1881	48	45	and	and	CCONJ
dpc-1881	48	46	availability	availability	NOUN
dpc-1881	48	47	of	of	ADP
dpc-1881	48	48	clinical	clinical	ADJ
dpc-1881	48	49	trials	trial	NOUN
dpc-1881	48	50	.	.	PUNCT
dpc-1881	49	1	this	this	DET
dpc-1881	49	2	review	review	NOUN
dpc-1881	49	3	will	will	AUX
dpc-1881	49	4	analyze	analyze	VERB
dpc-1881	49	5	the	the	DET
dpc-1881	49	6	therapeutic	therapeutic	ADJ
dpc-1881	49	7	tools	tool	NOUN
dpc-1881	49	8	available	available	ADJ
dpc-1881	49	9	for	for	ADP
dpc-1881	49	10	the	the	DET
dpc-1881	49	11	treatment	treatment	NOUN
dpc-1881	49	12	of	of	ADP
dpc-1881	49	13	patients	patient	NOUN
dpc-1881	49	14	with	with	ADP
dpc-1881	49	15	metastatic	metastatic	ADJ
dpc-1881	49	16	melanoma	melanoma	NOUN
dpc-1881	49	17	and	and	CCONJ
dpc-1881	49	18	will	will	AUX
dpc-1881	49	19	focus	focus	VERB
dpc-1881	49	20	on	on	ADP
dpc-1881	49	21	an	an	DET
dpc-1881	49	22	update	update	NOUN
dpc-1881	49	23	of	of	ADP
dpc-1881	49	24	results	result	NOUN
dpc-1881	49	25	obtained	obtain	VERB
dpc-1881	49	26	by	by	ADP
dpc-1881	49	27	the	the	DET
dpc-1881	49	28	new	new	ADJ
dpc-1881	49	29	treatments	treatment	NOUN
dpc-1881	49	30	(	(	PUNCT
dpc-1881	49	31	check	check	NOUN
dpc-1881	49	32	point	point	NOUN
dpc-1881	49	33	inhibitors	inhibitor	NOUN
dpc-1881	49	34	and	and	CCONJ
dpc-1881	49	35	targeted	target	VERB
dpc-1881	49	36	therapies	therapy	NOUN
dpc-1881	49	37	)	)	PUNCT
dpc-1881	49	38	which	which	PRON
dpc-1881	49	39	can	can	AUX
dpc-1881	49	40	be	be	AUX
dpc-1881	49	41	used	use	VERB
dpc-1881	49	42	in	in	ADP
dpc-1881	49	43	the	the	DET
dpc-1881	49	44	clinical	clinical	ADJ
dpc-1881	49	45	daily	daily	ADJ
dpc-1881	49	46	practice	practice	NOUN
dpc-1881	49	47	.	.	PUNCT
dpc-1881	50	1	anti	anti	ADJ
dpc-1881	50	2	-	-	ADJ
dpc-1881	50	3	braf	braf	ADJ
dpc-1881	50	4	and	and	CCONJ
dpc-1881	50	5	anti	anti	ADJ
dpc-1881	50	6	-	-	ADJ
dpc-1881	50	7	mek	mek	NOUN
dpc-1881	50	8	inhibitors	inhibitor	NOUN
dpc-1881	50	9	the	the	DET
dpc-1881	50	10	pharmacological	pharmacological	ADJ
dpc-1881	50	11	inhibition	inhibition	NOUN
dpc-1881	50	12	of	of	ADP
dpc-1881	50	13	the	the	DET
dpc-1881	50	14	mitogen	mitogen	NOUN
dpc-1881	50	15	-	-	PUNCT
dpc-1881	50	16	activated	activate	VERB
dpc-1881	50	17	protein	protein	NOUN
dpc-1881	50	18	kinases	kinase	NOUN
dpc-1881	50	19	(	(	PUNCT
dpc-1881	50	20	mapk	mapk	NOUN
dpc-1881	50	21	)	)	PUNCT
dpc-1881	50	22	pathway	pathway	NOUN
dpc-1881	50	23	by	by	ADP
dpc-1881	50	24	targeting	target	VERB
dpc-1881	50	25	the	the	DET
dpc-1881	50	26	mutant	mutant	ADJ
dpc-1881	50	27	v	v	ADJ
dpc-1881	50	28	-	-	PUNCT
dpc-1881	50	29	raf	raf	NOUN
dpc-1881	50	30	murine	murine	ADJ
dpc-1881	50	31	sarcoma	sarcoma	NOUN
dpc-1881	50	32	viral	viral	ADJ
dpc-1881	50	33	oncogene	oncogene	NOUN
dpc-1881	50	34	homolog	homolog	NOUN
dpc-1881	50	35	b1	b1	NOUN
dpc-1881	50	36	(	(	PUNCT
dpc-1881	50	37	braf	braf	PROPN
dpc-1881	50	38	)	)	PUNCT
dpc-1881	50	39	is	be	AUX
dpc-1881	50	40	a	a	DET
dpc-1881	50	41	milestone	milestone	NOUN
dpc-1881	50	42	in	in	ADP
dpc-1881	50	43	the	the	DET
dpc-1881	50	44	management	management	NOUN
dpc-1881	50	45	of	of	ADP
dpc-1881	50	46	metastatic	metastatic	ADJ
dpc-1881	50	47	melanoma	melanoma	NOUN
dpc-1881	50	48	.	.	PUNCT
dpc-1881	51	1	2	2	NUM
dpc-1881	51	2	randomized	randomize	VERB
dpc-1881	51	3	phase	phase	NOUN
dpc-1881	51	4	iii	iii	NUM
dpc-1881	51	5	studies	study	NOUN
dpc-1881	51	6	highlighted	highlight	VERB
dpc-1881	51	7	the	the	DET
dpc-1881	51	8	efficacy	efficacy	NOUN
dpc-1881	51	9	of	of	ADP
dpc-1881	51	10	the	the	DET
dpc-1881	51	11	dabrafenib	dabrafenib	NOUN
dpc-1881	51	12	-	-	PUNCT
dpc-1881	51	13	trametinib	trametinib	NOUN
dpc-1881	51	14	combination	combination	NOUN
dpc-1881	51	15	as	as	ADP
dpc-1881	51	16	first	first	ADJ
dpc-1881	51	17	-	-	PUNCT
dpc-1881	51	18	line	line	NOUN
dpc-1881	51	19	treatment	treatment	NOUN
dpc-1881	51	20	in	in	ADP
dpc-1881	51	21	metastatic	metastatic	ADJ
dpc-1881	51	22	melanoma	melanoma	NOUN
dpc-1881	51	23	:	:	PUNCT
dpc-1881	51	24	combi	combi	PROPN
dpc-1881	51	25	-	-	PROPN
dpc-1881	51	26	d	d	PROPN
dpc-1881	51	27	(	(	PUNCT
dpc-1881	51	28	n=423	n=423	PROPN
dpc-1881	51	29	,	,	PUNCT
dpc-1881	51	30	comparing	compare	VERB
dpc-1881	51	31	the	the	DET
dpc-1881	51	32	combination	combination	NOUN
dpc-1881	51	33	of	of	ADP
dpc-1881	51	34	dabrafenib	dabrafenib	NOUN
dpc-1881	51	35	/	/	SYM
dpc-1881	51	36	trametinib	trametinib	NOUN
dpc-1881	51	37	versus	versus	ADP
dpc-1881	51	38	dabrafenib	dabrafenib	NOUN
dpc-1881	51	39	)	)	PUNCT
dpc-1881	51	40	and	and	CCONJ
dpc-1881	51	41	combi	combi	PROPN
dpc-1881	51	42	-	-	PUNCT
dpc-1881	51	43	v	v	NOUN
dpc-1881	51	44	(	(	PUNCT
dpc-1881	51	45	n=704	n=704	NUM
dpc-1881	51	46	,	,	PUNCT
dpc-1881	51	47	which	which	PRON
dpc-1881	51	48	compared	compare	VERB
dpc-1881	51	49	the	the	DET
dpc-1881	51	50	combination	combination	NOUN
dpc-1881	51	51	versus	versus	ADP
dpc-1881	51	52	vemurafenib	vemurafenib	NOUN
dpc-1881	51	53	)	)	PUNCT
dpc-1881	51	54	.	.	PUNCT
dpc-1881	52	1	the	the	DET
dpc-1881	52	2	primary	primary	ADJ
dpc-1881	52	3	endpoint	endpoint	NOUN
dpc-1881	52	4	was	be	AUX
dpc-1881	52	5	progression	progression	NOUN
dpc-1881	52	6	-	-	PUNCT
dpc-1881	52	7	free	free	ADJ
dpc-1881	52	8	survival	survival	NOUN
dpc-1881	52	9	for	for	ADP
dpc-1881	52	10	the	the	DET
dpc-1881	52	11	combi	combi	PROPN
dpc-1881	52	12	-	-	PROPN
dpc-1881	52	13	d	d	PROPN
dpc-1881	52	14	trial	trial	NOUN
dpc-1881	52	15	and	and	CCONJ
dpc-1881	52	16	overall	overall	ADJ
dpc-1881	52	17	survival	survival	NOUN
dpc-1881	52	18	for	for	ADP
dpc-1881	52	19	combi	combi	PROPN
dpc-1881	52	20	-	-	PROPN
dpc-1881	52	21	v.	v.	NOUN
dpc-1881	52	22	in	in	ADP
dpc-1881	52	23	the	the	DET
dpc-1881	52	24	combi	combi	PROPN
dpc-1881	52	25	-	-	PROPN
dpc-1881	52	26	d	d	PROPN
dpc-1881	52	27	study	study	NOUN
dpc-1881	52	28	,	,	PUNCT
dpc-1881	52	29	the	the	DET
dpc-1881	52	30	rr	rr	PROPN
dpc-1881	52	31	was	be	AUX
dpc-1881	52	32	69	69	NUM
dpc-1881	52	33	%	%	NOUN
dpc-1881	52	34	for	for	ADP
dpc-1881	52	35	the	the	DET
dpc-1881	52	36	dabrafenib	dabrafenib	NOUN
dpc-1881	52	37	-	-	PUNCT
dpc-1881	52	38	trametinib	trametinib	NOUN
dpc-1881	52	39	combination	combination	NOUN
dpc-1881	52	40	and	and	CCONJ
dpc-1881	52	41	53	53	NUM
dpc-1881	52	42	%	%	NOUN
dpc-1881	52	43	for	for	ADP
dpc-1881	52	44	dabrafenib	dabrafenib	NOUN
dpc-1881	52	45	alone	alone	ADV
dpc-1881	52	46	(	(	PUNCT
dpc-1881	52	47	p=0.0014	p=0.0014	PROPN
dpc-1881	52	48	)	)	PUNCT
dpc-1881	52	49	.	.	PUNCT
dpc-1881	53	1	the	the	DET
dpc-1881	53	2	median	median	PROPN
dpc-1881	53	3	pfs	pfs	PROPN
dpc-1881	53	4	was	be	AUX
dpc-1881	53	5	11	11	NUM
dpc-1881	53	6	months	month	NOUN
dpc-1881	53	7	for	for	ADP
dpc-1881	53	8	the	the	DET
dpc-1881	53	9	dabrafenib	dabrafenib	NOUN
dpc-1881	53	10	-	-	PUNCT
dpc-1881	53	11	trametinib	trametinib	NOUN
dpc-1881	53	12	combination	combination	NOUN
dpc-1881	53	13	and	and	CCONJ
dpc-1881	53	14	8.8	8.8	NUM
dpc-1881	53	15	months	month	NOUN
dpc-1881	53	16	for	for	ADP
dpc-1881	53	17	dabrafenib	dabrafenib	NOUN
dpc-1881	53	18	monotherapy	monotherapy	NOUN
dpc-1881	53	19	(	(	PUNCT
dpc-1881	53	20	p=0.0004	p=0.0004	PROPN
dpc-1881	53	21	)	)	PUNCT
dpc-1881	53	22	;	;	PUNCT
dpc-1881	53	23	the	the	DET
dpc-1881	53	24	median	median	PROPN
dpc-1881	53	25	os	os	NOUN
dpc-1881	53	26	was	be	AUX
dpc-1881	53	27	25.1	25.1	NUM
dpc-1881	53	28	months	month	NOUN
dpc-1881	53	29	and	and	CCONJ
dpc-1881	53	30	18.7	18.7	NUM
dpc-1881	53	31	months	month	NOUN
dpc-1881	53	32	,	,	PUNCT
dpc-1881	53	33	respectively	respectively	ADV
dpc-1881	53	34	(	(	PUNCT
dpc-1881	53	35	p=0.01	p=0.01	NUM
dpc-1881	53	36	)	)	PUNCT
dpc-1881	54	1	[	[	X
dpc-1881	54	2	6	6	NUM
dpc-1881	54	3	]	]	PUNCT
dpc-1881	54	4	.	.	PUNCT
dpc-1881	55	1	furthermore	furthermore	ADV
dpc-1881	55	2	,	,	PUNCT
dpc-1881	55	3	the	the	DET
dpc-1881	55	4	dabrafenib	dabrafenib	NOUN
dpc-1881	55	5	-	-	PUNCT
dpc-1881	55	6	trametinib	trametinib	NOUN
dpc-1881	55	7	combination	combination	NOUN
dpc-1881	55	8	had	have	VERB
dpc-1881	55	9	a	a	DET
dpc-1881	55	10	better	well	ADJ
dpc-1881	55	11	safety	safety	NOUN
dpc-1881	55	12	profile	profile	NOUN
dpc-1881	55	13	and	and	CCONJ
dpc-1881	55	14	improved	improve	VERB
dpc-1881	55	15	health	health	NOUN
dpc-1881	55	16	-	-	PUNCT
dpc-1881	55	17	related	relate	VERB
dpc-1881	55	18	quality	quality	NOUN
dpc-1881	55	19	of	of	ADP
dpc-1881	55	20	life	life	NOUN
dpc-1881	55	21	as	as	ADV
dpc-1881	55	22	well	well	ADV
dpc-1881	55	23	as	as	ADP
dpc-1881	55	24	reducing	reduce	VERB
dpc-1881	55	25	pain	pain	NOUN
dpc-1881	55	26	[	[	X
dpc-1881	55	27	6	6	NUM
dpc-1881	55	28	,	,	PUNCT
dpc-1881	55	29	7	7	NUM
dpc-1881	55	30	]	]	PUNCT
dpc-1881	55	31	.	.	PUNCT
dpc-1881	56	1	as	as	ADP
dpc-1881	56	2	for	for	ADP
dpc-1881	56	3	the	the	DET
dpc-1881	56	4	combi	combi	PROPN
dpc-1881	56	5	-	-	PUNCT
dpc-1881	56	6	v	v	PROPN
dpc-1881	56	7	,	,	PUNCT
dpc-1881	56	8	the	the	DET
dpc-1881	56	9	objective	objective	ADJ
dpc-1881	56	10	rr	rr	PROPN
dpc-1881	56	11	was	be	AUX
dpc-1881	56	12	64	64	NUM
dpc-1881	56	13	%	%	NOUN
dpc-1881	56	14	in	in	ADP
dpc-1881	56	15	the	the	DET
dpc-1881	56	16	dabrafenib	dabrafenib	NOUN
dpc-1881	56	17	-	-	PUNCT
dpc-1881	56	18	trametinib	trametinib	NOUN
dpc-1881	56	19	combination	combination	NOUN
dpc-1881	56	20	arm	arm	NOUN
dpc-1881	56	21	and	and	CCONJ
dpc-1881	56	22	51	51	NUM
dpc-1881	56	23	%	%	NOUN
dpc-1881	56	24	in	in	ADP
dpc-1881	56	25	the	the	DET
dpc-1881	56	26	vemurafenib	vemurafenib	NOUN
dpc-1881	56	27	arm	arm	NOUN
dpc-1881	56	28	(	(	PUNCT
dpc-1881	56	29	p<0.001	p<0.001	PROPN
dpc-1881	56	30	)	)	PUNCT
dpc-1881	57	1	[	[	X
dpc-1881	57	2	8	8	NUM
dpc-1881	57	3	]	]	PUNCT
dpc-1881	57	4	.	.	PUNCT
dpc-1881	58	1	the	the	DET
dpc-1881	58	2	dabrafenib	dabrafenib	NOUN
dpc-1881	58	3	-	-	PUNCT
dpc-1881	58	4	trametinib	trametinib	NOUN
dpc-1881	58	5	combination	combination	NOUN
dpc-1881	58	6	significantly	significantly	ADV
dpc-1881	58	7	improved	improve	VERB
dpc-1881	58	8	os	os	ADV
dpc-1881	58	9	compared	compare	VERB
dpc-1881	58	10	to	to	PART
dpc-1881	58	11	vemurafenib	vemurafenib	VERB
dpc-1881	58	12	monotherapy	monotherapy	NOUN
dpc-1881	58	13	(	(	PUNCT
dpc-1881	58	14	26.1	26.1	NUM
dpc-1881	58	15	compared	compare	VERB
dpc-1881	58	16	the	the	DET
dpc-1881	58	17	decision	decision	NOUN
dpc-1881	58	18	-	-	PUNCT
dpc-1881	58	19	making	make	VERB
dpc-1881	58	20	factors	factor	NOUN
dpc-1881	58	21	that	that	PRON
dpc-1881	58	22	define	define	VERB
dpc-1881	58	23	the	the	DET
dpc-1881	58	24	best	good	ADJ
dpc-1881	58	25	treatment	treatment	NOUN
dpc-1881	58	26	approach	approach	NOUN
dpc-1881	58	27	in	in	ADP
dpc-1881	58	28	stage	stage	NOUN
dpc-1881	58	29	iv	iv	NUM
dpc-1881	58	30	patients	patient	NOUN
dpc-1881	58	31	with	with	ADP
dpc-1881	58	32	metastatic	metastatic	ADJ
dpc-1881	58	33	melanoma	melanoma	NOUN
dpc-1881	58	34	include	include	VERB
dpc-1881	58	35	the	the	DET
dpc-1881	58	36	mutation	mutation	NOUN
dpc-1881	58	37	pattern	pattern	NOUN
dpc-1881	58	38	,	,	PUNCT
dpc-1881	58	39	performance	performance	NOUN
dpc-1881	58	40	status	status	NOUN
dpc-1881	58	41	,	,	PUNCT
dpc-1881	58	42	high	high	ADJ
dpc-1881	58	43	/	/	SYM
dpc-1881	58	44	low	low	ADJ
dpc-1881	58	45	tumor	tumor	NOUN
dpc-1881	58	46	load	load	NOUN
dpc-1881	58	47	,	,	PUNCT
dpc-1881	58	48	brain	brain	NOUN
dpc-1881	58	49	metastases	metastasis	NOUN
dpc-1881	58	50	,	,	PUNCT
dpc-1881	58	51	progression	progression	NOUN
dpc-1881	58	52	pattern	pattern	NOUN
dpc-1881	58	53	(	(	PUNCT
dpc-1881	58	54	low	low	ADJ
dpc-1881	58	55	/	/	SYM
dpc-1881	58	56	fast	fast	ADJ
dpc-1881	58	57	)	)	PUNCT
dpc-1881	58	58	,	,	PUNCT
dpc-1881	58	59	and	and	CCONJ
dpc-1881	58	60	availability	availability	NOUN
dpc-1881	58	61	of	of	ADP
dpc-1881	58	62	clinical	clinical	ADJ
dpc-1881	58	63	trials	trial	NOUN
dpc-1881	58	64	.	.	PUNCT
dpc-1881	59	1	this	this	DET
dpc-1881	59	2	review	review	NOUN
dpc-1881	59	3	will	will	AUX
dpc-1881	59	4	analyze	analyze	VERB
dpc-1881	59	5	the	the	DET
dpc-1881	59	6	current	current	ADJ
dpc-1881	59	7	therapeutic	therapeutic	ADJ
dpc-1881	59	8	tools	tool	NOUN
dpc-1881	59	9	adopted	adopt	VERB
dpc-1881	59	10	for	for	ADP
dpc-1881	59	11	the	the	DET
dpc-1881	59	12	treatment	treatment	NOUN
dpc-1881	59	13	of	of	ADP
dpc-1881	59	14	metastatic	metastatic	ADJ
dpc-1881	59	15	melanoma	melanoma	NOUN
dpc-1881	59	16	patients	patient	NOUN
dpc-1881	59	17	.	.	PUNCT
dpc-1881	60	1	it	it	PRON
dpc-1881	60	2	will	will	AUX
dpc-1881	60	3	then	then	ADV
dpc-1881	60	4	focus	focus	VERB
dpc-1881	60	5	on	on	ADP
dpc-1881	60	6	the	the	DET
dpc-1881	60	7	latest	late	ADJ
dpc-1881	60	8	results	result	NOUN
dpc-1881	60	9	obtained	obtain	VERB
dpc-1881	60	10	by	by	ADP
dpc-1881	60	11	novel	novel	ADJ
dpc-1881	60	12	treatments	treatment	NOUN
dpc-1881	60	13	(	(	PUNCT
dpc-1881	60	14	checkpoint	checkpoint	NOUN
dpc-1881	60	15	inhibitors	inhibitor	NOUN
dpc-1881	60	16	and	and	CCONJ
dpc-1881	60	17	targeted	target	VERB
dpc-1881	60	18	therapies	therapy	NOUN
dpc-1881	60	19	)	)	PUNCT
dpc-1881	60	20	which	which	PRON
dpc-1881	60	21	can	can	AUX
dpc-1881	60	22	be	be	AUX
dpc-1881	60	23	used	use	VERB
dpc-1881	60	24	in	in	ADP
dpc-1881	60	25	the	the	DET
dpc-1881	60	26	clinical	clinical	ADJ
dpc-1881	60	27	daily	daily	ADJ
dpc-1881	60	28	practice	practice	NOUN
dpc-1881	60	29	.	.	PUNCT
dpc-1881	61	1	review	review	VERB
dpc-1881	61	2	|	|	ADV
dpc-1881	61	3	dermatol	dermatol	ADJ
dpc-1881	61	4	pract	pract	NOUN
dpc-1881	61	5	concept	concept	NOUN
dpc-1881	61	6	.	.	PUNCT
dpc-1881	62	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	62	2	):	):	PUNCT
dpc-1881	62	3	e2021164s	e2021164s	PROPN
dpc-1881	62	4	3	3	NUM
dpc-1881	62	5	to	to	ADP
dpc-1881	62	6	17.8	17.8	NUM
dpc-1881	62	7	months	month	NOUN
dpc-1881	62	8	)	)	PUNCT
dpc-1881	62	9	.	.	PUNCT
dpc-1881	63	1	median	median	PROPN
dpc-1881	63	2	pfs	pfs	PROPN
dpc-1881	63	3	in	in	ADP
dpc-1881	63	4	dabrafenib	dabrafenib	NOUN
dpc-1881	63	5	–	–	PUNCT
dpc-1881	63	6	trametinib	trametinib	NOUN
dpc-1881	63	7	arm	arm	NOUN
dpc-1881	63	8	was	be	AUX
dpc-1881	63	9	12.1	12.1	NUM
dpc-1881	63	10	months	month	NOUN
dpc-1881	63	11	and	and	CCONJ
dpc-1881	63	12	7.3	7.3	NUM
dpc-1881	63	13	months	month	NOUN
dpc-1881	63	14	in	in	ADP
dpc-1881	63	15	the	the	DET
dpc-1881	63	16	vemurafenib	vemurafenib	NOUN
dpc-1881	63	17	arm	arm	VERB
dpc-1881	64	1	[	[	X
dpc-1881	64	2	8	8	NUM
dpc-1881	64	3	]	]	PUNCT
dpc-1881	64	4	.	.	PUNCT
dpc-1881	65	1	in	in	ADP
dpc-1881	65	2	agreement	agreement	NOUN
dpc-1881	65	3	with	with	ADP
dpc-1881	65	4	combi	combi	PROPN
dpc-1881	65	5	-	-	PUNCT
dpc-1881	65	6	d	d	PROPN
dpc-1881	65	7	,	,	PUNCT
dpc-1881	65	8	the	the	DET
dpc-1881	65	9	side	side	NOUN
dpc-1881	65	10	effects	effect	NOUN
dpc-1881	65	11	’	'	PUNCT
dpc-1881	65	12	analysis	analysis	NOUN
dpc-1881	65	13	and	and	CCONJ
dpc-1881	65	14	quality	quality	NOUN
dpc-1881	65	15	of	of	ADP
dpc-1881	65	16	life	life	NOUN
dpc-1881	65	17	in	in	ADP
dpc-1881	65	18	the	the	DET
dpc-1881	65	19	combi	combi	PROPN
dpc-1881	65	20	-	-	PUNCT
dpc-1881	65	21	v	v	PROPN
dpc-1881	65	22	trial	trial	NOUN
dpc-1881	65	23	favored	favor	VERB
dpc-1881	65	24	the	the	DET
dpc-1881	65	25	combination	combination	NOUN
dpc-1881	65	26	over	over	ADP
dpc-1881	65	27	the	the	DET
dpc-1881	65	28	monotherapy	monotherapy	NOUN
dpc-1881	65	29	[	[	X
dpc-1881	65	30	8,9	8,9	NUM
dpc-1881	65	31	]	]	PUNCT
dpc-1881	65	32	.	.	PUNCT
dpc-1881	66	1	the	the	DET
dpc-1881	66	2	results	result	NOUN
dpc-1881	66	3	of	of	ADP
dpc-1881	66	4	the	the	DET
dpc-1881	66	5	pooled	pooled	ADJ
dpc-1881	66	6	analysis	analysis	NOUN
dpc-1881	66	7	of	of	ADP
dpc-1881	66	8	the	the	DET
dpc-1881	66	9	2	2	NUM
dpc-1881	66	10	trials	trial	NOUN
dpc-1881	66	11	were	be	AUX
dpc-1881	66	12	evaluated	evaluate	VERB
dpc-1881	66	13	after	after	ADP
dpc-1881	66	14	a	a	DET
dpc-1881	66	15	22	22	NUM
dpc-1881	66	16	month	month	NOUN
dpc-1881	66	17	-	-	PUNCT
dpc-1881	66	18	follow	follow	VERB
dpc-1881	66	19	-	-	PUNCT
dpc-1881	66	20	up	up	NOUN
dpc-1881	66	21	period	period	NOUN
dpc-1881	66	22	,	,	PUNCT
dpc-1881	66	23	on	on	ADP
dpc-1881	66	24	563	563	NUM
dpc-1881	66	25	patients	patient	NOUN
dpc-1881	66	26	in	in	ADP
dpc-1881	66	27	total	total	NOUN
dpc-1881	66	28	,	,	PUNCT
dpc-1881	66	29	with	with	ADP
dpc-1881	66	30	5	5	NUM
dpc-1881	66	31	-	-	PUNCT
dpc-1881	66	32	year	year	NOUN
dpc-1881	66	33	pfs	pfs	NOUN
dpc-1881	66	34	of	of	ADP
dpc-1881	66	35	19	19	NUM
dpc-1881	66	36	%	%	NOUN
dpc-1881	66	37	and	and	CCONJ
dpc-1881	66	38	5	5	NUM
dpc-1881	66	39	-	-	PUNCT
dpc-1881	66	40	year	year	NOUN
dpc-1881	66	41	os	os	NOUN
dpc-1881	66	42	of	of	ADP
dpc-1881	66	43	34	34	NUM
dpc-1881	66	44	%	%	NOUN
dpc-1881	66	45	.	.	PUNCT
dpc-1881	67	1	complete	complete	ADJ
dpc-1881	67	2	responses	response	NOUN
dpc-1881	67	3	occurred	occur	VERB
dpc-1881	67	4	in	in	ADP
dpc-1881	67	5	19	19	NUM
dpc-1881	67	6	%	%	NOUN
dpc-1881	67	7	of	of	ADP
dpc-1881	67	8	patients	patient	NOUN
dpc-1881	67	9	and	and	CCONJ
dpc-1881	67	10	were	be	AUX
dpc-1881	67	11	associated	associate	VERB
dpc-1881	67	12	with	with	ADP
dpc-1881	67	13	an	an	DET
dpc-1881	67	14	improved	improve	VERB
dpc-1881	67	15	long	long	ADJ
dpc-1881	67	16	-	-	PUNCT
dpc-1881	67	17	term	term	NOUN
dpc-1881	67	18	outcome	outcome	NOUN
dpc-1881	67	19	,	,	PUNCT
dpc-1881	67	20	with	with	ADP
dpc-1881	67	21	an	an	DET
dpc-1881	67	22	os	os	NOUN
dpc-1881	67	23	rate	rate	NOUN
dpc-1881	67	24	of	of	ADP
dpc-1881	67	25	71	71	NUM
dpc-1881	67	26	%	%	NOUN
dpc-1881	67	27	at	at	ADP
dpc-1881	67	28	5	5	NUM
dpc-1881	67	29	years	year	NOUN
dpc-1881	67	30	.	.	PUNCT
dpc-1881	68	1	in	in	ADP
dpc-1881	68	2	multivariate	multivariate	NOUN
dpc-1881	68	3	analysis	analysis	NOUN
dpc-1881	68	4	,	,	PUNCT
dpc-1881	68	5	several	several	ADJ
dpc-1881	68	6	baseline	baseline	ADJ
dpc-1881	68	7	factors	factor	NOUN
dpc-1881	68	8	(	(	PUNCT
dpc-1881	68	9	eg	eg	NOUN
dpc-1881	68	10	performance	performance	NOUN
dpc-1881	68	11	status	status	NOUN
dpc-1881	68	12	,	,	PUNCT
dpc-1881	68	13	age	age	NOUN
dpc-1881	68	14	,	,	PUNCT
dpc-1881	68	15	sex	sex	NOUN
dpc-1881	68	16	,	,	PUNCT
dpc-1881	68	17	number	number	NOUN
dpc-1881	68	18	of	of	ADP
dpc-1881	68	19	organ	organ	NOUN
dpc-1881	68	20	sites	site	NOUN
dpc-1881	68	21	with	with	ADP
dpc-1881	68	22	metastasis	metastasis	NOUN
dpc-1881	68	23	,	,	PUNCT
dpc-1881	68	24	and	and	CCONJ
dpc-1881	68	25	lactate	lactate	NOUN
dpc-1881	68	26	dehydrogenase	dehydrogenase	NOUN
dpc-1881	68	27	levels	level	NOUN
dpc-1881	68	28	)	)	PUNCT
dpc-1881	68	29	were	be	AUX
dpc-1881	68	30	significantly	significantly	ADV
dpc-1881	68	31	associated	associate	VERB
dpc-1881	68	32	with	with	ADP
dpc-1881	68	33	both	both	DET
dpc-1881	68	34	progression	progression	NOUN
dpc-1881	68	35	-	-	PUNCT
dpc-1881	68	36	free	free	ADJ
dpc-1881	68	37	survival	survival	NOUN
dpc-1881	68	38	(	(	PUNCT
dpc-1881	68	39	pfs	pfs	PROPN
dpc-1881	68	40	)	)	PUNCT
dpc-1881	68	41	and	and	CCONJ
dpc-1881	68	42	os	os	X
dpc-1881	69	1	[	[	X
dpc-1881	69	2	10	10	NUM
dpc-1881	69	3	]	]	PUNCT
dpc-1881	69	4	.	.	PUNCT
dpc-1881	70	1	in	in	ADP
dpc-1881	70	2	particular	particular	ADJ
dpc-1881	70	3	,	,	PUNCT
dpc-1881	70	4	in	in	ADP
dpc-1881	70	5	a	a	DET
dpc-1881	70	6	3	3	NUM
dpc-1881	70	7	-	-	PUNCT
dpc-1881	70	8	year	year	NOUN
dpc-1881	70	9	landmark	landmark	NOUN
dpc-1881	70	10	pooled	pool	VERB
dpc-1881	70	11	analysis	analysis	NOUN
dpc-1881	70	12	,	,	PUNCT
dpc-1881	70	13	baseline	baseline	ADJ
dpc-1881	70	14	ldh	ldh	NOUN
dpc-1881	70	15	level	level	NOUN
dpc-1881	70	16	and	and	CCONJ
dpc-1881	70	17	number	number	NOUN
dpc-1881	70	18	of	of	ADP
dpc-1881	70	19	organ	organ	NOUN
dpc-1881	70	20	sites	site	NOUN
dpc-1881	70	21	were	be	AUX
dpc-1881	70	22	confirmed	confirm	VERB
dpc-1881	70	23	to	to	PART
dpc-1881	70	24	be	be	AUX
dpc-1881	70	25	significantly	significantly	ADV
dpc-1881	70	26	associated	associate	VERB
dpc-1881	70	27	with	with	ADP
dpc-1881	70	28	pfs	pfs	PROPN
dpc-1881	70	29	and	and	CCONJ
dpc-1881	70	30	os	os	NOUN
dpc-1881	70	31	.	.	PUNCT
dpc-1881	71	1	in	in	ADP
dpc-1881	71	2	addition	addition	NOUN
dpc-1881	71	3	,	,	PUNCT
dpc-1881	71	4	baseline	baseline	ADJ
dpc-1881	71	5	sum	sum	NOUN
dpc-1881	71	6	of	of	ADP
dpc-1881	71	7	lesion	lesion	NOUN
dpc-1881	71	8	diameters	diameter	NOUN
dpc-1881	71	9	(	(	PUNCT
dpc-1881	71	10	sld	sld	NOUN
dpc-1881	71	11	)	)	PUNCT
dpc-1881	71	12	was	be	AUX
dpc-1881	71	13	identified	identify	VERB
dpc-1881	71	14	as	as	ADP
dpc-1881	71	15	a	a	DET
dpc-1881	71	16	predictor	predictor	NOUN
dpc-1881	71	17	for	for	ADP
dpc-1881	71	18	progression	progression	NOUN
dpc-1881	71	19	.	.	PUNCT
dpc-1881	72	1	in	in	ADP
dpc-1881	72	2	the	the	DET
dpc-1881	72	3	most	most	ADV
dpc-1881	72	4	favorable	favorable	ADJ
dpc-1881	72	5	prognostic	prognostic	ADJ
dpc-1881	72	6	group	group	NOUN
dpc-1881	72	7	(	(	PUNCT
dpc-1881	72	8	normal	normal	ADJ
dpc-1881	72	9	ldh	ldh	PROPN
dpc-1881	72	10	,	,	PUNCT
dpc-1881	72	11	sld	sld	PROPN
dpc-1881	72	12	<	<	PROPN
dpc-1881	72	13	66	66	NUM
dpc-1881	72	14	mm	mm	NOUN
dpc-1881	72	15	,	,	PUNCT
dpc-1881	72	16	<3	<3	ADJ
dpc-1881	72	17	organ	organ	NOUN
dpc-1881	72	18	sites	site	NOUN
dpc-1881	72	19	)	)	PUNCT
dpc-1881	72	20	,	,	PUNCT
dpc-1881	72	21	3	3	NUM
dpc-1881	72	22	-	-	PUNCT
dpc-1881	72	23	year	year	NOUN
dpc-1881	72	24	pfs	pfs	PROPN
dpc-1881	72	25	was	be	AUX
dpc-1881	72	26	42	42	NUM
dpc-1881	72	27	%	%	NOUN
dpc-1881	72	28	[	[	X
dpc-1881	72	29	11	11	NUM
dpc-1881	72	30	]	]	PUNCT
dpc-1881	72	31	.	.	PUNCT
dpc-1881	73	1	despite	despite	SCONJ
dpc-1881	73	2	significant	significant	ADJ
dpc-1881	73	3	improvements	improvement	NOUN
dpc-1881	73	4	with	with	ADP
dpc-1881	73	5	the	the	DET
dpc-1881	73	6	combination	combination	NOUN
dpc-1881	73	7	therapy	therapy	NOUN
dpc-1881	73	8	,	,	PUNCT
dpc-1881	73	9	braf	braf	PROPN
dpc-1881	73	10	/	/	SYM
dpc-1881	73	11	mek	mek	PROPN
dpc-1881	73	12	inhibition	inhibition	NOUN
dpc-1881	73	13	is	be	AUX
dpc-1881	73	14	still	still	ADV
dpc-1881	73	15	frequently	frequently	ADV
dpc-1881	73	16	complicated	complicate	VERB
dpc-1881	73	17	by	by	ADP
dpc-1881	73	18	acquired	acquire	VERB
dpc-1881	73	19	resistance	resistance	NOUN
dpc-1881	73	20	,	,	PUNCT
dpc-1881	73	21	most	most	ADV
dpc-1881	73	22	often	often	ADV
dpc-1881	73	23	via	via	ADP
dpc-1881	73	24	upregulation	upregulation	NOUN
dpc-1881	73	25	of	of	ADP
dpc-1881	73	26	mapk	mapk	NOUN
dpc-1881	73	27	signaling	signal	VERB
dpc-1881	73	28	.	.	PUNCT
dpc-1881	74	1	in	in	ADP
dpc-1881	74	2	the	the	DET
dpc-1881	74	3	clinical	clinical	ADJ
dpc-1881	74	4	management	management	NOUN
dpc-1881	74	5	,	,	PUNCT
dpc-1881	74	6	one	one	NUM
dpc-1881	74	7	possible	possible	ADJ
dpc-1881	74	8	therapeutic	therapeutic	ADJ
dpc-1881	74	9	strategy	strategy	NOUN
dpc-1881	74	10	is	be	AUX
dpc-1881	74	11	represented	represent	VERB
dpc-1881	74	12	by	by	ADP
dpc-1881	74	13	the	the	DET
dpc-1881	74	14	treatment	treatment	NOUN
dpc-1881	74	15	beyond	beyond	ADP
dpc-1881	74	16	progression	progression	NOUN
dpc-1881	74	17	.	.	PUNCT
dpc-1881	75	1	this	this	PRON
dpc-1881	75	2	is	be	AUX
dpc-1881	75	3	defined	define	VERB
dpc-1881	75	4	as	as	ADP
dpc-1881	75	5	the	the	DET
dpc-1881	75	6	continuation	continuation	NOUN
dpc-1881	75	7	of	of	ADP
dpc-1881	75	8	targeted	target	VERB
dpc-1881	75	9	therapy	therapy	NOUN
dpc-1881	75	10	in	in	ADP
dpc-1881	75	11	responding	respond	VERB
dpc-1881	75	12	patients	patient	NOUN
dpc-1881	75	13	who	who	PRON
dpc-1881	75	14	showed	show	VERB
dpc-1881	75	15	an	an	DET
dpc-1881	75	16	isolated	isolated	ADJ
dpc-1881	75	17	disease	disease	NOUN
dpc-1881	75	18	progression	progression	NOUN
dpc-1881	75	19	that	that	PRON
dpc-1881	75	20	can	can	AUX
dpc-1881	75	21	be	be	AUX
dpc-1881	75	22	treated	treat	VERB
dpc-1881	75	23	by	by	ADP
dpc-1881	75	24	a	a	DET
dpc-1881	75	25	loco	loco	PROPN
dpc-1881	75	26	-	-	PUNCT
dpc-1881	75	27	regional	regional	ADJ
dpc-1881	75	28	approach	approach	NOUN
dpc-1881	75	29	.	.	PUNCT
dpc-1881	76	1	retrospective	retrospective	ADJ
dpc-1881	76	2	data	datum	NOUN
dpc-1881	76	3	suggest	suggest	VERB
dpc-1881	76	4	that	that	SCONJ
dpc-1881	76	5	treatment	treatment	NOUN
dpc-1881	76	6	with	with	ADP
dpc-1881	76	7	braf	braf	NOUN
dpc-1881	76	8	inhibitors	inhibitor	NOUN
dpc-1881	76	9	beyond	beyond	ADP
dpc-1881	76	10	progression	progression	NOUN
dpc-1881	76	11	is	be	AUX
dpc-1881	76	12	associated	associate	VERB
dpc-1881	76	13	with	with	ADP
dpc-1881	76	14	improved	improved	ADJ
dpc-1881	76	15	survival	survival	NOUN
dpc-1881	76	16	,	,	PUNCT
dpc-1881	76	17	even	even	ADV
dpc-1881	76	18	if	if	SCONJ
dpc-1881	76	19	prospective	prospective	ADJ
dpc-1881	76	20	data	datum	NOUN
dpc-1881	76	21	are	be	AUX
dpc-1881	76	22	still	still	ADV
dpc-1881	76	23	needed	need	VERB
dpc-1881	76	24	[	[	X
dpc-1881	76	25	12,13	12,13	NUM
dpc-1881	76	26	]	]	PUNCT
dpc-1881	76	27	.	.	PUNCT
dpc-1881	77	1	besides	besides	SCONJ
dpc-1881	77	2	clinical	clinical	ADJ
dpc-1881	77	3	trials	trial	NOUN
dpc-1881	77	4	,	,	PUNCT
dpc-1881	77	5	compassionate	compassionate	ADJ
dpc-1881	77	6	-	-	PUNCT
dpc-1881	77	7	use	use	NOUN
dpc-1881	77	8	programs	program	NOUN
dpc-1881	77	9	provided	provide	VERB
dpc-1881	77	10	a	a	DET
dpc-1881	77	11	relevant	relevant	ADJ
dpc-1881	77	12	opportunity	opportunity	NOUN
dpc-1881	77	13	to	to	PART
dpc-1881	77	14	retrospectively	retrospectively	ADV
dpc-1881	77	15	evaluate	evaluate	VERB
dpc-1881	77	16	the	the	DET
dpc-1881	77	17	treatment	treatment	NOUN
dpc-1881	77	18	patterns	pattern	NOUN
dpc-1881	77	19	and	and	CCONJ
dpc-1881	77	20	clinical	clinical	ADJ
dpc-1881	77	21	outcomes	outcome	NOUN
dpc-1881	77	22	in	in	ADP
dpc-1881	77	23	a	a	DET
dpc-1881	77	24	real	real	ADJ
dpc-1881	77	25	-	-	PUNCT
dpc-1881	77	26	world	world	NOUN
dpc-1881	77	27	setting	setting	NOUN
dpc-1881	77	28	and	and	CCONJ
dpc-1881	77	29	to	to	PART
dpc-1881	77	30	validate	validate	VERB
dpc-1881	77	31	the	the	DET
dpc-1881	77	32	results	result	NOUN
dpc-1881	77	33	derived	derive	VERB
dpc-1881	77	34	from	from	ADP
dpc-1881	77	35	controlled	control	VERB
dpc-1881	77	36	randomized	randomize	VERB
dpc-1881	77	37	clinical	clinical	ADJ
dpc-1881	77	38	trials	trial	NOUN
dpc-1881	77	39	.	.	PUNCT
dpc-1881	78	1	in	in	ADP
dpc-1881	78	2	particular	particular	ADJ
dpc-1881	78	3	,	,	PUNCT
dpc-1881	78	4	describe	describe	VERB
dpc-1881	78	5	iii	iii	NUM
dpc-1881	78	6	was	be	AUX
dpc-1881	78	7	a	a	DET
dpc-1881	78	8	large	large	ADJ
dpc-1881	78	9	international	international	ADJ
dpc-1881	78	10	multicenter	multicenter	NOUN
dpc-1881	78	11	study	study	NOUN
dpc-1881	78	12	,	,	PUNCT
dpc-1881	78	13	which	which	PRON
dpc-1881	78	14	enrolled	enrol	VERB
dpc-1881	78	15	509	509	NUM
dpc-1881	78	16	patients	patient	NOUN
dpc-1881	78	17	.	.	PUNCT
dpc-1881	79	1	patients	patient	NOUN
dpc-1881	79	2	were	be	AUX
dpc-1881	79	3	categorized	categorize	VERB
dpc-1881	79	4	into	into	ADP
dpc-1881	79	5	3	3	NUM
dpc-1881	79	6	groups	group	NOUN
dpc-1881	79	7	based	base	VERB
dpc-1881	79	8	on	on	ADP
dpc-1881	79	9	their	their	PRON
dpc-1881	79	10	observed	observe	VERB
dpc-1881	79	11	treatment	treatment	NOUN
dpc-1881	79	12	duration	duration	NOUN
dpc-1881	79	13	:	:	PUNCT
dpc-1881	79	14	long	long	ADJ
dpc-1881	79	15	-	-	PUNCT
dpc-1881	79	16	term	term	NOUN
dpc-1881	79	17	(	(	PUNCT
dpc-1881	79	18	on	on	ADP
dpc-1881	79	19	therapy	therapy	NOUN
dpc-1881	79	20	≥12	≥12	ADP
dpc-1881	79	21	months	month	NOUN
dpc-1881	79	22	)	)	PUNCT
dpc-1881	79	23	,	,	PUNCT
dpc-1881	79	24	intermediate	intermediate	ADJ
dpc-1881	79	25	(	(	PUNCT
dpc-1881	79	26	on	on	ADP
dpc-1881	79	27	therapy	therapy	NOUN
dpc-1881	79	28	≥6	≥6	NUM
dpc-1881	79	29	months	month	NOUN
dpc-1881	79	30	and	and	CCONJ
dpc-1881	79	31	<	<	X
dpc-1881	79	32	12	12	NUM
dpc-1881	79	33	months	month	NOUN
dpc-1881	79	34	)	)	PUNCT
dpc-1881	79	35	,	,	PUNCT
dpc-1881	79	36	and	and	CCONJ
dpc-1881	79	37	short	short	ADJ
dpc-1881	79	38	-	-	PUNCT
dpc-1881	79	39	term	term	NOUN
dpc-1881	79	40	(	(	PUNCT
dpc-1881	79	41	on	on	ADP
dpc-1881	79	42	therapy	therapy	NOUN
dpc-1881	79	43	<	<	X
dpc-1881	79	44	6	6	NUM
dpc-1881	79	45	months	month	NOUN
dpc-1881	79	46	)	)	PUNCT
dpc-1881	79	47	duration	duration	NOUN
dpc-1881	79	48	of	of	ADP
dpc-1881	79	49	benefit	benefit	NOUN
dpc-1881	79	50	.	.	PUNCT
dpc-1881	80	1	in	in	ADP
dpc-1881	80	2	agreement	agreement	NOUN
dpc-1881	80	3	with	with	ADP
dpc-1881	80	4	the	the	DET
dpc-1881	80	5	results	result	NOUN
dpc-1881	80	6	of	of	ADP
dpc-1881	80	7	the	the	DET
dpc-1881	80	8	pooled	pooled	ADJ
dpc-1881	80	9	analysis	analysis	NOUN
dpc-1881	80	10	of	of	ADP
dpc-1881	80	11	combi	combi	PROPN
dpc-1881	80	12	-	-	PUNCT
dpc-1881	80	13	d	d	PROPN
dpc-1881	80	14	and	and	CCONJ
dpc-1881	80	15	combi	combi	PROPN
dpc-1881	80	16	-	-	PUNCT
dpc-1881	80	17	v	v	PROPN
dpc-1881	80	18	,	,	PUNCT
dpc-1881	80	19	normal	normal	ADJ
dpc-1881	80	20	ldh	ldh	NOUN
dpc-1881	80	21	level	level	NOUN
dpc-1881	80	22	and	and	CCONJ
dpc-1881	80	23	<3	<3	PRON
dpc-1881	80	24	metastatic	metastatic	ADJ
dpc-1881	80	25	sites	site	NOUN
dpc-1881	80	26	at	at	ADP
dpc-1881	80	27	baseline	baseline	NOUN
dpc-1881	80	28	,	,	PUNCT
dpc-1881	80	29	were	be	AUX
dpc-1881	80	30	associated	associate	VERB
dpc-1881	80	31	with	with	ADP
dpc-1881	80	32	a	a	DET
dpc-1881	80	33	longer	long	ADJ
dpc-1881	80	34	duration	duration	NOUN
dpc-1881	80	35	of	of	ADP
dpc-1881	80	36	treatment	treatment	NOUN
dpc-1881	80	37	benefit	benefit	NOUN
dpc-1881	80	38	in	in	ADP
dpc-1881	80	39	a	a	DET
dpc-1881	80	40	real	real	ADJ
dpc-1881	80	41	-	-	PUNCT
dpc-1881	80	42	world	world	NOUN
dpc-1881	80	43	setting	setting	NOUN
dpc-1881	80	44	[	[	X
dpc-1881	80	45	14	14	NUM
dpc-1881	80	46	]	]	PUNCT
dpc-1881	80	47	.	.	PUNCT
dpc-1881	81	1	also	also	ADV
dpc-1881	81	2	,	,	PUNCT
dpc-1881	81	3	the	the	DET
dpc-1881	81	4	combination	combination	NOUN
dpc-1881	81	5	of	of	ADP
dpc-1881	81	6	vemurafenib	vemurafenib	NOUN
dpc-1881	81	7	and	and	CCONJ
dpc-1881	81	8	cobimetinib	cobimetinib	PROPN
dpc-1881	81	9	had	have	VERB
dpc-1881	81	10	a	a	DET
dpc-1881	81	11	better	well	ADJ
dpc-1881	81	12	outcome	outcome	NOUN
dpc-1881	81	13	than	than	ADP
dpc-1881	81	14	vemurafenib	vemurafenib	NOUN
dpc-1881	81	15	alone	alone	ADV
dpc-1881	81	16	in	in	ADP
dpc-1881	81	17	a	a	DET
dpc-1881	81	18	phase	phase	NOUN
dpc-1881	81	19	3	3	NUM
dpc-1881	81	20	randomized	randomize	VERB
dpc-1881	81	21	clinical	clinical	ADJ
dpc-1881	81	22	trial	trial	NOUN
dpc-1881	81	23	performed	perform	VERB
dpc-1881	81	24	on	on	ADP
dpc-1881	81	25	495	495	NUM
dpc-1881	81	26	patients	patient	NOUN
dpc-1881	81	27	with	with	ADP
dpc-1881	81	28	previously	previously	ADV
dpc-1881	81	29	untreated	untreated	ADJ
dpc-1881	81	30	,	,	PUNCT
dpc-1881	81	31	unresectable	unresectable	ADJ
dpc-1881	81	32	,	,	PUNCT
dpc-1881	81	33	locally	locally	ADV
dpc-1881	81	34	advanced	advanced	ADJ
dpc-1881	81	35	,	,	PUNCT
dpc-1881	81	36	or	or	CCONJ
dpc-1881	81	37	metastatic	metastatic	ADJ
dpc-1881	81	38	braf	braf	NOUN
dpc-1881	81	39	v600	v600	PROPN
dpc-1881	81	40	mutation	mutation	NOUN
dpc-1881	81	41	-	-	PUNCT
dpc-1881	81	42	positive	positive	ADJ
dpc-1881	81	43	melanoma	melanoma	NOUN
dpc-1881	81	44	(	(	PUNCT
dpc-1881	81	45	cobrim	cobrim	PROPN
dpc-1881	81	46	)	)	PUNCT
dpc-1881	81	47	.	.	PUNCT
dpc-1881	82	1	the	the	DET
dpc-1881	82	2	combination	combination	NOUN
dpc-1881	82	3	showed	show	VERB
dpc-1881	82	4	a	a	DET
dpc-1881	82	5	significantly	significantly	ADV
dpc-1881	82	6	higher	high	ADJ
dpc-1881	82	7	clinical	clinical	ADJ
dpc-1881	82	8	activity	activity	NOUN
dpc-1881	82	9	in	in	ADP
dpc-1881	82	10	terms	term	NOUN
dpc-1881	82	11	of	of	ADP
dpc-1881	82	12	rr	rr	PROPN
dpc-1881	82	13	(	(	PUNCT
dpc-1881	82	14	68	68	NUM
dpc-1881	82	15	%	%	NOUN
dpc-1881	82	16	vs	vs	ADP
dpc-1881	82	17	45	45	NUM
dpc-1881	82	18	%	%	NOUN
dpc-1881	82	19	)	)	PUNCT
dpc-1881	82	20	,	,	PUNCT
dpc-1881	82	21	pfs	pfs	PROPN
dpc-1881	82	22	(	(	PUNCT
dpc-1881	82	23	median	median	NOUN
dpc-1881	82	24	:	:	PUNCT
dpc-1881	82	25	9.9	9.9	NUM
dpc-1881	82	26	vs	vs	ADP
dpc-1881	82	27	6.2	6.2	NUM
dpc-1881	82	28	months	month	NOUN
dpc-1881	82	29	)	)	PUNCT
dpc-1881	82	30	,	,	PUNCT
dpc-1881	82	31	and	and	CCONJ
dpc-1881	82	32	survival	survival	NOUN
dpc-1881	82	33	(	(	PUNCT
dpc-1881	82	34	9	9	NUM
dpc-1881	82	35	months	month	NOUN
dpc-1881	82	36	os	os	ADV
dpc-1881	82	37	81	81	NUM
dpc-1881	82	38	%	%	NOUN
dpc-1881	82	39	vs	vs	ADP
dpc-1881	82	40	73	73	NUM
dpc-1881	82	41	%	%	NOUN
dpc-1881	82	42	)	)	PUNCT
dpc-1881	83	1	[	[	X
dpc-1881	83	2	15	15	NUM
dpc-1881	83	3	]	]	PUNCT
dpc-1881	83	4	.	.	PUNCT
dpc-1881	84	1	at	at	ADP
dpc-1881	84	2	a	a	DET
dpc-1881	84	3	median	median	ADJ
dpc-1881	84	4	14.2	14.2	NUM
dpc-1881	84	5	-	-	PUNCT
dpc-1881	84	6	month	month	NOUN
dpc-1881	84	7	follow	follow	NOUN
dpc-1881	84	8	-	-	PUNCT
dpc-1881	84	9	up	up	NOUN
dpc-1881	84	10	,	,	PUNCT
dpc-1881	84	11	the	the	DET
dpc-1881	84	12	median	median	ADJ
dpc-1881	84	13	pfs	pfs	PROPN
dpc-1881	84	14	was	be	AUX
dpc-1881	84	15	12.3	12.3	NUM
dpc-1881	84	16	months	month	NOUN
dpc-1881	84	17	for	for	ADP
dpc-1881	84	18	the	the	DET
dpc-1881	84	19	combination	combination	NOUN
dpc-1881	84	20	versus	versus	ADP
dpc-1881	84	21	7.2	7.2	NUM
dpc-1881	84	22	months	month	NOUN
dpc-1881	84	23	for	for	ADP
dpc-1881	84	24	placebo	placebo	NOUN
dpc-1881	84	25	and	and	CCONJ
dpc-1881	84	26	vemurafenib	vemurafenib	PROPN
dpc-1881	84	27	(	(	PUNCT
dpc-1881	84	28	p<0.0001	p<0.0001	NOUN
dpc-1881	84	29	)	)	PUNCT
dpc-1881	84	30	.	.	PUNCT
dpc-1881	85	1	median	median	PROPN
dpc-1881	85	2	os	os	PROPN
dpc-1881	85	3	was	be	AUX
dpc-1881	85	4	22.3	22.3	NUM
dpc-1881	85	5	months	month	NOUN
dpc-1881	85	6	for	for	ADP
dpc-1881	85	7	cobimetinib	cobimetinib	NOUN
dpc-1881	85	8	and	and	CCONJ
dpc-1881	85	9	vemurafenib	vemurafenib	NOUN
dpc-1881	85	10	versus	versus	ADP
dpc-1881	85	11	17.4	17.4	NUM
dpc-1881	85	12	months	month	NOUN
dpc-1881	85	13	(	(	PUNCT
dpc-1881	85	14	for	for	ADP
dpc-1881	85	15	placebo	placebo	NOUN
dpc-1881	85	16	and	and	CCONJ
dpc-1881	85	17	vemurafenib	vemurafenib	NOUN
dpc-1881	85	18	;	;	PUNCT
dpc-1881	85	19	p=0.005	p=0.005	X
dpc-1881	85	20	)	)	PUNCT
dpc-1881	85	21	.	.	PUNCT
dpc-1881	86	1	the	the	DET
dpc-1881	86	2	safety	safety	NOUN
dpc-1881	86	3	profile	profile	NOUN
dpc-1881	86	4	for	for	ADP
dpc-1881	86	5	cobimetinib	cobimetinib	NOUN
dpc-1881	86	6	and	and	CCONJ
dpc-1881	86	7	vemurafenib	vemurafenib	PROPN
dpc-1881	86	8	was	be	AUX
dpc-1881	86	9	tolerable	tolerable	ADJ
dpc-1881	86	10	and	and	CCONJ
dpc-1881	86	11	manageable	manageable	ADJ
dpc-1881	86	12	,	,	PUNCT
dpc-1881	86	13	and	and	CCONJ
dpc-1881	86	14	no	no	DET
dpc-1881	86	15	new	new	ADJ
dpc-1881	86	16	safety	safety	NOUN
dpc-1881	86	17	signals	signal	NOUN
dpc-1881	86	18	were	be	AUX
dpc-1881	86	19	observed	observe	VERB
dpc-1881	86	20	with	with	ADP
dpc-1881	86	21	longer	long	ADJ
dpc-1881	86	22	follow	follow	NOUN
dpc-1881	86	23	-	-	PUNCT
dpc-1881	86	24	ups	up	NOUN
dpc-1881	86	25	[	[	X
dpc-1881	86	26	16	16	NUM
dpc-1881	86	27	]	]	PUNCT
dpc-1881	86	28	.	.	PUNCT
dpc-1881	87	1	the	the	DET
dpc-1881	87	2	clinical	clinical	ADJ
dpc-1881	87	3	activity	activity	NOUN
dpc-1881	87	4	of	of	ADP
dpc-1881	87	5	a	a	DET
dpc-1881	87	6	third	third	ADJ
dpc-1881	87	7	combination	combination	NOUN
dpc-1881	87	8	schedule	schedule	NOUN
dpc-1881	87	9	of	of	ADP
dpc-1881	87	10	anti	anti	ADJ
dpc-1881	87	11	-	-	ADJ
dpc-1881	87	12	braf	braf	ADJ
dpc-1881	87	13	/	/	SYM
dpc-1881	87	14	anti	anti	NOUN
dpc-1881	87	15	-	-	NOUN
dpc-1881	87	16	mek	mek	PROPN
dpc-1881	87	17	was	be	AUX
dpc-1881	87	18	investigated	investigate	VERB
dpc-1881	87	19	in	in	ADP
dpc-1881	87	20	the	the	DET
dpc-1881	87	21	clinical	clinical	ADJ
dpc-1881	87	22	trial	trial	NOUN
dpc-1881	87	23	columbus	columbus	PROPN
dpc-1881	87	24	.	.	PUNCT
dpc-1881	88	1	columbus	columbus	PROPN
dpc-1881	88	2	was	be	AUX
dpc-1881	88	3	a	a	DET
dpc-1881	88	4	2	2	NUM
dpc-1881	88	5	-	-	PUNCT
dpc-1881	88	6	part	part	NOUN
dpc-1881	88	7	,	,	PUNCT
dpc-1881	88	8	randomised	randomise	VERB
dpc-1881	88	9	,	,	PUNCT
dpc-1881	88	10	open	open	ADJ
dpc-1881	88	11	-	-	PUNCT
dpc-1881	88	12	label	label	NOUN
dpc-1881	88	13	,	,	PUNCT
dpc-1881	88	14	phase	phase	NOUN
dpc-1881	88	15	iii	iii	NUM
dpc-1881	88	16	study	study	NOUN
dpc-1881	88	17	.	.	PUNCT
dpc-1881	89	1	during	during	ADP
dpc-1881	89	2	part	part	NOUN
dpc-1881	89	3	1	1	NUM
dpc-1881	89	4	,	,	PUNCT
dpc-1881	89	5	patients	patient	NOUN
dpc-1881	89	6	were	be	AUX
dpc-1881	89	7	randomly	randomly	ADV
dpc-1881	89	8	assigned	assign	VERB
dpc-1881	89	9	(	(	PUNCT
dpc-1881	89	10	1:1:1	1:1:1	NOUN
dpc-1881	89	11	)	)	PUNCT
dpc-1881	89	12	to	to	PART
dpc-1881	89	13	receive	receive	VERB
dpc-1881	89	14	oral	oral	ADJ
dpc-1881	89	15	encorafenib	encorafenib	NOUN
dpc-1881	89	16	450	450	NUM
dpc-1881	89	17	mg	mg	NOUN
dpc-1881	89	18	once	once	ADV
dpc-1881	89	19	daily	daily	ADV
dpc-1881	89	20	,	,	PUNCT
dpc-1881	89	21	plus	plus	CCONJ
dpc-1881	89	22	oral	oral	ADJ
dpc-1881	89	23	binimetinib	binimetinib	NOUN
dpc-1881	89	24	45	45	NUM
dpc-1881	89	25	mg	mg	NOUN
dpc-1881	89	26	twice	twice	ADV
dpc-1881	89	27	daily	daily	ADV
dpc-1881	89	28	(	(	PUNCT
dpc-1881	89	29	encorafenib	encorafenib	NOUN
dpc-1881	89	30	plus	plus	CCONJ
dpc-1881	89	31	binimetinib	binimetinib	NOUN
dpc-1881	89	32	group	group	NOUN
dpc-1881	89	33	)	)	PUNCT
dpc-1881	89	34	,	,	PUNCT
dpc-1881	89	35	oral	oral	ADJ
dpc-1881	89	36	encorafenib	encorafenib	NOUN
dpc-1881	89	37	300	300	NUM
dpc-1881	89	38	mg	mg	ADP
dpc-1881	89	39	once	once	ADV
dpc-1881	89	40	daily	daily	ADV
dpc-1881	89	41	(	(	PUNCT
dpc-1881	89	42	encorafenib	encorafenib	NOUN
dpc-1881	89	43	group	group	NOUN
dpc-1881	89	44	)	)	PUNCT
dpc-1881	89	45	,	,	PUNCT
dpc-1881	89	46	or	or	CCONJ
dpc-1881	89	47	oral	oral	ADJ
dpc-1881	89	48	vemurafenib	vemurafenib	NOUN
dpc-1881	89	49	960	960	NUM
dpc-1881	89	50	mg	mg	ADP
dpc-1881	89	51	twice	twice	ADV
dpc-1881	89	52	daily	daily	PROPN
dpc-1881	89	53	(	(	PUNCT
dpc-1881	89	54	vemurafenib	vemurafenib	PROPN
dpc-1881	89	55	group	group	NOUN
dpc-1881	89	56	)	)	PUNCT
dpc-1881	89	57	.	.	PUNCT
dpc-1881	90	1	part	part	NOUN
dpc-1881	90	2	2	2	NUM
dpc-1881	90	3	of	of	ADP
dpc-1881	90	4	the	the	DET
dpc-1881	90	5	study	study	NOUN
dpc-1881	90	6	compared	compare	VERB
dpc-1881	90	7	encorafenib	encorafenib	NOUN
dpc-1881	90	8	300	300	NUM
dpc-1881	90	9	mg	mg	ADP
dpc-1881	90	10	once	once	ADV
dpc-1881	90	11	daily	daily	ADV
dpc-1881	90	12	plus	plus	CCONJ
dpc-1881	90	13	binimetinib	binimetinib	NOUN
dpc-1881	90	14	45	45	NUM
dpc-1881	90	15	mg	mg	NOUN
dpc-1881	90	16	twice	twice	ADV
dpc-1881	90	17	daily	daily	ADV
dpc-1881	90	18	with	with	ADP
dpc-1881	90	19	encorafenib	encorafenib	NOUN
dpc-1881	90	20	300	300	NUM
dpc-1881	90	21	mg	mg	ADP
dpc-1881	90	22	once	once	ADV
dpc-1881	90	23	daily	daily	ADV
dpc-1881	90	24	alone	alone	ADV
dpc-1881	90	25	.	.	PUNCT
dpc-1881	91	1	at	at	ADP
dpc-1881	91	2	3	3	NUM
dpc-1881	91	3	-	-	PUNCT
dpc-1881	91	4	year	year	NOUN
dpc-1881	91	5	analysis	analysis	NOUN
dpc-1881	91	6	,	,	PUNCT
dpc-1881	91	7	median	median	ADJ
dpc-1881	91	8	os	os	PROPN
dpc-1881	91	9	was	be	AUX
dpc-1881	91	10	33.6	33.6	NUM
dpc-1881	91	11	months	month	NOUN
dpc-1881	91	12	with	with	ADP
dpc-1881	91	13	encorafenib	encorafenib	NOUN
dpc-1881	91	14	plus	plus	CCONJ
dpc-1881	91	15	binimetinib	binimetinib	NOUN
dpc-1881	91	16	and	and	CCONJ
dpc-1881	91	17	16.9	16.9	NUM
dpc-1881	91	18	months	month	NOUN
dpc-1881	91	19	with	with	ADP
dpc-1881	91	20	vemurafenib	vemurafenib	PROPN
dpc-1881	91	21	[	[	X
dpc-1881	91	22	17	17	NUM
dpc-1881	91	23	,	,	PUNCT
dpc-1881	91	24	18	18	NUM
dpc-1881	91	25	]	]	PUNCT
dpc-1881	91	26	.	.	PUNCT
dpc-1881	92	1	median	median	PROPN
dpc-1881	92	2	pfs	pfs	PROPN
dpc-1881	92	3	was	be	AUX
dpc-1881	92	4	14.9	14.9	NUM
dpc-1881	92	5	months	month	NOUN
dpc-1881	92	6	in	in	ADP
dpc-1881	92	7	the	the	DET
dpc-1881	92	8	encorafenib	encorafenib	NOUN
dpc-1881	92	9	plus	plus	CCONJ
dpc-1881	92	10	binimetinib	binimetinib	NOUN
dpc-1881	92	11	group	group	NOUN
dpc-1881	92	12	and	and	CCONJ
dpc-1881	92	13	7.3	7.3	NUM
dpc-1881	92	14	months	month	NOUN
dpc-1881	92	15	in	in	ADP
dpc-1881	92	16	the	the	DET
dpc-1881	92	17	vemurafenib	vemurafenib	PROPN
dpc-1881	92	18	group	group	NOUN
dpc-1881	92	19	.	.	PUNCT
dpc-1881	93	1	a	a	DET
dpc-1881	93	2	confirmed	confirm	VERB
dpc-1881	93	3	overall	overall	ADJ
dpc-1881	93	4	response	response	NOUN
dpc-1881	93	5	by	by	ADP
dpc-1881	93	6	blinded	blind	VERB
dpc-1881	93	7	independent	independent	ADJ
dpc-1881	93	8	central	central	ADJ
dpc-1881	93	9	review	review	NOUN
dpc-1881	93	10	occurred	occur	VERB
dpc-1881	93	11	in	in	ADP
dpc-1881	93	12	63	63	NUM
dpc-1881	93	13	%	%	NOUN
dpc-1881	93	14	of	of	ADP
dpc-1881	93	15	patients	patient	NOUN
dpc-1881	93	16	in	in	ADP
dpc-1881	93	17	the	the	DET
dpc-1881	93	18	encorafenib	encorafenib	NOUN
dpc-1881	93	19	plus	plus	CCONJ
dpc-1881	93	20	binimetinib	binimetinib	PROPN
dpc-1881	93	21	group	group	NOUN
dpc-1881	93	22	compared	compare	VERB
dpc-1881	93	23	with	with	ADP
dpc-1881	93	24	51	51	NUM
dpc-1881	93	25	%	%	NOUN
dpc-1881	93	26	in	in	ADP
dpc-1881	93	27	the	the	DET
dpc-1881	93	28	encorafenib	encorafenib	NOUN
dpc-1881	93	29	group	group	NOUN
dpc-1881	93	30	,	,	PUNCT
dpc-1881	93	31	and	and	CCONJ
dpc-1881	93	32	40	40	NUM
dpc-1881	93	33	%	%	NOUN
dpc-1881	93	34	in	in	ADP
dpc-1881	93	35	the	the	DET
dpc-1881	93	36	vemurafenib	vemurafenib	PROPN
dpc-1881	93	37	group	group	NOUN
dpc-1881	93	38	.	.	PUNCT
dpc-1881	94	1	the	the	DET
dpc-1881	94	2	median	median	ADJ
dpc-1881	94	3	time	time	NOUN
dpc-1881	94	4	to	to	PART
dpc-1881	94	5	response	response	NOUN
dpc-1881	94	6	was	be	AUX
dpc-1881	94	7	1.8	1.8	NUM
dpc-1881	94	8	months	month	NOUN
dpc-1881	94	9	for	for	ADP
dpc-1881	94	10	the	the	DET
dpc-1881	94	11	encorafenib	encorafenib	NOUN
dpc-1881	94	12	plus	plus	CCONJ
dpc-1881	94	13	binimetinib	binimetinib	NOUN
dpc-1881	94	14	group	group	NOUN
dpc-1881	94	15	.	.	PUNCT
dpc-1881	95	1	the	the	DET
dpc-1881	95	2	most	most	ADV
dpc-1881	95	3	common	common	ADJ
dpc-1881	95	4	grade	grade	NOUN
dpc-1881	95	5	3	3	NUM
dpc-1881	95	6	-	-	SYM
dpc-1881	95	7	4	4	NUM
dpc-1881	95	8	adverse	adverse	ADJ
dpc-1881	95	9	events	event	NOUN
dpc-1881	95	10	seen	see	VERB
dpc-1881	95	11	in	in	ADP
dpc-1881	95	12	more	more	ADJ
dpc-1881	95	13	than	than	ADP
dpc-1881	95	14	5	5	NUM
dpc-1881	95	15	%	%	NOUN
dpc-1881	95	16	of	of	ADP
dpc-1881	95	17	patients	patient	NOUN
dpc-1881	95	18	in	in	ADP
dpc-1881	95	19	the	the	DET
dpc-1881	95	20	encorafenib	encorafenib	NOUN
dpc-1881	95	21	plus	plus	CCONJ
dpc-1881	95	22	binimetinib	binimetinib	NOUN
dpc-1881	95	23	group	group	NOUN
dpc-1881	95	24	were	be	AUX
dpc-1881	95	25	increased	increase	VERB
dpc-1881	95	26	γ	γ	NOUN
dpc-1881	95	27	-	-	PUNCT
dpc-1881	95	28	glutamyltransferase	glutamyltransferase	NOUN
dpc-1881	95	29	(	(	PUNCT
dpc-1881	95	30	9	9	NUM
dpc-1881	95	31	%	%	NOUN
dpc-1881	95	32	)	)	PUNCT
dpc-1881	95	33	,	,	PUNCT
dpc-1881	95	34	increased	increase	VERB
dpc-1881	95	35	creatine	creatine	NOUN
dpc-1881	95	36	phosphokinase	phosphokinase	NOUN
dpc-1881	95	37	(	(	PUNCT
dpc-1881	95	38	7	7	NUM
dpc-1881	95	39	%	%	NOUN
dpc-1881	95	40	)	)	PUNCT
dpc-1881	95	41	,	,	PUNCT
dpc-1881	95	42	and	and	CCONJ
dpc-1881	95	43	hypertension	hypertension	NOUN
dpc-1881	95	44	(	(	PUNCT
dpc-1881	95	45	6	6	NUM
dpc-1881	95	46	%	%	NOUN
dpc-1881	95	47	)	)	PUNCT
dpc-1881	95	48	.	.	PUNCT
dpc-1881	96	1	anti	anti	ADJ
dpc-1881	96	2	-	-	ADJ
dpc-1881	96	3	ctla4	ctla4	ADJ
dpc-1881	96	4	ipilimumab	ipilimumab	NOUN
dpc-1881	96	5	is	be	AUX
dpc-1881	96	6	a	a	DET
dpc-1881	96	7	fully	fully	ADV
dpc-1881	96	8	humanized	humanize	VERB
dpc-1881	96	9	monoclonal	monoclonal	NOUN
dpc-1881	96	10	antibody	antibody	NOUN
dpc-1881	96	11	that	that	PRON
dpc-1881	96	12	binds	bind	VERB
dpc-1881	96	13	to	to	ADP
dpc-1881	96	14	ctla-4	ctla-4	NUM
dpc-1881	96	15	,	,	PUNCT
dpc-1881	96	16	a	a	DET
dpc-1881	96	17	receptor	receptor	NOUN
dpc-1881	96	18	expressed	express	VERB
dpc-1881	96	19	on	on	ADP
dpc-1881	96	20	the	the	DET
dpc-1881	96	21	t	t	NOUN
dpc-1881	96	22	-	-	PUNCT
dpc-1881	96	23	cell	cell	NOUN
dpc-1881	96	24	surface	surface	NOUN
dpc-1881	96	25	that	that	PRON
dpc-1881	96	26	interacts	interact	VERB
dpc-1881	96	27	with	with	ADP
dpc-1881	96	28	cd80	cd80	PROPN
dpc-1881	96	29	(	(	PUNCT
dpc-1881	96	30	b7	b7	PROPN
dpc-1881	96	31	-	-	PUNCT
dpc-1881	96	32	1	1	NUM
dpc-1881	96	33	)	)	PUNCT
dpc-1881	96	34	and	and	CCONJ
dpc-1881	96	35	cd86	cd86	PROPN
dpc-1881	96	36	(	(	PUNCT
dpc-1881	96	37	b7	b7	PROPN
dpc-1881	96	38	-	-	PUNCT
dpc-1881	96	39	2	2	NUM
dpc-1881	96	40	)	)	PUNCT
dpc-1881	96	41	on	on	ADP
dpc-1881	96	42	the	the	DET
dpc-1881	96	43	antigen	antigen	NOUN
dpc-1881	96	44	-	-	PUNCT
dpc-1881	96	45	presenting	presenting	NOUN
dpc-1881	96	46	-	-	PUNCT
dpc-1881	96	47	cells	cell	NOUN
dpc-1881	96	48	(	(	PUNCT
dpc-1881	96	49	apcs	apc	NOUN
dpc-1881	96	50	)	)	PUNCT
dpc-1881	96	51	and	and	CCONJ
dpc-1881	96	52	downregulates	downregulate	VERB
dpc-1881	96	53	t	t	PROPN
dpc-1881	96	54	-	-	PUNCT
dpc-1881	96	55	cell	cell	NOUN
dpc-1881	96	56	response	response	NOUN
dpc-1881	96	57	.	.	PUNCT
dpc-1881	97	1	ctla-4	ctla-4	NOUN
dpc-1881	97	2	blockade	blockade	NOUN
dpc-1881	97	3	allows	allow	VERB
dpc-1881	97	4	cd28	cd28	PROPN
dpc-1881	97	5	to	to	PART
dpc-1881	97	6	bind	bind	VERB
dpc-1881	97	7	to	to	ADP
dpc-1881	97	8	b7	b7	PROPN
dpc-1881	97	9	-	-	PUNCT
dpc-1881	97	10	1	1	NUM
dpc-1881	97	11	receptors	receptor	NOUN
dpc-1881	97	12	,	,	PUNCT
dpc-1881	97	13	leading	lead	VERB
dpc-1881	97	14	to	to	ADP
dpc-1881	97	15	immune	immune	ADJ
dpc-1881	97	16	activation	activation	NOUN
dpc-1881	97	17	,	,	PUNCT
dpc-1881	97	18	il-2	il-2	ADJ
dpc-1881	97	19	secretion	secretion	NOUN
dpc-1881	97	20	,	,	PUNCT
dpc-1881	97	21	cytotoxic	cytotoxic	ADJ
dpc-1881	97	22	t	t	NOUN
dpc-1881	97	23	-	-	PUNCT
dpc-1881	97	24	cells	cell	NOUN
dpc-1881	97	25	expansion	expansion	NOUN
dpc-1881	97	26	,	,	PUNCT
dpc-1881	97	27	and	and	CCONJ
dpc-1881	97	28	proliferation	proliferation	NOUN
dpc-1881	97	29	[	[	X
dpc-1881	97	30	19	19	NUM
dpc-1881	97	31	]	]	PUNCT
dpc-1881	97	32	.	.	PUNCT
dpc-1881	98	1	the	the	DET
dpc-1881	98	2	interaction	interaction	NOUN
dpc-1881	98	3	between	between	ADP
dpc-1881	98	4	ctla-4	ctla-4	NUM
dpc-1881	98	5	and	and	CCONJ
dpc-1881	98	6	b7	b7	PROPN
dpc-1881	98	7	-	-	PUNCT
dpc-1881	98	8	1/2	1/2	NUM
dpc-1881	98	9	takes	take	VERB
dpc-1881	98	10	place	place	NOUN
dpc-1881	98	11	in	in	ADP
dpc-1881	98	12	an	an	DET
dpc-1881	98	13	early	early	ADJ
dpc-1881	98	14	phase	phase	NOUN
dpc-1881	98	15	of	of	ADP
dpc-1881	98	16	the	the	DET
dpc-1881	98	17	immune	immune	ADJ
dpc-1881	98	18	response	response	NOUN
dpc-1881	98	19	,	,	PUNCT
dpc-1881	98	20	involving	involve	VERB
dpc-1881	98	21	“	"	PUNCT
dpc-1881	98	22	naive	naive	ADJ
dpc-1881	98	23	”	"	PUNCT
dpc-1881	98	24	t	t	PROPN
dpc-1881	98	25	lymphocytes	lymphocyte	NOUN
dpc-1881	98	26	and	and	CCONJ
dpc-1881	98	27	the	the	DET
dpc-1881	98	28	apcs	apc	NOUN
dpc-1881	98	29	.	.	PUNCT
dpc-1881	99	1	this	this	DET
dpc-1881	99	2	mechanism	mechanism	NOUN
dpc-1881	99	3	of	of	ADP
dpc-1881	99	4	action	action	NOUN
dpc-1881	99	5	explains	explain	VERB
dpc-1881	99	6	the	the	DET
dpc-1881	99	7	characteristics	characteristic	NOUN
dpc-1881	99	8	of	of	ADP
dpc-1881	99	9	the	the	DET
dpc-1881	99	10	clinical	clinical	ADJ
dpc-1881	99	11	activity	activity	NOUN
dpc-1881	99	12	as	as	ADV
dpc-1881	99	13	well	well	ADV
dpc-1881	99	14	as	as	ADP
dpc-1881	99	15	the	the	DET
dpc-1881	99	16	common	common	ADJ
dpc-1881	99	17	side	side	NOUN
dpc-1881	99	18	effects	effect	NOUN
dpc-1881	99	19	of	of	ADP
dpc-1881	99	20	this	this	DET
dpc-1881	99	21	drug	drug	NOUN
dpc-1881	99	22	,	,	PUNCT
dpc-1881	99	23	consisting	consist	VERB
dpc-1881	99	24	of	of	ADP
dpc-1881	99	25	immune	immune	NOUN
dpc-1881	99	26	-	-	PUNCT
dpc-1881	99	27	mediated	mediate	VERB
dpc-1881	99	28	reactions	reaction	NOUN
dpc-1881	99	29	(	(	PUNCT
dpc-1881	99	30	iraes	iraes	X
dpc-1881	99	31	)	)	PUNCT
dpc-1881	99	32	developing	develop	VERB
dpc-1881	99	33	more	more	ADV
dpc-1881	99	34	frequently	frequently	ADV
dpc-1881	99	35	in	in	ADP
dpc-1881	99	36	the	the	DET
dpc-1881	99	37	skin	skin	NOUN
dpc-1881	99	38	,	,	PUNCT
dpc-1881	99	39	gastro	gastro	NOUN
dpc-1881	99	40	-	-	PUNCT
dpc-1881	99	41	intestinal	intestinal	ADJ
dpc-1881	99	42	tract	tract	NOUN
dpc-1881	99	43	(	(	PUNCT
dpc-1881	99	44	mainly	mainly	ADV
dpc-1881	99	45	diarrhea	diarrhea	PROPN
dpc-1881	99	46	)	)	PUNCT
dpc-1881	99	47	,	,	PUNCT
dpc-1881	99	48	liver	liver	NOUN
dpc-1881	99	49	and	and	CCONJ
dpc-1881	99	50	endocrinal	endocrinal	ADJ
dpc-1881	99	51	glands	gland	NOUN
dpc-1881	99	52	)	)	PUNCT
dpc-1881	99	53	.	.	PUNCT
dpc-1881	100	1	the	the	DET
dpc-1881	100	2	trial	trial	NOUN
dpc-1881	100	3	that	that	PRON
dpc-1881	100	4	led	lead	VERB
dpc-1881	100	5	to	to	ADP
dpc-1881	100	6	registration	registration	NOUN
dpc-1881	100	7	of	of	ADP
dpc-1881	100	8	ipilimumab	ipilimumab	NOUN
dpc-1881	100	9	in	in	ADP
dpc-1881	100	10	melanoma	melanoma	NOUN
dpc-1881	100	11	was	be	AUX
dpc-1881	100	12	a	a	DET
dpc-1881	100	13	phase	phase	NOUN
dpc-1881	100	14	iii	iii	NUM
dpc-1881	100	15	4	4	NUM
dpc-1881	100	16	review	review	NOUN
dpc-1881	100	17	|	|	ADV
dpc-1881	100	18	dermatol	dermatol	ADJ
dpc-1881	100	19	pract	pract	NOUN
dpc-1881	100	20	concept	concept	NOUN
dpc-1881	100	21	.	.	PUNCT
dpc-1881	101	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	101	2	):	):	PUNCT
dpc-1881	101	3	e2021164s	e2021164	VERB
dpc-1881	101	4	trial	trial	NOUN
dpc-1881	101	5	in	in	ADP
dpc-1881	101	6	which	which	PRON
dpc-1881	101	7	ipilimumab	ipilimumab	ADJ
dpc-1881	101	8	±	±	NUM
dpc-1881	101	9	glycoprotein	glycoprotein	NOUN
dpc-1881	101	10	100	100	NUM
dpc-1881	101	11	peptide	peptide	NOUN
dpc-1881	101	12	(	(	PUNCT
dpc-1881	101	13	gp100	gp100	NOUN
dpc-1881	101	14	)	)	PUNCT
dpc-1881	101	15	vaccine	vaccine	NOUN
dpc-1881	101	16	was	be	AUX
dpc-1881	101	17	compared	compare	VERB
dpc-1881	101	18	with	with	ADP
dpc-1881	101	19	gp100	gp100	PROPN
dpc-1881	101	20	vaccine	vaccine	NOUN
dpc-1881	101	21	monotherapy	monotherapy	NOUN
dpc-1881	101	22	in	in	ADP
dpc-1881	101	23	patients	patient	NOUN
dpc-1881	101	24	with	with	ADP
dpc-1881	101	25	unresectable	unresectable	ADJ
dpc-1881	101	26	stage	stage	NOUN
dpc-1881	101	27	iii	iii	NOUN
dpc-1881	101	28	or	or	CCONJ
dpc-1881	101	29	stage	stage	NOUN
dpc-1881	101	30	iv	iv	NUM
dpc-1881	101	31	melanoma	melanoma	NOUN
dpc-1881	101	32	.	.	PUNCT
dpc-1881	102	1	ipilimumab	ipilimumab	PROPN
dpc-1881	102	2	monotherapy	monotherapy	NOUN
dpc-1881	102	3	significantly	significantly	ADV
dpc-1881	102	4	improved	improve	VERB
dpc-1881	102	5	median	median	PROPN
dpc-1881	102	6	os	os	NOUN
dpc-1881	102	7	compared	compare	VERB
dpc-1881	102	8	with	with	ADP
dpc-1881	102	9	gp100	gp100	PROPN
dpc-1881	102	10	vaccine	vaccine	NOUN
dpc-1881	102	11	monotherapy	monotherapy	NOUN
dpc-1881	102	12	(	(	PUNCT
dpc-1881	102	13	10.1	10.1	NUM
dpc-1881	102	14	months	month	NOUN
dpc-1881	102	15	vs.	vs.	ADP
dpc-1881	102	16	6.4	6.4	NUM
dpc-1881	102	17	months	month	NOUN
dpc-1881	102	18	)	)	PUNCT
dpc-1881	103	1	[	[	X
dpc-1881	103	2	20	20	NUM
dpc-1881	103	3	]	]	PUNCT
dpc-1881	103	4	.	.	PUNCT
dpc-1881	104	1	in	in	ADP
dpc-1881	104	2	another	another	DET
dpc-1881	104	3	important	important	ADJ
dpc-1881	104	4	randomized	randomize	VERB
dpc-1881	104	5	phase	phase	NOUN
dpc-1881	104	6	iii	iii	NOUN
dpc-1881	104	7	trial	trial	NOUN
dpc-1881	104	8	,	,	PUNCT
dpc-1881	104	9	the	the	DET
dpc-1881	104	10	combination	combination	NOUN
dpc-1881	104	11	of	of	ADP
dpc-1881	104	12	ipilimumab	ipilimumab	NOUN
dpc-1881	104	13	(	(	PUNCT
dpc-1881	104	14	10	10	NUM
dpc-1881	104	15	mg	mg	NUM
dpc-1881	104	16	/	/	SYM
dpc-1881	104	17	kg	kg	NOUN
dpc-1881	104	18	)	)	PUNCT
dpc-1881	104	19	and	and	CCONJ
dpc-1881	104	20	dacarbazine	dacarbazine	NOUN
dpc-1881	104	21	(	(	PUNCT
dpc-1881	104	22	850	850	NUM
dpc-1881	104	23	mg	mg	PROPN
dpc-1881	104	24	/	/	SYM
dpc-1881	104	25	sqm	sqm	NOUN
dpc-1881	104	26	)	)	PUNCT
dpc-1881	104	27	resulted	result	VERB
dpc-1881	104	28	in	in	ADP
dpc-1881	104	29	significantly	significantly	ADV
dpc-1881	104	30	superior	superior	ADJ
dpc-1881	104	31	os	os	NOUN
dpc-1881	104	32	compared	compare	VERB
dpc-1881	104	33	to	to	ADP
dpc-1881	104	34	dacarbazine	dacarbazine	NOUN
dpc-1881	104	35	(	(	PUNCT
dpc-1881	104	36	850	850	NUM
dpc-1881	104	37	mg	mg	PROPN
dpc-1881	104	38	/	/	SYM
dpc-1881	104	39	sqm	sqm	NOUN
dpc-1881	104	40	)	)	PUNCT
dpc-1881	104	41	plus	plus	CCONJ
dpc-1881	104	42	placebo	placebo	NOUN
dpc-1881	104	43	(	(	PUNCT
dpc-1881	104	44	11.2	11.2	NUM
dpc-1881	104	45	months	month	NOUN
dpc-1881	104	46	vs.	vs.	ADP
dpc-1881	104	47	9.1	9.1	NUM
dpc-1881	104	48	months	month	NOUN
dpc-1881	104	49	)	)	PUNCT
dpc-1881	105	1	[	[	X
dpc-1881	105	2	21	21	NUM
dpc-1881	105	3	]	]	PUNCT
dpc-1881	105	4	.	.	PUNCT
dpc-1881	105	5	ipilimumab	ipilimumab	PROPN
dpc-1881	105	6	produced	produce	VERB
dpc-1881	105	7	a	a	DET
dpc-1881	105	8	plateau	plateau	NOUN
dpc-1881	105	9	in	in	ADP
dpc-1881	105	10	the	the	DET
dpc-1881	105	11	survival	survival	NOUN
dpc-1881	105	12	curves	curve	NOUN
dpc-1881	105	13	:	:	PUNCT
dpc-1881	105	14	a	a	DET
dpc-1881	105	15	recent	recent	ADJ
dpc-1881	105	16	pooled	pool	VERB
dpc-1881	105	17	analysis	analysis	NOUN
dpc-1881	105	18	of	of	ADP
dpc-1881	105	19	os	os	PROPN
dpc-1881	105	20	data	datum	NOUN
dpc-1881	105	21	for	for	ADP
dpc-1881	105	22	1.861	1.861	NUM
dpc-1881	105	23	patients	patient	NOUN
dpc-1881	105	24	enrolled	enrol	VERB
dpc-1881	105	25	in	in	ADP
dpc-1881	105	26	10	10	NUM
dpc-1881	105	27	prospective	prospective	ADJ
dpc-1881	105	28	and	and	CCONJ
dpc-1881	105	29	2	2	NUM
dpc-1881	105	30	retrospective	retrospective	ADJ
dpc-1881	105	31	trials	trial	NOUN
dpc-1881	105	32	,	,	PUNCT
dpc-1881	105	33	with	with	ADP
dpc-1881	105	34	up	up	ADP
dpc-1881	105	35	to	to	PART
dpc-1881	105	36	10	10	NUM
dpc-1881	105	37	-	-	PUNCT
dpc-1881	105	38	year	year	NOUN
dpc-1881	105	39	follow	follow	NOUN
dpc-1881	105	40	-	-	PUNCT
dpc-1881	105	41	up	up	NOUN
dpc-1881	105	42	,	,	PUNCT
dpc-1881	105	43	showed	show	VERB
dpc-1881	105	44	that	that	SCONJ
dpc-1881	105	45	the	the	DET
dpc-1881	105	46	survival	survival	NOUN
dpc-1881	105	47	curve	curve	NOUN
dpc-1881	105	48	began	begin	VERB
dpc-1881	105	49	to	to	PART
dpc-1881	105	50	plateau	plateau	VERB
dpc-1881	105	51	around	around	ADV
dpc-1881	105	52	3	3	NUM
dpc-1881	105	53	years	year	NOUN
dpc-1881	105	54	after	after	ADP
dpc-1881	105	55	treatment	treatment	NOUN
dpc-1881	105	56	.	.	PUNCT
dpc-1881	106	1	3	3	NUM
dpc-1881	106	2	-	-	PUNCT
dpc-1881	106	3	year	year	NOUN
dpc-1881	106	4	os	os	NOUN
dpc-1881	106	5	rates	rate	NOUN
dpc-1881	106	6	were	be	AUX
dpc-1881	106	7	22	22	NUM
dpc-1881	106	8	%	%	NOUN
dpc-1881	106	9	,	,	PUNCT
dpc-1881	106	10	26	26	NUM
dpc-1881	106	11	%	%	NOUN
dpc-1881	106	12	,	,	PUNCT
dpc-1881	106	13	and	and	CCONJ
dpc-1881	106	14	20	20	NUM
dpc-1881	106	15	%	%	NOUN
dpc-1881	106	16	for	for	ADP
dpc-1881	106	17	all	all	PRON
dpc-1881	106	18	,	,	PUNCT
dpc-1881	106	19	treatment	treatment	NOUN
dpc-1881	106	20	-	-	PUNCT
dpc-1881	106	21	naive	naive	ADJ
dpc-1881	106	22	,	,	PUNCT
dpc-1881	106	23	and	and	CCONJ
dpc-1881	106	24	previously	previously	ADV
dpc-1881	106	25	treated	treat	VERB
dpc-1881	106	26	patients	patient	NOUN
dpc-1881	106	27	,	,	PUNCT
dpc-1881	106	28	respectively	respectively	ADV
dpc-1881	106	29	[	[	X
dpc-1881	106	30	22	22	NUM
dpc-1881	106	31	]	]	PUNCT
dpc-1881	106	32	.	.	PUNCT
dpc-1881	107	1	moreover	moreover	ADV
dpc-1881	107	2	,	,	PUNCT
dpc-1881	107	3	the	the	DET
dpc-1881	107	4	results	result	NOUN
dpc-1881	107	5	of	of	ADP
dpc-1881	107	6	the	the	DET
dpc-1881	107	7	ipilimumab	ipilimumab	NOUN
dpc-1881	107	8	expanded	expand	VERB
dpc-1881	107	9	access	access	NOUN
dpc-1881	107	10	programme	programme	NOUN
dpc-1881	107	11	(	(	PUNCT
dpc-1881	107	12	eap	eap	NOUN
dpc-1881	107	13	)	)	PUNCT
dpc-1881	107	14	in	in	ADP
dpc-1881	107	15	italy	italy	PROPN
dpc-1881	107	16	resulted	result	VERB
dpc-1881	107	17	consistent	consistent	ADJ
dpc-1881	107	18	with	with	ADP
dpc-1881	107	19	these	these	DET
dpc-1881	107	20	data	datum	NOUN
dpc-1881	107	21	,	,	PUNCT
dpc-1881	107	22	confirming	confirm	VERB
dpc-1881	107	23	the	the	DET
dpc-1881	107	24	activity	activity	NOUN
dpc-1881	107	25	of	of	ADP
dpc-1881	107	26	the	the	DET
dpc-1881	107	27	drug	drug	NOUN
dpc-1881	107	28	also	also	ADV
dpc-1881	107	29	in	in	ADP
dpc-1881	107	30	specific	specific	ADJ
dpc-1881	107	31	patient	patient	NOUN
dpc-1881	107	32	’s	’s	PART
dpc-1881	107	33	subsets	subset	NOUN
dpc-1881	107	34	such	such	ADJ
dpc-1881	107	35	as	as	ADP
dpc-1881	107	36	the	the	DET
dpc-1881	107	37	elderly	elderly	ADJ
dpc-1881	107	38	,	,	PUNCT
dpc-1881	107	39	the	the	DET
dpc-1881	107	40	mucosal	mucosal	NOUN
dpc-1881	107	41	or	or	CCONJ
dpc-1881	107	42	uveal	uveal	ADJ
dpc-1881	107	43	primaries	primary	NOUN
dpc-1881	107	44	,	,	PUNCT
dpc-1881	107	45	and	and	CCONJ
dpc-1881	107	46	in	in	ADP
dpc-1881	107	47	the	the	DET
dpc-1881	107	48	presence	presence	NOUN
dpc-1881	107	49	of	of	ADP
dpc-1881	107	50	brain	brain	NOUN
dpc-1881	107	51	metastases	metastasis	NOUN
dpc-1881	107	52	[	[	X
dpc-1881	107	53	23	23	NUM
dpc-1881	107	54	]	]	PUNCT
dpc-1881	107	55	.	.	PUNCT
dpc-1881	108	1	anti	anti	NOUN
dpc-1881	108	2	-	-	NOUN
dpc-1881	108	3	pd1	pd1	NOUN
dpc-1881	108	4	pd-1	pd-1	ADJ
dpc-1881	108	5	represents	represent	VERB
dpc-1881	108	6	a	a	DET
dpc-1881	108	7	co	co	ADJ
dpc-1881	108	8	-	-	ADJ
dpc-1881	108	9	inhibitory	inhibitory	ADJ
dpc-1881	108	10	receptor	receptor	NOUN
dpc-1881	108	11	involved	involve	VERB
dpc-1881	108	12	in	in	ADP
dpc-1881	108	13	the	the	DET
dpc-1881	108	14	negative	negative	ADJ
dpc-1881	108	15	regulation	regulation	NOUN
dpc-1881	108	16	of	of	ADP
dpc-1881	108	17	t	t	NOUN
dpc-1881	108	18	-	-	PUNCT
dpc-1881	108	19	cell	cell	NOUN
dpc-1881	108	20	activation	activation	NOUN
dpc-1881	108	21	[	[	X
dpc-1881	108	22	24	24	NUM
dpc-1881	108	23	]	]	PUNCT
dpc-1881	108	24	.	.	PUNCT
dpc-1881	109	1	the	the	DET
dpc-1881	109	2	expression	expression	NOUN
dpc-1881	109	3	of	of	ADP
dpc-1881	109	4	pd-1	pd-1	ADJ
dpc-1881	109	5	ligand	ligand	PROPN
dpc-1881	109	6	(	(	PUNCT
dpc-1881	109	7	pd	pd	NOUN
dpc-1881	109	8	-	-	PUNCT
dpc-1881	109	9	l1	l1	PROPN
dpc-1881	109	10	)	)	PUNCT
dpc-1881	109	11	on	on	ADP
dpc-1881	109	12	tumor	tumor	NOUN
dpc-1881	109	13	cells	cell	NOUN
dpc-1881	109	14	induces	induce	VERB
dpc-1881	109	15	the	the	DET
dpc-1881	109	16	development	development	NOUN
dpc-1881	109	17	of	of	ADP
dpc-1881	109	18	an	an	DET
dpc-1881	109	19	immunosuppressing	immunosuppresse	VERB
dpc-1881	109	20	environment	environment	NOUN
dpc-1881	109	21	through	through	ADP
dpc-1881	109	22	the	the	DET
dpc-1881	109	23	ligand	ligand	NOUN
dpc-1881	109	24	with	with	ADP
dpc-1881	109	25	the	the	DET
dpc-1881	109	26	pd-1	pd-1	ADV
dpc-1881	109	27	expressed	express	VERB
dpc-1881	109	28	on	on	ADP
dpc-1881	109	29	t	t	PROPN
dpc-1881	109	30	lymphocytes	lymphocyte	NOUN
dpc-1881	109	31	,	,	PUNCT
dpc-1881	109	32	thus	thus	ADV
dpc-1881	109	33	leading	lead	VERB
dpc-1881	109	34	to	to	ADP
dpc-1881	109	35	t	t	NOUN
dpc-1881	109	36	-	-	PUNCT
dpc-1881	109	37	cell	cell	NOUN
dpc-1881	109	38	inhibition	inhibition	NOUN
dpc-1881	109	39	and	and	CCONJ
dpc-1881	109	40	cancer	cancer	NOUN
dpc-1881	109	41	immune	immune	ADJ
dpc-1881	109	42	system	system	NOUN
dpc-1881	109	43	escape	escape	NOUN
dpc-1881	109	44	.	.	PUNCT
dpc-1881	110	1	two	two	NUM
dpc-1881	110	2	anti	anti	ADJ
dpc-1881	110	3	-	-	ADJ
dpc-1881	110	4	pd-1	pd-1	ADJ
dpc-1881	110	5	monoclonal	monoclonal	NOUN
dpc-1881	110	6	antibodies	antibody	NOUN
dpc-1881	110	7	are	be	AUX
dpc-1881	110	8	available	available	ADJ
dpc-1881	110	9	in	in	ADP
dpc-1881	110	10	the	the	DET
dpc-1881	110	11	clinical	clinical	ADJ
dpc-1881	110	12	practice	practice	NOUN
dpc-1881	110	13	and	and	CCONJ
dpc-1881	110	14	can	can	AUX
dpc-1881	110	15	be	be	AUX
dpc-1881	110	16	used	use	VERB
dpc-1881	110	17	for	for	ADP
dpc-1881	110	18	the	the	DET
dpc-1881	110	19	treatment	treatment	NOUN
dpc-1881	110	20	of	of	ADP
dpc-1881	110	21	metastatic	metastatic	ADJ
dpc-1881	110	22	melanoma	melanoma	NOUN
dpc-1881	110	23	patients	patient	NOUN
dpc-1881	110	24	,	,	PUNCT
dpc-1881	110	25	ie	ie	X
dpc-1881	110	26	nivolumab	nivolumab	NOUN
dpc-1881	110	27	and	and	CCONJ
dpc-1881	110	28	pembrolizumab	pembrolizumab	NOUN
dpc-1881	110	29	.	.	PUNCT
dpc-1881	111	1	the	the	DET
dpc-1881	111	2	checkmate	checkmate	NOUN
dpc-1881	111	3	066	066	NUM
dpc-1881	111	4	trial	trial	NOUN
dpc-1881	111	5	investigated	investigate	VERB
dpc-1881	111	6	nivolumab	nivolumab	ADV
dpc-1881	111	7	monotherapy	monotherapy	NOUN
dpc-1881	111	8	as	as	ADP
dpc-1881	111	9	first	first	ADJ
dpc-1881	111	10	-	-	PUNCT
dpc-1881	111	11	line	line	NOUN
dpc-1881	111	12	treatment	treatment	NOUN
dpc-1881	111	13	for	for	ADP
dpc-1881	111	14	patients	patient	NOUN
dpc-1881	111	15	with	with	ADP
dpc-1881	111	16	previously	previously	ADV
dpc-1881	111	17	untreated	untreated	ADJ
dpc-1881	111	18	braf	braf	NOUN
dpc-1881	111	19	wild	wild	ADJ
dpc-1881	111	20	-	-	PUNCT
dpc-1881	111	21	type	type	NOUN
dpc-1881	111	22	advanced	advanced	ADJ
dpc-1881	111	23	melanoma	melanoma	NOUN
dpc-1881	111	24	.	.	PUNCT
dpc-1881	112	1	in	in	ADP
dpc-1881	112	2	this	this	DET
dpc-1881	112	3	multicenter	multicenter	NOUN
dpc-1881	112	4	,	,	PUNCT
dpc-1881	112	5	double	double	ADJ
dpc-1881	112	6	-	-	PUNCT
dpc-1881	112	7	blind	blind	ADJ
dpc-1881	112	8	,	,	PUNCT
dpc-1881	112	9	phase	phase	NOUN
dpc-1881	112	10	iii	iii	NUM
dpc-1881	112	11	study	study	NOUN
dpc-1881	112	12	,	,	PUNCT
dpc-1881	112	13	418	418	NUM
dpc-1881	112	14	patients	patient	NOUN
dpc-1881	112	15	with	with	ADP
dpc-1881	112	16	previously	previously	ADV
dpc-1881	112	17	untreated	untreated	ADJ
dpc-1881	112	18	,	,	PUNCT
dpc-1881	112	19	unresectable	unresectable	ADJ
dpc-1881	112	20	,	,	PUNCT
dpc-1881	112	21	stage	stage	NOUN
dpc-1881	112	22	iii	iii	SYM
dpc-1881	112	23	/	/	SYM
dpc-1881	112	24	iv	iv	NUM
dpc-1881	112	25	,	,	PUNCT
dpc-1881	112	26	wild	wild	ADJ
dpc-1881	112	27	-	-	PUNCT
dpc-1881	112	28	type	type	NOUN
dpc-1881	112	29	braf	braf	NOUN
dpc-1881	112	30	melanoma	melanoma	NOUN
dpc-1881	112	31	were	be	AUX
dpc-1881	112	32	randomly	randomly	ADV
dpc-1881	112	33	assigned	assign	VERB
dpc-1881	112	34	1:1	1:1	NUM
dpc-1881	112	35	to	to	PART
dpc-1881	112	36	receive	receive	VERB
dpc-1881	112	37	nivolumab	nivolumab	NOUN
dpc-1881	112	38	or	or	CCONJ
dpc-1881	112	39	dacarbazine	dacarbazine	NOUN
dpc-1881	112	40	,	,	PUNCT
dpc-1881	112	41	with	with	ADP
dpc-1881	112	42	os	os	NOUN
dpc-1881	112	43	as	as	ADP
dpc-1881	112	44	primary	primary	ADJ
dpc-1881	112	45	endpoint	endpoint	NOUN
dpc-1881	112	46	.	.	PUNCT
dpc-1881	113	1	the	the	DET
dpc-1881	113	2	results	result	NOUN
dpc-1881	113	3	demonstrated	demonstrate	VERB
dpc-1881	113	4	superior	superior	ADJ
dpc-1881	113	5	overall	overall	ADJ
dpc-1881	113	6	rr	rr	NOUN
dpc-1881	113	7	(	(	PUNCT
dpc-1881	113	8	40	40	NUM
dpc-1881	113	9	%	%	NOUN
dpc-1881	113	10	vs.	vs.	ADP
dpc-1881	113	11	13.9	13.9	NUM
dpc-1881	113	12	%	%	NOUN
dpc-1881	113	13	,	,	PUNCT
dpc-1881	113	14	respectively	respectively	ADV
dpc-1881	113	15	)	)	PUNCT
dpc-1881	113	16	and	and	CCONJ
dpc-1881	113	17	increased	increase	VERB
dpc-1881	113	18	1	1	NUM
dpc-1881	113	19	-	-	PUNCT
dpc-1881	113	20	year	year	NOUN
dpc-1881	113	21	os	os	NOUN
dpc-1881	113	22	(	(	PUNCT
dpc-1881	113	23	72.9	72.9	NUM
dpc-1881	113	24	%	%	NOUN
dpc-1881	113	25	vs.	vs.	ADP
dpc-1881	113	26	42.1	42.1	NUM
dpc-1881	113	27	%	%	NOUN
dpc-1881	113	28	,	,	PUNCT
dpc-1881	113	29	respectively	respectively	ADV
dpc-1881	113	30	)	)	PUNCT
dpc-1881	113	31	.	.	PUNCT
dpc-1881	114	1	moreover	moreover	ADV
dpc-1881	114	2	,	,	PUNCT
dpc-1881	114	3	nivolumab	nivolumab	ADV
dpc-1881	114	4	treatment	treatment	NOUN
dpc-1881	114	5	-	-	PUNCT
dpc-1881	114	6	related	relate	VERB
dpc-1881	114	7	adverse	adverse	ADJ
dpc-1881	114	8	events	event	NOUN
dpc-1881	114	9	occurred	occur	VERB
dpc-1881	114	10	in	in	ADP
dpc-1881	114	11	11.7	11.7	NUM
dpc-1881	114	12	%	%	NOUN
dpc-1881	114	13	of	of	ADP
dpc-1881	114	14	the	the	DET
dpc-1881	114	15	patients	patient	NOUN
dpc-1881	114	16	receiving	receive	VERB
dpc-1881	114	17	nivolumab	nivolumab	NOUN
dpc-1881	114	18	and	and	CCONJ
dpc-1881	114	19	17.6	17.6	NUM
dpc-1881	114	20	%	%	NOUN
dpc-1881	114	21	of	of	ADP
dpc-1881	114	22	the	the	DET
dpc-1881	114	23	patients	patient	NOUN
dpc-1881	114	24	receiving	receive	VERB
dpc-1881	114	25	dacarbazine	dacarbazine	NOUN
dpc-1881	114	26	,	,	PUNCT
dpc-1881	114	27	respectively	respectively	ADV
dpc-1881	114	28	[	[	X
dpc-1881	114	29	25	25	NUM
dpc-1881	114	30	]	]	PUNCT
dpc-1881	114	31	.	.	PUNCT
dpc-1881	115	1	at	at	ADP
dpc-1881	115	2	5	5	NUM
dpc-1881	115	3	-	-	PUNCT
dpc-1881	115	4	year	year	NOUN
dpc-1881	115	5	analysis	analysis	NOUN
dpc-1881	115	6	[	[	X
dpc-1881	115	7	26	26	NUM
dpc-1881	115	8	]	]	PUNCT
dpc-1881	115	9	,	,	PUNCT
dpc-1881	115	10	orr	orr	PROPN
dpc-1881	115	11	was	be	AUX
dpc-1881	115	12	42	42	NUM
dpc-1881	115	13	%	%	NOUN
dpc-1881	115	14	with	with	ADP
dpc-1881	115	15	nivolumab	nivolumab	NOUN
dpc-1881	115	16	and	and	CCONJ
dpc-1881	115	17	14	14	NUM
dpc-1881	115	18	%	%	NOUN
dpc-1881	115	19	with	with	ADP
dpc-1881	115	20	dacarbazine	dacarbazine	NOUN
dpc-1881	115	21	.	.	PUNCT
dpc-1881	116	1	fiveyear	fiveyear	NOUN
dpc-1881	116	2	os	os	PROPN
dpc-1881	116	3	rates	rate	NOUN
dpc-1881	116	4	were	be	AUX
dpc-1881	116	5	39	39	NUM
dpc-1881	116	6	%	%	NOUN
dpc-1881	116	7	with	with	ADP
dpc-1881	116	8	nivolumab	nivolumab	NOUN
dpc-1881	116	9	and	and	CCONJ
dpc-1881	116	10	17	17	NUM
dpc-1881	116	11	%	%	NOUN
dpc-1881	116	12	with	with	ADP
dpc-1881	116	13	dacarbazine	dacarbazine	NOUN
dpc-1881	116	14	;	;	PUNCT
dpc-1881	116	15	pfs	pfs	PROPN
dpc-1881	116	16	rates	rate	NOUN
dpc-1881	116	17	were	be	AUX
dpc-1881	116	18	28	28	NUM
dpc-1881	116	19	%	%	NOUN
dpc-1881	116	20	and	and	CCONJ
dpc-1881	116	21	3	3	NUM
dpc-1881	116	22	%	%	NOUN
dpc-1881	116	23	,	,	PUNCT
dpc-1881	116	24	respectively	respectively	ADV
dpc-1881	116	25	.	.	PUNCT
dpc-1881	117	1	among	among	ADP
dpc-1881	117	2	patients	patient	NOUN
dpc-1881	117	3	treated	treat	VERB
dpc-1881	117	4	with	with	ADP
dpc-1881	117	5	nivolumab	nivolumab	NOUN
dpc-1881	117	6	who	who	PRON
dpc-1881	117	7	had	have	VERB
dpc-1881	117	8	a	a	DET
dpc-1881	117	9	complete	complete	ADJ
dpc-1881	117	10	response	response	NOUN
dpc-1881	117	11	(	(	PUNCT
dpc-1881	117	12	20	20	NUM
dpc-1881	117	13	%	%	NOUN
dpc-1881	117	14	)	)	PUNCT
dpc-1881	117	15	,	,	PUNCT
dpc-1881	117	16	88	88	NUM
dpc-1881	117	17	%	%	NOUN
dpc-1881	117	18	(	(	PUNCT
dpc-1881	117	19	37	37	NUM
dpc-1881	117	20	of	of	ADP
dpc-1881	117	21	42	42	NUM
dpc-1881	117	22	)	)	PUNCT
dpc-1881	117	23	were	be	AUX
dpc-1881	117	24	alive	alive	ADJ
dpc-1881	117	25	as	as	ADP
dpc-1881	117	26	of	of	ADP
dpc-1881	117	27	the	the	DET
dpc-1881	117	28	5	5	NUM
dpc-1881	117	29	-	-	PUNCT
dpc-1881	117	30	year	year	NOUN
dpc-1881	117	31	analysis	analysis	NOUN
dpc-1881	117	32	.	.	PUNCT
dpc-1881	118	1	in	in	ADP
dpc-1881	118	2	checkmate	checkmate	NOUN
dpc-1881	118	3	037	037	NUM
dpc-1881	118	4	phase	phase	NOUN
dpc-1881	118	5	iii	iii	NOUN
dpc-1881	118	6	trial	trial	NOUN
dpc-1881	118	7	,	,	PUNCT
dpc-1881	118	8	patients	patient	NOUN
dpc-1881	118	9	were	be	AUX
dpc-1881	118	10	randomly	randomly	ADV
dpc-1881	118	11	assigned	assign	VERB
dpc-1881	118	12	2:1	2:1	NUM
dpc-1881	118	13	to	to	PART
dpc-1881	118	14	receive	receive	VERB
dpc-1881	118	15	nivolumab	nivolumab	NOUN
dpc-1881	118	16	3	3	NUM
dpc-1881	118	17	mg	mg	PROPN
dpc-1881	118	18	/	/	SYM
dpc-1881	118	19	kg	kg	NOUN
dpc-1881	118	20	every	every	DET
dpc-1881	118	21	2	2	NUM
dpc-1881	118	22	weeks	week	NOUN
dpc-1881	118	23	or	or	CCONJ
dpc-1881	118	24	investigators	investigator	NOUN
dpc-1881	118	25	’	’	PART
dpc-1881	118	26	choice	choice	NOUN
dpc-1881	118	27	chemotherapy	chemotherapy	NOUN
dpc-1881	118	28	(	(	PUNCT
dpc-1881	118	29	icc	icc	PROPN
dpc-1881	118	30	)	)	PUNCT
dpc-1881	118	31	in	in	ADP
dpc-1881	118	32	ipilimumab	ipilimumab	ADJ
dpc-1881	118	33	-	-	PUNCT
dpc-1881	118	34	refractory	refractory	NOUN
dpc-1881	118	35	patients	patient	NOUN
dpc-1881	118	36	with	with	ADP
dpc-1881	118	37	advanced	advanced	ADJ
dpc-1881	118	38	melanoma	melanoma	NOUN
dpc-1881	119	1	[	[	X
dpc-1881	119	2	27	27	NUM
dpc-1881	119	3	]	]	PUNCT
dpc-1881	119	4	.	.	PUNCT
dpc-1881	120	1	primary	primary	ADJ
dpc-1881	120	2	endpoints	endpoint	NOUN
dpc-1881	120	3	were	be	AUX
dpc-1881	120	4	the	the	DET
dpc-1881	120	5	proportion	proportion	NOUN
dpc-1881	120	6	of	of	ADP
dpc-1881	120	7	patients	patient	NOUN
dpc-1881	120	8	who	who	PRON
dpc-1881	120	9	had	have	VERB
dpc-1881	120	10	an	an	DET
dpc-1881	120	11	objective	objective	ADJ
dpc-1881	120	12	response	response	NOUN
dpc-1881	120	13	and	and	CCONJ
dpc-1881	120	14	os	os	NOUN
dpc-1881	120	15	.	.	PUNCT
dpc-1881	121	1	at	at	ADP
dpc-1881	121	2	first	first	ADJ
dpc-1881	121	3	interim	interim	ADJ
dpc-1881	121	4	analysis	analysis	NOUN
dpc-1881	121	5	on	on	ADP
dpc-1881	121	6	120	120	NUM
dpc-1881	121	7	and	and	CCONJ
dpc-1881	121	8	47	47	NUM
dpc-1881	121	9	randomized	randomized	ADJ
dpc-1881	121	10	patients	patient	NOUN
dpc-1881	121	11	,	,	PUNCT
dpc-1881	121	12	confirmed	confirm	VERB
dpc-1881	121	13	objective	objective	ADJ
dpc-1881	121	14	responses	response	NOUN
dpc-1881	121	15	were	be	AUX
dpc-1881	121	16	reported	report	VERB
dpc-1881	121	17	in	in	ADP
dpc-1881	121	18	31.7	31.7	NUM
dpc-1881	121	19	%	%	NOUN
dpc-1881	121	20	of	of	ADP
dpc-1881	121	21	patients	patient	NOUN
dpc-1881	121	22	in	in	ADP
dpc-1881	121	23	the	the	DET
dpc-1881	121	24	nivolumab	nivolumab	NOUN
dpc-1881	121	25	group	group	NOUN
dpc-1881	121	26	vs.	vs.	ADP
dpc-1881	121	27	10.6	10.6	NUM
dpc-1881	121	28	%	%	NOUN
dpc-1881	121	29	of	of	ADP
dpc-1881	121	30	patients	patient	NOUN
dpc-1881	121	31	in	in	ADP
dpc-1881	121	32	the	the	DET
dpc-1881	121	33	icc	icc	NOUN
dpc-1881	121	34	group	group	NOUN
dpc-1881	121	35	;	;	PUNCT
dpc-1881	121	36	no	no	DET
dpc-1881	121	37	treatment	treatment	NOUN
dpc-1881	121	38	-	-	PUNCT
dpc-1881	121	39	related	relate	VERB
dpc-1881	121	40	deaths	death	NOUN
dpc-1881	121	41	occurred	occur	VERB
dpc-1881	121	42	.	.	PUNCT
dpc-1881	122	1	in	in	ADP
dpc-1881	122	2	the	the	DET
dpc-1881	122	3	final	final	ADJ
dpc-1881	122	4	2018	2018	NUM
dpc-1881	122	5	report	report	NOUN
dpc-1881	122	6	[	[	X
dpc-1881	122	7	28	28	NUM
dpc-1881	122	8	]	]	PUNCT
dpc-1881	122	9	,	,	PUNCT
dpc-1881	122	10	the	the	DET
dpc-1881	122	11	overall	overall	ADJ
dpc-1881	122	12	rr	rr	NOUN
dpc-1881	122	13	(	(	PUNCT
dpc-1881	122	14	27	27	NUM
dpc-1881	122	15	%	%	NOUN
dpc-1881	122	16	v	v	ADP
dpc-1881	122	17	10	10	NUM
dpc-1881	122	18	%	%	NOUN
dpc-1881	122	19	)	)	PUNCT
dpc-1881	122	20	and	and	CCONJ
dpc-1881	122	21	median	median	ADJ
dpc-1881	122	22	duration	duration	NOUN
dpc-1881	122	23	of	of	ADP
dpc-1881	122	24	response	response	NOUN
dpc-1881	122	25	(	(	PUNCT
dpc-1881	122	26	32	32	NUM
dpc-1881	122	27	versus	versus	ADP
dpc-1881	122	28	13	13	NUM
dpc-1881	122	29	months	month	NOUN
dpc-1881	122	30	)	)	PUNCT
dpc-1881	122	31	were	be	AUX
dpc-1881	122	32	significantly	significantly	ADV
dpc-1881	122	33	higher	high	ADJ
dpc-1881	122	34	for	for	ADP
dpc-1881	122	35	nivolumab	nivolumab	NOUN
dpc-1881	122	36	versus	versus	ADP
dpc-1881	122	37	icc	icc	NOUN
dpc-1881	122	38	.	.	PUNCT
dpc-1881	123	1	fewer	few	ADJ
dpc-1881	123	2	grade	grade	NOUN
dpc-1881	123	3	3	3	NUM
dpc-1881	123	4	and	and	CCONJ
dpc-1881	123	5	4	4	NUM
dpc-1881	123	6	treatment	treatment	NOUN
dpc-1881	123	7	-	-	PUNCT
dpc-1881	123	8	related	relate	VERB
dpc-1881	123	9	adverse	adverse	ADJ
dpc-1881	123	10	events	event	NOUN
dpc-1881	123	11	were	be	AUX
dpc-1881	123	12	observed	observe	VERB
dpc-1881	123	13	in	in	ADP
dpc-1881	123	14	patients	patient	NOUN
dpc-1881	123	15	on	on	ADP
dpc-1881	123	16	nivolumab	nivolumab	NOUN
dpc-1881	123	17	(	(	PUNCT
dpc-1881	123	18	14	14	NUM
dpc-1881	123	19	%	%	NOUN
dpc-1881	123	20	v	v	ADP
dpc-1881	123	21	34	34	NUM
dpc-1881	123	22	%	%	NOUN
dpc-1881	123	23	)	)	PUNCT
dpc-1881	123	24	.	.	PUNCT
dpc-1881	124	1	median	median	PROPN
dpc-1881	124	2	os	os	PROPN
dpc-1881	124	3	was	be	AUX
dpc-1881	124	4	16	16	NUM
dpc-1881	124	5	months	month	NOUN
dpc-1881	124	6	for	for	ADP
dpc-1881	124	7	nivolumab	nivolumab	NOUN
dpc-1881	124	8	versus	versus	ADP
dpc-1881	124	9	14	14	NUM
dpc-1881	124	10	months	month	NOUN
dpc-1881	124	11	for	for	ADP
dpc-1881	124	12	icc	icc	NOUN
dpc-1881	124	13	;	;	PUNCT
dpc-1881	124	14	this	this	DET
dpc-1881	124	15	data	datum	NOUN
dpc-1881	124	16	should	should	AUX
dpc-1881	124	17	however	however	ADV
dpc-1881	124	18	be	be	AUX
dpc-1881	124	19	interpreted	interpret	VERB
dpc-1881	124	20	with	with	ADP
dpc-1881	124	21	caution	caution	NOUN
dpc-1881	124	22	as	as	SCONJ
dpc-1881	124	23	patients	patient	NOUN
dpc-1881	124	24	enrolled	enrol	VERB
dpc-1881	124	25	in	in	ADP
dpc-1881	124	26	the	the	DET
dpc-1881	124	27	icc	icc	NOUN
dpc-1881	124	28	group	group	NOUN
dpc-1881	124	29	could	could	AUX
dpc-1881	124	30	thereafter	thereafter	ADV
dpc-1881	124	31	be	be	AUX
dpc-1881	124	32	treated	treat	VERB
dpc-1881	124	33	by	by	ADP
dpc-1881	124	34	anti	anti	ADJ
dpc-1881	124	35	-	-	ADJ
dpc-1881	124	36	pd1	pd1	NOUN
dpc-1881	124	37	or	or	CCONJ
dpc-1881	124	38	anti	anti	ADJ
dpc-1881	124	39	-	-	ADJ
dpc-1881	124	40	braf	braf	ADJ
dpc-1881	124	41	targeted	target	VERB
dpc-1881	124	42	therapies	therapy	NOUN
dpc-1881	124	43	.	.	PUNCT
dpc-1881	125	1	as	as	SCONJ
dpc-1881	125	2	to	to	PART
dpc-1881	125	3	pembrolizumab	pembrolizumab	VERB
dpc-1881	125	4	,	,	PUNCT
dpc-1881	125	5	keynote-006	keynote-006	ADJ
dpc-1881	125	6	was	be	AUX
dpc-1881	125	7	an	an	DET
dpc-1881	125	8	open	open	ADJ
dpc-1881	125	9	-	-	PUNCT
dpc-1881	125	10	label	label	NOUN
dpc-1881	125	11	,	,	PUNCT
dpc-1881	125	12	multicenter	multicenter	NOUN
dpc-1881	125	13	,	,	PUNCT
dpc-1881	125	14	randomized	randomize	VERB
dpc-1881	125	15	,	,	PUNCT
dpc-1881	125	16	controlled	control	VERB
dpc-1881	125	17	,	,	PUNCT
dpc-1881	125	18	phase	phase	NOUN
dpc-1881	125	19	3	3	NUM
dpc-1881	125	20	study	study	NOUN
dpc-1881	125	21	in	in	ADP
dpc-1881	125	22	which	which	PRON
dpc-1881	125	23	834	834	NUM
dpc-1881	125	24	patients	patient	NOUN
dpc-1881	125	25	with	with	ADP
dpc-1881	125	26	advanced	advanced	ADJ
dpc-1881	125	27	melanoma	melanoma	NOUN
dpc-1881	125	28	were	be	AUX
dpc-1881	125	29	randomized	randomize	VERB
dpc-1881	125	30	to	to	PART
dpc-1881	125	31	receive	receive	VERB
dpc-1881	125	32	pembrolizumab	pembrolizumab	NOUN
dpc-1881	125	33	at	at	ADP
dpc-1881	125	34	a	a	DET
dpc-1881	125	35	dose	dose	NOUN
dpc-1881	125	36	of	of	ADP
dpc-1881	125	37	10	10	NUM
dpc-1881	125	38	mg	mg	NOUN
dpc-1881	125	39	/	/	SYM
dpc-1881	125	40	kg	kg	NOUN
dpc-1881	125	41	every	every	DET
dpc-1881	125	42	2	2	NUM
dpc-1881	125	43	or	or	CCONJ
dpc-1881	125	44	every	every	DET
dpc-1881	125	45	3	3	NUM
dpc-1881	125	46	weeks	week	NOUN
dpc-1881	125	47	,	,	PUNCT
dpc-1881	125	48	or	or	CCONJ
dpc-1881	125	49	with	with	ADP
dpc-1881	125	50	4	4	NUM
dpc-1881	125	51	doses	dose	NOUN
dpc-1881	125	52	of	of	ADP
dpc-1881	125	53	ipilimumab	ipilimumab	NOUN
dpc-1881	125	54	(	(	PUNCT
dpc-1881	125	55	3	3	NUM
dpc-1881	125	56	mg	mg	PROPN
dpc-1881	125	57	/	/	SYM
dpc-1881	125	58	kg	kg	NOUN
dpc-1881	125	59	every	every	DET
dpc-1881	125	60	3	3	NUM
dpc-1881	125	61	weeks	week	NOUN
dpc-1881	125	62	)	)	PUNCT
dpc-1881	125	63	.	.	PUNCT
dpc-1881	126	1	the	the	DET
dpc-1881	126	2	estimated	estimate	VERB
dpc-1881	126	3	6	6	NUM
dpc-1881	126	4	-	-	PUNCT
dpc-1881	126	5	months	month	NOUN
dpc-1881	126	6	pfs	pfs	PROPN
dpc-1881	126	7	rates	rate	NOUN
dpc-1881	126	8	were	be	AUX
dpc-1881	126	9	47.3	47.3	NUM
dpc-1881	126	10	%	%	NOUN
dpc-1881	126	11	for	for	ADP
dpc-1881	126	12	pembrolizumab	pembrolizumab	NOUN
dpc-1881	126	13	every	every	DET
dpc-1881	126	14	2	2	NUM
dpc-1881	126	15	weeks	week	NOUN
dpc-1881	126	16	,	,	PUNCT
dpc-1881	126	17	46.4	46.4	NUM
dpc-1881	126	18	%	%	NOUN
dpc-1881	126	19	for	for	ADP
dpc-1881	126	20	pembrolizumab	pembrolizumab	NOUN
dpc-1881	126	21	every	every	DET
dpc-1881	126	22	3	3	NUM
dpc-1881	126	23	weeks	week	NOUN
dpc-1881	126	24	,	,	PUNCT
dpc-1881	126	25	and	and	CCONJ
dpc-1881	126	26	26.5	26.5	NUM
dpc-1881	126	27	%	%	NOUN
dpc-1881	126	28	for	for	ADP
dpc-1881	126	29	ipilimumab	ipilimumab	NOUN
dpc-1881	126	30	,	,	PUNCT
dpc-1881	126	31	respectively	respectively	ADV
dpc-1881	126	32	.	.	PUNCT
dpc-1881	127	1	estimated	estimate	VERB
dpc-1881	127	2	1	1	NUM
dpc-1881	127	3	-	-	PUNCT
dpc-1881	127	4	year	year	NOUN
dpc-1881	127	5	os	os	NOUN
dpc-1881	127	6	rates	rate	NOUN
dpc-1881	127	7	were	be	AUX
dpc-1881	127	8	74.1	74.1	NUM
dpc-1881	127	9	%	%	NOUN
dpc-1881	127	10	,	,	PUNCT
dpc-1881	127	11	68.4	68.4	NUM
dpc-1881	127	12	%	%	NOUN
dpc-1881	127	13	,	,	PUNCT
dpc-1881	127	14	and	and	CCONJ
dpc-1881	127	15	58.2	58.2	NUM
dpc-1881	127	16	%	%	NOUN
dpc-1881	127	17	,	,	PUNCT
dpc-1881	127	18	respectively	respectively	ADV
dpc-1881	127	19	.	.	PUNCT
dpc-1881	128	1	the	the	DET
dpc-1881	128	2	rr	rr	PROPN
dpc-1881	128	3	was	be	AUX
dpc-1881	128	4	improved	improve	VERB
dpc-1881	128	5	when	when	SCONJ
dpc-1881	128	6	pembrolizumab	pembrolizumab	NOUN
dpc-1881	128	7	was	be	AUX
dpc-1881	128	8	administered	administer	VERB
dpc-1881	128	9	either	either	CCONJ
dpc-1881	128	10	every	every	DET
dpc-1881	128	11	2	2	NUM
dpc-1881	128	12	or	or	CCONJ
dpc-1881	128	13	3	3	NUM
dpc-1881	128	14	weeks	week	NOUN
dpc-1881	128	15	,	,	PUNCT
dpc-1881	128	16	as	as	SCONJ
dpc-1881	128	17	compared	compare	VERB
dpc-1881	128	18	with	with	ADP
dpc-1881	128	19	ipilimumab	ipilimumab	NOUN
dpc-1881	128	20	.	.	PUNCT
dpc-1881	129	1	treatment	treatment	NOUN
dpc-1881	129	2	-	-	PUNCT
dpc-1881	129	3	related	relate	VERB
dpc-1881	129	4	adverse	adverse	ADJ
dpc-1881	129	5	events	event	NOUN
dpc-1881	129	6	of	of	ADP
dpc-1881	129	7	grade	grade	NOUN
dpc-1881	129	8	3–5	3–5	NUM
dpc-1881	129	9	severity	severity	NOUN
dpc-1881	129	10	were	be	AUX
dpc-1881	129	11	lower	low	ADJ
dpc-1881	129	12	in	in	ADP
dpc-1881	129	13	the	the	DET
dpc-1881	129	14	pembrolizumab	pembrolizumab	NOUN
dpc-1881	129	15	groups	group	NOUN
dpc-1881	129	16	(	(	PUNCT
dpc-1881	129	17	13.3	13.3	NUM
dpc-1881	129	18	%	%	NOUN
dpc-1881	129	19	and	and	CCONJ
dpc-1881	129	20	10.1	10.1	NUM
dpc-1881	129	21	%	%	NOUN
dpc-1881	129	22	)	)	PUNCT
dpc-1881	130	1	[	[	X
dpc-1881	130	2	29	29	NUM
dpc-1881	130	3	]	]	PUNCT
dpc-1881	130	4	.	.	PUNCT
dpc-1881	131	1	at	at	ADP
dpc-1881	131	2	the	the	DET
dpc-1881	131	3	final	final	ADJ
dpc-1881	131	4	5	5	NUM
dpc-1881	131	5	-	-	PUNCT
dpc-1881	131	6	year	year	NOUN
dpc-1881	131	7	follow	follow	NOUN
dpc-1881	131	8	-	-	PUNCT
dpc-1881	131	9	up	up	ADP
dpc-1881	131	10	data	datum	NOUN
dpc-1881	131	11	,	,	PUNCT
dpc-1881	131	12	median	median	ADJ
dpc-1881	131	13	overall	overall	ADJ
dpc-1881	131	14	survival	survival	NOUN
dpc-1881	131	15	was	be	AUX
dpc-1881	131	16	32.7	32.7	NUM
dpc-1881	131	17	months	month	NOUN
dpc-1881	131	18	in	in	ADP
dpc-1881	131	19	the	the	DET
dpc-1881	131	20	combined	combine	VERB
dpc-1881	131	21	pembrolizumab	pembrolizumab	NOUN
dpc-1881	131	22	groups	group	NOUN
dpc-1881	131	23	and	and	CCONJ
dpc-1881	131	24	15.9	15.9	NUM
dpc-1881	131	25	months	month	NOUN
dpc-1881	131	26	in	in	ADP
dpc-1881	131	27	the	the	DET
dpc-1881	131	28	ipilimumab	ipilimumab	NOUN
dpc-1881	131	29	group	group	NOUN
dpc-1881	131	30	(	(	PUNCT
dpc-1881	131	31	p=0·00049	p=0·00049	PROPN
dpc-1881	131	32	)	)	PUNCT
dpc-1881	131	33	.	.	PUNCT
dpc-1881	132	1	median	median	PROPN
dpc-1881	132	2	pfs	pfs	PROPN
dpc-1881	132	3	was	be	AUX
dpc-1881	132	4	8.4	8.4	NUM
dpc-1881	132	5	months	month	NOUN
dpc-1881	132	6	and	and	CCONJ
dpc-1881	132	7	3.4	3.4	NUM
dpc-1881	132	8	months	month	NOUN
dpc-1881	132	9	,	,	PUNCT
dpc-1881	132	10	respectively	respectively	ADV
dpc-1881	132	11	[	[	X
dpc-1881	132	12	30	30	NUM
dpc-1881	132	13	]	]	PUNCT
dpc-1881	132	14	.	.	PUNCT
dpc-1881	133	1	a	a	DET
dpc-1881	133	2	relevant	relevant	ADJ
dpc-1881	133	3	analysis	analysis	NOUN
dpc-1881	133	4	from	from	ADP
dpc-1881	133	5	this	this	DET
dpc-1881	133	6	study	study	NOUN
dpc-1881	133	7	was	be	AUX
dpc-1881	133	8	done	do	VERB
dpc-1881	133	9	in	in	ADP
dpc-1881	133	10	patients	patient	NOUN
dpc-1881	133	11	who	who	PRON
dpc-1881	133	12	stopped	stop	VERB
dpc-1881	133	13	pembrolizumab	pembrolizumab	NOUN
dpc-1881	133	14	after	after	ADP
dpc-1881	133	15	24	24	NUM
dpc-1881	133	16	months	month	NOUN
dpc-1881	133	17	as	as	ADP
dpc-1881	133	18	per	per	ADP
dpc-1881	133	19	protocol	protocol	NOUN
dpc-1881	133	20	.	.	PUNCT
dpc-1881	134	1	after	after	ADP
dpc-1881	134	2	a	a	DET
dpc-1881	134	3	median	median	ADJ
dpc-1881	134	4	follow	follow	NOUN
dpc-1881	134	5	-	-	PUNCT
dpc-1881	134	6	up	up	NOUN
dpc-1881	134	7	of	of	ADP
dpc-1881	134	8	34·2	34·2	NUM
dpc-1881	134	9	months	month	NOUN
dpc-1881	134	10	from	from	ADP
dpc-1881	134	11	completion	completion	NOUN
dpc-1881	134	12	of	of	ADP
dpc-1881	134	13	pembrolizumab	pembrolizumab	NOUN
dpc-1881	134	14	,	,	PUNCT
dpc-1881	134	15	the	the	DET
dpc-1881	134	16	estimated	estimate	VERB
dpc-1881	134	17	24	24	NUM
dpc-1881	134	18	-	-	PUNCT
dpc-1881	134	19	month	month	NOUN
dpc-1881	134	20	pfs	pfs	PROPN
dpc-1881	134	21	from	from	ADP
dpc-1881	134	22	treatment	treatment	NOUN
dpc-1881	134	23	interruption	interruption	NOUN
dpc-1881	134	24	for	for	ADP
dpc-1881	134	25	all	all	DET
dpc-1881	134	26	103	103	NUM
dpc-1881	134	27	patients	patient	NOUN
dpc-1881	134	28	was	be	AUX
dpc-1881	134	29	78.4	78.4	NUM
dpc-1881	134	30	%	%	NOUN
dpc-1881	134	31	and	and	CCONJ
dpc-1881	134	32	36	36	NUM
dpc-1881	134	33	-	-	PUNCT
dpc-1881	134	34	month	month	NOUN
dpc-1881	134	35	os	os	NOUN
dpc-1881	134	36	was	be	AUX
dpc-1881	134	37	93.8	93.8	NUM
dpc-1881	134	38	%	%	NOUN
dpc-1881	134	39	.	.	PUNCT
dpc-1881	135	1	estimated	estimate	VERB
dpc-1881	135	2	24	24	NUM
dpc-1881	135	3	-	-	PUNCT
dpc-1881	135	4	month	month	NOUN
dpc-1881	135	5	pfs	pfs	PROPN
dpc-1881	135	6	was	be	AUX
dpc-1881	135	7	85.4	85.4	NUM
dpc-1881	135	8	%	%	NOUN
dpc-1881	135	9	for	for	ADP
dpc-1881	135	10	patients	patient	NOUN
dpc-1881	135	11	with	with	ADP
dpc-1881	135	12	complete	complete	ADJ
dpc-1881	135	13	response	response	NOUN
dpc-1881	135	14	,	,	PUNCT
dpc-1881	135	15	82.3	82.3	NUM
dpc-1881	135	16	%	%	NOUN
dpc-1881	135	17	for	for	ADP
dpc-1881	135	18	patients	patient	NOUN
dpc-1881	135	19	with	with	ADP
dpc-1881	135	20	partial	partial	ADJ
dpc-1881	135	21	response	response	NOUN
dpc-1881	135	22	,	,	PUNCT
dpc-1881	135	23	and	and	CCONJ
dpc-1881	135	24	only	only	ADV
dpc-1881	135	25	39.9	39.9	NUM
dpc-1881	135	26	%	%	NOUN
dpc-1881	135	27	for	for	ADP
dpc-1881	135	28	patients	patient	NOUN
dpc-1881	135	29	with	with	ADP
dpc-1881	135	30	stable	stable	ADJ
dpc-1881	135	31	disease	disease	NOUN
dpc-1881	135	32	.	.	PUNCT
dpc-1881	136	1	these	these	DET
dpc-1881	136	2	data	datum	NOUN
dpc-1881	136	3	pave	pave	VERB
dpc-1881	136	4	the	the	DET
dpc-1881	136	5	way	way	NOUN
dpc-1881	136	6	for	for	ADP
dpc-1881	136	7	the	the	DET
dpc-1881	136	8	possibility	possibility	NOUN
dpc-1881	136	9	of	of	ADP
dpc-1881	136	10	interruption	interruption	NOUN
dpc-1881	136	11	of	of	ADP
dpc-1881	136	12	anti	anti	ADJ
dpc-1881	136	13	-	-	ADJ
dpc-1881	136	14	pd1	pd1	VERB
dpc-1881	136	15	treatment	treatment	NOUN
dpc-1881	136	16	in	in	ADP
dpc-1881	136	17	responding	respond	VERB
dpc-1881	136	18	patients	patient	NOUN
dpc-1881	136	19	after	after	ADP
dpc-1881	136	20	2	2	NUM
dpc-1881	136	21	years	year	NOUN
dpc-1881	136	22	of	of	ADP
dpc-1881	136	23	therapy	therapy	NOUN
dpc-1881	136	24	.	.	PUNCT
dpc-1881	137	1	keynote-002	keynote-002	PROPN
dpc-1881	137	2	study	study	PROPN
dpc-1881	137	3	was	be	AUX
dpc-1881	137	4	a	a	DET
dpc-1881	137	5	randomized	randomized	ADJ
dpc-1881	137	6	phase	phase	NOUN
dpc-1881	137	7	ii	ii	NOUN
dpc-1881	137	8	multicenter	multicenter	NOUN
dpc-1881	137	9	trial	trial	NOUN
dpc-1881	137	10	in	in	ADP
dpc-1881	137	11	which	which	PRON
dpc-1881	137	12	advanced	advanced	ADJ
dpc-1881	137	13	melanoma	melanoma	NOUN
dpc-1881	137	14	patients	patient	NOUN
dpc-1881	137	15	with	with	ADP
dpc-1881	137	16	progression	progression	NOUN
dpc-1881	137	17	after	after	ADP
dpc-1881	137	18	ipilimumab	ipilimumab	NOUN
dpc-1881	137	19	and/or	and/or	CCONJ
dpc-1881	137	20	braf	braf	PROPN
dpc-1881	137	21	/	/	SYM
dpc-1881	137	22	mek	mek	PROPN
dpc-1881	137	23	inhibitors	inhibitor	NOUN
dpc-1881	137	24	were	be	AUX
dpc-1881	137	25	randomized	randomize	VERB
dpc-1881	137	26	to	to	PART
dpc-1881	137	27	pembrolizumab	pembrolizumab	VERB
dpc-1881	137	28	2	2	NUM
dpc-1881	137	29	mg	mg	NUM
dpc-1881	137	30	/	/	SYM
dpc-1881	137	31	kg	kg	PROPN
dpc-1881	137	32	or	or	CCONJ
dpc-1881	137	33	10	10	NUM
dpc-1881	137	34	mg	mg	NUM
dpc-1881	137	35	/	/	SYM
dpc-1881	137	36	kg	kg	NOUN
dpc-1881	137	37	every	every	DET
dpc-1881	137	38	3	3	NUM
dpc-1881	137	39	weeks	week	NOUN
dpc-1881	137	40	or	or	CCONJ
dpc-1881	137	41	investigator	investigator	NOUN
dpc-1881	137	42	-	-	PUNCT
dpc-1881	137	43	choice	choice	NOUN
dpc-1881	137	44	chemotherapy	chemotherapy	NOUN
dpc-1881	137	45	.	.	PUNCT
dpc-1881	138	1	crossreview	crossreview	NOUN
dpc-1881	138	2	|	|	ADV
dpc-1881	138	3	dermatol	dermatol	ADJ
dpc-1881	138	4	pract	pract	NOUN
dpc-1881	138	5	concept	concept	NOUN
dpc-1881	138	6	.	.	PUNCT
dpc-1881	139	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	139	2	):	):	PUNCT
dpc-1881	139	3	e2021164s	e2021164s	PROPN
dpc-1881	139	4	5	5	NUM
dpc-1881	139	5	over	over	ADP
dpc-1881	139	6	to	to	ADP
dpc-1881	139	7	pembrolizumab	pembrolizumab	NOUN
dpc-1881	139	8	was	be	AUX
dpc-1881	139	9	allowed	allow	VERB
dpc-1881	139	10	following	follow	VERB
dpc-1881	139	11	progression	progression	NOUN
dpc-1881	139	12	on	on	ADP
dpc-1881	139	13	chemotherapy	chemotherapy	NOUN
dpc-1881	139	14	.	.	PUNCT
dpc-1881	140	1	a	a	DET
dpc-1881	140	2	total	total	NOUN
dpc-1881	140	3	of	of	ADP
dpc-1881	140	4	180	180	NUM
dpc-1881	140	5	patients	patient	NOUN
dpc-1881	140	6	were	be	AUX
dpc-1881	140	7	randomized	randomize	VERB
dpc-1881	140	8	to	to	PART
dpc-1881	140	9	pembrolizumab	pembrolizumab	VERB
dpc-1881	140	10	2	2	NUM
dpc-1881	140	11	mg	mg	PROPN
dpc-1881	140	12	/	/	SYM
dpc-1881	140	13	kg	kg	PROPN
dpc-1881	140	14	,	,	PUNCT
dpc-1881	140	15	181	181	NUM
dpc-1881	140	16	to	to	PART
dpc-1881	140	17	pembrolizumab	pembrolizumab	VERB
dpc-1881	140	18	10	10	NUM
dpc-1881	140	19	mg	mg	NUM
dpc-1881	140	20	/	/	SYM
dpc-1881	140	21	kg	kg	PROPN
dpc-1881	140	22	and	and	CCONJ
dpc-1881	140	23	179	179	NUM
dpc-1881	140	24	to	to	ADP
dpc-1881	140	25	chemotherapy	chemotherapy	NOUN
dpc-1881	140	26	.	.	PUNCT
dpc-1881	141	1	6	6	NUM
dpc-1881	141	2	-	-	PUNCT
dpc-1881	141	3	month	month	NOUN
dpc-1881	141	4	pfs	pfs	PROPN
dpc-1881	141	5	was	be	AUX
dpc-1881	141	6	34	34	NUM
dpc-1881	141	7	%	%	NOUN
dpc-1881	141	8	in	in	ADP
dpc-1881	141	9	the	the	DET
dpc-1881	141	10	pembrolizumab	pembrolizumab	NOUN
dpc-1881	141	11	2	2	NUM
dpc-1881	141	12	mg	mg	PROPN
dpc-1881	141	13	/	/	SYM
dpc-1881	141	14	kg	kg	PROPN
dpc-1881	141	15	group	group	NOUN
dpc-1881	141	16	,	,	PUNCT
dpc-1881	141	17	38	38	NUM
dpc-1881	141	18	%	%	NOUN
dpc-1881	141	19	in	in	ADP
dpc-1881	141	20	the	the	DET
dpc-1881	141	21	10	10	NUM
dpc-1881	141	22	mg	mg	PROPN
dpc-1881	141	23	/	/	SYM
dpc-1881	141	24	kg	kg	PROPN
dpc-1881	141	25	group	group	NOUN
dpc-1881	141	26	,	,	PUNCT
dpc-1881	141	27	and	and	CCONJ
dpc-1881	141	28	16	16	NUM
dpc-1881	141	29	%	%	NOUN
dpc-1881	141	30	in	in	ADP
dpc-1881	141	31	the	the	DET
dpc-1881	141	32	chemotherapy	chemotherapy	NOUN
dpc-1881	141	33	group	group	NOUN
dpc-1881	141	34	[	[	X
dpc-1881	141	35	31	31	NUM
dpc-1881	141	36	]	]	PUNCT
dpc-1881	141	37	.	.	PUNCT
dpc-1881	142	1	at	at	ADP
dpc-1881	142	2	the	the	DET
dpc-1881	142	3	final	final	ADJ
dpc-1881	142	4	post	post	ADJ
dpc-1881	142	5	-	-	ADJ
dpc-1881	142	6	hoc	hoc	ADJ
dpc-1881	142	7	5	5	NUM
dpc-1881	142	8	-	-	PUNCT
dpc-1881	142	9	year	year	NOUN
dpc-1881	142	10	analysis	analysis	NOUN
dpc-1881	142	11	,	,	PUNCT
dpc-1881	142	12	the	the	DET
dpc-1881	142	13	orr	orr	PROPN
dpc-1881	142	14	was	be	AUX
dpc-1881	142	15	22	22	NUM
dpc-1881	142	16	%	%	NOUN
dpc-1881	142	17	and	and	CCONJ
dpc-1881	142	18	28	28	NUM
dpc-1881	142	19	%	%	NOUN
dpc-1881	142	20	in	in	ADP
dpc-1881	142	21	patients	patient	NOUN
dpc-1881	142	22	receiving	receive	VERB
dpc-1881	142	23	pembrolizumab	pembrolizumab	NOUN
dpc-1881	142	24	,	,	PUNCT
dpc-1881	142	25	versus	versus	ADP
dpc-1881	142	26	4	4	NUM
dpc-1881	142	27	%	%	NOUN
dpc-1881	142	28	in	in	ADP
dpc-1881	142	29	patients	patient	NOUN
dpc-1881	142	30	receiving	receive	VERB
dpc-1881	142	31	chemotherapy	chemotherapy	NOUN
dpc-1881	142	32	(	(	PUNCT
dpc-1881	142	33	p<0.0001	p<0.0001	NOUN
dpc-1881	142	34	for	for	ADP
dpc-1881	142	35	both	both	DET
dpc-1881	142	36	pembrolizumab	pembrolizumab	NOUN
dpc-1881	142	37	doses	dose	NOUN
dpc-1881	142	38	versus	versus	ADP
dpc-1881	142	39	chemotherapy	chemotherapy	NOUN
dpc-1881	142	40	)	)	PUNCT
dpc-1881	143	1	[	[	X
dpc-1881	143	2	32	32	NUM
dpc-1881	143	3	]	]	PUNCT
dpc-1881	143	4	.	.	PUNCT
dpc-1881	143	5	anti	anti	ADJ
dpc-1881	143	6	-	-	ADJ
dpc-1881	143	7	ctla-4	ctla-4	NOUN
dpc-1881	143	8	/	/	SYM
dpc-1881	143	9	anti	anti	ADJ
dpc-1881	143	10	-	-	ADJ
dpc-1881	143	11	pd-1	pd-1	ADJ
dpc-1881	143	12	combo	combo	NOUN
dpc-1881	143	13	regimens	regimen	NOUN
dpc-1881	143	14	preclinical	preclinical	ADJ
dpc-1881	143	15	models	model	NOUN
dpc-1881	143	16	have	have	AUX
dpc-1881	143	17	shown	show	VERB
dpc-1881	143	18	that	that	SCONJ
dpc-1881	143	19	double	double	ADJ
dpc-1881	143	20	inhibition	inhibition	NOUN
dpc-1881	143	21	of	of	ADP
dpc-1881	143	22	ctla-4	ctla-4	NOUN
dpc-1881	143	23	and	and	CCONJ
dpc-1881	143	24	pd-1	pd-1	ADV
dpc-1881	143	25	,	,	PUNCT
dpc-1881	143	26	when	when	SCONJ
dpc-1881	143	27	compared	compare	VERB
dpc-1881	143	28	with	with	ADP
dpc-1881	143	29	single	single	ADJ
dpc-1881	143	30	-	-	PUNCT
dpc-1881	143	31	molecule	molecule	NOUN
dpc-1881	143	32	inhibition	inhibition	NOUN
dpc-1881	143	33	alone	alone	ADV
dpc-1881	143	34	,	,	PUNCT
dpc-1881	143	35	synergistically	synergistically	ADV
dpc-1881	143	36	increases	increase	VERB
dpc-1881	143	37	anticancer	anticancer	NOUN
dpc-1881	143	38	responses	response	NOUN
dpc-1881	143	39	173	173	NUM
dpc-1881	143	40	.	.	PUNCT
dpc-1881	144	1	in	in	ADP
dpc-1881	144	2	the	the	DET
dpc-1881	144	3	double	double	ADJ
dpc-1881	144	4	-	-	PUNCT
dpc-1881	144	5	blind	blind	ADJ
dpc-1881	144	6	phase	phase	NOUN
dpc-1881	144	7	ii	ii	PROPN
dpc-1881	144	8	checkmate	checkmate	VERB
dpc-1881	144	9	069	069	NUM
dpc-1881	144	10	study	study	NOUN
dpc-1881	144	11	,	,	PUNCT
dpc-1881	144	12	patients	patient	NOUN
dpc-1881	144	13	were	be	AUX
dpc-1881	144	14	randomized	randomize	VERB
dpc-1881	144	15	to	to	ADP
dpc-1881	144	16	treatment	treatment	NOUN
dpc-1881	144	17	with	with	ADP
dpc-1881	144	18	ipilimumab	ipilimumab	NOUN
dpc-1881	144	19	+	+	CCONJ
dpc-1881	144	20	nivolumab	nivolumab	NOUN
dpc-1881	144	21	or	or	CCONJ
dpc-1881	144	22	with	with	ADP
dpc-1881	144	23	ipilimumab	ipilimumab	NOUN
dpc-1881	144	24	+	+	CCONJ
dpc-1881	144	25	placebo	placebo	NOUN
dpc-1881	144	26	.	.	PUNCT
dpc-1881	145	1	at	at	ADP
dpc-1881	145	2	a	a	DET
dpc-1881	145	3	median	median	ADJ
dpc-1881	145	4	follow	follow	VERB
dpc-1881	145	5	-	-	PUNCT
dpc-1881	145	6	up	up	NOUN
dpc-1881	145	7	time	time	NOUN
dpc-1881	145	8	of	of	ADP
dpc-1881	145	9	24.5	24.5	NUM
dpc-1881	145	10	months	month	NOUN
dpc-1881	145	11	,	,	PUNCT
dpc-1881	145	12	the	the	DET
dpc-1881	145	13	two	two	NUM
dpc-1881	145	14	-	-	PUNCT
dpc-1881	145	15	year	year	NOUN
dpc-1881	145	16	survival	survival	NOUN
dpc-1881	145	17	was	be	AUX
dpc-1881	145	18	63.8	63.8	NUM
dpc-1881	145	19	%	%	NOUN
dpc-1881	145	20	for	for	ADP
dpc-1881	145	21	patients	patient	NOUN
dpc-1881	145	22	treated	treat	VERB
dpc-1881	145	23	with	with	ADP
dpc-1881	145	24	nivolumab	nivolumab	NOUN
dpc-1881	145	25	and	and	CCONJ
dpc-1881	145	26	ipilimumab	ipilimumab	VERB
dpc-1881	145	27	in	in	ADP
dpc-1881	145	28	combination	combination	NOUN
dpc-1881	145	29	and	and	CCONJ
dpc-1881	145	30	53.6	53.6	NUM
dpc-1881	145	31	%	%	NOUN
dpc-1881	145	32	for	for	ADP
dpc-1881	145	33	patients	patient	NOUN
dpc-1881	145	34	treated	treat	VERB
dpc-1881	145	35	with	with	ADP
dpc-1881	145	36	ipilimumab	ipilimumab	NOUN
dpc-1881	145	37	alone	alone	ADV
dpc-1881	145	38	.	.	PUNCT
dpc-1881	146	1	in	in	ADP
dpc-1881	146	2	patients	patient	NOUN
dpc-1881	146	3	with	with	ADP
dpc-1881	146	4	wild	wild	ADJ
dpc-1881	146	5	type	type	NOUN
dpc-1881	146	6	braf	braf	NOUN
dpc-1881	146	7	melanoma	melanoma	NOUN
dpc-1881	146	8	,	,	PUNCT
dpc-1881	146	9	the	the	DET
dpc-1881	146	10	rr	rr	PROPN
dpc-1881	146	11	was	be	AUX
dpc-1881	146	12	61	61	NUM
dpc-1881	146	13	%	%	NOUN
dpc-1881	146	14	in	in	ADP
dpc-1881	146	15	the	the	DET
dpc-1881	146	16	group	group	NOUN
dpc-1881	146	17	of	of	ADP
dpc-1881	146	18	patients	patient	NOUN
dpc-1881	146	19	who	who	PRON
dpc-1881	146	20	received	receive	VERB
dpc-1881	146	21	combination	combination	NOUN
dpc-1881	146	22	therapy	therapy	NOUN
dpc-1881	146	23	compared	compare	VERB
dpc-1881	146	24	to	to	ADP
dpc-1881	146	25	11	11	NUM
dpc-1881	146	26	%	%	NOUN
dpc-1881	146	27	of	of	ADP
dpc-1881	146	28	patients	patient	NOUN
dpc-1881	146	29	who	who	PRON
dpc-1881	146	30	received	receive	VERB
dpc-1881	146	31	ipilimumab	ipilimumab	NOUN
dpc-1881	146	32	+	+	CCONJ
dpc-1881	146	33	placebo	placebo	NOUN
dpc-1881	146	34	(	(	PUNCT
dpc-1881	146	35	p	p	X
dpc-1881	146	36	<	<	X
dpc-1881	146	37	0.001	0.001	NUM
dpc-1881	146	38	)	)	PUNCT
dpc-1881	146	39	,	,	PUNCT
dpc-1881	146	40	with	with	ADP
dpc-1881	146	41	complete	complete	ADJ
dpc-1881	146	42	responses	response	NOUN
dpc-1881	146	43	.	.	PUNCT
dpc-1881	147	1	reported	report	VERB
dpc-1881	147	2	in	in	ADP
dpc-1881	147	3	22	22	NUM
dpc-1881	147	4	%	%	NOUN
dpc-1881	147	5	of	of	ADP
dpc-1881	147	6	patients	patient	NOUN
dpc-1881	147	7	in	in	ADP
dpc-1881	147	8	the	the	DET
dpc-1881	147	9	first	first	ADJ
dpc-1881	147	10	group	group	NOUN
dpc-1881	147	11	and	and	CCONJ
dpc-1881	147	12	none	none	NOUN
dpc-1881	147	13	in	in	ADP
dpc-1881	147	14	patients	patient	NOUN
dpc-1881	147	15	treated	treat	VERB
dpc-1881	147	16	with	with	ADP
dpc-1881	147	17	ipilimumab	ipilimumab	NOUN
dpc-1881	147	18	alone	alone	ADV
dpc-1881	147	19	[	[	X
dpc-1881	147	20	33	33	NUM
dpc-1881	147	21	]	]	PUNCT
dpc-1881	147	22	.	.	PUNCT
dpc-1881	148	1	the	the	DET
dpc-1881	148	2	phase	phase	NOUN
dpc-1881	148	3	iii	iii	NOUN
dpc-1881	148	4	checkmate	checkmate	NOUN
dpc-1881	148	5	067	067	NUM
dpc-1881	149	1	[	[	X
dpc-1881	149	2	34,35	34,35	NOUN
dpc-1881	149	3	]	]	PUNCT
dpc-1881	149	4	study	study	NOUN
dpc-1881	149	5	assigned	assign	VERB
dpc-1881	149	6	patients	patient	NOUN
dpc-1881	149	7	with	with	ADP
dpc-1881	149	8	previously	previously	ADV
dpc-1881	149	9	untreated	untreated	ADJ
dpc-1881	149	10	advanced	advanced	ADJ
dpc-1881	149	11	melanoma	melanoma	NOUN
dpc-1881	149	12	to	to	PART
dpc-1881	149	13	receive	receive	VERB
dpc-1881	149	14	one	one	NUM
dpc-1881	149	15	of	of	ADP
dpc-1881	149	16	the	the	DET
dpc-1881	149	17	following	follow	VERB
dpc-1881	149	18	regimens	regimen	NOUN
dpc-1881	149	19	:	:	PUNCT
dpc-1881	149	20	nivolumab	nivolumab	NOUN
dpc-1881	149	21	(	(	PUNCT
dpc-1881	149	22	at	at	ADP
dpc-1881	149	23	a	a	DET
dpc-1881	149	24	dose	dose	NOUN
dpc-1881	149	25	of	of	ADP
dpc-1881	149	26	1	1	NUM
dpc-1881	149	27	mg	mg	NOUN
dpc-1881	149	28	per	per	ADP
dpc-1881	149	29	kilogram	kilogram	PROPN
dpc-1881	149	30	of	of	ADP
dpc-1881	149	31	body	body	NOUN
dpc-1881	149	32	weight	weight	NOUN
dpc-1881	149	33	)	)	PUNCT
dpc-1881	149	34	plus	plus	CCONJ
dpc-1881	149	35	ipilimumab	ipilimumab	NOUN
dpc-1881	149	36	(	(	PUNCT
dpc-1881	149	37	3	3	NUM
dpc-1881	149	38	mg	mg	NOUN
dpc-1881	149	39	per	per	ADP
dpc-1881	149	40	kilogram	kilogram	NOUN
dpc-1881	149	41	)	)	PUNCT
dpc-1881	149	42	every	every	DET
dpc-1881	149	43	3	3	NUM
dpc-1881	149	44	weeks	week	NOUN
dpc-1881	149	45	for	for	ADP
dpc-1881	149	46	4	4	NUM
dpc-1881	149	47	doses	dose	NOUN
dpc-1881	149	48	,	,	PUNCT
dpc-1881	149	49	followed	follow	VERB
dpc-1881	149	50	by	by	ADP
dpc-1881	149	51	nivolumab	nivolumab	NOUN
dpc-1881	149	52	(	(	PUNCT
dpc-1881	149	53	3	3	NUM
dpc-1881	149	54	mg	mg	NOUN
dpc-1881	149	55	per	per	ADP
dpc-1881	149	56	kilogram	kilogram	PROPN
dpc-1881	149	57	every	every	DET
dpc-1881	149	58	2	2	NUM
dpc-1881	149	59	weeks	week	NOUN
dpc-1881	149	60	)	)	PUNCT
dpc-1881	149	61	;	;	PUNCT
dpc-1881	149	62	nivolumab	nivolumab	NOUN
dpc-1881	149	63	(	(	PUNCT
dpc-1881	149	64	3	3	NUM
dpc-1881	149	65	mg	mg	NOUN
dpc-1881	149	66	per	per	ADP
dpc-1881	149	67	kilogram	kilogram	PROPN
dpc-1881	149	68	every	every	DET
dpc-1881	149	69	2	2	NUM
dpc-1881	149	70	weeks	week	NOUN
dpc-1881	149	71	)	)	PUNCT
dpc-1881	149	72	plus	plus	CCONJ
dpc-1881	149	73	ipilimumab	ipilimumab	ADV
dpc-1881	149	74	-	-	PUNCT
dpc-1881	149	75	matched	match	VERB
dpc-1881	149	76	placebo	placebo	NOUN
dpc-1881	149	77	;	;	PUNCT
dpc-1881	149	78	or	or	CCONJ
dpc-1881	149	79	ipilimumab	ipilimumab	NOUN
dpc-1881	149	80	(	(	PUNCT
dpc-1881	149	81	3	3	NUM
dpc-1881	149	82	mg	mg	NOUN
dpc-1881	149	83	per	per	ADP
dpc-1881	149	84	kilogram	kilogram	PROPN
dpc-1881	149	85	every	every	DET
dpc-1881	149	86	3	3	NUM
dpc-1881	149	87	weeks	week	NOUN
dpc-1881	149	88	for	for	ADP
dpc-1881	149	89	four	four	NUM
dpc-1881	149	90	doses	dose	NOUN
dpc-1881	149	91	)	)	PUNCT
dpc-1881	149	92	plus	plus	CCONJ
dpc-1881	149	93	nivolumab	nivolumab	ADV
dpc-1881	149	94	-	-	PUNCT
dpc-1881	149	95	matched	match	VERB
dpc-1881	149	96	placebo	placebo	NOUN
dpc-1881	149	97	.	.	PUNCT
dpc-1881	150	1	the	the	DET
dpc-1881	150	2	2	2	NUM
dpc-1881	150	3	primary	primary	ADJ
dpc-1881	150	4	end	end	NOUN
dpc-1881	150	5	points	point	NOUN
dpc-1881	150	6	were	be	AUX
dpc-1881	150	7	pfs	pf	VERB
dpc-1881	150	8	and	and	CCONJ
dpc-1881	150	9	os	os	NOUN
dpc-1881	150	10	in	in	ADP
dpc-1881	150	11	the	the	DET
dpc-1881	150	12	nivolumab	nivolumab	NOUN
dpc-1881	150	13	-	-	PUNCT
dpc-1881	150	14	plus	plus	CCONJ
dpc-1881	150	15	-	-	PUNCT
dpc-1881	150	16	ipilimumab	ipilimumab	NOUN
dpc-1881	150	17	group	group	NOUN
dpc-1881	150	18	and	and	CCONJ
dpc-1881	150	19	in	in	ADP
dpc-1881	150	20	the	the	DET
dpc-1881	150	21	nivolumab	nivolumab	NOUN
dpc-1881	150	22	group	group	NOUN
dpc-1881	150	23	,	,	PUNCT
dpc-1881	150	24	as	as	SCONJ
dpc-1881	150	25	compared	compare	VERB
dpc-1881	150	26	with	with	ADP
dpc-1881	150	27	the	the	DET
dpc-1881	150	28	ipilimumab	ipilimumab	NOUN
dpc-1881	150	29	group	group	NOUN
dpc-1881	150	30	.	.	PUNCT
dpc-1881	151	1	945	945	NUM
dpc-1881	151	2	patients	patient	NOUN
dpc-1881	151	3	with	with	ADP
dpc-1881	151	4	advanced	advanced	ADJ
dpc-1881	151	5	melanoma	melanoma	NOUN
dpc-1881	151	6	not	not	PART
dpc-1881	151	7	treated	treat	VERB
dpc-1881	151	8	with	with	ADP
dpc-1881	151	9	previous	previous	ADJ
dpc-1881	151	10	therapies	therapy	NOUN
dpc-1881	151	11	were	be	AUX
dpc-1881	151	12	recruited	recruit	VERB
dpc-1881	151	13	.	.	PUNCT
dpc-1881	152	1	combination	combination	NOUN
dpc-1881	152	2	therapy	therapy	NOUN
dpc-1881	152	3	showed	show	VERB
dpc-1881	152	4	significantly	significantly	ADV
dpc-1881	152	5	higher	high	ADJ
dpc-1881	152	6	pfs	pfs	PROPN
dpc-1881	152	7	(	(	PUNCT
dpc-1881	152	8	11.5	11.5	NUM
dpc-1881	152	9	months	month	NOUN
dpc-1881	152	10	,	,	PUNCT
dpc-1881	152	11	95	95	NUM
dpc-1881	152	12	%	%	NOUN
dpc-1881	152	13	ci	ci	NOUN
dpc-1881	152	14	8.9	8.9	NUM
dpc-1881	152	15	-	-	SYM
dpc-1881	152	16	16.7	16.7	NUM
dpc-1881	152	17	)	)	PUNCT
dpc-1881	152	18	than	than	ADP
dpc-1881	152	19	nivolumab	nivolumab	NOUN
dpc-1881	152	20	monotherapy	monotherapy	NOUN
dpc-1881	152	21	(	(	PUNCT
dpc-1881	152	22	6.9	6.9	NUM
dpc-1881	152	23	months	month	NOUN
dpc-1881	152	24	,	,	PUNCT
dpc-1881	152	25	95	95	NUM
dpc-1881	152	26	%	%	NOUN
dpc-1881	152	27	ci	ci	NOUN
dpc-1881	152	28	4.3	4.3	NUM
dpc-1881	152	29	-	-	SYM
dpc-1881	152	30	9.5	9.5	NUM
dpc-1881	152	31	)	)	PUNCT
dpc-1881	152	32	,	,	PUNCT
dpc-1881	152	33	or	or	CCONJ
dpc-1881	152	34	ipilimumab	ipilimumab	NOUN
dpc-1881	152	35	(	(	PUNCT
dpc-1881	152	36	2.9	2.9	NUM
dpc-1881	152	37	months	month	NOUN
dpc-1881	152	38	,	,	PUNCT
dpc-1881	152	39	95	95	NUM
dpc-1881	152	40	%	%	NOUN
dpc-1881	152	41	ci	ci	NOUN
dpc-1881	152	42	2.8	2.8	NUM
dpc-1881	152	43	-	-	SYM
dpc-1881	152	44	3.4	3.4	NUM
dpc-1881	152	45	)	)	PUNCT
dpc-1881	152	46	.	.	PUNCT
dpc-1881	153	1	the	the	DET
dpc-1881	153	2	risk	risk	NOUN
dpc-1881	153	3	of	of	ADP
dpc-1881	153	4	death	death	NOUN
dpc-1881	153	5	or	or	CCONJ
dpc-1881	153	6	tumor	tumor	NOUN
dpc-1881	153	7	progression	progression	NOUN
dpc-1881	153	8	was	be	AUX
dpc-1881	153	9	reduced	reduce	VERB
dpc-1881	153	10	by	by	ADP
dpc-1881	153	11	58	58	NUM
dpc-1881	153	12	%	%	NOUN
dpc-1881	153	13	compared	compare	VERB
dpc-1881	153	14	with	with	ADP
dpc-1881	153	15	ipilimumab	ipilimumab	NOUN
dpc-1881	153	16	monotherapy	monotherapy	NOUN
dpc-1881	153	17	(	(	PUNCT
dpc-1881	153	18	hr	hr	NOUN
dpc-1881	153	19	0.42	0.42	NUM
dpc-1881	153	20	;	;	PUNCT
dpc-1881	153	21	99.5	99.5	NUM
dpc-1881	153	22	%	%	NOUN
dpc-1881	153	23	ci	ci	NOUN
dpc-1881	153	24	0.31	0.31	NUM
dpc-1881	153	25	-	-	SYM
dpc-1881	153	26	0.57	0.57	NUM
dpc-1881	153	27	)	)	PUNCT
dpc-1881	153	28	.	.	PUNCT
dpc-1881	154	1	the	the	DET
dpc-1881	154	2	orr	orr	PROPN
dpc-1881	154	3	was	be	AUX
dpc-1881	154	4	57.6	57.6	NUM
dpc-1881	154	5	%	%	NOUN
dpc-1881	154	6	(	(	PUNCT
dpc-1881	154	7	95	95	NUM
dpc-1881	154	8	%	%	NOUN
dpc-1881	154	9	ci	ci	NOUN
dpc-1881	154	10	,	,	PUNCT
dpc-1881	154	11	52.0	52.0	NUM
dpc-1881	154	12	-	-	SYM
dpc-1881	154	13	63.2	63.2	NUM
dpc-1881	154	14	)	)	PUNCT
dpc-1881	154	15	in	in	ADP
dpc-1881	154	16	the	the	DET
dpc-1881	154	17	combination	combination	NOUN
dpc-1881	154	18	cohort	cohort	NOUN
dpc-1881	154	19	versus	versus	ADP
dpc-1881	154	20	43.7	43.7	NUM
dpc-1881	154	21	%	%	NOUN
dpc-1881	154	22	in	in	ADP
dpc-1881	154	23	nivolumab	nivolumab	NOUN
dpc-1881	154	24	(	(	PUNCT
dpc-1881	154	25	95	95	NUM
dpc-1881	154	26	%	%	NOUN
dpc-1881	154	27	ci	ci	NOUN
dpc-1881	154	28	,	,	PUNCT
dpc-1881	154	29	38.1	38.1	NUM
dpc-1881	154	30	-	-	SYM
dpc-1881	154	31	49.3	49.3	NUM
dpc-1881	154	32	)	)	PUNCT
dpc-1881	154	33	and	and	CCONJ
dpc-1881	154	34	19	19	NUM
dpc-1881	154	35	%	%	NOUN
dpc-1881	154	36	(	(	PUNCT
dpc-1881	154	37	95	95	NUM
dpc-1881	154	38	%	%	NOUN
dpc-1881	154	39	ci	ci	NOUN
dpc-1881	154	40	,	,	PUNCT
dpc-1881	154	41	14.9	14.9	NUM
dpc-1881	154	42	-	-	SYM
dpc-1881	154	43	23.8	23.8	NUM
dpc-1881	154	44	)	)	PUNCT
dpc-1881	154	45	in	in	ADP
dpc-1881	154	46	the	the	DET
dpc-1881	154	47	ipilimumab	ipilimumab	NOUN
dpc-1881	154	48	monotherapy	monotherapy	NOUN
dpc-1881	154	49	group	group	NOUN
dpc-1881	154	50	.	.	PUNCT
dpc-1881	155	1	patients	patient	NOUN
dpc-1881	155	2	treated	treat	VERB
dpc-1881	155	3	with	with	ADP
dpc-1881	155	4	the	the	DET
dpc-1881	155	5	combination	combination	NOUN
dpc-1881	155	6	therapy	therapy	NOUN
dpc-1881	155	7	showed	show	VERB
dpc-1881	155	8	a	a	DET
dpc-1881	155	9	complete	complete	ADJ
dpc-1881	155	10	response	response	NOUN
dpc-1881	155	11	in	in	ADP
dpc-1881	155	12	11.5	11.5	NUM
dpc-1881	155	13	%	%	NOUN
dpc-1881	155	14	(	(	PUNCT
dpc-1881	155	15	compared	compare	VERB
dpc-1881	155	16	with	with	ADP
dpc-1881	155	17	8.9	8.9	NUM
dpc-1881	155	18	%	%	NOUN
dpc-1881	155	19	with	with	ADP
dpc-1881	155	20	nivolumab	nivolumab	NOUN
dpc-1881	155	21	and	and	CCONJ
dpc-1881	155	22	2.2	2.2	NUM
dpc-1881	155	23	%	%	NOUN
dpc-1881	155	24	with	with	ADP
dpc-1881	155	25	ipilimumab	ipilimumab	NOUN
dpc-1881	155	26	monotherapy	monotherapy	NOUN
dpc-1881	155	27	)	)	PUNCT
dpc-1881	155	28	.	.	PUNCT
dpc-1881	156	1	most	most	ADV
dpc-1881	156	2	interestingly	interestingly	ADV
dpc-1881	156	3	,	,	PUNCT
dpc-1881	156	4	when	when	SCONJ
dpc-1881	156	5	patients	patient	NOUN
dpc-1881	156	6	were	be	AUX
dpc-1881	156	7	stratified	stratify	VERB
dpc-1881	156	8	for	for	ADP
dpc-1881	156	9	pd	pd	PROPN
dpc-1881	156	10	-	-	PROPN
dpc-1881	156	11	l1	l1	PROPN
dpc-1881	156	12	negativity	negativity	NOUN
dpc-1881	156	13	or	or	CCONJ
dpc-1881	156	14	immunohistochemical	immunohistochemical	ADJ
dpc-1881	156	15	staining	stain	VERB
dpc-1881	156	16	positivity	positivity	NOUN
dpc-1881	156	17	(	(	PUNCT
dpc-1881	156	18	less	less	ADJ
dpc-1881	156	19	or	or	CCONJ
dpc-1881	156	20	more	more	ADJ
dpc-1881	156	21	than	than	ADP
dpc-1881	156	22	5	5	NUM
dpc-1881	156	23	%	%	NOUN
dpc-1881	156	24	of	of	ADP
dpc-1881	156	25	pd	pd	PROPN
dpc-1881	156	26	-	-	PUNCT
dpc-1881	156	27	l1	l1	PROPN
dpc-1881	156	28	stained	stain	VERB
dpc-1881	156	29	tumor	tumor	NOUN
dpc-1881	156	30	cells	cell	NOUN
dpc-1881	156	31	in	in	ADP
dpc-1881	156	32	a	a	DET
dpc-1881	156	33	section	section	NOUN
dpc-1881	156	34	of	of	ADP
dpc-1881	156	35	at	at	ADV
dpc-1881	156	36	least	least	ADV
dpc-1881	156	37	100	100	NUM
dpc-1881	156	38	tumor	tumor	NOUN
dpc-1881	156	39	cells	cell	NOUN
dpc-1881	156	40	)	)	PUNCT
dpc-1881	156	41	,	,	PUNCT
dpc-1881	156	42	the	the	DET
dpc-1881	156	43	median	median	ADJ
dpc-1881	156	44	pfs	pfs	PROPN
dpc-1881	156	45	was	be	AUX
dpc-1881	156	46	14.0	14.0	NUM
dpc-1881	156	47	months	month	NOUN
dpc-1881	156	48	for	for	ADP
dpc-1881	156	49	patients	patient	NOUN
dpc-1881	156	50	with	with	ADP
dpc-1881	156	51	pd	pd	PROPN
dpc-1881	156	52	-	-	PROPN
dpc-1881	156	53	l1	l1	PROPN
dpc-1881	156	54	positive	positive	ADJ
dpc-1881	156	55	tumors	tumor	NOUN
dpc-1881	156	56	in	in	ADP
dpc-1881	156	57	both	both	CCONJ
dpc-1881	156	58	the	the	DET
dpc-1881	156	59	nivolumab	nivolumab	NOUN
dpc-1881	156	60	-	-	PUNCT
dpc-1881	156	61	plus	plus	CCONJ
dpc-1881	156	62	-	-	PUNCT
dpc-1881	156	63	ipilimumab	ipilimumab	NOUN
dpc-1881	156	64	group	group	NOUN
dpc-1881	156	65	,	,	PUNCT
dpc-1881	156	66	and	and	CCONJ
dpc-1881	156	67	the	the	DET
dpc-1881	156	68	nivolumab	nivolumab	NOUN
dpc-1881	156	69	group	group	NOUN
dpc-1881	156	70	.	.	PUNCT
dpc-1881	157	1	in	in	ADP
dpc-1881	157	2	contrast	contrast	NOUN
dpc-1881	157	3	,	,	PUNCT
dpc-1881	157	4	in	in	ADP
dpc-1881	157	5	patients	patient	NOUN
dpc-1881	157	6	with	with	ADP
dpc-1881	157	7	pd	pd	PROPN
dpc-1881	157	8	-	-	PUNCT
dpc-1881	157	9	l1	l1	NOUN
dpc-1881	157	10	-	-	PUNCT
dpc-1881	157	11	negative	negative	ADJ
dpc-1881	157	12	tumors	tumor	NOUN
dpc-1881	157	13	,	,	PUNCT
dpc-1881	157	14	pfs	pfs	PROPN
dpc-1881	157	15	was	be	AUX
dpc-1881	157	16	longer	long	ADJ
dpc-1881	157	17	with	with	ADP
dpc-1881	157	18	combination	combination	NOUN
dpc-1881	157	19	therapy	therapy	NOUN
dpc-1881	157	20	than	than	ADP
dpc-1881	157	21	with	with	ADP
dpc-1881	157	22	nivolumab	nivolumab	NOUN
dpc-1881	157	23	alone	alone	ADV
dpc-1881	157	24	(	(	PUNCT
dpc-1881	157	25	11.2	11.2	NUM
dpc-1881	157	26	months	month	NOUN
dpc-1881	157	27	[	[	X
dpc-1881	157	28	95	95	NUM
dpc-1881	157	29	%	%	NOUN
dpc-1881	157	30	ci	ci	NOUN
dpc-1881	157	31	,	,	PUNCT
dpc-1881	157	32	8.0	8.0	NUM
dpc-1881	157	33	a	a	PRON
dpc-1881	157	34	not	not	PART
dpc-1881	157	35	achieved	achieve	VERB
dpc-1881	157	36	]	]	PUNCT
dpc-1881	157	37	vs.	vs.	ADP
dpc-1881	157	38	5.3	5.3	NUM
dpc-1881	157	39	months	month	NOUN
dpc-1881	157	40	[	[	X
dpc-1881	157	41	95	95	NUM
dpc-1881	157	42	%	%	NOUN
dpc-1881	157	43	ci	ci	NOUN
dpc-1881	157	44	,	,	PUNCT
dpc-1881	157	45	2.8	2.8	NUM
dpc-1881	157	46	to	to	PART
dpc-1881	157	47	7.1	7.1	NUM
dpc-1881	157	48	]	]	PUNCT
dpc-1881	157	49	)	)	PUNCT
dpc-1881	157	50	.	.	PUNCT
dpc-1881	158	1	in	in	ADP
dpc-1881	158	2	this	this	DET
dpc-1881	158	3	study	study	NOUN
dpc-1881	158	4	,	,	PUNCT
dpc-1881	158	5	nivolumab	nivolumab	ADP
dpc-1881	158	6	combination	combination	NOUN
dpc-1881	158	7	therapy	therapy	NOUN
dpc-1881	158	8	was	be	AUX
dpc-1881	158	9	superior	superior	ADJ
dpc-1881	158	10	to	to	ADP
dpc-1881	158	11	nivolumab	nivolumab	NOUN
dpc-1881	158	12	monotherapy	monotherapy	NOUN
dpc-1881	158	13	or	or	CCONJ
dpc-1881	158	14	ipilimumab	ipilimumab	NOUN
dpc-1881	158	15	alone	alone	ADV
dpc-1881	158	16	in	in	ADP
dpc-1881	158	17	patients	patient	NOUN
dpc-1881	158	18	with	with	ADP
dpc-1881	158	19	pd	pd	PROPN
dpc-1881	158	20	-	-	PROPN
dpc-1881	158	21	l1	l1	PROPN
dpc-1881	158	22	negative	negative	ADJ
dpc-1881	158	23	tumors	tumor	NOUN
dpc-1881	158	24	,	,	PUNCT
dpc-1881	158	25	whereas	whereas	SCONJ
dpc-1881	158	26	in	in	ADP
dpc-1881	158	27	patients	patient	NOUN
dpc-1881	158	28	with	with	ADP
dpc-1881	158	29	pd	pd	PROPN
dpc-1881	158	30	-	-	PROPN
dpc-1881	158	31	l1	l1	PROPN
dpc-1881	158	32	positive	positive	ADJ
dpc-1881	158	33	tumors	tumor	NOUN
dpc-1881	158	34	there	there	PRON
dpc-1881	158	35	was	be	VERB
dpc-1881	158	36	no	no	DET
dpc-1881	158	37	significant	significant	ADJ
dpc-1881	158	38	difference	difference	NOUN
dpc-1881	158	39	between	between	ADP
dpc-1881	158	40	nivolumab	nivolumab	NOUN
dpc-1881	158	41	monotherapy	monotherapy	NOUN
dpc-1881	158	42	and	and	CCONJ
dpc-1881	158	43	combined	combined	ADJ
dpc-1881	158	44	therapy	therapy	NOUN
dpc-1881	158	45	.	.	PUNCT
dpc-1881	159	1	overall	overall	ADJ
dpc-1881	159	2	survival	survival	NOUN
dpc-1881	159	3	at	at	ADP
dpc-1881	159	4	5	5	NUM
dpc-1881	159	5	years	year	NOUN
dpc-1881	159	6	was	be	AUX
dpc-1881	159	7	52	52	NUM
dpc-1881	159	8	%	%	NOUN
dpc-1881	159	9	in	in	ADP
dpc-1881	159	10	the	the	DET
dpc-1881	159	11	nivolumab	nivolumab	NOUN
dpc-1881	159	12	-	-	PUNCT
dpc-1881	159	13	plus	plus	CCONJ
dpc-1881	159	14	-	-	PUNCT
dpc-1881	159	15	ipilimumab	ipilimumab	NOUN
dpc-1881	159	16	group	group	NOUN
dpc-1881	159	17	and	and	CCONJ
dpc-1881	159	18	44	44	NUM
dpc-1881	159	19	%	%	NOUN
dpc-1881	159	20	in	in	ADP
dpc-1881	159	21	the	the	DET
dpc-1881	159	22	nivolumab	nivolumab	NOUN
dpc-1881	159	23	group	group	NOUN
dpc-1881	159	24	,	,	PUNCT
dpc-1881	159	25	as	as	SCONJ
dpc-1881	159	26	compared	compare	VERB
dpc-1881	159	27	with	with	ADP
dpc-1881	159	28	26	26	NUM
dpc-1881	159	29	%	%	NOUN
dpc-1881	159	30	in	in	ADP
dpc-1881	159	31	the	the	DET
dpc-1881	159	32	ipilimumab	ipilimumab	NOUN
dpc-1881	159	33	group	group	NOUN
dpc-1881	159	34	.	.	PUNCT
dpc-1881	160	1	no	no	DET
dpc-1881	160	2	sustained	sustained	ADJ
dpc-1881	160	3	deterioration	deterioration	NOUN
dpc-1881	160	4	of	of	ADP
dpc-1881	160	5	health	health	NOUN
dpc-1881	160	6	-	-	PUNCT
dpc-1881	160	7	related	relate	VERB
dpc-1881	160	8	quality	quality	NOUN
dpc-1881	160	9	of	of	ADP
dpc-1881	160	10	life	life	NOUN
dpc-1881	160	11	was	be	AUX
dpc-1881	160	12	observed	observe	VERB
dpc-1881	160	13	during	during	ADP
dpc-1881	160	14	or	or	CCONJ
dpc-1881	160	15	after	after	ADP
dpc-1881	160	16	treatment	treatment	NOUN
dpc-1881	160	17	with	with	ADP
dpc-1881	160	18	nivolumab	nivolumab	NOUN
dpc-1881	160	19	plus	plus	CCONJ
dpc-1881	160	20	ipilimumab	ipilimumab	NOUN
dpc-1881	160	21	or	or	CCONJ
dpc-1881	160	22	with	with	ADP
dpc-1881	160	23	nivolumab	nivolumab	NOUN
dpc-1881	160	24	alone	alone	ADV
dpc-1881	160	25	[	[	X
dpc-1881	160	26	36	36	NUM
dpc-1881	160	27	]	]	PUNCT
dpc-1881	160	28	.	.	PUNCT
dpc-1881	161	1	grade	grade	NOUN
dpc-1881	161	2	3	3	NUM
dpc-1881	161	3	or	or	CCONJ
dpc-1881	161	4	4	4	NUM
dpc-1881	161	5	treatment	treatment	NOUN
dpc-1881	161	6	-	-	PUNCT
dpc-1881	161	7	related	relate	VERB
dpc-1881	161	8	adverse	adverse	ADJ
dpc-1881	161	9	events	event	NOUN
dpc-1881	161	10	occurred	occur	VERB
dpc-1881	161	11	in	in	ADP
dpc-1881	161	12	59	59	NUM
dpc-1881	161	13	%	%	NOUN
dpc-1881	161	14	,	,	PUNCT
dpc-1881	161	15	23	23	NUM
dpc-1881	161	16	%	%	NOUN
dpc-1881	161	17	,	,	PUNCT
dpc-1881	161	18	and	and	CCONJ
dpc-1881	161	19	28	28	NUM
dpc-1881	161	20	%	%	NOUN
dpc-1881	161	21	of	of	ADP
dpc-1881	161	22	the	the	DET
dpc-1881	161	23	patients	patient	NOUN
dpc-1881	161	24	in	in	ADP
dpc-1881	161	25	the	the	DET
dpc-1881	161	26	nivolumab	nivolumab	NOUN
dpc-1881	161	27	-	-	PUNCT
dpc-1881	161	28	plus	plus	CCONJ
dpc-1881	161	29	-	-	PUNCT
dpc-1881	161	30	ipilimumab	ipilimumab	NOUN
dpc-1881	161	31	,	,	PUNCT
dpc-1881	161	32	nivolumab	nivolumab	NOUN
dpc-1881	161	33	,	,	PUNCT
dpc-1881	161	34	and	and	CCONJ
dpc-1881	161	35	ipilimumab	ipilimumab	ADJ
dpc-1881	161	36	groups	group	NOUN
dpc-1881	161	37	,	,	PUNCT
dpc-1881	161	38	respectively	respectively	ADV
dpc-1881	161	39	.	.	PUNCT
dpc-1881	162	1	this	this	DET
dpc-1881	162	2	combination	combination	NOUN
dpc-1881	162	3	therapy	therapy	NOUN
dpc-1881	162	4	was	be	AUX
dpc-1881	162	5	approved	approve	VERB
dpc-1881	162	6	in	in	ADP
dpc-1881	162	7	europe	europe	PROPN
dpc-1881	162	8	by	by	ADP
dpc-1881	162	9	the	the	DET
dpc-1881	162	10	ema	ema	PROPN
dpc-1881	162	11	on	on	ADP
dpc-1881	162	12	may	may	PROPN
dpc-1881	162	13	2016	2016	NUM
dpc-1881	162	14	,	,	PUNCT
dpc-1881	162	15	regardless	regardless	ADV
dpc-1881	162	16	of	of	ADP
dpc-1881	162	17	patients	patient	NOUN
dpc-1881	162	18	’	'	PUNCT
dpc-1881	162	19	pd	pd	PROPN
dpc-1881	162	20	-	-	PUNCT
dpc-1881	162	21	l1	l1	PROPN
dpc-1881	162	22	status	status	NOUN
dpc-1881	162	23	.	.	PUNCT
dpc-1881	163	1	ckit	ckit	NOUN
dpc-1881	163	2	inhibitors	inhibitor	NOUN
dpc-1881	163	3	mutations	mutation	NOUN
dpc-1881	163	4	and	and	CCONJ
dpc-1881	163	5	amplification	amplification	NOUN
dpc-1881	163	6	of	of	ADP
dpc-1881	163	7	the	the	DET
dpc-1881	163	8	kit	kit	NOUN
dpc-1881	163	9	oncogene	oncogene	NOUN
dpc-1881	163	10	are	be	AUX
dpc-1881	163	11	more	more	ADV
dpc-1881	163	12	frequent	frequent	ADJ
dpc-1881	163	13	in	in	ADP
dpc-1881	163	14	melanomas	melanomas	NOUN
dpc-1881	163	15	arising	arise	VERB
dpc-1881	163	16	in	in	ADP
dpc-1881	163	17	the	the	DET
dpc-1881	163	18	skin	skin	NOUN
dpc-1881	163	19	with	with	ADP
dpc-1881	163	20	chronic	chronic	ADJ
dpc-1881	163	21	sun	sun	NOUN
dpc-1881	163	22	damage	damage	NOUN
dpc-1881	163	23	,	,	PUNCT
dpc-1881	163	24	acral	acral	ADJ
dpc-1881	163	25	sites	site	NOUN
dpc-1881	163	26	,	,	PUNCT
dpc-1881	163	27	or	or	CCONJ
dpc-1881	163	28	mucosal	mucosal	NOUN
dpc-1881	163	29	melanomas	melanoma	NOUN
dpc-1881	163	30	.	.	PUNCT
dpc-1881	164	1	a	a	DET
dpc-1881	164	2	number	number	NOUN
dpc-1881	164	3	of	of	ADP
dpc-1881	164	4	evidences	evidence	NOUN
dpc-1881	164	5	from	from	ADP
dpc-1881	164	6	laboratory	laboratory	NOUN
dpc-1881	164	7	analysis	analysis	NOUN
dpc-1881	164	8	and	and	CCONJ
dpc-1881	164	9	preclinical	preclinical	ADJ
dpc-1881	164	10	studies	study	NOUN
dpc-1881	164	11	showed	show	VERB
dpc-1881	164	12	that	that	SCONJ
dpc-1881	164	13	hot	hot	ADJ
dpc-1881	164	14	-	-	PUNCT
dpc-1881	164	15	spot	spot	NOUN
dpc-1881	164	16	mutations	mutation	NOUN
dpc-1881	164	17	,	,	PUNCT
dpc-1881	164	18	most	most	ADV
dpc-1881	164	19	frequently	frequently	ADV
dpc-1881	164	20	constituted	constitute	VERB
dpc-1881	164	21	by	by	ADP
dpc-1881	164	22	substitutions	substitution	NOUN
dpc-1881	164	23	at	at	ADP
dpc-1881	164	24	exons	exon	NOUN
dpc-1881	164	25	11	11	NUM
dpc-1881	164	26	and	and	CCONJ
dpc-1881	164	27	13	13	NUM
dpc-1881	164	28	,	,	PUNCT
dpc-1881	164	29	induce	induce	VERB
dpc-1881	164	30	a	a	DET
dpc-1881	164	31	pathological	pathological	ADJ
dpc-1881	164	32	activation	activation	NOUN
dpc-1881	164	33	of	of	ADP
dpc-1881	164	34	the	the	DET
dpc-1881	164	35	kit	kit	NOUN
dpc-1881	164	36	,	,	PUNCT
dpc-1881	164	37	thus	thus	ADV
dpc-1881	164	38	an	an	DET
dpc-1881	164	39	upregulation	upregulation	NOUN
dpc-1881	164	40	of	of	ADP
dpc-1881	164	41	the	the	DET
dpc-1881	164	42	downstream	downstream	ADJ
dpc-1881	164	43	signal	signal	NOUN
dpc-1881	164	44	transduction	transduction	NOUN
dpc-1881	164	45	pathways	pathway	NOUN
dpc-1881	164	46	,	,	PUNCT
dpc-1881	164	47	which	which	PRON
dpc-1881	164	48	are	be	AUX
dpc-1881	164	49	not	not	PART
dpc-1881	164	50	only	only	ADV
dpc-1881	164	51	the	the	DET
dpc-1881	164	52	mapkinase	mapkinase	NOUN
dpc-1881	164	53	,	,	PUNCT
dpc-1881	164	54	but	but	CCONJ
dpc-1881	164	55	also	also	ADV
dpc-1881	164	56	the	the	DET
dpc-1881	164	57	pi3k	pi3k	PROPN
dpc-1881	164	58	/	/	SYM
dpc-1881	164	59	akt	akt	PROPN
dpc-1881	164	60	,	,	PUNCT
dpc-1881	164	61	and	and	CCONJ
dpc-1881	164	62	jak	jak	PROPN
dpc-1881	164	63	/	/	SYM
dpc-1881	164	64	stat	stat	PROPN
dpc-1881	164	65	pathways	pathway	NOUN
dpc-1881	164	66	.	.	PUNCT
dpc-1881	165	1	kit	kit	NOUN
dpc-1881	165	2	gene	gene	NOUN
dpc-1881	165	3	expression	expression	NOUN
dpc-1881	165	4	has	have	AUX
dpc-1881	165	5	been	be	AUX
dpc-1881	165	6	correlated	correlate	VERB
dpc-1881	165	7	with	with	ADP
dpc-1881	165	8	activating	activate	VERB
dpc-1881	165	9	mutations	mutation	NOUN
dpc-1881	165	10	,	,	PUNCT
dpc-1881	165	11	which	which	PRON
dpc-1881	165	12	indicates	indicate	VERB
dpc-1881	165	13	the	the	DET
dpc-1881	165	14	role	role	NOUN
dpc-1881	165	15	of	of	ADP
dpc-1881	165	16	kit	kit	NOUN
dpc-1881	165	17	in	in	ADP
dpc-1881	165	18	tumorigenesis	tumorigenesis	NOUN
dpc-1881	165	19	in	in	ADP
dpc-1881	165	20	melanoma	melanoma	NOUN
dpc-1881	165	21	.	.	PUNCT
dpc-1881	166	1	therefore	therefore	ADV
dpc-1881	166	2	,	,	PUNCT
dpc-1881	166	3	kit	kit	NOUN
dpc-1881	166	4	has	have	AUX
dpc-1881	166	5	been	be	AUX
dpc-1881	166	6	suggested	suggest	VERB
dpc-1881	166	7	to	to	PART
dpc-1881	166	8	be	be	AUX
dpc-1881	166	9	a	a	DET
dpc-1881	166	10	potential	potential	ADJ
dpc-1881	166	11	therapeutic	therapeutic	ADJ
dpc-1881	166	12	target	target	NOUN
dpc-1881	166	13	for	for	ADP
dpc-1881	166	14	malignant	malignant	ADJ
dpc-1881	166	15	melanoma	melanoma	NOUN
dpc-1881	166	16	.	.	PUNCT
dpc-1881	167	1	several	several	ADJ
dpc-1881	167	2	trials	trial	NOUN
dpc-1881	167	3	have	have	AUX
dpc-1881	167	4	been	be	AUX
dpc-1881	167	5	conducted	conduct	VERB
dpc-1881	167	6	using	use	VERB
dpc-1881	167	7	kit	kit	NOUN
dpc-1881	167	8	-	-	PUNCT
dpc-1881	167	9	targeted	target	VERB
dpc-1881	167	10	tyrosine	tyrosine	NOUN
dpc-1881	167	11	kinase	kinase	NOUN
dpc-1881	167	12	inhibitors	inhibitor	NOUN
dpc-1881	167	13	in	in	ADP
dpc-1881	167	14	melanoma	melanoma	NOUN
dpc-1881	167	15	in	in	ADP
dpc-1881	167	16	both	both	PRON
dpc-1881	167	17	selected	select	VERB
dpc-1881	167	18	and	and	CCONJ
dpc-1881	167	19	unselected	unselected	ADJ
dpc-1881	167	20	patient	patient	NOUN
dpc-1881	167	21	populations	population	NOUN
dpc-1881	167	22	.	.	PUNCT
dpc-1881	168	1	trials	trial	NOUN
dpc-1881	168	2	with	with	ADP
dpc-1881	168	3	imatinib	imatinib	NOUN
dpc-1881	168	4	showed	show	VERB
dpc-1881	168	5	responses	response	NOUN
dpc-1881	168	6	if	if	SCONJ
dpc-1881	168	7	kit	kit	NOUN
dpc-1881	168	8	was	be	AUX
dpc-1881	168	9	mutated	mutate	VERB
dpc-1881	168	10	but	but	CCONJ
dpc-1881	168	11	not	not	PART
dpc-1881	168	12	if	if	SCONJ
dpc-1881	168	13	it	it	PRON
dpc-1881	168	14	was	be	AUX
dpc-1881	168	15	wild	wild	ADJ
dpc-1881	168	16	-	-	PUNCT
dpc-1881	168	17	type	type	NOUN
dpc-1881	168	18	and	and	CCONJ
dpc-1881	168	19	amplified	amplify	VERB
dpc-1881	168	20	[	[	PUNCT
dpc-1881	168	21	37	37	NUM
dpc-1881	168	22	-	-	SYM
dpc-1881	168	23	39	39	NUM
dpc-1881	168	24	]	]	PUNCT
dpc-1881	168	25	.	.	PUNCT
dpc-1881	169	1	other	other	ADJ
dpc-1881	169	2	kit	kit	NOUN
dpc-1881	169	3	inhibitors	inhibitor	NOUN
dpc-1881	169	4	such	such	ADJ
dpc-1881	169	5	as	as	ADP
dpc-1881	169	6	dasatinib	dasatinib	NOUN
dpc-1881	169	7	,	,	PUNCT
dpc-1881	169	8	sunitinib	sunitinib	NOUN
dpc-1881	169	9	,	,	PUNCT
dpc-1881	169	10	and	and	CCONJ
dpc-1881	169	11	nilotininb	nilotininb	PROPN
dpc-1881	169	12	have	have	AUX
dpc-1881	169	13	also	also	ADV
dpc-1881	169	14	exhibited	exhibit	VERB
dpc-1881	169	15	responses	response	NOUN
dpc-1881	169	16	in	in	ADP
dpc-1881	169	17	kit	kit	ADJ
dpc-1881	169	18	-	-	PUNCT
dpc-1881	169	19	mutant	mutant	ADJ
dpc-1881	169	20	melanomas	melanomas	NOUN
dpc-1881	169	21	.	.	PUNCT
dpc-1881	170	1	however	however	ADV
dpc-1881	170	2	,	,	PUNCT
dpc-1881	170	3	taken	take	VERB
dpc-1881	170	4	together	together	ADV
dpc-1881	170	5	,	,	PUNCT
dpc-1881	170	6	these	these	DET
dpc-1881	170	7	studies	study	NOUN
dpc-1881	170	8	showed	show	VERB
dpc-1881	170	9	a	a	DET
dpc-1881	170	10	percentage	percentage	NOUN
dpc-1881	170	11	of	of	ADP
dpc-1881	170	12	responses	response	NOUN
dpc-1881	170	13	around	around	ADP
dpc-1881	170	14	20	20	NUM
dpc-1881	170	15	%	%	NOUN
dpc-1881	170	16	and	and	CCONJ
dpc-1881	170	17	30	30	NUM
dpc-1881	170	18	%	%	NOUN
dpc-1881	170	19	,	,	PUNCT
dpc-1881	170	20	mostly	mostly	ADV
dpc-1881	170	21	of	of	ADP
dpc-1881	170	22	short	short	ADJ
dpc-1881	170	23	duration	duration	NOUN
dpc-1881	170	24	without	without	ADP
dpc-1881	170	25	a	a	DET
dpc-1881	170	26	significant	significant	ADJ
dpc-1881	170	27	impact	impact	NOUN
dpc-1881	170	28	on	on	ADP
dpc-1881	170	29	survival	survival	NOUN
dpc-1881	170	30	.	.	PUNCT
dpc-1881	171	1	moreover	moreover	ADV
dpc-1881	171	2	,	,	PUNCT
dpc-1881	171	3	all	all	DET
dpc-1881	171	4	these	these	DET
dpc-1881	171	5	studies	study	NOUN
dpc-1881	171	6	were	be	AUX
dpc-1881	171	7	performed	perform	VERB
dpc-1881	171	8	on	on	ADP
dpc-1881	171	9	a	a	DET
dpc-1881	171	10	relatively	relatively	ADV
dpc-1881	171	11	small	small	ADJ
dpc-1881	171	12	number	number	NOUN
dpc-1881	171	13	of	of	ADP
dpc-1881	171	14	patients	patient	NOUN
dpc-1881	171	15	and	and	CCONJ
dpc-1881	171	16	there	there	PRON
dpc-1881	171	17	is	be	VERB
dpc-1881	171	18	no	no	DET
dpc-1881	171	19	available	available	ADJ
dpc-1881	171	20	6	6	NUM
dpc-1881	171	21	review	review	NOUN
dpc-1881	171	22	|	|	ADV
dpc-1881	171	23	dermatol	dermatol	ADJ
dpc-1881	171	24	pract	pract	NOUN
dpc-1881	171	25	concept	concept	NOUN
dpc-1881	171	26	.	.	PUNCT
dpc-1881	172	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	172	2	):	):	PUNCT
dpc-1881	172	3	e2021164s	e2021164s	AUX
dpc-1881	172	4	randomized	randomize	VERB
dpc-1881	172	5	trial	trial	NOUN
dpc-1881	172	6	.	.	PUNCT
dpc-1881	173	1	in	in	ADP
dpc-1881	173	2	a	a	DET
dpc-1881	173	3	recent	recent	ADJ
dpc-1881	173	4	retrospective	retrospective	ADJ
dpc-1881	173	5	analysis	analysis	NOUN
dpc-1881	173	6	of	of	ADP
dpc-1881	173	7	78	78	NUM
dpc-1881	173	8	patients	patient	NOUN
dpc-1881	173	9	with	with	ADP
dpc-1881	173	10	metastatic	metastatic	ADJ
dpc-1881	173	11	melanoma	melanoma	NOUN
dpc-1881	173	12	harboring	harbor	VERB
dpc-1881	173	13	c	c	NOUN
dpc-1881	173	14	-	-	PUNCT
dpc-1881	173	15	kit	kit	NOUN
dpc-1881	173	16	mutations	mutation	NOUN
dpc-1881	173	17	or	or	CCONJ
dpc-1881	173	18	amplifications	amplification	NOUN
dpc-1881	173	19	treated	treat	VERB
dpc-1881	173	20	with	with	ADP
dpc-1881	173	21	imatinib	imatinib	NOUN
dpc-1881	173	22	,	,	PUNCT
dpc-1881	173	23	orr	orr	PROPN
dpc-1881	173	24	and	and	CCONJ
dpc-1881	173	25	dcr	dcr	PROPN
dpc-1881	173	26	were	be	AUX
dpc-1881	173	27	21.8	21.8	NUM
dpc-1881	173	28	%	%	NOUN
dpc-1881	173	29	and	and	CCONJ
dpc-1881	173	30	60.3	60.3	NUM
dpc-1881	173	31	%	%	NOUN
dpc-1881	173	32	,	,	PUNCT
dpc-1881	173	33	respectively	respectively	ADV
dpc-1881	173	34	.	.	PUNCT
dpc-1881	174	1	the	the	DET
dpc-1881	174	2	median	median	PROPN
dpc-1881	174	3	os	os	NOUN
dpc-1881	174	4	and	and	CCONJ
dpc-1881	174	5	pfs	pfs	PROPN
dpc-1881	174	6	of	of	ADP
dpc-1881	174	7	all	all	DET
dpc-1881	174	8	patients	patient	NOUN
dpc-1881	174	9	were	be	AUX
dpc-1881	174	10	13.1	13.1	NUM
dpc-1881	174	11	[	[	X
dpc-1881	174	12	40	40	NUM
dpc-1881	174	13	]	]	PUNCT
dpc-1881	174	14	.	.	PUNCT
dpc-1881	175	1	the	the	DET
dpc-1881	175	2	limited	limited	ADJ
dpc-1881	175	3	clinical	clinical	ADJ
dpc-1881	175	4	activity	activity	NOUN
dpc-1881	175	5	of	of	ADP
dpc-1881	175	6	targeting	target	VERB
dpc-1881	175	7	ckit	ckit	NOUN
dpc-1881	175	8	imply	imply	ADV
dpc-1881	175	9	that	that	SCONJ
dpc-1881	175	10	ckit	ckit	NOUN
dpc-1881	175	11	mutant	mutant	ADJ
dpc-1881	175	12	patients	patient	NOUN
dpc-1881	175	13	should	should	AUX
dpc-1881	175	14	be	be	AUX
dpc-1881	175	15	treated	treat	VERB
dpc-1881	175	16	as	as	ADP
dpc-1881	175	17	first	first	ADJ
dpc-1881	175	18	line	line	NOUN
dpc-1881	175	19	with	with	ADP
dpc-1881	175	20	immune	immune	ADJ
dpc-1881	175	21	check	check	NOUN
dpc-1881	175	22	point	point	NOUN
dpc-1881	175	23	inhibitors	inhibitor	NOUN
dpc-1881	175	24	and	and	CCONJ
dpc-1881	175	25	only	only	ADV
dpc-1881	175	26	after	after	ADP
dpc-1881	175	27	the	the	DET
dpc-1881	175	28	failure	failure	NOUN
dpc-1881	175	29	of	of	ADP
dpc-1881	175	30	these	these	DET
dpc-1881	175	31	regimens	regimen	NOUN
dpc-1881	175	32	,	,	PUNCT
dpc-1881	175	33	consider	consider	VERB
dpc-1881	175	34	the	the	DET
dpc-1881	175	35	potential	potential	NOUN
dpc-1881	175	36	of	of	ADP
dpc-1881	175	37	ckit	ckit	NOUN
dpc-1881	175	38	inhibitors	inhibitor	NOUN
dpc-1881	175	39	.	.	PUNCT
dpc-1881	176	1	nras	nras	PROPN
dpc-1881	176	2	mutant	mutant	PROPN
dpc-1881	176	3	patients	patient	NOUN
dpc-1881	176	4	nras	nras	PROPN
dpc-1881	176	5	mutations	mutation	NOUN
dpc-1881	176	6	(	(	PUNCT
dpc-1881	176	7	codons	codon	NOUN
dpc-1881	176	8	12	12	NUM
dpc-1881	176	9	,	,	PUNCT
dpc-1881	176	10	13	13	NUM
dpc-1881	176	11	,	,	PUNCT
dpc-1881	176	12	and	and	CCONJ
dpc-1881	176	13	61	61	NUM
dpc-1881	176	14	)	)	PUNCT
dpc-1881	176	15	can	can	AUX
dpc-1881	176	16	be	be	AUX
dpc-1881	176	17	detected	detect	VERB
dpc-1881	176	18	in	in	ADP
dpc-1881	176	19	15	15	NUM
dpc-1881	176	20	-	-	SYM
dpc-1881	176	21	20	20	NUM
dpc-1881	176	22	%	%	NOUN
dpc-1881	176	23	of	of	ADP
dpc-1881	176	24	all	all	DET
dpc-1881	176	25	melanomas	melanoma	NOUN
dpc-1881	176	26	.	.	PUNCT
dpc-1881	177	1	these	these	DET
dpc-1881	177	2	alterations	alteration	NOUN
dpc-1881	177	3	have	have	AUX
dpc-1881	177	4	been	be	AUX
dpc-1881	177	5	associated	associate	VERB
dpc-1881	177	6	with	with	ADP
dpc-1881	177	7	aggressive	aggressive	ADJ
dpc-1881	177	8	clinical	clinical	ADJ
dpc-1881	177	9	behavior	behavior	NOUN
dpc-1881	177	10	and	and	CCONJ
dpc-1881	177	11	a	a	DET
dpc-1881	177	12	poor	poor	ADJ
dpc-1881	177	13	prognosis	prognosis	NOUN
dpc-1881	177	14	;	;	PUNCT
dpc-1881	177	15	however	however	ADV
dpc-1881	177	16	,	,	PUNCT
dpc-1881	177	17	a	a	DET
dpc-1881	177	18	recent	recent	ADJ
dpc-1881	177	19	retrospective	retrospective	ADJ
dpc-1881	177	20	multicenter	multicenter	ADJ
dpc-1881	177	21	italian	italian	ADJ
dpc-1881	177	22	study	study	NOUN
dpc-1881	177	23	did	do	AUX
dpc-1881	177	24	not	not	PART
dpc-1881	177	25	confirm	confirm	VERB
dpc-1881	177	26	the	the	DET
dpc-1881	177	27	unfavorable	unfavorable	ADJ
dpc-1881	177	28	prognostic	prognostic	ADJ
dpc-1881	177	29	significance	significance	NOUN
dpc-1881	177	30	of	of	ADP
dpc-1881	177	31	nras	nras	PROPN
dpc-1881	177	32	mutation	mutation	PROPN
dpc-1881	177	33	.	.	PUNCT
dpc-1881	178	1	a	a	DET
dpc-1881	178	2	cohort	cohort	NOUN
dpc-1881	178	3	of	of	ADP
dpc-1881	178	4	331	331	NUM
dpc-1881	178	5	patients	patient	NOUN
dpc-1881	178	6	treated	treat	VERB
dpc-1881	178	7	with	with	ADP
dpc-1881	178	8	immunotherapy	immunotherapy	NOUN
dpc-1881	178	9	as	as	SCONJ
dpc-1881	178	10	first	first	ADJ
dpc-1881	178	11	-	-	PUNCT
dpc-1881	178	12	line	line	NOUN
dpc-1881	178	13	were	be	AUX
dpc-1881	178	14	retrospectively	retrospectively	ADV
dpc-1881	178	15	recruited	recruit	VERB
dpc-1881	178	16	:	:	PUNCT
dpc-1881	178	17	162	162	NUM
dpc-1881	178	18	nras	nra	NOUN
dpc-1881	178	19	-	-	ADJ
dpc-1881	178	20	mutant	mutant	ADJ
dpc-1881	178	21	/	/	SYM
dpc-1881	178	22	braf	braf	NOUN
dpc-1881	178	23	wild	wild	ADJ
dpc-1881	178	24	-	-	PUNCT
dpc-1881	178	25	type	type	NOUN
dpc-1881	178	26	(	(	PUNCT
dpc-1881	178	27	mut	mut	NOUN
dpc-1881	178	28	/	/	SYM
dpc-1881	178	29	wt	wt	PROPN
dpc-1881	178	30	)	)	PUNCT
dpc-1881	178	31	and	and	CCONJ
dpc-1881	178	32	169	169	NUM
dpc-1881	178	33	wt/	wt/	PROPN
dpc-1881	178	34	wt	wt	VERB
dpc-1881	178	35	.	.	PUNCT
dpc-1881	179	1	regarding	regard	VERB
dpc-1881	179	2	the	the	DET
dpc-1881	179	3	outcomes	outcome	NOUN
dpc-1881	179	4	,	,	PUNCT
dpc-1881	179	5	no	no	DET
dpc-1881	179	6	significant	significant	ADJ
dpc-1881	179	7	differences	difference	NOUN
dpc-1881	179	8	were	be	AUX
dpc-1881	179	9	reported	report	VERB
dpc-1881	179	10	in	in	ADP
dpc-1881	179	11	overall	overall	ADJ
dpc-1881	179	12	rr	rr	PROPN
dpc-1881	179	13	,	,	PUNCT
dpc-1881	179	14	pfs	pfs	PROPN
dpc-1881	179	15	or	or	CCONJ
dpc-1881	179	16	os	os	NOUN
dpc-1881	179	17	.	.	PROPN
dpc-1881	179	18	irrespectively	irrespectively	ADV
dpc-1881	179	19	of	of	ADP
dpc-1881	179	20	the	the	DET
dpc-1881	179	21	mutational	mutational	ADJ
dpc-1881	179	22	status	status	NOUN
dpc-1881	179	23	,	,	PUNCT
dpc-1881	179	24	a	a	PRON
dpc-1881	179	25	longer	long	ADJ
dpc-1881	179	26	os	os	NOUN
dpc-1881	179	27	was	be	AUX
dpc-1881	179	28	significantly	significantly	ADV
dpc-1881	179	29	associated	associate	VERB
dpc-1881	179	30	with	with	ADP
dpc-1881	179	31	normal	normal	ADJ
dpc-1881	179	32	ldh	ldh	NOUN
dpc-1881	179	33	,	,	PUNCT
dpc-1881	179	34	<3	<3	X
dpc-1881	179	35	metastatic	metastatic	ADJ
dpc-1881	179	36	sites	site	NOUN
dpc-1881	179	37	,	,	PUNCT
dpc-1881	179	38	lower	low	ADJ
dpc-1881	179	39	white	white	ADJ
dpc-1881	179	40	blood	blood	NOUN
dpc-1881	179	41	cell	cell	NOUN
dpc-1881	179	42	and	and	CCONJ
dpc-1881	179	43	platelet	platelet	NOUN
dpc-1881	179	44	count	count	NOUN
dpc-1881	179	45	,	,	PUNCT
dpc-1881	179	46	lower	low	ADJ
dpc-1881	179	47	neutrophil	neutrophil	NOUN
dpc-1881	179	48	-	-	PUNCT
dpc-1881	179	49	to	to	ADP
dpc-1881	179	50	-	-	PUNCT
dpc-1881	179	51	lymphocyte	lymphocyte	NOUN
dpc-1881	179	52	(	(	PUNCT
dpc-1881	179	53	n	n	CCONJ
dpc-1881	179	54	/	/	SYM
dpc-1881	179	55	l	l	NOUN
dpc-1881	179	56	)	)	PUNCT
dpc-1881	179	57	ratio	ratio	NOUN
dpc-1881	180	1	[	[	X
dpc-1881	180	2	41	41	NUM
dpc-1881	180	3	]	]	PUNCT
dpc-1881	180	4	.	.	PUNCT
dpc-1881	181	1	some	some	DET
dpc-1881	181	2	studies	study	NOUN
dpc-1881	181	3	have	have	AUX
dpc-1881	181	4	been	be	AUX
dpc-1881	181	5	reported	report	VERB
dpc-1881	181	6	analyzing	analyze	VERB
dpc-1881	181	7	the	the	DET
dpc-1881	181	8	clinical	clinical	ADJ
dpc-1881	181	9	activity	activity	NOUN
dpc-1881	181	10	of	of	ADP
dpc-1881	181	11	anti	anti	ADJ
dpc-1881	181	12	-	-	ADJ
dpc-1881	181	13	mek	mek	ADJ
dpc-1881	181	14	inhibitors	inhibitor	NOUN
dpc-1881	181	15	in	in	ADP
dpc-1881	181	16	these	these	DET
dpc-1881	181	17	patients	patient	NOUN
dpc-1881	181	18	.	.	PUNCT
dpc-1881	182	1	based	base	VERB
dpc-1881	182	2	on	on	ADP
dpc-1881	182	3	these	these	DET
dpc-1881	182	4	data	datum	NOUN
dpc-1881	182	5	,	,	PUNCT
dpc-1881	182	6	a	a	DET
dpc-1881	182	7	randomized	randomized	ADJ
dpc-1881	182	8	phase	phase	NOUN
dpc-1881	182	9	iii	iii	NOUN
dpc-1881	182	10	trial	trial	NOUN
dpc-1881	182	11	was	be	AUX
dpc-1881	182	12	designed	design	VERB
dpc-1881	182	13	,	,	PUNCT
dpc-1881	182	14	comparing	compare	VERB
dpc-1881	182	15	binimetinib	binimetinib	NOUN
dpc-1881	182	16	with	with	ADP
dpc-1881	182	17	dacarbazine	dacarbazine	NOUN
dpc-1881	182	18	.	.	PUNCT
dpc-1881	183	1	the	the	DET
dpc-1881	183	2	study	study	NOUN
dpc-1881	183	3	enrolled	enrol	VERB
dpc-1881	183	4	269	269	NUM
dpc-1881	183	5	patients	patient	NOUN
dpc-1881	183	6	in	in	ADP
dpc-1881	183	7	the	the	DET
dpc-1881	183	8	binimetinib	binimetinib	NOUN
dpc-1881	183	9	arm	arm	NOUN
dpc-1881	183	10	and	and	CCONJ
dpc-1881	183	11	133	133	NUM
dpc-1881	183	12	in	in	ADP
dpc-1881	183	13	the	the	DET
dpc-1881	183	14	dacarbazine	dacarbazine	NOUN
dpc-1881	183	15	arm	arm	NOUN
dpc-1881	183	16	.	.	PUNCT
dpc-1881	184	1	binimetinib	binimetinib	PROPN
dpc-1881	184	2	significantly	significantly	ADV
dpc-1881	184	3	prolonged	prolong	VERB
dpc-1881	184	4	pfs	pfs	PROPN
dpc-1881	184	5	and	and	CCONJ
dpc-1881	184	6	improved	improve	VERB
dpc-1881	184	7	rr	rr	NOUN
dpc-1881	184	8	with	with	ADP
dpc-1881	184	9	respect	respect	NOUN
dpc-1881	184	10	to	to	ADP
dpc-1881	184	11	the	the	DET
dpc-1881	184	12	control	control	NOUN
dpc-1881	184	13	arm	arm	NOUN
dpc-1881	184	14	even	even	ADV
dpc-1881	184	15	if	if	SCONJ
dpc-1881	184	16	the	the	DET
dpc-1881	184	17	clinical	clinical	ADJ
dpc-1881	184	18	benefit	benefit	NOUN
dpc-1881	184	19	is	be	AUX
dpc-1881	184	20	slow	slow	ADJ
dpc-1881	184	21	,	,	PUNCT
dpc-1881	184	22	with	with	ADP
dpc-1881	184	23	median	median	PROPN
dpc-1881	184	24	pfs	pfs	PROPN
dpc-1881	184	25	of	of	ADP
dpc-1881	184	26	2.8	2.8	NUM
dpc-1881	184	27	months	month	NOUN
dpc-1881	184	28	compared	compare	VERB
dpc-1881	184	29	to	to	ADP
dpc-1881	184	30	1.5	1.5	NUM
dpc-1881	184	31	.	.	PUNCT
dpc-1881	185	1	furthermore	furthermore	ADV
dpc-1881	185	2	,	,	PUNCT
dpc-1881	185	3	no	no	DET
dpc-1881	185	4	differences	difference	NOUN
dpc-1881	185	5	in	in	ADP
dpc-1881	185	6	os	os	NOUN
dpc-1881	185	7	were	be	AUX
dpc-1881	185	8	achieved	achieve	VERB
dpc-1881	185	9	.	.	PUNCT
dpc-1881	186	1	an	an	DET
dpc-1881	186	2	interesting	interesting	ADJ
dpc-1881	186	3	point	point	NOUN
dpc-1881	186	4	was	be	AUX
dpc-1881	186	5	that	that	SCONJ
dpc-1881	186	6	the	the	DET
dpc-1881	186	7	benefit	benefit	NOUN
dpc-1881	186	8	in	in	ADP
dpc-1881	186	9	terms	term	NOUN
dpc-1881	186	10	of	of	ADP
dpc-1881	186	11	pfs	pfs	PROPN
dpc-1881	186	12	appear	appear	VERB
dpc-1881	186	13	to	to	PART
dpc-1881	186	14	be	be	AUX
dpc-1881	186	15	higher	high	ADJ
dpc-1881	186	16	in	in	ADP
dpc-1881	186	17	patients	patient	NOUN
dpc-1881	186	18	with	with	ADP
dpc-1881	186	19	a	a	DET
dpc-1881	186	20	prior	prior	ADJ
dpc-1881	186	21	immunotherapy	immunotherapy	NOUN
dpc-1881	186	22	(	(	PUNCT
dpc-1881	186	23	median	median	NOUN
dpc-1881	186	24	5.5	5.5	NUM
dpc-1881	186	25	months	month	NOUN
dpc-1881	186	26	)	)	PUNCT
dpc-1881	186	27	even	even	ADV
dpc-1881	186	28	if	if	SCONJ
dpc-1881	186	29	this	this	PRON
dpc-1881	186	30	is	be	AUX
dpc-1881	186	31	a	a	DET
dpc-1881	186	32	retrospective	retrospective	ADJ
dpc-1881	186	33	analysis	analysis	NOUN
dpc-1881	186	34	and	and	CCONJ
dpc-1881	186	35	thus	thus	ADV
dpc-1881	186	36	caution	caution	NOUN
dpc-1881	186	37	should	should	AUX
dpc-1881	186	38	be	be	AUX
dpc-1881	186	39	taken	take	VERB
dpc-1881	186	40	[	[	PUNCT
dpc-1881	186	41	42	42	NUM
dpc-1881	186	42	]	]	PUNCT
dpc-1881	186	43	.	.	PUNCT
dpc-1881	187	1	patients	patient	NOUN
dpc-1881	187	2	with	with	ADP
dpc-1881	187	3	brain	brain	NOUN
dpc-1881	187	4	metastases	metastasis	NOUN
dpc-1881	187	5	the	the	DET
dpc-1881	187	6	presence	presence	NOUN
dpc-1881	187	7	of	of	ADP
dpc-1881	187	8	brain	brain	NOUN
dpc-1881	187	9	metastases	metastasis	NOUN
dpc-1881	187	10	is	be	AUX
dpc-1881	187	11	now	now	ADV
dpc-1881	187	12	classified	classify	VERB
dpc-1881	187	13	as	as	ADP
dpc-1881	187	14	stage	stage	NOUN
dpc-1881	187	15	iv	iv	NUM
dpc-1881	187	16	m1d	m1d	NOUN
dpc-1881	187	17	and	and	CCONJ
dpc-1881	187	18	it	it	PRON
dpc-1881	187	19	is	be	AUX
dpc-1881	187	20	associated	associate	VERB
dpc-1881	187	21	with	with	ADP
dpc-1881	187	22	a	a	DET
dpc-1881	187	23	poor	poor	ADJ
dpc-1881	187	24	prognosis	prognosis	NOUN
dpc-1881	187	25	(	(	PUNCT
dpc-1881	187	26	median	median	ADJ
dpc-1881	187	27	survival	survival	NOUN
dpc-1881	187	28	4	4	NUM
dpc-1881	187	29	months	month	NOUN
dpc-1881	187	30	)	)	PUNCT
dpc-1881	188	1	[	[	X
dpc-1881	188	2	43	43	NUM
dpc-1881	188	3	,	,	PUNCT
dpc-1881	188	4	44	44	NUM
dpc-1881	188	5	]	]	PUNCT
dpc-1881	188	6	patients	patient	NOUN
dpc-1881	188	7	with	with	ADP
dpc-1881	188	8	active	active	ADJ
dpc-1881	188	9	brain	brain	NOUN
dpc-1881	188	10	metastases	metastasis	NOUN
dpc-1881	188	11	are	be	AUX
dpc-1881	188	12	in	in	ADP
dpc-1881	188	13	fact	fact	NOUN
dpc-1881	188	14	in	in	ADP
dpc-1881	188	15	most	most	ADJ
dpc-1881	188	16	cases	case	NOUN
dpc-1881	188	17	excluded	exclude	VERB
dpc-1881	188	18	from	from	ADP
dpc-1881	188	19	phase	phase	NOUN
dpc-1881	188	20	iii	iii	NUM
dpc-1881	188	21	clinical	clinical	ADJ
dpc-1881	188	22	trials	trial	NOUN
dpc-1881	188	23	,	,	PUNCT
dpc-1881	188	24	particularly	particularly	ADV
dpc-1881	188	25	those	those	PRON
dpc-1881	188	26	involving	involve	VERB
dpc-1881	188	27	immunotherapies	immunotherapy	NOUN
dpc-1881	188	28	[	[	X
dpc-1881	188	29	45,46	45,46	NOUN
dpc-1881	188	30	]	]	PUNCT
dpc-1881	188	31	as	as	ADP
dpc-1881	188	32	to	to	ADP
dpc-1881	188	33	targeted	target	VERB
dpc-1881	188	34	therapies	therapy	NOUN
dpc-1881	188	35	,	,	PUNCT
dpc-1881	188	36	the	the	DET
dpc-1881	188	37	combi	combi	PROPN
dpc-1881	188	38	-	-	PUNCT
dpc-1881	188	39	mb	mb	PROPN
dpc-1881	188	40	was	be	AUX
dpc-1881	188	41	a	a	DET
dpc-1881	188	42	multicenter	multicenter	NOUN
dpc-1881	188	43	,	,	PUNCT
dpc-1881	188	44	multicohort	multicohort	NOUN
dpc-1881	188	45	,	,	PUNCT
dpc-1881	188	46	open	open	ADJ
dpc-1881	188	47	-	-	PUNCT
dpc-1881	188	48	label	label	NOUN
dpc-1881	188	49	,	,	PUNCT
dpc-1881	188	50	phase	phase	NOUN
dpc-1881	188	51	2	2	NUM
dpc-1881	188	52	study	study	NOUN
dpc-1881	188	53	evaluating	evaluate	VERB
dpc-1881	188	54	the	the	DET
dpc-1881	188	55	combination	combination	NOUN
dpc-1881	188	56	of	of	ADP
dpc-1881	188	57	dabrafenib	dabrafenib	NOUN
dpc-1881	188	58	/	/	SYM
dpc-1881	188	59	trametinib	trametinib	NOUN
dpc-1881	188	60	in	in	ADP
dpc-1881	188	61	4	4	NUM
dpc-1881	188	62	patient	patient	ADJ
dpc-1881	188	63	cohorts	cohort	NOUN
dpc-1881	188	64	with	with	ADP
dpc-1881	188	65	melanoma	melanoma	ADJ
dpc-1881	188	66	brain	brain	NOUN
dpc-1881	188	67	metastases	metastasis	NOUN
dpc-1881	188	68	(	(	PUNCT
dpc-1881	188	69	based	base	VERB
dpc-1881	188	70	on	on	ADP
dpc-1881	188	71	the	the	DET
dpc-1881	188	72	presence	presence	NOUN
dpc-1881	188	73	of	of	ADP
dpc-1881	188	74	symptoms	symptom	NOUN
dpc-1881	188	75	,	,	PUNCT
dpc-1881	188	76	ecog	ecog	NOUN
dpc-1881	188	77	,	,	PUNCT
dpc-1881	188	78	and	and	CCONJ
dpc-1881	188	79	previous	previous	ADJ
dpc-1881	188	80	radiotherapy	radiotherapy	NOUN
dpc-1881	188	81	)	)	PUNCT
dpc-1881	188	82	.	.	PUNCT
dpc-1881	189	1	percentages	percentage	NOUN
dpc-1881	189	2	of	of	ADP
dpc-1881	189	3	intracranial	intracranial	ADJ
dpc-1881	189	4	responses	response	NOUN
dpc-1881	189	5	ranged	range	VERB
dpc-1881	189	6	from	from	ADP
dpc-1881	189	7	44	44	NUM
dpc-1881	189	8	%	%	NOUN
dpc-1881	189	9	to	to	ADP
dpc-1881	189	10	59	59	NUM
dpc-1881	189	11	%	%	NOUN
dpc-1881	189	12	with	with	ADP
dpc-1881	189	13	pfs	pfs	PROPN
dpc-1881	189	14	lower	low	ADJ
dpc-1881	189	15	than	than	ADP
dpc-1881	189	16	that	that	PRON
dpc-1881	189	17	found	find	VERB
dpc-1881	189	18	in	in	ADP
dpc-1881	189	19	patients	patient	NOUN
dpc-1881	189	20	with	with	ADP
dpc-1881	189	21	no	no	DET
dpc-1881	189	22	brain	brain	NOUN
dpc-1881	189	23	metastases	metastasis	NOUN
dpc-1881	189	24	(	(	PUNCT
dpc-1881	189	25	19	19	NUM
dpc-1881	189	26	%	%	NOUN
dpc-1881	189	27	pfs	pf	VERB
dpc-1881	189	28	at	at	ADP
dpc-1881	189	29	12	12	NUM
dpc-1881	189	30	months	month	NOUN
dpc-1881	189	31	)	)	PUNCT
dpc-1881	189	32	.	.	PUNCT
dpc-1881	190	1	dabrafenib	dabrafenib	NOUN
dpc-1881	190	2	plus	plus	CCONJ
dpc-1881	190	3	trametinib	trametinib	NOUN
dpc-1881	190	4	was	be	AUX
dpc-1881	190	5	active	active	ADJ
dpc-1881	190	6	with	with	ADP
dpc-1881	190	7	a	a	DET
dpc-1881	190	8	manageable	manageable	ADJ
dpc-1881	190	9	safety	safety	NOUN
dpc-1881	190	10	profile	profile	NOUN
dpc-1881	190	11	in	in	ADP
dpc-1881	190	12	this	this	DET
dpc-1881	190	13	melanoma	melanoma	NOUN
dpc-1881	190	14	population	population	NOUN
dpc-1881	190	15	that	that	PRON
dpc-1881	190	16	was	be	AUX
dpc-1881	190	17	consistent	consistent	ADJ
dpc-1881	190	18	with	with	ADP
dpc-1881	190	19	previous	previous	ADJ
dpc-1881	190	20	dabrafenib	dabrafenib	NOUN
dpc-1881	190	21	plus	plus	CCONJ
dpc-1881	190	22	trametinib	trametinib	NOUN
dpc-1881	190	23	studies	study	NOUN
dpc-1881	190	24	in	in	ADP
dpc-1881	190	25	patients	patient	NOUN
dpc-1881	190	26	with	with	ADP
dpc-1881	190	27	brafv600	brafv600	NOUN
dpc-1881	190	28	-	-	PUNCT
dpc-1881	190	29	mutant	mutant	ADJ
dpc-1881	190	30	melanoma	melanoma	NOUN
dpc-1881	190	31	without	without	ADP
dpc-1881	190	32	brain	brain	NOUN
dpc-1881	190	33	metastases	metastasis	NOUN
dpc-1881	190	34	,	,	PUNCT
dpc-1881	190	35	but	but	CCONJ
dpc-1881	190	36	the	the	DET
dpc-1881	190	37	median	median	ADJ
dpc-1881	190	38	duration	duration	NOUN
dpc-1881	190	39	of	of	ADP
dpc-1881	190	40	response	response	NOUN
dpc-1881	190	41	was	be	AUX
dpc-1881	190	42	relatively	relatively	ADV
dpc-1881	190	43	short	short	ADJ
dpc-1881	190	44	[	[	X
dpc-1881	190	45	47	47	NUM
dpc-1881	190	46	]	]	PUNCT
dpc-1881	190	47	.	.	PUNCT
dpc-1881	191	1	in	in	ADP
dpc-1881	191	2	phase	phase	NOUN
dpc-1881	191	3	ii	ii	NOUN
dpc-1881	191	4	studies	study	NOUN
dpc-1881	191	5	that	that	PRON
dpc-1881	191	6	involved	involve	VERB
dpc-1881	191	7	the	the	DET
dpc-1881	191	8	use	use	NOUN
dpc-1881	191	9	of	of	ADP
dpc-1881	191	10	nivolumab	nivolumab	NOUN
dpc-1881	191	11	or	or	CCONJ
dpc-1881	191	12	pembrolizumab	pembrolizumab	NOUN
dpc-1881	191	13	alone	alone	ADV
dpc-1881	191	14	in	in	ADP
dpc-1881	191	15	patients	patient	NOUN
dpc-1881	191	16	with	with	ADP
dpc-1881	191	17	brain	brain	NOUN
dpc-1881	191	18	metastases	metastasis	NOUN
dpc-1881	191	19	,	,	PUNCT
dpc-1881	191	20	the	the	DET
dpc-1881	191	21	percentage	percentage	NOUN
dpc-1881	191	22	of	of	ADP
dpc-1881	191	23	responses	response	NOUN
dpc-1881	191	24	varied	varied	ADJ
dpc-1881	191	25	from	from	ADP
dpc-1881	191	26	16	16	NUM
dpc-1881	191	27	%	%	NOUN
dpc-1881	191	28	to	to	PART
dpc-1881	191	29	25	25	NUM
dpc-1881	191	30	%	%	NOUN
dpc-1881	191	31	,	,	PUNCT
dpc-1881	191	32	that	that	PRON
dpc-1881	191	33	is	be	AUX
dpc-1881	191	34	clearly	clearly	ADV
dpc-1881	191	35	lower	low	ADJ
dpc-1881	191	36	than	than	ADP
dpc-1881	191	37	the	the	DET
dpc-1881	191	38	standard	standard	ADJ
dpc-1881	191	39	immunotherapy	immunotherapy	NOUN
dpc-1881	191	40	rr	rr	NOUN
dpc-1881	191	41	of	of	ADP
dpc-1881	191	42	around	around	ADV
dpc-1881	191	43	40	40	NUM
dpc-1881	191	44	%	%	NOUN
dpc-1881	191	45	-50	-50	NUM
dpc-1881	191	46	%	%	NOUN
dpc-1881	191	47	.	.	PUNCT
dpc-1881	192	1	the	the	DET
dpc-1881	192	2	duration	duration	NOUN
dpc-1881	192	3	of	of	ADP
dpc-1881	192	4	the	the	DET
dpc-1881	192	5	responses	response	NOUN
dpc-1881	192	6	was	be	AUX
dpc-1881	192	7	also	also	ADV
dpc-1881	192	8	significantly	significantly	ADV
dpc-1881	192	9	shorter	short	ADJ
dpc-1881	192	10	[	[	X
dpc-1881	192	11	45	45	NUM
dpc-1881	192	12	]	]	PUNCT
dpc-1881	192	13	.	.	PUNCT
dpc-1881	193	1	the	the	DET
dpc-1881	193	2	results	result	NOUN
dpc-1881	193	3	of	of	ADP
dpc-1881	193	4	3	3	NUM
dpc-1881	193	5	studies	study	NOUN
dpc-1881	193	6	carried	carry	VERB
dpc-1881	193	7	out	out	ADP
dpc-1881	193	8	in	in	ADP
dpc-1881	193	9	patients	patient	NOUN
dpc-1881	193	10	with	with	ADP
dpc-1881	193	11	active	active	ADJ
dpc-1881	193	12	brain	brain	NOUN
dpc-1881	193	13	metastases	metastasis	NOUN
dpc-1881	193	14	have	have	AUX
dpc-1881	193	15	instead	instead	ADV
dpc-1881	193	16	highlighted	highlight	VERB
dpc-1881	193	17	the	the	DET
dpc-1881	193	18	clinical	clinical	ADJ
dpc-1881	193	19	activity	activity	NOUN
dpc-1881	193	20	of	of	ADP
dpc-1881	193	21	the	the	DET
dpc-1881	193	22	combination	combination	NOUN
dpc-1881	193	23	of	of	ADP
dpc-1881	193	24	anti	anti	NOUN
dpc-1881	193	25	-	-	ADJ
dpc-1881	193	26	pd1	pd1	VERB
dpc-1881	193	27	nivolumab	nivolumab	ADV
dpc-1881	193	28	with	with	ADP
dpc-1881	193	29	ipilimumab	ipilimumab	NOUN
dpc-1881	193	30	in	in	ADP
dpc-1881	193	31	these	these	DET
dpc-1881	193	32	patients	patient	NOUN
dpc-1881	193	33	with	with	ADP
dpc-1881	193	34	rr	rr	NOUN
dpc-1881	193	35	ranging	range	VERB
dpc-1881	193	36	from	from	ADP
dpc-1881	193	37	46	46	NUM
dpc-1881	193	38	%	%	NOUN
dpc-1881	193	39	to	to	ADP
dpc-1881	193	40	55	55	NUM
dpc-1881	193	41	%	%	NOUN
dpc-1881	193	42	.	.	PUNCT
dpc-1881	194	1	in	in	ADP
dpc-1881	194	2	particular	particular	ADJ
dpc-1881	194	3	,	,	PUNCT
dpc-1881	194	4	the	the	DET
dpc-1881	194	5	abc	abc	PROPN
dpc-1881	194	6	study	study	NOUN
dpc-1881	194	7	is	be	AUX
dpc-1881	194	8	a	a	DET
dpc-1881	194	9	phase	phase	NOUN
dpc-1881	194	10	2	2	NUM
dpc-1881	194	11	study	study	NOUN
dpc-1881	194	12	that	that	PRON
dpc-1881	194	13	randomized	randomize	VERB
dpc-1881	194	14	patients	patient	NOUN
dpc-1881	194	15	with	with	ADP
dpc-1881	194	16	asymptomatic	asymptomatic	ADJ
dpc-1881	194	17	brain	brain	NOUN
dpc-1881	194	18	metastases	metastasis	NOUN
dpc-1881	194	19	to	to	PART
dpc-1881	194	20	receive	receive	VERB
dpc-1881	194	21	the	the	DET
dpc-1881	194	22	combination	combination	NOUN
dpc-1881	194	23	nivolumab	nivolumab	NOUN
dpc-1881	194	24	+	+	CCONJ
dpc-1881	194	25	ipilimumab	ipilimumab	ADJ
dpc-1881	194	26	,	,	PUNCT
dpc-1881	194	27	versus	versus	ADP
dpc-1881	194	28	nivolumab	nivolumab	NOUN
dpc-1881	194	29	alone	alone	ADV
dpc-1881	194	30	.	.	PUNCT
dpc-1881	195	1	a	a	DET
dpc-1881	195	2	third	third	ADJ
dpc-1881	195	3	arm	arm	NOUN
dpc-1881	195	4	involved	involve	VERB
dpc-1881	195	5	the	the	DET
dpc-1881	195	6	inclusion	inclusion	NOUN
dpc-1881	195	7	of	of	ADP
dpc-1881	195	8	patients	patient	NOUN
dpc-1881	195	9	with	with	ADP
dpc-1881	195	10	symptomatic	symptomatic	ADJ
dpc-1881	195	11	brain	brain	NOUN
dpc-1881	195	12	metastases	metastasis	NOUN
dpc-1881	195	13	to	to	PART
dpc-1881	195	14	receive	receive	VERB
dpc-1881	195	15	exclusively	exclusively	ADV
dpc-1881	195	16	nivolumab	nivolumab	ADV
dpc-1881	195	17	.	.	PUNCT
dpc-1881	196	1	intracranial	intracranial	ADJ
dpc-1881	196	2	rr	rr	PROPN
dpc-1881	196	3	were	be	AUX
dpc-1881	196	4	51	51	NUM
dpc-1881	196	5	%	%	NOUN
dpc-1881	196	6	in	in	ADP
dpc-1881	196	7	patients	patient	NOUN
dpc-1881	196	8	treated	treat	VERB
dpc-1881	196	9	with	with	ADP
dpc-1881	196	10	the	the	DET
dpc-1881	196	11	combination	combination	NOUN
dpc-1881	196	12	,	,	PUNCT
dpc-1881	196	13	20	20	NUM
dpc-1881	196	14	%	%	NOUN
dpc-1881	196	15	in	in	ADP
dpc-1881	196	16	asymptomatic	asymptomatic	ADJ
dpc-1881	196	17	patients	patient	NOUN
dpc-1881	196	18	treated	treat	VERB
dpc-1881	196	19	with	with	ADP
dpc-1881	196	20	nivolumab	nivolumab	NOUN
dpc-1881	196	21	,	,	PUNCT
dpc-1881	196	22	and	and	CCONJ
dpc-1881	196	23	6	6	NUM
dpc-1881	196	24	%	%	NOUN
dpc-1881	196	25	in	in	ADP
dpc-1881	196	26	symptomatic	symptomatic	ADJ
dpc-1881	196	27	patients	patient	NOUN
dpc-1881	196	28	treated	treat	VERB
dpc-1881	196	29	with	with	ADP
dpc-1881	196	30	nivolumab	nivolumab	NOUN
dpc-1881	196	31	.	.	PUNCT
dpc-1881	197	1	the	the	DET
dpc-1881	197	2	rate	rate	NOUN
dpc-1881	197	3	of	of	ADP
dpc-1881	197	4	intracranial	intracranial	ADJ
dpc-1881	197	5	responses	response	NOUN
dpc-1881	197	6	increased	increase	VERB
dpc-1881	197	7	to	to	ADP
dpc-1881	197	8	59	59	NUM
dpc-1881	197	9	%	%	NOUN
dpc-1881	197	10	with	with	ADP
dpc-1881	197	11	the	the	DET
dpc-1881	197	12	combination	combination	NOUN
dpc-1881	197	13	in	in	ADP
dpc-1881	197	14	naive	naive	ADJ
dpc-1881	197	15	,	,	PUNCT
dpc-1881	197	16	non	non	ADJ
dpc-1881	197	17	-	-	ADJ
dpc-1881	197	18	pretreated	pretreated	ADJ
dpc-1881	197	19	patients	patient	NOUN
dpc-1881	197	20	,	,	PUNCT
dpc-1881	197	21	compared	compare	VERB
dpc-1881	197	22	to	to	ADP
dpc-1881	197	23	21	21	NUM
dpc-1881	197	24	%	%	NOUN
dpc-1881	197	25	with	with	ADP
dpc-1881	197	26	monotherapy	monotherapy	NOUN
dpc-1881	197	27	.	.	PUNCT
dpc-1881	198	1	pfs	pfs	PROPN
dpc-1881	198	2	was	be	AUX
dpc-1881	198	3	also	also	ADV
dpc-1881	198	4	significantly	significantly	ADV
dpc-1881	198	5	different	different	ADJ
dpc-1881	198	6	,	,	PUNCT
dpc-1881	198	7	43	43	NUM
dpc-1881	198	8	%	%	NOUN
dpc-1881	198	9	at	at	ADP
dpc-1881	198	10	3	3	NUM
dpc-1881	198	11	years	year	NOUN
dpc-1881	198	12	with	with	ADP
dpc-1881	198	13	the	the	DET
dpc-1881	198	14	combination	combination	NOUN
dpc-1881	198	15	versus	versus	ADP
dpc-1881	198	16	15	15	NUM
dpc-1881	198	17	%	%	NOUN
dpc-1881	198	18	and	and	CCONJ
dpc-1881	198	19	6	6	NUM
dpc-1881	198	20	%	%	NOUN
dpc-1881	198	21	with	with	ADP
dpc-1881	198	22	monotherapy	monotherapy	NOUN
dpc-1881	198	23	,	,	PUNCT
dpc-1881	198	24	respectively	respectively	ADV
dpc-1881	198	25	.	.	PUNCT
dpc-1881	199	1	the	the	DET
dpc-1881	199	2	safety	safety	NOUN
dpc-1881	199	3	profile	profile	NOUN
dpc-1881	199	4	did	do	AUX
dpc-1881	199	5	not	not	PART
dpc-1881	199	6	report	report	VERB
dpc-1881	199	7	significant	significant	ADJ
dpc-1881	199	8	differences	difference	NOUN
dpc-1881	199	9	with	with	ADP
dpc-1881	199	10	respect	respect	NOUN
dpc-1881	199	11	to	to	ADP
dpc-1881	199	12	that	that	PRON
dpc-1881	199	13	highlighted	highlight	VERB
dpc-1881	199	14	in	in	ADP
dpc-1881	199	15	previous	previous	ADJ
dpc-1881	199	16	studies	study	NOUN
dpc-1881	199	17	of	of	ADP
dpc-1881	199	18	immune	immune	ADJ
dpc-1881	199	19	combo	combo	NOUN
dpc-1881	199	20	with	with	ADP
dpc-1881	199	21	a	a	DET
dpc-1881	199	22	percentage	percentage	NOUN
dpc-1881	199	23	of	of	ADP
dpc-1881	199	24	adverse	adverse	ADJ
dpc-1881	199	25	events	event	NOUN
dpc-1881	199	26	grade	grade	NOUN
dpc-1881	199	27	¾	¾	NOUN
dpc-1881	199	28	higher	high	ADJ
dpc-1881	199	29	than	than	ADP
dpc-1881	199	30	monotherapy	monotherapy	NOUN
dpc-1881	199	31	but	but	CCONJ
dpc-1881	199	32	still	still	ADV
dpc-1881	199	33	manageable	manageable	ADJ
dpc-1881	199	34	from	from	ADP
dpc-1881	199	35	a	a	DET
dpc-1881	199	36	clinical	clinical	ADJ
dpc-1881	199	37	point	point	NOUN
dpc-1881	199	38	of	of	ADP
dpc-1881	199	39	view	view	NOUN
dpc-1881	199	40	in	in	ADP
dpc-1881	199	41	a	a	DET
dpc-1881	199	42	patient	patient	NOUN
dpc-1881	199	43	setting	setting	NOUN
dpc-1881	199	44	with	with	ADP
dpc-1881	199	45	such	such	DET
dpc-1881	199	46	a	a	DET
dpc-1881	199	47	severe	severe	ADJ
dpc-1881	199	48	prognosis	prognosis	NOUN
dpc-1881	199	49	as	as	ADP
dpc-1881	199	50	those	those	PRON
dpc-1881	199	51	included	include	VERB
dpc-1881	199	52	in	in	ADP
dpc-1881	199	53	the	the	DET
dpc-1881	199	54	study	study	NOUN
dpc-1881	199	55	[	[	X
dpc-1881	199	56	48	48	NUM
dpc-1881	199	57	]	]	PUNCT
dpc-1881	199	58	.	.	PUNCT
dpc-1881	200	1	a	a	DET
dpc-1881	200	2	second	second	ADJ
dpc-1881	200	3	study	study	NOUN
dpc-1881	200	4	reporting	report	VERB
dpc-1881	200	5	the	the	DET
dpc-1881	200	6	results	result	NOUN
dpc-1881	200	7	of	of	ADP
dpc-1881	200	8	the	the	DET
dpc-1881	200	9	ipi	ipi	PROPN
dpc-1881	200	10	nivo	nivo	PROPN
dpc-1881	200	11	combination	combination	NOUN
dpc-1881	200	12	in	in	ADP
dpc-1881	200	13	patients	patient	NOUN
dpc-1881	200	14	with	with	ADP
dpc-1881	200	15	brain	brain	NOUN
dpc-1881	200	16	metastases	metastasis	NOUN
dpc-1881	200	17	is	be	AUX
dpc-1881	200	18	the	the	DET
dpc-1881	200	19	phase	phase	NOUN
dpc-1881	200	20	ii	ii	PROPN
dpc-1881	200	21	checkmate	checkmate	VERB
dpc-1881	200	22	204	204	NUM
dpc-1881	200	23	study	study	NOUN
dpc-1881	200	24	,	,	PUNCT
dpc-1881	200	25	which	which	PRON
dpc-1881	200	26	enrolled	enrol	VERB
dpc-1881	200	27	75	75	NUM
dpc-1881	200	28	patients	patient	NOUN
dpc-1881	200	29	,	,	PUNCT
dpc-1881	200	30	with	with	ADP
dpc-1881	200	31	55	55	NUM
dpc-1881	200	32	%	%	NOUN
dpc-1881	200	33	intracranial	intracranial	ADJ
dpc-1881	200	34	and	and	CCONJ
dpc-1881	200	35	53	53	NUM
dpc-1881	200	36	%	%	NOUN
dpc-1881	200	37	global	global	PROPN
dpc-1881	200	38	rr	rr	PROPN
dpc-1881	200	39	,	,	PUNCT
dpc-1881	200	40	2.8	2.8	NUM
dpc-1881	200	41	months	month	NOUN
dpc-1881	200	42	’	’	PART
dpc-1881	200	43	time	time	NOUN
dpc-1881	200	44	to	to	PART
dpc-1881	200	45	response	response	NOUN
dpc-1881	200	46	and	and	CCONJ
dpc-1881	200	47	median	median	ADJ
dpc-1881	200	48	duration	duration	NOUN
dpc-1881	200	49	of	of	ADP
dpc-1881	200	50	responses	response	NOUN
dpc-1881	200	51	not	not	PART
dpc-1881	200	52	yet	yet	ADV
dpc-1881	200	53	achieved	achieve	VERB
dpc-1881	200	54	[	[	X
dpc-1881	200	55	49	49	NUM
dpc-1881	200	56	]	]	PUNCT
dpc-1881	200	57	.	.	PUNCT
dpc-1881	201	1	the	the	DET
dpc-1881	201	2	third	third	ADJ
dpc-1881	201	3	nibit	nibit	NOUN
dpc-1881	201	4	-	-	PUNCT
dpc-1881	201	5	m2	m2	PROPN
dpc-1881	201	6	study	study	NOUN
dpc-1881	201	7	is	be	AUX
dpc-1881	201	8	a	a	DET
dpc-1881	201	9	randomized	randomized	ADJ
dpc-1881	201	10	phase	phase	NOUN
dpc-1881	201	11	3	3	NUM
dpc-1881	201	12	study	study	NOUN
dpc-1881	201	13	that	that	PRON
dpc-1881	201	14	included	include	VERB
dpc-1881	201	15	patients	patient	NOUN
dpc-1881	201	16	with	with	ADP
dpc-1881	201	17	brain	brain	NOUN
dpc-1881	201	18	metastases	metastasis	NOUN
dpc-1881	201	19	randomizing	randomize	VERB
dpc-1881	201	20	them	they	PRON
dpc-1881	201	21	into	into	ADP
dpc-1881	201	22	three	three	NUM
dpc-1881	201	23	arms	arm	NOUN
dpc-1881	201	24	(	(	PUNCT
dpc-1881	201	25	fotemustine	fotemustine	NOUN
dpc-1881	201	26	,	,	PUNCT
dpc-1881	201	27	fotemnustine	fotemnustine	NOUN
dpc-1881	201	28	+	+	CCONJ
dpc-1881	201	29	ipilimumab	ipilimumab	ADJ
dpc-1881	201	30	,	,	PUNCT
dpc-1881	201	31	and	and	CCONJ
dpc-1881	201	32	nivolumab	nivolumab	NOUN
dpc-1881	201	33	+	+	CCONJ
dpc-1881	201	34	ipilimumab	ipilimumab	NOUN
dpc-1881	201	35	)	)	PUNCT
dpc-1881	201	36	.	.	PUNCT
dpc-1881	202	1	the	the	DET
dpc-1881	202	2	arm	arm	NOUN
dpc-1881	202	3	treated	treat	VERB
dpc-1881	202	4	with	with	ADP
dpc-1881	202	5	the	the	DET
dpc-1881	202	6	immune	immune	ADJ
dpc-1881	202	7	combo	combo	NOUN
dpc-1881	202	8	obtained	obtain	VERB
dpc-1881	202	9	44	44	NUM
dpc-1881	202	10	%	%	NOUN
dpc-1881	202	11	intracranial	intracranial	ADJ
dpc-1881	202	12	response	response	NOUN
dpc-1881	202	13	with	with	ADP
dpc-1881	202	14	pfs	pfs	PROPN
dpc-1881	202	15	36	36	NUM
dpc-1881	202	16	%	%	NOUN
dpc-1881	202	17	at	at	ADP
dpc-1881	202	18	4	4	NUM
dpc-1881	202	19	years	year	NOUN
dpc-1881	202	20	and	and	CCONJ
dpc-1881	202	21	41	41	NUM
dpc-1881	202	22	%	%	NOUN
dpc-1881	202	23	os	os	NOUN
dpc-1881	202	24	at	at	ADP
dpc-1881	202	25	4	4	NUM
dpc-1881	202	26	years	year	NOUN
dpc-1881	202	27	[	[	X
dpc-1881	202	28	50	50	NUM
dpc-1881	202	29	]	]	PUNCT
dpc-1881	202	30	.	.	PUNCT
dpc-1881	203	1	new	new	ADJ
dpc-1881	203	2	scenarios	scenario	NOUN
dpc-1881	203	3	:	:	PUNCT
dpc-1881	203	4	combining	combine	VERB
dpc-1881	203	5	targeted	target	VERB
dpc-1881	203	6	and	and	CCONJ
dpc-1881	203	7	immunotherapies	immunotherapie	VERB
dpc-1881	203	8	a	a	DET
dpc-1881	203	9	novel	novel	ADJ
dpc-1881	203	10	approach	approach	NOUN
dpc-1881	203	11	which	which	PRON
dpc-1881	203	12	is	be	AUX
dpc-1881	203	13	emerging	emerge	VERB
dpc-1881	203	14	for	for	ADP
dpc-1881	203	15	braf	braf	NOUN
dpc-1881	203	16	-	-	PUNCT
dpc-1881	203	17	mutant	mutant	NOUN
dpc-1881	203	18	patients	patient	NOUN
dpc-1881	203	19	is	be	AUX
dpc-1881	203	20	represented	represent	VERB
dpc-1881	203	21	by	by	ADP
dpc-1881	203	22	the	the	DET
dpc-1881	203	23	combination	combination	NOUN
dpc-1881	203	24	of	of	ADP
dpc-1881	203	25	targeted	target	VERB
dpc-1881	203	26	therapies	therapy	NOUN
dpc-1881	203	27	and	and	CCONJ
dpc-1881	203	28	immune	immune	NOUN
dpc-1881	203	29	-	-	PUNCT
dpc-1881	203	30	checkpoint	checkpoint	NOUN
dpc-1881	203	31	inhibitors	inhibitor	NOUN
dpc-1881	203	32	[	[	X
dpc-1881	203	33	51	51	NUM
dpc-1881	203	34	]	]	PUNCT
dpc-1881	203	35	,	,	PUNCT
dpc-1881	203	36	commonly	commonly	ADV
dpc-1881	203	37	review	review	VERB
dpc-1881	203	38	|	|	ADV
dpc-1881	203	39	dermatol	dermatol	ADJ
dpc-1881	203	40	pract	pract	NOUN
dpc-1881	203	41	concept	concept	NOUN
dpc-1881	203	42	.	.	PUNCT
dpc-1881	204	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	204	2	):	):	PUNCT
dpc-1881	204	3	e2021164s	e2021164s	PROPN
dpc-1881	204	4	7	7	NUM
dpc-1881	204	5	referred	refer	VERB
dpc-1881	204	6	as	as	ADP
dpc-1881	204	7	“	"	PUNCT
dpc-1881	204	8	triplets	triplet	NOUN
dpc-1881	204	9	”	"	PUNCT
dpc-1881	204	10	.	.	PUNCT
dpc-1881	205	1	the	the	DET
dpc-1881	205	2	rationale	rationale	NOUN
dpc-1881	205	3	for	for	ADP
dpc-1881	205	4	this	this	DET
dpc-1881	205	5	association	association	NOUN
dpc-1881	205	6	is	be	AUX
dpc-1881	205	7	2	2	NUM
dpc-1881	205	8	-	-	NOUN
dpc-1881	205	9	fold	fold	ADJ
dpc-1881	205	10	.	.	PUNCT
dpc-1881	206	1	from	from	ADP
dpc-1881	206	2	the	the	DET
dpc-1881	206	3	clinical	clinical	ADJ
dpc-1881	206	4	point	point	NOUN
dpc-1881	206	5	of	of	ADP
dpc-1881	206	6	view	view	NOUN
dpc-1881	206	7	,	,	PUNCT
dpc-1881	206	8	it	it	PRON
dpc-1881	206	9	could	could	AUX
dpc-1881	206	10	couple	couple	VERB
dpc-1881	206	11	the	the	DET
dpc-1881	206	12	principal	principal	ADJ
dpc-1881	206	13	benefits	benefit	NOUN
dpc-1881	206	14	of	of	ADP
dpc-1881	206	15	the	the	DET
dpc-1881	206	16	2	2	NUM
dpc-1881	206	17	regimens	regimen	NOUN
dpc-1881	206	18	,	,	PUNCT
dpc-1881	206	19	thus	thus	ADV
dpc-1881	206	20	the	the	DET
dpc-1881	206	21	high	high	ADJ
dpc-1881	206	22	response	response	NOUN
dpc-1881	206	23	rate	rate	NOUN
dpc-1881	206	24	of	of	ADP
dpc-1881	206	25	the	the	DET
dpc-1881	206	26	targeted	target	VERB
dpc-1881	206	27	therapies	therapy	NOUN
dpc-1881	206	28	and	and	CCONJ
dpc-1881	206	29	the	the	DET
dpc-1881	206	30	remission	remission	NOUN
dpc-1881	206	31	duration	duration	NOUN
dpc-1881	206	32	of	of	ADP
dpc-1881	206	33	immunotherapies	immunotherapy	NOUN
dpc-1881	206	34	in	in	ADP
dpc-1881	206	35	an	an	DET
dpc-1881	206	36	attempt	attempt	NOUN
dpc-1881	206	37	to	to	PART
dpc-1881	206	38	overcome	overcome	VERB
dpc-1881	206	39	the	the	DET
dpc-1881	206	40	development	development	NOUN
dpc-1881	206	41	of	of	ADP
dpc-1881	206	42	acquired	acquire	VERB
dpc-1881	206	43	resistance	resistance	NOUN
dpc-1881	206	44	.	.	PUNCT
dpc-1881	207	1	from	from	ADP
dpc-1881	207	2	the	the	DET
dpc-1881	207	3	biological	biological	ADJ
dpc-1881	207	4	point	point	NOUN
dpc-1881	207	5	of	of	ADP
dpc-1881	207	6	view	view	NOUN
dpc-1881	207	7	,	,	PUNCT
dpc-1881	207	8	antibraf	antibraf	NOUN
dpc-1881	207	9	targeted	target	VERB
dpc-1881	207	10	therapies	therapy	NOUN
dpc-1881	207	11	have	have	AUX
dpc-1881	207	12	been	be	AUX
dpc-1881	207	13	recognized	recognize	VERB
dpc-1881	207	14	to	to	PART
dpc-1881	207	15	positively	positively	ADV
dpc-1881	207	16	modulate	modulate	VERB
dpc-1881	207	17	the	the	DET
dpc-1881	207	18	immune	immune	ADJ
dpc-1881	207	19	regulation	regulation	NOUN
dpc-1881	207	20	,	,	PUNCT
dpc-1881	207	21	by	by	ADP
dpc-1881	207	22	promoting	promote	VERB
dpc-1881	207	23	t	t	NOUN
dpc-1881	207	24	-	-	PUNCT
dpc-1881	207	25	cell	cell	NOUN
dpc-1881	207	26	infiltration	infiltration	NOUN
dpc-1881	207	27	with	with	ADP
dpc-1881	207	28	reduction	reduction	NOUN
dpc-1881	207	29	of	of	ADP
dpc-1881	207	30	regulatory	regulatory	ADJ
dpc-1881	207	31	t	t	PROPN
dpc-1881	207	32	-	-	PUNCT
dpc-1881	207	33	cells	cell	NOUN
dpc-1881	207	34	,	,	PUNCT
dpc-1881	207	35	inducing	induce	VERB
dpc-1881	207	36	melanoma	melanoma	NOUN
dpc-1881	207	37	antigen	antigen	NOUN
dpc-1881	207	38	-	-	PUNCT
dpc-1881	207	39	expression	expression	NOUN
dpc-1881	207	40	,	,	PUNCT
dpc-1881	207	41	and	and	CCONJ
dpc-1881	207	42	restoring	restore	VERB
dpc-1881	207	43	the	the	DET
dpc-1881	207	44	impaired	impaired	ADJ
dpc-1881	207	45	mhc	mhc	PROPN
dpc-1881	207	46	-	-	PUNCT
dpc-1881	207	47	i	i	PROPN
dpc-1881	207	48	surface	surface	NOUN
dpc-1881	207	49	expression	expression	NOUN
dpc-1881	207	50	,	,	PUNCT
dpc-1881	207	51	thus	thus	ADV
dpc-1881	207	52	reducing	reduce	VERB
dpc-1881	207	53	the	the	DET
dpc-1881	207	54	immunosuppression	immunosuppression	NOUN
dpc-1881	207	55	and	and	CCONJ
dpc-1881	207	56	immune	immune	ADJ
dpc-1881	207	57	escape	escape	NOUN
dpc-1881	207	58	associated	associate	VERB
dpc-1881	207	59	with	with	ADP
dpc-1881	207	60	the	the	DET
dpc-1881	207	61	braf	braf	NOUN
dpc-1881	207	62	mutated	mutate	VERB
dpc-1881	207	63	oncogenic	oncogenic	ADJ
dpc-1881	207	64	pathway	pathway	NOUN
dpc-1881	207	65	[	[	X
dpc-1881	207	66	52	52	NUM
dpc-1881	207	67	]	]	PUNCT
dpc-1881	207	68	.	.	PUNCT
dpc-1881	208	1	the	the	DET
dpc-1881	208	2	keynote-022	keynote-022	NOUN
dpc-1881	208	3	trial	trial	NOUN
dpc-1881	208	4	[	[	X
dpc-1881	208	5	53	53	NUM
dpc-1881	208	6	]	]	PUNCT
dpc-1881	208	7	,	,	PUNCT
dpc-1881	208	8	the	the	DET
dpc-1881	208	9	first	first	ADJ
dpc-1881	208	10	phase	phase	NOUN
dpc-1881	208	11	ii	ii	NOUN
dpc-1881	208	12	trial	trial	NOUN
dpc-1881	208	13	investigating	investigate	VERB
dpc-1881	208	14	a	a	DET
dpc-1881	208	15	triplet	triplet	NOUN
dpc-1881	208	16	in	in	ADP
dpc-1881	208	17	melanoma	melanoma	NOUN
dpc-1881	208	18	,	,	PUNCT
dpc-1881	208	19	randomized	randomize	VERB
dpc-1881	208	20	120	120	NUM
dpc-1881	208	21	patients	patient	NOUN
dpc-1881	208	22	to	to	PART
dpc-1881	208	23	receive	receive	VERB
dpc-1881	208	24	dabrafenib	dabrafenib	NOUN
dpc-1881	208	25	/	/	SYM
dpc-1881	208	26	trametinib	trametinib	NOUN
dpc-1881	208	27	plus	plus	CCONJ
dpc-1881	208	28	pembrolizumab	pembrolizumab	NOUN
dpc-1881	208	29	or	or	CCONJ
dpc-1881	208	30	placebo	placebo	NOUN
dpc-1881	208	31	,	,	PUNCT
dpc-1881	208	32	with	with	ADP
dpc-1881	208	33	pfs	pfs	PROPN
dpc-1881	208	34	as	as	ADP
dpc-1881	208	35	primary	primary	ADJ
dpc-1881	208	36	endpoint	endpoint	NOUN
dpc-1881	208	37	.	.	PUNCT
dpc-1881	209	1	the	the	DET
dpc-1881	209	2	study	study	NOUN
dpc-1881	209	3	did	do	AUX
dpc-1881	209	4	not	not	PART
dpc-1881	209	5	show	show	VERB
dpc-1881	209	6	a	a	DET
dpc-1881	209	7	statistically	statistically	ADV
dpc-1881	209	8	significant	significant	ADJ
dpc-1881	209	9	difference	difference	NOUN
dpc-1881	209	10	in	in	ADP
dpc-1881	209	11	pfs	pfs	PROPN
dpc-1881	209	12	,	,	PUNCT
dpc-1881	209	13	even	even	ADV
dpc-1881	209	14	if	if	SCONJ
dpc-1881	209	15	a	a	DET
dpc-1881	209	16	non	non	ADJ
dpc-1881	209	17	-	-	ADJ
dpc-1881	209	18	statistically	statistically	ADV
dpc-1881	209	19	longer	long	ADJ
dpc-1881	209	20	pfs	pfs	PROPN
dpc-1881	209	21	was	be	AUX
dpc-1881	209	22	found	find	VERB
dpc-1881	209	23	in	in	ADP
dpc-1881	209	24	patients	patient	NOUN
dpc-1881	209	25	treated	treat	VERB
dpc-1881	209	26	with	with	ADP
dpc-1881	209	27	the	the	DET
dpc-1881	209	28	triplet	triplet	NOUN
dpc-1881	209	29	(	(	PUNCT
dpc-1881	209	30	16.9	16.9	NUM
dpc-1881	209	31	vs	vs	ADP
dpc-1881	209	32	10.7	10.7	NUM
dpc-1881	209	33	months	month	NOUN
dpc-1881	209	34	at	at	ADP
dpc-1881	209	35	36	36	NUM
dpc-1881	209	36	months	month	NOUN
dpc-1881	209	37	follow	follow	VERB
dpc-1881	209	38	-	-	PUNCT
dpc-1881	209	39	up	up	NOUN
dpc-1881	209	40	)	)	PUNCT
dpc-1881	209	41	;	;	PUNCT
dpc-1881	209	42	moreover	moreover	ADV
dpc-1881	209	43	,	,	PUNCT
dpc-1881	209	44	median	median	ADJ
dpc-1881	209	45	duration	duration	NOUN
dpc-1881	209	46	of	of	ADP
dpc-1881	209	47	response	response	NOUN
dpc-1881	209	48	was	be	AUX
dpc-1881	209	49	25.1	25.1	NUM
dpc-1881	209	50	months	month	NOUN
dpc-1881	209	51	in	in	ADP
dpc-1881	209	52	the	the	DET
dpc-1881	209	53	triplet	triplet	NOUN
dpc-1881	209	54	cohort	cohort	NOUN
dpc-1881	209	55	and	and	CCONJ
dpc-1881	209	56	12.1	12.1	NUM
dpc-1881	209	57	months	month	NOUN
dpc-1881	209	58	in	in	ADP
dpc-1881	209	59	the	the	DET
dpc-1881	209	60	control	control	NOUN
dpc-1881	209	61	group	group	NOUN
dpc-1881	209	62	.	.	PUNCT
dpc-1881	210	1	patients	patient	NOUN
dpc-1881	210	2	treated	treat	VERB
dpc-1881	210	3	with	with	ADP
dpc-1881	210	4	the	the	DET
dpc-1881	210	5	triplet	triplet	NOUN
dpc-1881	210	6	experienced	experience	VERB
dpc-1881	210	7	however	however	ADV
dpc-1881	210	8	higher	high	ADJ
dpc-1881	210	9	toxicity	toxicity	NOUN
dpc-1881	210	10	rates	rate	NOUN
dpc-1881	210	11	,	,	PUNCT
dpc-1881	210	12	with	with	ADP
dpc-1881	210	13	58.3	58.3	NUM
dpc-1881	210	14	%	%	NOUN
dpc-1881	210	15	developing	develop	VERB
dpc-1881	210	16	grade	grade	NOUN
dpc-1881	210	17	3	3	NUM
dpc-1881	210	18	-	-	SYM
dpc-1881	210	19	5	5	NUM
dpc-1881	210	20	treatment	treatment	NOUN
dpc-1881	210	21	-	-	PUNCT
dpc-1881	210	22	related	relate	VERB
dpc-1881	210	23	adverse	adverse	ADJ
dpc-1881	210	24	event	event	NOUN
dpc-1881	210	25	versus	versus	ADP
dpc-1881	210	26	26.7	26.7	NUM
dpc-1881	210	27	%	%	NOUN
dpc-1881	210	28	.	.	PUNCT
dpc-1881	211	1	the	the	DET
dpc-1881	211	2	imspire150	imspire150	PROPN
dpc-1881	211	3	trial	trial	NOUN
dpc-1881	211	4	was	be	AUX
dpc-1881	211	5	a	a	DET
dpc-1881	211	6	randomized	randomized	ADJ
dpc-1881	211	7	phase	phase	NOUN
dpc-1881	211	8	3	3	NUM
dpc-1881	211	9	study	study	NOUN
dpc-1881	211	10	comparing	compare	VERB
dpc-1881	211	11	the	the	DET
dpc-1881	211	12	triplet	triplet	NOUN
dpc-1881	211	13	atezolizumab	atezolizumab	NOUN
dpc-1881	211	14	,	,	PUNCT
dpc-1881	211	15	vemurafenib	vemurafenib	NOUN
dpc-1881	211	16	,	,	PUNCT
dpc-1881	211	17	and	and	CCONJ
dpc-1881	211	18	cobimetinib	cobimetinib	NOUN
dpc-1881	211	19	versus	versus	ADP
dpc-1881	211	20	vemurafenib	vemurafenib	PROPN
dpc-1881	211	21	,	,	PUNCT
dpc-1881	211	22	cobimetinib	cobimetinib	NOUN
dpc-1881	211	23	and	and	CCONJ
dpc-1881	211	24	placebo	placebo	NOUN
dpc-1881	211	25	,	,	PUNCT
dpc-1881	211	26	with	with	ADP
dpc-1881	211	27	the	the	DET
dpc-1881	211	28	primary	primary	ADJ
dpc-1881	211	29	endpoint	endpoint	NOUN
dpc-1881	211	30	of	of	ADP
dpc-1881	211	31	pfs	pfs	PROPN
dpc-1881	211	32	.	.	PUNCT
dpc-1881	212	1	a	a	DET
dpc-1881	212	2	total	total	NOUN
dpc-1881	212	3	of	of	ADP
dpc-1881	212	4	514	514	NUM
dpc-1881	212	5	patients	patient	NOUN
dpc-1881	212	6	were	be	AUX
dpc-1881	212	7	enrolled	enrol	VERB
dpc-1881	212	8	.	.	PUNCT
dpc-1881	213	1	at	at	ADP
dpc-1881	213	2	a	a	DET
dpc-1881	213	3	median	median	ADJ
dpc-1881	213	4	18.9	18.9	NUM
dpc-1881	213	5	month	month	NOUN
dpc-1881	213	6	follow	follow	NOUN
dpc-1881	213	7	-	-	PUNCT
dpc-1881	213	8	up	up	NOUN
dpc-1881	213	9	,	,	PUNCT
dpc-1881	213	10	investigator	investigator	NOUN
dpc-1881	213	11	–	–	PUNCT
dpc-1881	213	12	assessed	assess	VERB
dpc-1881	213	13	pfs	pf	NOUN
dpc-1881	213	14	was	be	AUX
dpc-1881	213	15	significantly	significantly	ADV
dpc-1881	213	16	longer	long	ADJ
dpc-1881	213	17	in	in	ADP
dpc-1881	213	18	the	the	DET
dpc-1881	213	19	triplet	triplet	NOUN
dpc-1881	213	20	group	group	NOUN
dpc-1881	213	21	versus	versus	ADP
dpc-1881	213	22	control	control	NOUN
dpc-1881	213	23	(	(	PUNCT
dpc-1881	213	24	15.1	15.1	NUM
dpc-1881	213	25	vs	vs	ADP
dpc-1881	213	26	10.6	10.6	NUM
dpc-1881	213	27	months	month	NOUN
dpc-1881	213	28	;	;	PUNCT
dpc-1881	213	29	p=0.025	p=0.025	NUM
dpc-1881	213	30	)	)	PUNCT
dpc-1881	213	31	.	.	PUNCT
dpc-1881	214	1	the	the	DET
dpc-1881	214	2	triplet	triplet	NOUN
dpc-1881	214	3	figure	figure	NOUN
dpc-1881	214	4	1	1	NUM
dpc-1881	214	5	.	.	PUNCT
dpc-1881	214	6	clinical	clinical	ADJ
dpc-1881	214	7	activity	activity	NOUN
dpc-1881	214	8	of	of	ADP
dpc-1881	214	9	the	the	DET
dpc-1881	214	10	3	3	NUM
dpc-1881	214	11	main	main	ADJ
dpc-1881	214	12	combinations	combination	NOUN
dpc-1881	214	13	of	of	ADP
dpc-1881	214	14	targeted	target	VERB
dpc-1881	214	15	therapy	therapy	NOUN
dpc-1881	214	16	.	.	PUNCT
dpc-1881	215	1	orr=	orr=	VERB
dpc-1881	215	2	overall	overall	ADJ
dpc-1881	215	3	response	response	NOUN
dpc-1881	215	4	rate	rate	NOUN
dpc-1881	215	5	;	;	PUNCT
dpc-1881	215	6	pfs=	pfs=	PROPN
dpc-1881	215	7	progression	progression	NOUN
dpc-1881	215	8	-	-	PUNCT
dpc-1881	215	9	free	free	ADJ
dpc-1881	215	10	-	-	PUNCT
dpc-1881	215	11	survival	survival	NOUN
dpc-1881	215	12	;	;	PUNCT
dpc-1881	215	13	os=	os=	PROPN
dpc-1881	215	14	overall	overall	ADJ
dpc-1881	215	15	survival	survival	PROPN
dpc-1881	215	16	endpoint	endpoint	PROPN
dpc-1881	215	17	orr	orr	PROPN
dpc-1881	215	18	,	,	PUNCT
dpc-1881	215	19	%	%	NOUN
dpc-1881	215	20	median	median	PROPN
dpc-1881	215	21	pfs	pfs	PROPN
dpc-1881	215	22	,	,	PUNCT
dpc-1881	215	23	months	month	NOUN
dpc-1881	215	24	median	median	PROPN
dpc-1881	215	25	os	os	NOUN
dpc-1881	215	26	,	,	PUNCT
dpc-1881	215	27	months	month	NOUN
dpc-1881	215	28	(	(	PUNCT
dpc-1881	215	29	hr	hr	NOUN
dpc-1881	215	30	;	;	PUNCT
dpc-1881	215	31	95	95	NUM
dpc-1881	215	32	%	%	NOUN
dpc-1881	215	33	cl	cl	NOUN
dpc-1881	215	34	)	)	PUNCT
dpc-1881	215	35	69	69	NUM
dpc-1881	215	36	11	11	NUM
dpc-1881	215	37	25.1	25.1	NUM
dpc-1881	215	38	69.6	69.6	NUM
dpc-1881	215	39	12.3	12.3	NUM
dpc-1881	215	40	22.3	22.3	NUM
dpc-1881	215	41	65.8	65.8	NUM
dpc-1881	215	42	12.6	12.6	NUM
dpc-1881	215	43	25.6	25.6	NUM
dpc-1881	215	44	64	64	NUM
dpc-1881	215	45	-	-	SYM
dpc-1881	215	46	76	76	NUM
dpc-1881	215	47	14,9	14,9	NUM
dpc-1881	215	48	33.6	33.6	NUM
dpc-1881	215	49	combi	combi	NOUN
dpc-1881	215	50	-	-	PROPN
dpc-1881	215	51	d	d	PROPN
dpc-1881	215	52	dbarafenib+	dbarafenib+	X
dpc-1881	215	53	trametinib	trametinib	NOUN
dpc-1881	215	54	vs.	vs.	ADP
dpc-1881	215	55	dabrafenib	dabrafenib	NOUN
dpc-1881	215	56	cobrim4	cobrim4	PROPN
dpc-1881	216	1	cobimetinib	cobimetinib	NOUN
dpc-1881	216	2	+	+	CCONJ
dpc-1881	216	3	vemurafenib	vemurafenib	PROPN
dpc-1881	216	4	vs.	vs.	ADP
dpc-1881	216	5	vemurafenib	vemurafenib	PROPN
dpc-1881	216	6	combi	combi	PROPN
dpc-1881	216	7	-	-	PUNCT
dpc-1881	216	8	v5	v5	PROPN
dpc-1881	216	9	dabrafenib	dabrafenib	NOUN
dpc-1881	216	10	+	+	CCONJ
dpc-1881	216	11	trametinib‡	trametinib‡	NOUN
dpc-1881	216	12	vs.	vs.	X
dpc-1881	216	13	vemurafenib	vemurafenib	PROPN
dpc-1881	216	14	colombus	colombus	NOUN
dpc-1881	216	15	encorafenib	encorafenib	NOUN
dpc-1881	216	16	+	+	CCONJ
dpc-1881	216	17	binimetinib	binimetinib	NOUN
dpc-1881	216	18	vs	vs	ADP
dpc-1881	216	19	encorafenib	encorafenib	NOUN
dpc-1881	216	20	vs	vs	ADP
dpc-1881	216	21	vemurafenib	vemurafenib	PROPN
dpc-1881	216	22	figure	figure	NOUN
dpc-1881	216	23	2	2	NUM
dpc-1881	216	24	.	.	PUNCT
dpc-1881	217	1	(	(	PUNCT
dpc-1881	217	2	a	a	PRON
dpc-1881	217	3	,	,	PUNCT
dpc-1881	217	4	b	b	NOUN
dpc-1881	217	5	)	)	PUNCT
dpc-1881	217	6	development	development	NOUN
dpc-1881	217	7	of	of	ADP
dpc-1881	217	8	response	response	NOUN
dpc-1881	217	9	in	in	ADP
dpc-1881	217	10	a	a	DET
dpc-1881	217	11	representative	representative	ADJ
dpc-1881	217	12	patient	patient	NOUN
dpc-1881	217	13	with	with	ADP
dpc-1881	217	14	braf	braf	NOUN
dpc-1881	217	15	mutant	mutant	NOUN
dpc-1881	217	16	metastatic	metastatic	ADJ
dpc-1881	217	17	melanoma	melanoma	NOUN
dpc-1881	217	18	with	with	ADP
dpc-1881	217	19	lung	lung	NOUN
dpc-1881	217	20	and	and	CCONJ
dpc-1881	217	21	skin	skin	NOUN
dpc-1881	217	22	metastases	metastasis	NOUN
dpc-1881	217	23	:	:	PUNCT
dpc-1881	217	24	response	response	NOUN
dpc-1881	217	25	achieved	achieve	VERB
dpc-1881	217	26	as	as	ADP
dpc-1881	217	27	clinically	clinically	ADV
dpc-1881	217	28	evident	evident	ADJ
dpc-1881	217	29	at	at	ADP
dpc-1881	217	30	the	the	DET
dpc-1881	217	31	7th	7th	ADJ
dpc-1881	217	32	week	week	NOUN
dpc-1881	217	33	from	from	ADP
dpc-1881	217	34	the	the	DET
dpc-1881	217	35	beginning	beginning	NOUN
dpc-1881	217	36	of	of	ADP
dpc-1881	217	37	treatment	treatment	NOUN
dpc-1881	217	38	.	.	PUNCT
dpc-1881	218	1	(	(	PUNCT
dpc-1881	218	2	c	c	X
dpc-1881	218	3	-	-	SYM
dpc-1881	218	4	f	f	NOUN
dpc-1881	218	5	)	)	PUNCT
dpc-1881	218	6	ct	ct	PROPN
dpc-1881	218	7	scan	scan	PROPN
dpc-1881	218	8	performed	perform	VERB
dpc-1881	218	9	3	3	NUM
dpc-1881	218	10	months	month	NOUN
dpc-1881	218	11	after	after	ADP
dpc-1881	218	12	the	the	DET
dpc-1881	218	13	beginning	beginning	NOUN
dpc-1881	218	14	showing	show	VERB
dpc-1881	218	15	the	the	DET
dpc-1881	218	16	complete	complete	ADJ
dpc-1881	218	17	clearance	clearance	NOUN
dpc-1881	218	18	of	of	ADP
dpc-1881	218	19	lung	lung	NOUN
dpc-1881	218	20	metastases	metastasis	NOUN
dpc-1881	218	21	8	8	NUM
dpc-1881	218	22	review	review	NOUN
dpc-1881	218	23	|	|	ADV
dpc-1881	218	24	dermatol	dermatol	ADJ
dpc-1881	218	25	pract	pract	NOUN
dpc-1881	218	26	concept	concept	NOUN
dpc-1881	218	27	.	.	PUNCT
dpc-1881	219	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	219	2	):	):	PUNCT
dpc-1881	219	3	e2021164s	e2021164	NOUN
dpc-1881	219	4	was	be	AUX
dpc-1881	219	5	approved	approve	VERB
dpc-1881	219	6	by	by	ADP
dpc-1881	219	7	fda	fda	PROPN
dpc-1881	219	8	;	;	PUNCT
dpc-1881	219	9	however	however	ADV
dpc-1881	219	10	,	,	PUNCT
dpc-1881	219	11	even	even	ADV
dpc-1881	219	12	if	if	SCONJ
dpc-1881	219	13	the	the	DET
dpc-1881	219	14	study	study	NOUN
dpc-1881	219	15	met	meet	VERB
dpc-1881	219	16	its	its	PRON
dpc-1881	219	17	primary	primary	ADJ
dpc-1881	219	18	endpoint	endpoint	NOUN
dpc-1881	219	19	,	,	PUNCT
dpc-1881	219	20	the	the	DET
dpc-1881	219	21	values	value	NOUN
dpc-1881	219	22	of	of	ADP
dpc-1881	219	23	the	the	DET
dpc-1881	219	24	median	median	PROPN
dpc-1881	219	25	pfs	pfs	PROPN
dpc-1881	219	26	reached	reach	VERB
dpc-1881	219	27	is	be	AUX
dpc-1881	219	28	similar	similar	ADJ
dpc-1881	219	29	to	to	ADP
dpc-1881	219	30	that	that	PRON
dpc-1881	219	31	of	of	ADP
dpc-1881	219	32	the	the	DET
dpc-1881	219	33	keynote-022	keynote-022	NOUN
dpc-1881	219	34	.	.	PUNCT
dpc-1881	220	1	the	the	DET
dpc-1881	220	2	frequency	frequency	NOUN
dpc-1881	220	3	of	of	ADP
dpc-1881	220	4	grade	grade	NOUN
dpc-1881	220	5	3	3	NUM
dpc-1881	220	6	-	-	SYM
dpc-1881	220	7	4	4	NUM
dpc-1881	220	8	adverse	adverse	ADJ
dpc-1881	220	9	events	event	NOUN
dpc-1881	220	10	was	be	AUX
dpc-1881	220	11	similar	similar	ADJ
dpc-1881	220	12	(	(	PUNCT
dpc-1881	220	13	79	79	NUM
dpc-1881	220	14	%	%	NOUN
dpc-1881	220	15	versus	versus	ADP
dpc-1881	220	16	73	73	NUM
dpc-1881	220	17	%	%	NOUN
dpc-1881	220	18	)	)	PUNCT
dpc-1881	220	19	;	;	PUNCT
dpc-1881	220	20	no	no	DET
dpc-1881	220	21	major	major	ADJ
dpc-1881	220	22	adverse	adverse	ADJ
dpc-1881	220	23	events	event	NOUN
dpc-1881	220	24	were	be	AUX
dpc-1881	220	25	found	find	VERB
dpc-1881	220	26	in	in	ADP
dpc-1881	220	27	the	the	DET
dpc-1881	220	28	triplet	triplet	NOUN
dpc-1881	220	29	group	group	NOUN
dpc-1881	220	30	and	and	CCONJ
dpc-1881	220	31	the	the	DET
dpc-1881	220	32	percentage	percentage	NOUN
dpc-1881	220	33	of	of	ADP
dpc-1881	220	34	patients	patient	NOUN
dpc-1881	220	35	who	who	PRON
dpc-1881	220	36	stopped	stop	VERB
dpc-1881	220	37	all	all	DET
dpc-1881	220	38	treatment	treatment	NOUN
dpc-1881	220	39	due	due	ADJ
dpc-1881	220	40	to	to	ADP
dpc-1881	220	41	adverse	adverse	ADJ
dpc-1881	220	42	events	event	NOUN
dpc-1881	220	43	was	be	AUX
dpc-1881	220	44	similar	similar	ADJ
dpc-1881	220	45	(	(	PUNCT
dpc-1881	220	46	13	13	NUM
dpc-1881	220	47	%	%	NOUN
dpc-1881	220	48	in	in	ADP
dpc-1881	220	49	the	the	DET
dpc-1881	220	50	triplet	triplet	NOUN
dpc-1881	220	51	versus	versus	ADP
dpc-1881	220	52	16	16	NUM
dpc-1881	220	53	%	%	NOUN
dpc-1881	220	54	)	)	PUNCT
dpc-1881	221	1	[	[	X
dpc-1881	221	2	54	54	NUM
dpc-1881	221	3	]	]	PUNCT
dpc-1881	221	4	.	.	PUNCT
dpc-1881	222	1	more	more	ADV
dpc-1881	222	2	recently	recently	ADV
dpc-1881	222	3	,	,	PUNCT
dpc-1881	222	4	the	the	DET
dpc-1881	222	5	results	result	NOUN
dpc-1881	222	6	of	of	ADP
dpc-1881	222	7	the	the	DET
dpc-1881	222	8	part	part	NOUN
dpc-1881	222	9	3	3	NUM
dpc-1881	222	10	of	of	ADP
dpc-1881	222	11	the	the	DET
dpc-1881	222	12	combi	combi	PROPN
dpc-1881	222	13	-	-	PUNCT
dpc-1881	222	14	i	i	PROPN
dpc-1881	222	15	trial	trial	NOUN
dpc-1881	222	16	were	be	AUX
dpc-1881	222	17	presented	present	VERB
dpc-1881	222	18	[	[	PUNCT
dpc-1881	222	19	55	55	NUM
dpc-1881	222	20	]	]	PUNCT
dpc-1881	222	21	.	.	PUNCT
dpc-1881	223	1	this	this	DET
dpc-1881	223	2	phase	phase	NOUN
dpc-1881	223	3	iii	iii	NOUN
dpc-1881	223	4	randomized	randomize	VERB
dpc-1881	223	5	clinical	clinical	ADJ
dpc-1881	223	6	trial	trial	NOUN
dpc-1881	223	7	enrolled	enrol	VERB
dpc-1881	223	8	532	532	NUM
dpc-1881	223	9	patients	patient	NOUN
dpc-1881	223	10	to	to	PART
dpc-1881	223	11	compare	compare	VERB
dpc-1881	223	12	the	the	DET
dpc-1881	223	13	combination	combination	NOUN
dpc-1881	223	14	of	of	ADP
dpc-1881	223	15	dabrafenib	dabrafenib	NOUN
dpc-1881	223	16	and	and	CCONJ
dpc-1881	223	17	trametinib	trametinib	NOUN
dpc-1881	223	18	plus	plus	CCONJ
dpc-1881	223	19	spartalizumab	spartalizumab	NOUN
dpc-1881	223	20	or	or	CCONJ
dpc-1881	223	21	placebo	placebo	NOUN
dpc-1881	223	22	.	.	PUNCT
dpc-1881	224	1	the	the	DET
dpc-1881	224	2	pfs	pfs	PROPN
dpc-1881	224	3	was	be	AUX
dpc-1881	224	4	longer	long	ADJ
dpc-1881	224	5	in	in	ADP
dpc-1881	224	6	the	the	DET
dpc-1881	224	7	triplet	triplet	NOUN
dpc-1881	224	8	group	group	NOUN
dpc-1881	224	9	even	even	ADV
dpc-1881	224	10	if	if	SCONJ
dpc-1881	224	11	the	the	DET
dpc-1881	224	12	difference	difference	NOUN
dpc-1881	224	13	did	do	AUX
dpc-1881	224	14	not	not	PART
dpc-1881	224	15	meet	meet	VERB
dpc-1881	224	16	a	a	DET
dpc-1881	224	17	statistical	statistical	ADJ
dpc-1881	224	18	significance	significance	NOUN
dpc-1881	224	19	(	(	PUNCT
dpc-1881	224	20	16.2	16.2	NUM
dpc-1881	224	21	versus	versus	ADP
dpc-1881	224	22	12	12	NUM
dpc-1881	224	23	months	month	NOUN
dpc-1881	224	24	)	)	PUNCT
dpc-1881	224	25	.	.	PUNCT
dpc-1881	225	1	the	the	DET
dpc-1881	225	2	objective	objective	ADJ
dpc-1881	225	3	response	response	NOUN
dpc-1881	225	4	rate	rate	NOUN
dpc-1881	225	5	was	be	AUX
dpc-1881	225	6	69	69	NUM
dpc-1881	225	7	%	%	NOUN
dpc-1881	225	8	versus	versus	ADP
dpc-1881	225	9	64	64	NUM
dpc-1881	225	10	%	%	NOUN
dpc-1881	225	11	.	.	PUNCT
dpc-1881	226	1	the	the	DET
dpc-1881	226	2	percentage	percentage	NOUN
dpc-1881	226	3	of	of	ADP
dpc-1881	226	4	patients	patient	NOUN
dpc-1881	226	5	showing	show	VERB
dpc-1881	226	6	grade	grade	NOUN
dpc-1881	226	7	3	3	NUM
dpc-1881	226	8	or	or	CCONJ
dpc-1881	226	9	more	more	ADJ
dpc-1881	226	10	treatment	treatment	NOUN
dpc-1881	226	11	related	relate	VERB
dpc-1881	226	12	side	side	NOUN
dpc-1881	226	13	effects	effect	NOUN
dpc-1881	226	14	was	be	AUX
dpc-1881	226	15	55	55	NUM
dpc-1881	226	16	%	%	NOUN
dpc-1881	226	17	in	in	ADP
dpc-1881	226	18	the	the	DET
dpc-1881	226	19	triplet	triplet	NOUN
dpc-1881	226	20	group	group	NOUN
dpc-1881	226	21	versus	versus	ADP
dpc-1881	226	22	33	33	NUM
dpc-1881	226	23	%	%	NOUN
dpc-1881	226	24	in	in	ADP
dpc-1881	226	25	the	the	DET
dpc-1881	226	26	control	control	NOUN
dpc-1881	226	27	arm	arm	NOUN
dpc-1881	226	28	.	.	PUNCT
dpc-1881	227	1	the	the	DET
dpc-1881	227	2	results	result	NOUN
dpc-1881	227	3	of	of	ADP
dpc-1881	227	4	the	the	DET
dpc-1881	227	5	large	large	ADJ
dpc-1881	227	6	randomized	randomized	ADJ
dpc-1881	227	7	trials	trial	NOUN
dpc-1881	227	8	comparing	compare	VERB
dpc-1881	227	9	the	the	DET
dpc-1881	227	10	triplets	triplet	NOUN
dpc-1881	227	11	versus	versus	ADP
dpc-1881	227	12	the	the	DET
dpc-1881	227	13	standard	standard	ADJ
dpc-1881	227	14	targeted	target	VERB
dpc-1881	227	15	regimens	regimen	NOUN
dpc-1881	227	16	did	do	AUX
dpc-1881	227	17	not	not	PART
dpc-1881	227	18	completely	completely	ADV
dpc-1881	227	19	confirm	confirm	VERB
dpc-1881	227	20	thus	thus	ADV
dpc-1881	227	21	until	until	ADP
dpc-1881	227	22	now	now	ADV
dpc-1881	227	23	the	the	DET
dpc-1881	227	24	promising	promising	ADJ
dpc-1881	227	25	preliminary	preliminary	ADJ
dpc-1881	227	26	data	datum	NOUN
dpc-1881	227	27	,	,	PUNCT
dpc-1881	227	28	also	also	ADV
dpc-1881	227	29	showing	show	VERB
dpc-1881	227	30	a	a	DET
dpc-1881	227	31	less	less	ADV
dpc-1881	227	32	favorable	favorable	ADJ
dpc-1881	227	33	toxicity	toxicity	NOUN
dpc-1881	227	34	profile	profile	NOUN
dpc-1881	227	35	for	for	ADP
dpc-1881	227	36	this	this	DET
dpc-1881	227	37	associations	association	NOUN
dpc-1881	227	38	.	.	PUNCT
dpc-1881	228	1	however	however	ADV
dpc-1881	228	2	,	,	PUNCT
dpc-1881	228	3	all	all	DET
dpc-1881	228	4	the	the	DET
dpc-1881	228	5	studies	study	NOUN
dpc-1881	228	6	identified	identify	VERB
dpc-1881	228	7	a	a	DET
dpc-1881	228	8	longer	long	ADJ
dpc-1881	228	9	pfs	pf	NOUN
dpc-1881	228	10	of	of	ADP
dpc-1881	228	11	the	the	DET
dpc-1881	228	12	triplet	triplet	NOUN
dpc-1881	228	13	versus	versus	ADP
dpc-1881	228	14	the	the	DET
dpc-1881	228	15	control	control	NOUN
dpc-1881	228	16	arm	arm	NOUN
dpc-1881	228	17	(	(	PUNCT
dpc-1881	228	18	with	with	ADP
dpc-1881	228	19	a	a	DET
dpc-1881	228	20	statistical	statistical	ADJ
dpc-1881	228	21	significance	significance	NOUN
dpc-1881	228	22	only	only	ADV
dpc-1881	228	23	in	in	ADP
dpc-1881	228	24	the	the	DET
dpc-1881	228	25	imspire	imspire	NOUN
dpc-1881	228	26	trial	trial	NOUN
dpc-1881	228	27	but	but	CCONJ
dpc-1881	228	28	with	with	ADP
dpc-1881	228	29	similar	similar	ADJ
dpc-1881	228	30	values	value	NOUN
dpc-1881	228	31	across	across	ADP
dpc-1881	228	32	the	the	DET
dpc-1881	228	33	different	different	ADJ
dpc-1881	228	34	studies	study	NOUN
dpc-1881	228	35	)	)	PUNCT
dpc-1881	228	36	,	,	PUNCT
dpc-1881	228	37	thus	thus	ADV
dpc-1881	228	38	it	it	PRON
dpc-1881	228	39	is	be	AUX
dpc-1881	228	40	justified	justify	VERB
dpc-1881	228	41	to	to	PART
dpc-1881	228	42	wait	wait	VERB
dpc-1881	228	43	for	for	ADP
dpc-1881	228	44	a	a	DET
dpc-1881	228	45	longer	long	ADV
dpc-1881	228	46	follow	follow	VERB
dpc-1881	228	47	-	-	PUNCT
dpc-1881	228	48	up	up	ADP
dpc-1881	228	49	time	time	NOUN
dpc-1881	228	50	to	to	PART
dpc-1881	228	51	better	well	ADV
dpc-1881	228	52	characterize	characterize	VERB
dpc-1881	228	53	the	the	DET
dpc-1881	228	54	role	role	NOUN
dpc-1881	228	55	of	of	ADP
dpc-1881	228	56	the	the	DET
dpc-1881	228	57	combination	combination	NOUN
dpc-1881	228	58	of	of	ADP
dpc-1881	228	59	targeted	target	VERB
dpc-1881	228	60	and	and	CCONJ
dpc-1881	228	61	immunotherapies	immunotherapy	NOUN
dpc-1881	228	62	,	,	PUNCT
dpc-1881	228	63	and	and	CCONJ
dpc-1881	228	64	to	to	PART
dpc-1881	228	65	identify	identify	VERB
dpc-1881	228	66	which	which	PRON
dpc-1881	228	67	could	could	AUX
dpc-1881	228	68	be	be	AUX
dpc-1881	228	69	the	the	DET
dpc-1881	228	70	patients	patient	NOUN
dpc-1881	228	71	that	that	PRON
dpc-1881	228	72	could	could	AUX
dpc-1881	228	73	benefit	benefit	VERB
dpc-1881	228	74	more	more	ADJ
dpc-1881	228	75	from	from	ADP
dpc-1881	228	76	this	this	DET
dpc-1881	228	77	treatment	treatment	NOUN
dpc-1881	228	78	.	.	PUNCT
dpc-1881	229	1	figure	figure	NOUN
dpc-1881	229	2	3	3	NUM
dpc-1881	229	3	.	.	PUNCT
dpc-1881	230	1	clinical	clinical	ADJ
dpc-1881	230	2	activity	activity	NOUN
dpc-1881	230	3	of	of	ADP
dpc-1881	230	4	immune	immune	ADJ
dpc-1881	230	5	check	check	NOUN
dpc-1881	230	6	point	point	NOUN
dpc-1881	230	7	inhibitors	inhibitor	NOUN
dpc-1881	230	8	.	.	PUNCT
dpc-1881	231	1	rr=	rr=	NOUN
dpc-1881	231	2	response	response	NOUN
dpc-1881	231	3	rate	rate	NOUN
dpc-1881	231	4	;	;	PUNCT
dpc-1881	231	5	cr=	cr=	NOUN
dpc-1881	231	6	complete	complete	ADJ
dpc-1881	231	7	response	response	NOUN
dpc-1881	231	8	inclusion	inclusion	NOUN
dpc-1881	231	9	drug	drug	NOUN
dpc-1881	231	10	%	%	NOUN
dpc-1881	231	11	rr	rr	PROPN
dpc-1881	231	12	40%nivolumab	40%nivolumab	NUM
dpc-1881	231	13	nivolumab	nivolumab	NOUN
dpc-1881	231	14	pembrolizumab	pembrolizumab	NOUN
dpc-1881	231	15	pembrolizumab	pembrolizumab	NOUN
dpc-1881	231	16	nivolumab+	nivolumab+	NOUN
dpc-1881	231	17	ipilimumab	ipilimumab	PROPN
dpc-1881	231	18	untreated	untreated	ADJ
dpc-1881	231	19	untreated	untreated	ADJ
dpc-1881	231	20	ipi	ipi	PROPN
dpc-1881	231	21	refractory	refractory	PROPN
dpc-1881	231	22	ipi	ipi	PROPN
dpc-1881	231	23	progressed	progress	VERB
dpc-1881	231	24	untreatedcheckmate	untreatedcheckmate	ADJ
dpc-1881	231	25	066	066	NUM
dpc-1881	231	26	checkmate	checkmate	NOUN
dpc-1881	231	27	037	037	NUM
dpc-1881	231	28	keynote	keynote	NOUN
dpc-1881	231	29	002	002	NUM
dpc-1881	231	30	keynote	keynote	NOUN
dpc-1881	231	31	006	006	NUM
dpc-1881	231	32	checkmate	checkmate	VERB
dpc-1881	231	33	067	067	NUM
dpc-1881	231	34	31,3	31,3	NUM
dpc-1881	231	35	%	%	NOUN
dpc-1881	231	36	%	%	NOUN
dpc-1881	231	37	cr	cr	NOUN
dpc-1881	231	38	7,6	7,6	NUM
dpc-1881	231	39	%	%	NOUN
dpc-1881	231	40	3,3	3,3	NUM
dpc-1881	231	41	%	%	NOUN
dpc-1881	231	42	2	2	NUM
dpc-1881	231	43	-	-	SYM
dpc-1881	231	44	3	3	NUM
dpc-1881	231	45	%	%	NOUN
dpc-1881	231	46	12	12	NUM
dpc-1881	231	47	-	-	SYM
dpc-1881	231	48	13	13	NUM
dpc-1881	231	49	%	%	NOUN
dpc-1881	231	50	21,3%58,3	21,3%58,3	NUM
dpc-1881	231	51	%	%	NOUN
dpc-1881	231	52	36	36	NUM
dpc-1881	231	53	-	-	SYM
dpc-1881	231	54	37	37	NUM
dpc-1881	231	55	%	%	NOUN
dpc-1881	231	56	29	29	NUM
dpc-1881	231	57	-	-	SYM
dpc-1881	231	58	31	31	NUM
dpc-1881	231	59	%	%	NOUN
dpc-1881	231	60	figure	figure	NOUN
dpc-1881	231	61	4	4	NUM
dpc-1881	231	62	.	.	PUNCT
dpc-1881	232	1	(	(	PUNCT
dpc-1881	232	2	a	a	X
dpc-1881	232	3	)	)	PUNCT
dpc-1881	232	4	pattern	pattern	NOUN
dpc-1881	232	5	of	of	ADP
dpc-1881	232	6	response	response	NOUN
dpc-1881	232	7	following	follow	VERB
dpc-1881	232	8	immune	immune	ADJ
dpc-1881	232	9	therapy	therapy	NOUN
dpc-1881	232	10	in	in	ADP
dpc-1881	232	11	a	a	DET
dpc-1881	232	12	patient	patient	NOUN
dpc-1881	232	13	with	with	ADP
dpc-1881	232	14	multiple	multiple	ADJ
dpc-1881	232	15	in	in	ADP
dpc-1881	232	16	-	-	PUNCT
dpc-1881	232	17	transit	transit	NOUN
dpc-1881	232	18	skin	skin	NOUN
dpc-1881	232	19	metastasis	metastasis	NOUN
dpc-1881	232	20	localised	localise	VERB
dpc-1881	232	21	in	in	ADP
dpc-1881	232	22	the	the	DET
dpc-1881	232	23	lower	low	ADJ
dpc-1881	232	24	limb	limb	NOUN
dpc-1881	232	25	.	.	PUNCT
dpc-1881	233	1	(	(	PUNCT
dpc-1881	233	2	b	b	X
dpc-1881	233	3	-	-	PUNCT
dpc-1881	233	4	d	d	NOUN
dpc-1881	233	5	)	)	PUNCT
dpc-1881	233	6	response	response	NOUN
dpc-1881	233	7	developed	develop	VERB
dpc-1881	233	8	during	during	ADP
dpc-1881	233	9	1	1	NUM
dpc-1881	233	10	year	year	NOUN
dpc-1881	233	11	of	of	ADP
dpc-1881	233	12	treatment	treatment	NOUN
dpc-1881	233	13	with	with	ADP
dpc-1881	233	14	induction	induction	NOUN
dpc-1881	233	15	of	of	ADP
dpc-1881	233	16	inflammation	inflammation	NOUN
dpc-1881	233	17	.	.	PUNCT
dpc-1881	234	1	(	(	PUNCT
dpc-1881	234	2	e	e	NOUN
dpc-1881	234	3	)	)	PUNCT
dpc-1881	234	4	immune	immune	ADJ
dpc-1881	234	5	activation	activation	NOUN
dpc-1881	234	6	around	around	ADP
dpc-1881	234	7	the	the	DET
dpc-1881	234	8	skin	skin	NOUN
dpc-1881	234	9	metastases	metastasis	NOUN
dpc-1881	234	10	,	,	PUNCT
dpc-1881	234	11	towards	towards	ADP
dpc-1881	234	12	complete	complete	ADJ
dpc-1881	234	13	clearance	clearance	NOUN
dpc-1881	234	14	confirmed	confirm	VERB
dpc-1881	234	15	at	at	ADP
dpc-1881	234	16	histology	histology	NOUN
dpc-1881	234	17	with	with	ADP
dpc-1881	234	18	development	development	NOUN
dpc-1881	234	19	of	of	ADP
dpc-1881	234	20	peri	peri	NOUN
dpc-1881	234	21	-	-	PUNCT
dpc-1881	234	22	lesional	lesional	ADJ
dpc-1881	234	23	vitiligo	vitiligo	NOUN
dpc-1881	234	24	.	.	PUNCT
dpc-1881	235	1	review	review	VERB
dpc-1881	235	2	|	|	ADV
dpc-1881	235	3	dermatol	dermatol	ADJ
dpc-1881	235	4	pract	pract	NOUN
dpc-1881	235	5	concept	concept	NOUN
dpc-1881	235	6	.	.	PUNCT
dpc-1881	236	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	236	2	):	):	PUNCT
dpc-1881	236	3	e2021164s	e2021164s	PROPN
dpc-1881	236	4	9	9	NUM
dpc-1881	236	5	conclusions	conclusion	NOUN
dpc-1881	236	6	the	the	DET
dpc-1881	236	7	comparison	comparison	NOUN
dpc-1881	236	8	between	between	ADP
dpc-1881	236	9	os	os	NOUN
dpc-1881	236	10	rates	rate	NOUN
dpc-1881	236	11	before	before	ADP
dpc-1881	236	12	the	the	DET
dpc-1881	236	13	development	development	NOUN
dpc-1881	236	14	of	of	ADP
dpc-1881	236	15	new	new	ADJ
dpc-1881	236	16	drugs	drug	NOUN
dpc-1881	236	17	(	(	PUNCT
dpc-1881	236	18	1	1	NUM
dpc-1881	236	19	-	-	PUNCT
dpc-1881	236	20	year	year	NOUN
dpc-1881	236	21	survival	survival	NOUN
dpc-1881	236	22	25	25	NUM
dpc-1881	236	23	%	%	NOUN
dpc-1881	236	24	,	,	PUNCT
dpc-1881	236	25	median	median	ADJ
dpc-1881	236	26	survival	survival	NOUN
dpc-1881	236	27	6	6	NUM
dpc-1881	236	28	months	month	NOUN
dpc-1881	236	29	)	)	PUNCT
dpc-1881	237	1	[	[	X
dpc-1881	237	2	2	2	X
dpc-1881	237	3	]	]	PUNCT
dpc-1881	237	4	and	and	CCONJ
dpc-1881	237	5	those	those	PRON
dpc-1881	237	6	achieved	achieve	VERB
dpc-1881	237	7	with	with	ADP
dpc-1881	237	8	both	both	DET
dpc-1881	237	9	targeted	target	VERB
dpc-1881	237	10	therapies	therapy	NOUN
dpc-1881	237	11	and	and	CCONJ
dpc-1881	237	12	immune	immune	ADJ
dpc-1881	237	13	check	check	NOUN
dpc-1881	237	14	point	point	NOUN
dpc-1881	237	15	inhibitors	inhibitor	NOUN
dpc-1881	237	16	(	(	PUNCT
dpc-1881	237	17	5	5	NUM
dpc-1881	237	18	-	-	PUNCT
dpc-1881	237	19	year	year	NOUN
dpc-1881	237	20	survival	survival	NOUN
dpc-1881	237	21	35	35	NUM
dpc-1881	237	22	%	%	NOUN
dpc-1881	237	23	,	,	PUNCT
dpc-1881	237	24	median	median	ADJ
dpc-1881	237	25	survival	survival	NOUN
dpc-1881	237	26	24	24	NUM
dpc-1881	237	27	months	month	NOUN
dpc-1881	237	28	)	)	PUNCT
dpc-1881	237	29	clearly	clearly	ADV
dpc-1881	237	30	highlights	highlight	VERB
dpc-1881	237	31	the	the	DET
dpc-1881	237	32	relevant	relevant	ADJ
dpc-1881	237	33	impact	impact	NOUN
dpc-1881	237	34	that	that	PRON
dpc-1881	237	35	these	these	DET
dpc-1881	237	36	new	new	ADJ
dpc-1881	237	37	treatment	treatment	NOUN
dpc-1881	237	38	approaches	approach	NOUN
dpc-1881	237	39	are	be	AUX
dpc-1881	237	40	having	have	VERB
dpc-1881	237	41	in	in	ADP
dpc-1881	237	42	the	the	DET
dpc-1881	237	43	disease	disease	NOUN
dpc-1881	237	44	course	course	NOUN
dpc-1881	237	45	of	of	ADP
dpc-1881	237	46	advanced	advanced	ADJ
dpc-1881	237	47	metastatic	metastatic	ADJ
dpc-1881	237	48	melanoma	melanoma	NOUN
dpc-1881	237	49	and	and	CCONJ
dpc-1881	237	50	this	this	PRON
dpc-1881	237	51	is	be	AUX
dpc-1881	237	52	well	well	ADV
dpc-1881	237	53	recognized	recognize	VERB
dpc-1881	237	54	by	by	ADP
dpc-1881	237	55	the	the	DET
dpc-1881	237	56	main	main	ADJ
dpc-1881	237	57	italian	italian	ADJ
dpc-1881	237	58	national	national	ADJ
dpc-1881	237	59	,	,	PUNCT
dpc-1881	237	60	european	european	ADJ
dpc-1881	237	61	and	and	CCONJ
dpc-1881	237	62	american	american	ADJ
dpc-1881	237	63	guidelines	guideline	NOUN
dpc-1881	237	64	[	[	X
dpc-1881	237	65	5,56,57	5,56,57	NUM
dpc-1881	237	66	]	]	PUNCT
dpc-1881	237	67	.	.	PUNCT
dpc-1881	238	1	however	however	ADV
dpc-1881	238	2	,	,	PUNCT
dpc-1881	238	3	when	when	SCONJ
dpc-1881	238	4	considering	consider	VERB
dpc-1881	238	5	the	the	DET
dpc-1881	238	6	curves	curve	NOUN
dpc-1881	238	7	from	from	ADP
dpc-1881	238	8	the	the	DET
dpc-1881	238	9	other	other	ADJ
dpc-1881	238	10	side	side	NOUN
dpc-1881	238	11	,	,	PUNCT
dpc-1881	238	12	it	it	PRON
dpc-1881	238	13	is	be	AUX
dpc-1881	238	14	evident	evident	ADJ
dpc-1881	238	15	that	that	SCONJ
dpc-1881	238	16	at	at	ADP
dpc-1881	238	17	5	5	NUM
dpc-1881	238	18	years	year	NOUN
dpc-1881	238	19	,	,	PUNCT
dpc-1881	238	20	65	65	NUM
dpc-1881	238	21	%	%	NOUN
dpc-1881	238	22	of	of	ADP
dpc-1881	238	23	patients	patient	NOUN
dpc-1881	238	24	die	die	VERB
dpc-1881	238	25	due	due	ADJ
dpc-1881	238	26	to	to	ADP
dpc-1881	238	27	disease	disease	NOUN
dpc-1881	238	28	progression	progression	NOUN
dpc-1881	238	29	,	,	PUNCT
dpc-1881	238	30	supporting	support	VERB
dpc-1881	238	31	the	the	DET
dpc-1881	238	32	need	need	NOUN
dpc-1881	238	33	of	of	ADP
dpc-1881	238	34	more	more	ADV
dpc-1881	238	35	active	active	ADJ
dpc-1881	238	36	treatment	treatment	NOUN
dpc-1881	238	37	strategies	strategy	NOUN
dpc-1881	238	38	or	or	CCONJ
dpc-1881	238	39	combinations	combination	NOUN
dpc-1881	238	40	.	.	PUNCT
dpc-1881	239	1	the	the	DET
dpc-1881	239	2	results	result	NOUN
dpc-1881	239	3	from	from	ADP
dpc-1881	239	4	the	the	DET
dpc-1881	239	5	trials	trial	NOUN
dpc-1881	239	6	analyzing	analyze	VERB
dpc-1881	239	7	the	the	DET
dpc-1881	239	8	clinical	clinical	ADJ
dpc-1881	239	9	activity	activity	NOUN
dpc-1881	239	10	of	of	ADP
dpc-1881	239	11	the	the	DET
dpc-1881	239	12	so	so	ADV
dpc-1881	239	13	-	-	PUNCT
dpc-1881	239	14	called	call	VERB
dpc-1881	239	15	triplets	triplet	NOUN
dpc-1881	239	16	(	(	PUNCT
dpc-1881	239	17	combo	combo	NOUN
dpc-1881	239	18	-	-	PUNCT
dpc-1881	239	19	target	target	NOUN
dpc-1881	239	20	plus	plus	CCONJ
dpc-1881	239	21	anti	anti	ADJ
dpc-1881	239	22	-	-	ADJ
dpc-1881	239	23	pd1	pd1	NOUN
dpc-1881	239	24	)	)	PUNCT
dpc-1881	239	25	gave	give	VERB
dpc-1881	239	26	conflicting	conflicting	ADJ
dpc-1881	239	27	results	result	NOUN
dpc-1881	239	28	and	and	CCONJ
dpc-1881	239	29	it	it	PRON
dpc-1881	239	30	is	be	AUX
dpc-1881	239	31	reasonable	reasonable	ADJ
dpc-1881	239	32	to	to	PART
dpc-1881	239	33	think	think	VERB
dpc-1881	239	34	that	that	SCONJ
dpc-1881	239	35	more	more	ADJ
dpc-1881	239	36	follow	follow	VERB
dpc-1881	239	37	-	-	PUNCT
dpc-1881	239	38	up	up	NOUN
dpc-1881	239	39	is	be	AUX
dpc-1881	239	40	needed	need	VERB
dpc-1881	239	41	.	.	PUNCT
dpc-1881	240	1	in	in	ADP
dpc-1881	240	2	the	the	DET
dpc-1881	240	3	daily	daily	ADJ
dpc-1881	240	4	clinical	clinical	ADJ
dpc-1881	240	5	practice	practice	NOUN
dpc-1881	240	6	,	,	PUNCT
dpc-1881	240	7	the	the	DET
dpc-1881	240	8	challenges	challenge	NOUN
dpc-1881	240	9	are	be	AUX
dpc-1881	240	10	represented	represent	VERB
dpc-1881	240	11	by	by	ADP
dpc-1881	240	12	the	the	DET
dpc-1881	240	13	management	management	NOUN
dpc-1881	240	14	of	of	ADP
dpc-1881	240	15	patients	patient	NOUN
dpc-1881	240	16	with	with	ADP
dpc-1881	240	17	aggressive	aggressive	ADJ
dpc-1881	240	18	disease	disease	NOUN
dpc-1881	240	19	and/or	and/or	CCONJ
dpc-1881	240	20	multiple	multiple	ADJ
dpc-1881	240	21	visceral	visceral	ADJ
dpc-1881	240	22	sites	site	NOUN
dpc-1881	240	23	,	,	PUNCT
dpc-1881	240	24	as	as	ADV
dpc-1881	240	25	well	well	ADV
dpc-1881	240	26	as	as	ADP
dpc-1881	240	27	those	those	PRON
dpc-1881	240	28	with	with	ADP
dpc-1881	240	29	brain	brain	NOUN
dpc-1881	240	30	metastases	metastasis	NOUN
dpc-1881	240	31	or	or	CCONJ
dpc-1881	240	32	mucosal	mucosal	NOUN
dpc-1881	240	33	/	/	SYM
dpc-1881	240	34	coroidal	coroidal	ADJ
dpc-1881	240	35	primaries	primary	NOUN
dpc-1881	240	36	.	.	PUNCT
dpc-1881	241	1	the	the	DET
dpc-1881	241	2	availability	availability	NOUN
dpc-1881	241	3	of	of	ADP
dpc-1881	241	4	adjuvant	adjuvant	ADJ
dpc-1881	241	5	treatments	treatment	NOUN
dpc-1881	241	6	is	be	AUX
dpc-1881	241	7	improving	improve	VERB
dpc-1881	241	8	the	the	DET
dpc-1881	241	9	disease	disease	NOUN
dpc-1881	241	10	course	course	NOUN
dpc-1881	241	11	in	in	ADP
dpc-1881	241	12	stage	stage	NOUN
dpc-1881	241	13	iii	iii	NUM
dpc-1881	241	14	patients	patient	NOUN
dpc-1881	241	15	disease	disease	NOUN
dpc-1881	241	16	-	-	PUNCT
dpc-1881	241	17	free	free	ADJ
dpc-1881	241	18	after	after	ADP
dpc-1881	241	19	surgery	surgery	NOUN
dpc-1881	241	20	but	but	CCONJ
dpc-1881	241	21	the	the	DET
dpc-1881	241	22	management	management	NOUN
dpc-1881	241	23	of	of	ADP
dpc-1881	241	24	the	the	DET
dpc-1881	241	25	progressions	progression	NOUN
dpc-1881	241	26	occurring	occur	VERB
dpc-1881	241	27	during	during	ADP
dpc-1881	241	28	adjuvant	adjuvant	ADJ
dpc-1881	241	29	treatment	treatment	NOUN
dpc-1881	241	30	,	,	PUNCT
dpc-1881	241	31	particularly	particularly	ADV
dpc-1881	241	32	in	in	ADP
dpc-1881	241	33	braf	braf	NOUN
dpc-1881	241	34	wild	wild	ADJ
dpc-1881	241	35	-	-	PUNCT
dpc-1881	241	36	type	type	NOUN
dpc-1881	241	37	patients	patient	NOUN
dpc-1881	241	38	,	,	PUNCT
dpc-1881	241	39	still	still	ADV
dpc-1881	241	40	represents	represent	VERB
dpc-1881	241	41	another	another	DET
dpc-1881	241	42	clinical	clinical	ADJ
dpc-1881	241	43	challenge	challenge	NOUN
dpc-1881	241	44	.	.	PUNCT
dpc-1881	242	1	the	the	DET
dpc-1881	242	2	availability	availability	NOUN
dpc-1881	242	3	of	of	ADP
dpc-1881	242	4	data	datum	NOUN
dpc-1881	242	5	coming	come	VERB
dpc-1881	242	6	from	from	ADP
dpc-1881	242	7	real	real	ADJ
dpc-1881	242	8	life	life	NOUN
dpc-1881	242	9	experiences	experience	NOUN
dpc-1881	242	10	together	together	ADV
dpc-1881	242	11	with	with	ADP
dpc-1881	242	12	the	the	DET
dpc-1881	242	13	results	result	NOUN
dpc-1881	242	14	of	of	ADP
dpc-1881	242	15	ongoing	ongoing	ADJ
dpc-1881	242	16	clinical	clinical	ADJ
dpc-1881	242	17	trials	trial	NOUN
dpc-1881	242	18	will	will	AUX
dpc-1881	242	19	provide	provide	VERB
dpc-1881	242	20	relevant	relevant	ADJ
dpc-1881	242	21	informations	information	NOUN
dpc-1881	242	22	to	to	PART
dpc-1881	242	23	improve	improve	VERB
dpc-1881	242	24	the	the	DET
dpc-1881	242	25	management	management	NOUN
dpc-1881	242	26	of	of	ADP
dpc-1881	242	27	these	these	DET
dpc-1881	242	28	patients	patient	NOUN
dpc-1881	242	29	,	,	PUNCT
dpc-1881	242	30	as	as	ADV
dpc-1881	242	31	well	well	ADV
dpc-1881	242	32	as	as	ADP
dpc-1881	242	33	the	the	DET
dpc-1881	242	34	identification	identification	NOUN
dpc-1881	242	35	of	of	ADP
dpc-1881	242	36	both	both	CCONJ
dpc-1881	242	37	prognostic	prognostic	ADJ
dpc-1881	242	38	and	and	CCONJ
dpc-1881	242	39	predictive	predictive	ADJ
dpc-1881	242	40	factors	factor	NOUN
dpc-1881	242	41	associated	associate	VERB
dpc-1881	242	42	with	with	ADP
dpc-1881	242	43	the	the	DET
dpc-1881	242	44	disease	disease	NOUN
dpc-1881	242	45	course	course	NOUN
dpc-1881	242	46	and	and	CCONJ
dpc-1881	242	47	response	response	NOUN
dpc-1881	242	48	to	to	ADP
dpc-1881	242	49	treatment	treatment	NOUN
dpc-1881	242	50	.	.	PUNCT
dpc-1881	243	1	references	reference	NOUN
dpc-1881	243	2	1	1	NUM
dpc-1881	243	3	.	.	PUNCT
dpc-1881	243	4	gershenwald	gershenwald	PROPN
dpc-1881	243	5	je	je	PROPN
dpc-1881	243	6	,	,	PUNCT
dpc-1881	243	7	scolyer	scolyer	PROPN
dpc-1881	243	8	ra	ra	PROPN
dpc-1881	243	9	,	,	PUNCT
dpc-1881	243	10	hess	hess	PROPN
dpc-1881	243	11	kr	kr	PROPN
dpc-1881	243	12	,	,	PUNCT
dpc-1881	243	13	et	et	PROPN
dpc-1881	243	14	al	al	PROPN
dpc-1881	243	15	.	.	PROPN
dpc-1881	244	1	for	for	ADP
dpc-1881	244	2	members	member	NOUN
dpc-1881	244	3	of	of	ADP
dpc-1881	244	4	the	the	DET
dpc-1881	244	5	american	american	PROPN
dpc-1881	244	6	joint	joint	PROPN
dpc-1881	244	7	committee	committee	PROPN
dpc-1881	244	8	on	on	ADP
dpc-1881	244	9	cancer	cancer	NOUN
dpc-1881	244	10	melanoma	melanoma	PROPN
dpc-1881	244	11	expert	expert	NOUN
dpc-1881	244	12	panel	panel	NOUN
dpc-1881	244	13	and	and	CCONJ
dpc-1881	244	14	the	the	DET
dpc-1881	244	15	international	international	ADJ
dpc-1881	244	16	melanoma	melanoma	NOUN
dpc-1881	244	17	database	database	NOUN
dpc-1881	244	18	and	and	CCONJ
dpc-1881	244	19	discovery	discovery	NOUN
dpc-1881	244	20	platform	platform	NOUN
dpc-1881	244	21	.	.	PUNCT
dpc-1881	245	1	melanoma	melanoma	NOUN
dpc-1881	245	2	staging	staging	NOUN
dpc-1881	245	3	:	:	PUNCT
dpc-1881	245	4	evidence	evidence	NOUN
dpc-1881	245	5	-	-	PUNCT
dpc-1881	245	6	based	base	VERB
dpc-1881	245	7	changes	change	NOUN
dpc-1881	245	8	in	in	ADP
dpc-1881	245	9	the	the	DET
dpc-1881	245	10	american	american	PROPN
dpc-1881	245	11	joint	joint	PROPN
dpc-1881	245	12	committee	committee	PROPN
dpc-1881	245	13	on	on	ADP
dpc-1881	245	14	cancer	cancer	NOUN
dpc-1881	245	15	eighth	eighth	PROPN
dpc-1881	245	16	edition	edition	NOUN
dpc-1881	245	17	cancer	cancer	NOUN
dpc-1881	245	18	staging	staging	NOUN
dpc-1881	245	19	manual	manual	NOUN
dpc-1881	245	20	.	.	PUNCT
dpc-1881	246	1	ca	can	AUX
dpc-1881	246	2	cancer	cancer	PROPN
dpc-1881	246	3	j	j	PROPN
dpc-1881	246	4	clin	clin	PROPN
dpc-1881	246	5	.	.	PUNCT
dpc-1881	247	1	2017;67(6):472	2017;67(6):472	NUM
dpc-1881	247	2	-	-	SYM
dpc-1881	247	3	492	492	NUM
dpc-1881	247	4	.	.	PUNCT
dpc-1881	248	1	doi	doi	NOUN
dpc-1881	248	2	:	:	PUNCT
dpc-1881	248	3	10.3322/	10.3322/	NUM
dpc-1881	248	4	caac.21409	caac.21409	X
dpc-1881	248	5	.	.	PUNCT
dpc-1881	249	1	pmid	pmid	NOUN
dpc-1881	249	2	:	:	PUNCT
dpc-1881	249	3	29028110	29028110	NUM
dpc-1881	249	4	.	.	PUNCT
dpc-1881	250	1	2	2	X
dpc-1881	250	2	.	.	X
dpc-1881	250	3	korn	korn	PROPN
dpc-1881	250	4	el	el	PROPN
dpc-1881	250	5	,	,	PUNCT
dpc-1881	250	6	liu	liu	PROPN
dpc-1881	250	7	py	py	PROPN
dpc-1881	250	8	,	,	PUNCT
dpc-1881	250	9	lee	lee	PROPN
dpc-1881	250	10	sj	sj	PROPN
dpc-1881	250	11	,	,	PUNCT
dpc-1881	250	12	chapman	chapman	PROPN
dpc-1881	250	13	ja	ja	PROPN
dpc-1881	250	14	,	,	PUNCT
dpc-1881	250	15	et	et	PROPN
dpc-1881	250	16	al	al	PROPN
dpc-1881	250	17	.	.	PUNCT
dpc-1881	251	1	meta	meta	VERB
dpc-1881	251	2	-	-	PUNCT
dpc-1881	251	3	analysis	analysis	NOUN
dpc-1881	251	4	of	of	ADP
dpc-1881	251	5	phase	phase	NOUN
dpc-1881	251	6	ii	ii	PROPN
dpc-1881	251	7	cooperative	cooperative	ADJ
dpc-1881	251	8	group	group	NOUN
dpc-1881	251	9	trials	trial	NOUN
dpc-1881	251	10	in	in	ADP
dpc-1881	251	11	metastatic	metastatic	ADJ
dpc-1881	251	12	stage	stage	NOUN
dpc-1881	251	13	iv	iv	NUM
dpc-1881	251	14	melanoma	melanoma	NOUN
dpc-1881	251	15	to	to	PART
dpc-1881	251	16	determine	determine	VERB
dpc-1881	251	17	progression	progression	NOUN
dpc-1881	251	18	-	-	PUNCT
dpc-1881	251	19	free	free	ADJ
dpc-1881	251	20	and	and	CCONJ
dpc-1881	251	21	overall	overall	ADJ
dpc-1881	251	22	survival	survival	NOUN
dpc-1881	251	23	benchmarks	benchmark	NOUN
dpc-1881	251	24	for	for	ADP
dpc-1881	251	25	future	future	ADJ
dpc-1881	251	26	phase	phase	NOUN
dpc-1881	251	27	ii	ii	PROPN
dpc-1881	251	28	trials	trial	NOUN
dpc-1881	251	29	.	.	PUNCT
dpc-1881	252	1	j	j	PROPN
dpc-1881	252	2	clin	clin	PROPN
dpc-1881	252	3	oncol	oncol	PROPN
dpc-1881	252	4	2008;26	2008;26	NOUN
dpc-1881	252	5	:	:	PUNCT
dpc-1881	252	6	527	527	NUM
dpc-1881	252	7	-	-	SYM
dpc-1881	252	8	34	34	NUM
dpc-1881	252	9	.	.	PUNCT
dpc-1881	253	1	doi	doi	NOUN
dpc-1881	253	2	:	:	PUNCT
dpc-1881	253	3	10.1200	10.1200	NUM
dpc-1881	253	4	/	/	SYM
dpc-1881	253	5	jco.2007.12.7837	jco.2007.12.7837	PROPN
dpc-1881	253	6	.	.	PUNCT
dpc-1881	254	1	pmid	pmid	NOUN
dpc-1881	254	2	:	:	PUNCT
dpc-1881	254	3	18235113	18235113	NUM
dpc-1881	254	4	.	.	PUNCT
dpc-1881	255	1	3	3	X
dpc-1881	255	2	.	.	PUNCT
dpc-1881	255	3	ugurel	ugurel	PROPN
dpc-1881	255	4	s	s	PART
dpc-1881	255	5	,	,	PUNCT
dpc-1881	255	6	röhmel	röhmel	PROPN
dpc-1881	255	7	j	j	PROPN
dpc-1881	255	8	,	,	PUNCT
dpc-1881	255	9	ascierto	ascierto	PROPN
dpc-1881	255	10	pa	pa	PROPN
dpc-1881	255	11	,	,	PUNCT
dpc-1881	255	12	et	et	PROPN
dpc-1881	255	13	al	al	PROPN
dpc-1881	255	14	.	.	PROPN
dpc-1881	255	15	survival	survival	NOUN
dpc-1881	255	16	of	of	ADP
dpc-1881	255	17	patients	patient	NOUN
dpc-1881	255	18	with	with	ADP
dpc-1881	255	19	advanced	advanced	ADJ
dpc-1881	255	20	metastatic	metastatic	ADJ
dpc-1881	255	21	melanoma	melanoma	NOUN
dpc-1881	255	22	:	:	PUNCT
dpc-1881	255	23	the	the	DET
dpc-1881	255	24	impact	impact	NOUN
dpc-1881	255	25	of	of	ADP
dpc-1881	255	26	map	map	NOUN
dpc-1881	255	27	kinase	kinase	PROPN
dpc-1881	255	28	pathway	pathway	NOUN
dpc-1881	255	29	inhibition	inhibition	NOUN
dpc-1881	255	30	and	and	CCONJ
dpc-1881	255	31	immune	immune	ADJ
dpc-1881	255	32	checkpoint	checkpoint	NOUN
dpc-1881	255	33	inhibition	inhibition	NOUN
dpc-1881	255	34	update	update	NOUN
dpc-1881	255	35	2019	2019	NUM
dpc-1881	255	36	.	.	PUNCT
dpc-1881	256	1	eur	eur	PROPN
dpc-1881	256	2	j	j	PROPN
dpc-1881	256	3	cancer	cancer	NOUN
dpc-1881	256	4	.	.	PUNCT
dpc-1881	257	1	2020	2020	NUM
dpc-1881	257	2	;	;	PUNCT
dpc-1881	258	1	130:126	130:126	NOUN
dpc-1881	258	2	-	-	SYM
dpc-1881	258	3	138	138	NUM
dpc-1881	258	4	.	.	PUNCT
dpc-1881	259	1	doi	doi	NOUN
dpc-1881	259	2	:	:	PUNCT
dpc-1881	259	3	10.1016	10.1016	NUM
dpc-1881	259	4	/	/	SYM
dpc-1881	259	5	j.ejca.2020.02.021	j.ejca.2020.02.021	PROPN
dpc-1881	259	6	.	.	PUNCT
dpc-1881	260	1	pmid	pmid	NOUN
dpc-1881	260	2	:	:	PUNCT
dpc-1881	260	3	32179447	32179447	NUM
dpc-1881	260	4	.	.	PUNCT
dpc-1881	261	1	4	4	X
dpc-1881	261	2	.	.	X
dpc-1881	261	3	cancer	cancer	NOUN
dpc-1881	261	4	genome	genome	NOUN
dpc-1881	261	5	atlas	atlas	PROPN
dpc-1881	261	6	network	network	PROPN
dpc-1881	261	7	.	.	PUNCT
dpc-1881	262	1	genomic	genomic	ADJ
dpc-1881	262	2	classification	classification	NOUN
dpc-1881	262	3	of	of	ADP
dpc-1881	262	4	cutaneous	cutaneous	ADJ
dpc-1881	262	5	melanoma	melanoma	NOUN
dpc-1881	262	6	.	.	PUNCT
dpc-1881	263	1	cell	cell	NOUN
dpc-1881	263	2	2015	2015	NUM
dpc-1881	263	3	;	;	PUNCT
dpc-1881	263	4	161:1681	161:1681	NUM
dpc-1881	263	5	-	-	SYM
dpc-1881	263	6	96	96	NUM
dpc-1881	263	7	.	.	PUNCT
dpc-1881	264	1	doi	doi	NOUN
dpc-1881	264	2	:	:	PUNCT
dpc-1881	264	3	10.1016	10.1016	NUM
dpc-1881	264	4	/	/	SYM
dpc-1881	264	5	j.	j.	PROPN
dpc-1881	264	6	cell.2015.05.044	cell.2015.05.044	PROPN
dpc-1881	264	7	.	.	PUNCT
dpc-1881	265	1	pmid	pmid	PROPN
dpc-1881	265	2	:	:	PUNCT
dpc-1881	265	3	26091043	26091043	NUM
dpc-1881	265	4	.	.	PUNCT
dpc-1881	266	1	5	5	X
dpc-1881	266	2	.	.	X
dpc-1881	266	3	keilholz	keilholz	PROPN
dpc-1881	266	4	u	u	PROPN
dpc-1881	266	5	,	,	PUNCT
dpc-1881	266	6	ascierto	ascierto	PROPN
dpc-1881	266	7	pa	pa	PROPN
dpc-1881	266	8	,	,	PUNCT
dpc-1881	266	9	dummer	dummer	PROPN
dpc-1881	266	10	r	r	PROPN
dpc-1881	266	11	,	,	PUNCT
dpc-1881	266	12	et	et	PROPN
dpc-1881	266	13	al	al	PROPN
dpc-1881	266	14	.	.	PROPN
dpc-1881	266	15	esmo	esmo	PROPN
dpc-1881	266	16	consensus	consensus	NOUN
dpc-1881	266	17	conference	conference	NOUN
dpc-1881	266	18	recommendations	recommendation	NOUN
dpc-1881	266	19	on	on	ADP
dpc-1881	266	20	the	the	DET
dpc-1881	266	21	management	management	NOUN
dpc-1881	266	22	of	of	ADP
dpc-1881	266	23	metastatic	metastatic	ADJ
dpc-1881	266	24	melanoma	melanoma	NOUN
dpc-1881	266	25	:	:	PUNCT
dpc-1881	266	26	under	under	ADP
dpc-1881	266	27	the	the	DET
dpc-1881	266	28	auspices	auspex	NOUN
dpc-1881	266	29	of	of	ADP
dpc-1881	266	30	the	the	DET
dpc-1881	266	31	esmo	esmo	NOUN
dpc-1881	266	32	guidelines	guideline	NOUN
dpc-1881	266	33	committee	committee	NOUN
dpc-1881	266	34	.	.	PUNCT
dpc-1881	267	1	ann	ann	PROPN
dpc-1881	267	2	oncol	oncol	PROPN
dpc-1881	267	3	.	.	PUNCT
dpc-1881	268	1	2020;31(11):1435	2020;31(11):1435	NUM
dpc-1881	268	2	-	-	SYM
dpc-1881	268	3	1448	1448	NUM
dpc-1881	268	4	.	.	PUNCT
dpc-1881	269	1	doi	doi	NOUN
dpc-1881	269	2	:	:	PUNCT
dpc-1881	269	3	10.1016	10.1016	NUM
dpc-1881	269	4	/	/	SYM
dpc-1881	269	5	j.	j.	PROPN
dpc-1881	269	6	annonc.2020.07.004	annonc.2020.07.004	PROPN
dpc-1881	269	7	.	.	PUNCT
dpc-1881	270	1	pmid	pmid	NOUN
dpc-1881	270	2	:	:	PUNCT
dpc-1881	270	3	32763453	32763453	NUM
dpc-1881	270	4	.	.	PUNCT
dpc-1881	271	1	6	6	NUM
dpc-1881	271	2	.	.	X
dpc-1881	271	3	long	long	ADJ
dpc-1881	271	4	gv	gv	ADP
dpc-1881	271	5	,	,	PUNCT
dpc-1881	271	6	stroyakovskiy	stroyakovskiy	NOUN
dpc-1881	271	7	d	d	PROPN
dpc-1881	271	8	,	,	PUNCT
dpc-1881	271	9	gogas	gogas	NOUN
dpc-1881	271	10	h	h	NOUN
dpc-1881	271	11	,	,	PUNCT
dpc-1881	271	12	et	et	PROPN
dpc-1881	271	13	al	al	PROPN
dpc-1881	271	14	.	.	PROPN
dpc-1881	271	15	dabrafenib	dabrafenib	NOUN
dpc-1881	271	16	and	and	CCONJ
dpc-1881	271	17	trametinib	trametinib	NOUN
dpc-1881	271	18	versus	versus	ADP
dpc-1881	271	19	dabrafenib	dabrafenib	NOUN
dpc-1881	271	20	and	and	CCONJ
dpc-1881	271	21	placebo	placebo	NOUN
dpc-1881	271	22	for	for	ADP
dpc-1881	271	23	val600	val600	NOUN
dpc-1881	271	24	braf	braf	NOUN
dpc-1881	271	25	-	-	PUNCT
dpc-1881	271	26	mutant	mutant	ADJ
dpc-1881	271	27	melanoma	melanoma	NOUN
dpc-1881	271	28	:	:	PUNCT
dpc-1881	271	29	a	a	DET
dpc-1881	271	30	multicentre	multicentre	NOUN
dpc-1881	271	31	,	,	PUNCT
dpc-1881	271	32	double	double	ADJ
dpc-1881	271	33	-	-	PUNCT
dpc-1881	271	34	blind	blind	ADJ
dpc-1881	271	35	,	,	PUNCT
dpc-1881	271	36	phase	phase	NOUN
dpc-1881	271	37	3	3	NUM
dpc-1881	271	38	randomised	randomise	VERB
dpc-1881	271	39	controlled	control	VERB
dpc-1881	271	40	trial	trial	NOUN
dpc-1881	271	41	.	.	PUNCT
dpc-1881	272	1	lancet	lancet	NOUN
dpc-1881	272	2	.	.	PUNCT
dpc-1881	273	1	2015	2015	NUM
dpc-1881	273	2	;	;	PUNCT
dpc-1881	273	3	386(9992):444	386(9992):444	NUM
dpc-1881	273	4	-	-	SYM
dpc-1881	273	5	51	51	NUM
dpc-1881	273	6	.	.	PUNCT
dpc-1881	274	1	doi	doi	NOUN
dpc-1881	274	2	:	:	PUNCT
dpc-1881	274	3	10.1016/	10.1016/	NUM
dpc-1881	274	4	s0140	s0140	PROPN
dpc-1881	274	5	-	-	PUNCT
dpc-1881	274	6	6736(15)60898	6736(15)60898	NUM
dpc-1881	274	7	-	-	PUNCT
dpc-1881	274	8	4	4	NUM
dpc-1881	274	9	.	.	NOUN
dpc-1881	274	10	7	7	NUM
dpc-1881	274	11	.	.	X
dpc-1881	275	1	schadendorf	schadendorf	PROPN
dpc-1881	275	2	d	d	PROPN
dpc-1881	275	3	,	,	PUNCT
dpc-1881	275	4	amonkar	amonkar	PROPN
dpc-1881	275	5	mm	mm	PROPN
dpc-1881	275	6	,	,	PUNCT
dpc-1881	275	7	stroyakovskiy	stroyakovskiy	NOUN
dpc-1881	275	8	d	d	PROPN
dpc-1881	275	9	,	,	PUNCT
dpc-1881	275	10	et	et	PROPN
dpc-1881	275	11	al	al	PROPN
dpc-1881	275	12	.	.	PUNCT
dpc-1881	275	13	health	health	NOUN
dpc-1881	275	14	-	-	PUNCT
dpc-1881	275	15	related	relate	VERB
dpc-1881	275	16	quality	quality	NOUN
dpc-1881	275	17	of	of	ADP
dpc-1881	275	18	life	life	NOUN
dpc-1881	275	19	impact	impact	NOUN
dpc-1881	275	20	in	in	ADP
dpc-1881	275	21	a	a	DET
dpc-1881	275	22	randomised	randomised	ADJ
dpc-1881	275	23	phase	phase	NOUN
dpc-1881	275	24	iii	iii	NUM
dpc-1881	275	25	study	study	NOUN
dpc-1881	275	26	of	of	ADP
dpc-1881	275	27	the	the	DET
dpc-1881	275	28	combination	combination	NOUN
dpc-1881	275	29	of	of	ADP
dpc-1881	275	30	dabrafenib	dabrafenib	NOUN
dpc-1881	275	31	and	and	CCONJ
dpc-1881	275	32	trametinib	trametinib	NOUN
dpc-1881	275	33	versus	versus	ADP
dpc-1881	275	34	dabrafenib	dabrafenib	NOUN
dpc-1881	275	35	monotherapy	monotherapy	NOUN
dpc-1881	275	36	in	in	ADP
dpc-1881	275	37	patients	patient	NOUN
dpc-1881	275	38	with	with	ADP
dpc-1881	275	39	braf	braf	NOUN
dpc-1881	275	40	v600	v600	PROPN
dpc-1881	275	41	metastatic	metastatic	ADJ
dpc-1881	275	42	melanoma	melanoma	NOUN
dpc-1881	275	43	.	.	PUNCT
dpc-1881	276	1	eur	eur	PROPN
dpc-1881	276	2	j	j	PROPN
dpc-1881	276	3	cancer	cancer	NOUN
dpc-1881	276	4	.	.	PUNCT
dpc-1881	277	1	2015;51(7):833	2015;51(7):833	NUM
dpc-1881	277	2	-	-	SYM
dpc-1881	277	3	40	40	NUM
dpc-1881	277	4	.	.	PUNCT
dpc-1881	278	1	doi	doi	NOUN
dpc-1881	278	2	:	:	PUNCT
dpc-1881	278	3	10.1016	10.1016	NUM
dpc-1881	278	4	/	/	SYM
dpc-1881	278	5	j.	j.	PROPN
dpc-1881	278	6	ejca.2015.03.004	ejca.2015.03.004	PROPN
dpc-1881	278	7	.	.	PUNCT
dpc-1881	279	1	pmid	pmid	NOUN
dpc-1881	279	2	:	:	PUNCT
dpc-1881	279	3	25794603	25794603	NUM
dpc-1881	279	4	.	.	PUNCT
dpc-1881	280	1	8	8	X
dpc-1881	280	2	.	.	PUNCT
dpc-1881	280	3	robert	robert	PROPN
dpc-1881	280	4	c	c	PROPN
dpc-1881	280	5	,	,	PUNCT
dpc-1881	280	6	karaszewska	karaszewska	PROPN
dpc-1881	280	7	b	b	NUM
dpc-1881	280	8	,	,	PUNCT
dpc-1881	280	9	schachter	schachter	PROPN
dpc-1881	280	10	j	j	PROPN
dpc-1881	280	11	,	,	PUNCT
dpc-1881	280	12	et	et	PROPN
dpc-1881	280	13	al	al	PROPN
dpc-1881	280	14	.	.	PROPN
dpc-1881	280	15	improved	improve	VERB
dpc-1881	280	16	overall	overall	ADJ
dpc-1881	280	17	survival	survival	NOUN
dpc-1881	280	18	in	in	ADP
dpc-1881	280	19	melanoma	melanoma	NOUN
dpc-1881	280	20	with	with	ADP
dpc-1881	280	21	combined	combined	ADJ
dpc-1881	280	22	dabrafenib	dabrafenib	NOUN
dpc-1881	280	23	and	and	CCONJ
dpc-1881	280	24	trametinib	trametinib	NOUN
dpc-1881	280	25	.	.	PUNCT
dpc-1881	281	1	n	n	PROPN
dpc-1881	281	2	engl	engl	PROPN
dpc-1881	281	3	j	j	PROPN
dpc-1881	281	4	med	med	PROPN
dpc-1881	281	5	.	.	PUNCT
dpc-1881	282	1	2015;372(1):30	2015;372(1):30	NUM
dpc-1881	282	2	-	-	SYM
dpc-1881	282	3	9	9	NUM
dpc-1881	282	4	.	.	PUNCT
dpc-1881	282	5	doi	doi	NOUN
dpc-1881	282	6	:	:	PUNCT
dpc-1881	282	7	10.1056	10.1056	NUM
dpc-1881	282	8	/	/	SYM
dpc-1881	282	9	nejmoa1412690	nejmoa1412690	NOUN
dpc-1881	282	10	.	.	PUNCT
dpc-1881	283	1	pmid	pmid	NOUN
dpc-1881	283	2	:	:	PUNCT
dpc-1881	283	3	25399551	25399551	NUM
dpc-1881	283	4	.	.	PUNCT
dpc-1881	284	1	9	9	X
dpc-1881	284	2	.	.	X
dpc-1881	285	1	grob	grob	PROPN
dpc-1881	285	2	jj	jj	PROPN
dpc-1881	285	3	,	,	PUNCT
dpc-1881	285	4	amonkar	amonkar	VERB
dpc-1881	285	5	mm	mm	PROPN
dpc-1881	285	6	,	,	PUNCT
dpc-1881	285	7	karaszewska	karaszewska	PROPN
dpc-1881	285	8	b	b	PROPN
dpc-1881	285	9	,	,	PUNCT
dpc-1881	285	10	et	et	PROPN
dpc-1881	285	11	al	al	PROPN
dpc-1881	285	12	.	.	PROPN
dpc-1881	285	13	comparison	comparison	NOUN
dpc-1881	285	14	of	of	ADP
dpc-1881	285	15	dabrafenib	dabrafenib	NOUN
dpc-1881	285	16	and	and	CCONJ
dpc-1881	285	17	trametinib	trametinib	NOUN
dpc-1881	285	18	combination	combination	NOUN
dpc-1881	285	19	therapy	therapy	NOUN
dpc-1881	285	20	with	with	ADP
dpc-1881	285	21	vemurafenib	vemurafenib	PROPN
dpc-1881	285	22	monotherapy	monotherapy	NOUN
dpc-1881	285	23	on	on	ADP
dpc-1881	285	24	health	health	NOUN
dpc-1881	285	25	-	-	PUNCT
dpc-1881	285	26	related	relate	VERB
dpc-1881	285	27	quality	quality	NOUN
dpc-1881	285	28	of	of	ADP
dpc-1881	285	29	life	life	NOUN
dpc-1881	285	30	in	in	ADP
dpc-1881	285	31	patients	patient	NOUN
dpc-1881	285	32	with	with	ADP
dpc-1881	285	33	unresectable	unresectable	ADJ
dpc-1881	285	34	or	or	CCONJ
dpc-1881	285	35	metastatic	metastatic	ADJ
dpc-1881	285	36	cutaneous	cutaneous	ADJ
dpc-1881	285	37	braf	braf	NOUN
dpc-1881	285	38	val600	val600	ADJ
dpc-1881	285	39	-	-	PUNCT
dpc-1881	285	40	mutation	mutation	NOUN
dpc-1881	285	41	-	-	PUNCT
dpc-1881	285	42	positive	positive	ADJ
dpc-1881	285	43	melanoma	melanoma	NOUN
dpc-1881	285	44	(	(	PUNCT
dpc-1881	285	45	combi	combi	NOUN
dpc-1881	285	46	-	-	PUNCT
dpc-1881	285	47	v	v	NOUN
dpc-1881	285	48	):	):	PUNCT
dpc-1881	285	49	results	result	NOUN
dpc-1881	285	50	of	of	ADP
dpc-1881	285	51	a	a	DET
dpc-1881	285	52	phase	phase	NOUN
dpc-1881	285	53	3	3	NUM
dpc-1881	285	54	,	,	PUNCT
dpc-1881	285	55	open	open	ADJ
dpc-1881	285	56	-	-	PUNCT
dpc-1881	285	57	label	label	NOUN
dpc-1881	285	58	,	,	PUNCT
dpc-1881	285	59	randomised	randomise	VERB
dpc-1881	285	60	trial	trial	NOUN
dpc-1881	285	61	.	.	PUNCT
dpc-1881	286	1	lancet	lancet	PROPN
dpc-1881	286	2	oncol	oncol	PROPN
dpc-1881	286	3	.	.	PUNCT
dpc-1881	287	1	2015	2015	NUM
dpc-1881	287	2	;	;	PUNCT
dpc-1881	287	3	16(13):1389	16(13):1389	NUM
dpc-1881	287	4	-	-	SYM
dpc-1881	287	5	98	98	NUM
dpc-1881	287	6	.	.	PUNCT
dpc-1881	288	1	doi	doi	NOUN
dpc-1881	288	2	:	:	PUNCT
dpc-1881	288	3	10.1016	10.1016	NUM
dpc-1881	288	4	/	/	SYM
dpc-1881	288	5	s1470	s1470	PROPN
dpc-1881	288	6	-	-	PUNCT
dpc-1881	288	7	2045(15)00087	2045(15)00087	NOUN
dpc-1881	288	8	-	-	PUNCT
dpc-1881	288	9	x.	x.	NOUN
dpc-1881	288	10	10	10	NUM
dpc-1881	288	11	.	.	PUNCT
dpc-1881	289	1	robert	robert	PROPN
dpc-1881	289	2	c	c	PROPN
dpc-1881	289	3	,	,	PUNCT
dpc-1881	289	4	grob	grob	PROPN
dpc-1881	289	5	jj	jj	PROPN
dpc-1881	289	6	,	,	PUNCT
dpc-1881	289	7	stroyakovskiy	stroyakovskiy	PROPN
dpc-1881	289	8	d	d	PROPN
dpc-1881	289	9	,	,	PUNCT
dpc-1881	289	10	et	et	PROPN
dpc-1881	289	11	al	al	PROPN
dpc-1881	289	12	.	.	PROPN
dpc-1881	289	13	five	five	NUM
dpc-1881	289	14	-	-	PUNCT
dpc-1881	289	15	year	year	NOUN
dpc-1881	289	16	outcomes	outcome	NOUN
dpc-1881	289	17	with	with	ADP
dpc-1881	289	18	dabrafenib	dabrafenib	NOUN
dpc-1881	289	19	plus	plus	CCONJ
dpc-1881	289	20	trametinib	trametinib	NOUN
dpc-1881	289	21	in	in	ADP
dpc-1881	289	22	metastatic	metastatic	ADJ
dpc-1881	289	23	melanoma	melanoma	NOUN
dpc-1881	289	24	.	.	PUNCT
dpc-1881	290	1	n	n	PRON
dpc-1881	290	2	engl	engl	PROPN
dpc-1881	290	3	j	j	PROPN
dpc-1881	290	4	med	med	PROPN
dpc-1881	290	5	.	.	PROPN
dpc-1881	290	6	2019	2019	NUM
dpc-1881	290	7	;	;	PUNCT
dpc-1881	290	8	381(7):626	381(7):626	NUM
dpc-1881	290	9	-	-	SYM
dpc-1881	290	10	636	636	NUM
dpc-1881	290	11	.	.	PUNCT
dpc-1881	291	1	doi	doi	NOUN
dpc-1881	291	2	.	.	PUNCT
dpc-1881	291	3	10.1056	10.1056	NUM
dpc-1881	291	4	/	/	SYM
dpc-1881	291	5	nejmoa1904059	nejmoa1904059	PROPN
dpc-1881	291	6	.	.	PUNCT
dpc-1881	292	1	pmid	pmid	NOUN
dpc-1881	292	2	:	:	PUNCT
dpc-1881	292	3	31166680	31166680	NUM
dpc-1881	292	4	.	.	PUNCT
dpc-1881	293	1	11	11	NUM
dpc-1881	293	2	.	.	PUNCT
dpc-1881	294	1	schadendorf	schadendorf	PROPN
dpc-1881	294	2	d	d	PROPN
dpc-1881	294	3	,	,	PUNCT
dpc-1881	294	4	long	long	ADV
dpc-1881	294	5	gv	gv	ADP
dpc-1881	294	6	,	,	PUNCT
dpc-1881	294	7	stroiakovski	stroiakovski	PROPN
dpc-1881	294	8	d	d	PROPN
dpc-1881	294	9	,	,	PUNCT
dpc-1881	294	10	et	et	PROPN
dpc-1881	294	11	al	al	PROPN
dpc-1881	294	12	.	.	PROPN
dpc-1881	295	1	three	three	NUM
dpc-1881	295	2	-	-	PUNCT
dpc-1881	295	3	year	year	NOUN
dpc-1881	295	4	pooled	pool	VERB
dpc-1881	295	5	analysis	analysis	NOUN
dpc-1881	295	6	of	of	ADP
dpc-1881	295	7	factors	factor	NOUN
dpc-1881	295	8	associated	associate	VERB
dpc-1881	295	9	with	with	ADP
dpc-1881	295	10	clinical	clinical	ADJ
dpc-1881	295	11	outcomes	outcome	NOUN
dpc-1881	295	12	across	across	ADP
dpc-1881	295	13	dabrafenib	dabrafenib	NOUN
dpc-1881	295	14	and	and	CCONJ
dpc-1881	295	15	trametinib	trametinib	NOUN
dpc-1881	295	16	combination	combination	NOUN
dpc-1881	295	17	therapy	therapy	NOUN
dpc-1881	295	18	phase	phase	NOUN
dpc-1881	295	19	3	3	NUM
dpc-1881	295	20	randomised	randomise	VERB
dpc-1881	295	21	trials	trial	NOUN
dpc-1881	295	22	.	.	PUNCT
dpc-1881	296	1	eur	eur	PROPN
dpc-1881	296	2	j	j	PROPN
dpc-1881	296	3	cancer	cancer	NOUN
dpc-1881	296	4	.	.	PUNCT
dpc-1881	297	1	2017	2017	NUM
dpc-1881	297	2	;	;	PUNCT
dpc-1881	297	3	82:45	82:45	NUM
dpc-1881	297	4	-	-	SYM
dpc-1881	297	5	55	55	NUM
dpc-1881	297	6	.	.	PUNCT
dpc-1881	298	1	doi	doi	NOUN
dpc-1881	298	2	:	:	PUNCT
dpc-1881	298	3	10.1016	10.1016	NUM
dpc-1881	298	4	/	/	SYM
dpc-1881	298	5	j.	j.	PROPN
dpc-1881	298	6	ejca.2017.05.033	ejca.2017.05.033	PROPN
dpc-1881	298	7	.	.	PUNCT
dpc-1881	299	1	pmid	pmid	PROPN
dpc-1881	299	2	:	:	PUNCT
dpc-1881	299	3	28648698	28648698	NUM
dpc-1881	299	4	.	.	PUNCT
dpc-1881	300	1	12	12	NUM
dpc-1881	300	2	.	.	PUNCT
dpc-1881	301	1	chan	chan	PROPN
dpc-1881	301	2	mm	mm	PROPN
dpc-1881	301	3	,	,	PUNCT
dpc-1881	301	4	haydu	haydu	PROPN
dpc-1881	301	5	le	le	PROPN
dpc-1881	301	6	,	,	PUNCT
dpc-1881	301	7	menzies	menzie	NOUN
dpc-1881	301	8	am	be	AUX
dpc-1881	301	9	,	,	PUNCT
dpc-1881	301	10	et	et	PROPN
dpc-1881	301	11	al	al	PROPN
dpc-1881	301	12	.	.	PUNCT
dpc-1881	302	1	the	the	DET
dpc-1881	302	2	nature	nature	NOUN
dpc-1881	302	3	and	and	CCONJ
dpc-1881	302	4	management	management	NOUN
dpc-1881	302	5	of	of	ADP
dpc-1881	302	6	metastatic	metastatic	ADJ
dpc-1881	302	7	melanoma	melanoma	NOUN
dpc-1881	302	8	after	after	ADP
dpc-1881	302	9	progression	progression	NOUN
dpc-1881	302	10	on	on	ADP
dpc-1881	302	11	brafinhibitors	brafinhibitor	NOUN
dpc-1881	302	12	:	:	PUNCT
dpc-1881	302	13	effects	effect	NOUN
dpc-1881	302	14	of	of	ADP
dpc-1881	302	15	extended	extended	ADJ
dpc-1881	302	16	braf	braf	NOUN
dpc-1881	302	17	inhibition	inhibition	NOUN
dpc-1881	302	18	.	.	PUNCT
dpc-1881	303	1	cancer	cancer	NOUN
dpc-1881	303	2	.	.	PUNCT
dpc-1881	304	1	2014,120	2014,120	NUM
dpc-1881	304	2	,	,	PUNCT
dpc-1881	304	3	3142–3153	3142–3153	NUM
dpc-1881	304	4	.	.	PUNCT
dpc-1881	304	5	doi	doi	NOUN
dpc-1881	304	6	:	:	PUNCT
dpc-1881	304	7	10.1002	10.1002	NUM
dpc-1881	304	8	/	/	SYM
dpc-1881	304	9	cncr.28851	cncr.28851	PROPN
dpc-1881	304	10	.	.	PUNCT
dpc-1881	304	11	pmid	pmid	NOUN
dpc-1881	304	12	:	:	PUNCT
dpc-1881	304	13	24985732	24985732	NUM
dpc-1881	304	14	.	.	PUNCT
dpc-1881	305	1	13	13	NUM
dpc-1881	305	2	.	.	PUNCT
dpc-1881	306	1	hassel	hassel	PROPN
dpc-1881	306	2	jc	jc	PROPN
dpc-1881	306	3	,	,	PUNCT
dpc-1881	306	4	buder	buder	NOUN
dpc-1881	306	5	-	-	PUNCT
dpc-1881	306	6	bakhaya	bakhaya	NOUN
dpc-1881	306	7	k	k	PROPN
dpc-1881	306	8	,	,	PUNCT
dpc-1881	306	9	bender	bender	NOUN
dpc-1881	306	10	c	c	AUX
dpc-1881	306	11	,	,	PUNCT
dpc-1881	306	12	et	et	PROPN
dpc-1881	306	13	al	al	PROPN
dpc-1881	306	14	.	.	PUNCT
dpc-1881	306	15	german	german	ADJ
dpc-1881	306	16	dermatooncology	dermatooncology	NOUN
dpc-1881	306	17	group	group	NOUN
dpc-1881	306	18	(	(	PUNCT
dpc-1881	306	19	decog	decog	VERB
dpc-1881	306	20	/	/	SYM
dpc-1881	306	21	ado	ado	NOUN
dpc-1881	306	22	)	)	PUNCT
dpc-1881	306	23	.	.	PUNCT
dpc-1881	307	1	progression	progression	NOUN
dpc-1881	307	2	patterns	pattern	NOUN
dpc-1881	307	3	under	under	ADP
dpc-1881	307	4	braf	braf	NOUN
dpc-1881	307	5	inhibitor	inhibitor	NOUN
dpc-1881	307	6	treatment	treatment	NOUN
dpc-1881	307	7	andtreatment	andtreatment	NOUN
dpc-1881	307	8	beyond	beyond	ADP
dpc-1881	307	9	progression	progression	NOUN
dpc-1881	307	10	in	in	ADP
dpc-1881	307	11	patients	patient	NOUN
dpc-1881	307	12	with	with	ADP
dpc-1881	307	13	metastatic	metastatic	ADJ
dpc-1881	307	14	melanoma	melanoma	NOUN
dpc-1881	307	15	.	.	PUNCT
dpc-1881	308	1	cancer	cancer	NOUN
dpc-1881	308	2	med	med	PROPN
dpc-1881	308	3	.	.	PUNCT
dpc-1881	309	1	2018,7	2018,7	NUM
dpc-1881	309	2	,	,	PUNCT
dpc-1881	309	3	95–104	95–104	PROPN
dpc-1881	309	4	.	.	PUNCT
dpc-1881	309	5	doi	doi	PROPN
dpc-1881	309	6	:	:	PUNCT
dpc-1881	309	7	10.1002	10.1002	NUM
dpc-1881	309	8	/	/	SYM
dpc-1881	309	9	cam4.1267	cam4.1267	NOUN
dpc-1881	309	10	.	.	PUNCT
dpc-1881	310	1	pmid	pmid	NOUN
dpc-1881	310	2	:	:	PUNCT
dpc-1881	310	3	29266761	29266761	NUM
dpc-1881	310	4	.	.	PUNCT
dpc-1881	311	1	14	14	NUM
dpc-1881	311	2	.	.	PUNCT
dpc-1881	312	1	atkinson	atkinson	PROPN
dpc-1881	312	2	vg	vg	PROPN
dpc-1881	312	3	,	,	PUNCT
dpc-1881	312	4	quaglino	quaglino	NOUN
dpc-1881	312	5	p	p	X
dpc-1881	312	6	,	,	PUNCT
dpc-1881	312	7	aglietta	aglietta	PROPN
dpc-1881	312	8	m	m	NOUN
dpc-1881	312	9	,	,	PUNCT
dpc-1881	312	10	et	et	PROPN
dpc-1881	312	11	al	al	PROPN
dpc-1881	312	12	.	.	PROPN
dpc-1881	313	1	describe	describe	VERB
dpc-1881	313	2	iii	iii	NUM
dpc-1881	313	3	update	update	NOUN
dpc-1881	313	4	:	:	PUNCT
dpc-1881	313	5	a	a	DET
dpc-1881	313	6	retrospective	retrospective	ADJ
dpc-1881	313	7	analysis	analysis	NOUN
dpc-1881	313	8	of	of	ADP
dpc-1881	313	9	dabrafenib	dabrafenib	NOUN
dpc-1881	313	10	and/or	and/or	CCONJ
dpc-1881	313	11	dabrafenib	dabrafenib	NOUN
dpc-1881	313	12	+	+	CCONJ
dpc-1881	313	13	trametinib	trametinib	NOUN
dpc-1881	313	14	in	in	ADP
dpc-1881	313	15	patients	patient	NOUN
dpc-1881	313	16	)	)	PUNCT
dpc-1881	313	17	with	with	ADP
dpc-1881	313	18	metastatic	metastatic	ADJ
dpc-1881	313	19	melanoma	melanoma	NOUN
dpc-1881	313	20	.	.	PUNCT
dpc-1881	314	1	presented	present	VERB
dpc-1881	314	2	at	at	ADP
dpc-1881	314	3	eado2019	eado2019	PROPN
dpc-1881	314	4	,	,	PUNCT
dpc-1881	314	5	paris	paris	PROPN
dpc-1881	314	6	.	.	PUNCT
dpc-1881	315	1	15	15	X
dpc-1881	315	2	.	.	X
dpc-1881	316	1	larkin	larkin	PROPN
dpc-1881	316	2	j	j	PROPN
dpc-1881	316	3	,	,	PUNCT
dpc-1881	316	4	ascierto	ascierto	PROPN
dpc-1881	316	5	pa	pa	PROPN
dpc-1881	316	6	,	,	PUNCT
dpc-1881	316	7	dréno	dréno	VERB
dpc-1881	316	8	b	b	NUM
dpc-1881	316	9	,	,	PUNCT
dpc-1881	316	10	et	et	PROPN
dpc-1881	316	11	al	al	PROPN
dpc-1881	316	12	.	.	PROPN
dpc-1881	316	13	combined	combine	VERB
dpc-1881	316	14	vemurafenib	vemurafenib	NOUN
dpc-1881	316	15	and	and	CCONJ
dpc-1881	316	16	cobimetinib	cobimetinib	NOUN
dpc-1881	316	17	in	in	ADP
dpc-1881	316	18	braf	braf	NOUN
dpc-1881	316	19	-	-	PUNCT
dpc-1881	316	20	mutated	mutate	VERB
dpc-1881	316	21	melanoma	melanoma	NOUN
dpc-1881	316	22	.	.	PUNCT
dpc-1881	317	1	n	n	PRON
dpc-1881	317	2	engl	engl	PROPN
dpc-1881	317	3	j	j	PROPN
dpc-1881	317	4	med	med	PROPN
dpc-1881	317	5	.	.	PROPN
dpc-1881	317	6	2014	2014	NUM
dpc-1881	317	7	;	;	PUNCT
dpc-1881	317	8	371	371	NUM
dpc-1881	317	9	:	:	SYM
dpc-1881	317	10	1867	1867	NUM
dpc-1881	317	11	-	-	SYM
dpc-1881	317	12	76	76	NUM
dpc-1881	317	13	.	.	PUNCT
dpc-1881	318	1	doi	doi	NOUN
dpc-1881	318	2	:	:	PUNCT
dpc-1881	318	3	10.1056	10.1056	NUM
dpc-1881	318	4	/	/	SYM
dpc-1881	318	5	nejmoa1408868	nejmoa1408868	PROPN
dpc-1881	318	6	.	.	PUNCT
dpc-1881	319	1	pmid	pmid	NOUN
dpc-1881	319	2	:	:	PUNCT
dpc-1881	319	3	25265494	25265494	NUM
dpc-1881	319	4	.	.	PUNCT
dpc-1881	320	1	16	16	NUM
dpc-1881	320	2	.	.	PUNCT
dpc-1881	321	1	ascierto	ascierto	PROPN
dpc-1881	321	2	pa	pa	PROPN
dpc-1881	321	3	,	,	PUNCT
dpc-1881	321	4	mcarthur	mcarthur	PROPN
dpc-1881	321	5	ga	ga	PROPN
dpc-1881	321	6	,	,	PUNCT
dpc-1881	321	7	dréno	dréno	VERB
dpc-1881	321	8	b	b	NUM
dpc-1881	321	9	,	,	PUNCT
dpc-1881	321	10	et	et	PROPN
dpc-1881	321	11	al	al	PROPN
dpc-1881	321	12	.	.	PUNCT
dpc-1881	321	13	cobimetinib	cobimetinib	PROPN
dpc-1881	321	14	combined	combine	VERB
dpc-1881	321	15	with	with	ADP
dpc-1881	321	16	vemurafenib	vemurafenib	NOUN
dpc-1881	321	17	in	in	ADP
dpc-1881	321	18	advanced	advanced	PROPN
dpc-1881	321	19	braf(v600)-mutant	braf(v600)-mutant	X
dpc-1881	321	20	melanoma	melanoma	NOUN
dpc-1881	321	21	(	(	PUNCT
dpc-1881	321	22	cobrim	cobrim	PROPN
dpc-1881	321	23	):	):	PUNCT
dpc-1881	321	24	updated	update	VERB
dpc-1881	321	25	efficacy	efficacy	NOUN
dpc-1881	321	26	results	result	VERB
dpc-1881	321	27	from	from	ADP
dpc-1881	321	28	a	a	DET
dpc-1881	321	29	randomised	randomised	ADJ
dpc-1881	321	30	,	,	PUNCT
dpc-1881	321	31	double	double	ADJ
dpc-1881	321	32	-	-	PUNCT
dpc-1881	321	33	blind	blind	ADJ
dpc-1881	321	34	,	,	PUNCT
dpc-1881	321	35	phase	phase	NOUN
dpc-1881	321	36	3	3	NUM
dpc-1881	321	37	trial	trial	NOUN
dpc-1881	321	38	.	.	PUNCT
dpc-1881	322	1	lancet	lancet	PROPN
dpc-1881	322	2	oncol	oncol	PROPN
dpc-1881	322	3	.	.	PUNCT
dpc-1881	323	1	2016;17(9):1248	2016;17(9):1248	NUM
dpc-1881	323	2	-	-	SYM
dpc-1881	323	3	60	60	NUM
dpc-1881	323	4	.	.	PUNCT
dpc-1881	324	1	doi	doi	NOUN
dpc-1881	324	2	:	:	PUNCT
dpc-1881	324	3	10.1016	10.1016	NUM
dpc-1881	324	4	/	/	SYM
dpc-1881	324	5	s1470	s1470	PROPN
dpc-1881	324	6	-	-	PUNCT
dpc-1881	324	7	2045(16)30122	2045(16)30122	NOUN
dpc-1881	324	8	-	-	PUNCT
dpc-1881	324	9	x.	x.	NOUN
dpc-1881	324	10	17	17	NUM
dpc-1881	324	11	.	.	PUNCT
dpc-1881	325	1	dummer	dummer	PROPN
dpc-1881	325	2	r	r	PROPN
dpc-1881	325	3	,	,	PUNCT
dpc-1881	325	4	ascierto	ascierto	PROPN
dpc-1881	325	5	pa	pa	PROPN
dpc-1881	325	6	,	,	PUNCT
dpc-1881	325	7	gogas	gogas	PROPN
dpc-1881	325	8	hj	hj	PROPN
dpc-1881	325	9	,	,	PUNCT
dpc-1881	325	10	et	et	PROPN
dpc-1881	325	11	al	al	PROPN
dpc-1881	325	12	.	.	PROPN
dpc-1881	325	13	encorafenib	encorafenib	NOUN
dpc-1881	325	14	plus	plus	CCONJ
dpc-1881	325	15	binimetinib	binimetinib	NOUN
dpc-1881	325	16	versus	versus	ADP
dpc-1881	325	17	vemurafenib	vemurafenib	NOUN
dpc-1881	325	18	or	or	CCONJ
dpc-1881	325	19	encorafenib	encorafenib	NOUN
dpc-1881	325	20	in	in	ADP
dpc-1881	325	21	patients	patient	NOUN
dpc-1881	325	22	with	with	ADP
dpc-1881	325	23	10	10	NUM
dpc-1881	325	24	review	review	NOUN
dpc-1881	325	25	|	|	ADV
dpc-1881	325	26	dermatol	dermatol	ADJ
dpc-1881	325	27	pract	pract	NOUN
dpc-1881	325	28	concept	concept	NOUN
dpc-1881	325	29	.	.	PUNCT
dpc-1881	326	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	326	2	):	):	PUNCT
dpc-1881	326	3	e2021164s	e2021164s	PROPN
dpc-1881	326	4	braf	braf	NOUN
dpc-1881	326	5	-	-	PUNCT
dpc-1881	326	6	mutant	mutant	ADJ
dpc-1881	326	7	melanoma	melanoma	NOUN
dpc-1881	326	8	(	(	PUNCT
dpc-1881	326	9	columbus	columbus	PROPN
dpc-1881	326	10	):	):	PUNCT
dpc-1881	326	11	a	a	DET
dpc-1881	326	12	multicentre	multicentre	NOUN
dpc-1881	326	13	,	,	PUNCT
dpc-1881	326	14	open	open	ADJ
dpc-1881	326	15	-	-	PUNCT
dpc-1881	326	16	label	label	NOUN
dpc-1881	326	17	,	,	PUNCT
dpc-1881	326	18	randomised	randomise	VERB
dpc-1881	326	19	phase	phase	NOUN
dpc-1881	326	20	3	3	NUM
dpc-1881	326	21	trial	trial	NOUN
dpc-1881	326	22	.	.	PUNCT
dpc-1881	327	1	lancet	lancet	PROPN
dpc-1881	327	2	oncol	oncol	PROPN
dpc-1881	327	3	.	.	PUNCT
dpc-1881	328	1	2018;19(5):603	2018;19(5):603	NOUN
dpc-1881	328	2	-	-	SYM
dpc-1881	328	3	615	615	NUM
dpc-1881	328	4	.	.	PUNCT
dpc-1881	329	1	doi	doi	NOUN
dpc-1881	329	2	:	:	PUNCT
dpc-1881	329	3	10.1016	10.1016	NUM
dpc-1881	329	4	/	/	SYM
dpc-1881	329	5	s1470	s1470	PROPN
dpc-1881	329	6	-	-	PUNCT
dpc-1881	329	7	2045(18)30142	2045(18)30142	NUM
dpc-1881	329	8	-	-	PUNCT
dpc-1881	329	9	6	6	NUM
dpc-1881	329	10	.	.	NOUN
dpc-1881	329	11	18	18	NUM
dpc-1881	329	12	.	.	PUNCT
dpc-1881	330	1	dummer	dummer	PROPN
dpc-1881	330	2	r	r	PROPN
dpc-1881	330	3	,	,	PUNCT
dpc-1881	330	4	ascierto	ascierto	PROPN
dpc-1881	330	5	pa	pa	PROPN
dpc-1881	330	6	,	,	PUNCT
dpc-1881	330	7	gogas	gogas	PROPN
dpc-1881	330	8	hj	hj	PROPN
dpc-1881	330	9	,	,	PUNCT
dpc-1881	330	10	et	et	PROPN
dpc-1881	330	11	al	al	PROPN
dpc-1881	330	12	.	.	PUNCT
dpc-1881	331	1	overall	overall	ADJ
dpc-1881	331	2	survival	survival	NOUN
dpc-1881	331	3	in	in	ADP
dpc-1881	331	4	patients	patient	NOUN
dpc-1881	331	5	with	with	ADP
dpc-1881	331	6	braf	braf	NOUN
dpc-1881	331	7	-	-	PUNCT
dpc-1881	331	8	mutant	mutant	ADJ
dpc-1881	331	9	melanoma	melanoma	NOUN
dpc-1881	331	10	receiving	receive	VERB
dpc-1881	331	11	encorafenib	encorafenib	NOUN
dpc-1881	331	12	plus	plus	CCONJ
dpc-1881	331	13	binimetinib	binimetinib	NOUN
dpc-1881	331	14	versus	versus	ADP
dpc-1881	331	15	vemurafenib	vemurafenib	NOUN
dpc-1881	331	16	or	or	CCONJ
dpc-1881	331	17	encorafenib	encorafenib	NOUN
dpc-1881	331	18	(	(	PUNCT
dpc-1881	331	19	columbus	columbus	PROPN
dpc-1881	331	20	):	):	PUNCT
dpc-1881	331	21	a	a	DET
dpc-1881	331	22	multicentre	multicentre	NOUN
dpc-1881	331	23	,	,	PUNCT
dpc-1881	331	24	open	open	ADJ
dpc-1881	331	25	-	-	PUNCT
dpc-1881	331	26	label	label	NOUN
dpc-1881	331	27	,	,	PUNCT
dpc-1881	331	28	randomised	randomise	VERB
dpc-1881	331	29	,	,	PUNCT
dpc-1881	331	30	phase	phase	NOUN
dpc-1881	331	31	3	3	NUM
dpc-1881	331	32	trial	trial	NOUN
dpc-1881	331	33	.	.	PUNCT
dpc-1881	332	1	lancet	lancet	PROPN
dpc-1881	332	2	oncol	oncol	PROPN
dpc-1881	332	3	.	.	PUNCT
dpc-1881	333	1	2018	2018	NUM
dpc-1881	333	2	;	;	PUNCT
dpc-1881	333	3	19(10):1315	19(10):1315	NUM
dpc-1881	333	4	-	-	SYM
dpc-1881	333	5	1327	1327	NUM
dpc-1881	333	6	.	.	PUNCT
dpc-1881	334	1	doi:10.1016	doi:10.1016	PROPN
dpc-1881	334	2	/	/	SYM
dpc-1881	334	3	s1470	s1470	PROPN
dpc-1881	334	4	-	-	PUNCT
dpc-1881	334	5	2045(18)304972	2045(18)304972	PROPN
dpc-1881	334	6	.	.	PROPN
dpc-1881	335	1	19	19	NUM
dpc-1881	335	2	.	.	PUNCT
dpc-1881	335	3	callahan	callahan	PROPN
dpc-1881	335	4	mk	mk	PROPN
dpc-1881	335	5	,	,	PUNCT
dpc-1881	335	6	flaherty	flaherty	PROPN
dpc-1881	335	7	cr	cr	PROPN
dpc-1881	335	8	,	,	PUNCT
dpc-1881	335	9	postow	postow	PROPN
dpc-1881	335	10	ma	ma	PROPN
dpc-1881	335	11	.	.	PROPN
dpc-1881	335	12	checkpoint	checkpoint	NOUN
dpc-1881	335	13	blockade	blockade	NOUN
dpc-1881	335	14	for	for	ADP
dpc-1881	335	15	the	the	DET
dpc-1881	335	16	treatment	treatment	NOUN
dpc-1881	335	17	of	of	ADP
dpc-1881	335	18	advanced	advanced	ADJ
dpc-1881	335	19	melanoma	melanoma	NOUN
dpc-1881	335	20	.	.	PUNCT
dpc-1881	336	1	cancer	cancer	NOUN
dpc-1881	336	2	treat	treat	NOUN
dpc-1881	336	3	res	re	NOUN
dpc-1881	336	4	.	.	PUNCT
dpc-1881	336	5	2016	2016	NUM
dpc-1881	336	6	;	;	PUNCT
dpc-1881	336	7	167:231	167:231	NUM
dpc-1881	336	8	-	-	SYM
dpc-1881	336	9	50	50	NUM
dpc-1881	336	10	.	.	PUNCT
dpc-1881	337	1	doi	doi	NOUN
dpc-1881	337	2	:	:	PUNCT
dpc-1881	337	3	10.1007/978	10.1007/978	NUM
dpc-1881	337	4	-	-	SYM
dpc-1881	337	5	3	3	NUM
dpc-1881	337	6	-	-	NUM
dpc-1881	337	7	319	319	NUM
dpc-1881	337	8	-	-	PUNCT
dpc-1881	337	9	22539	22539	NUM
dpc-1881	337	10	-	-	PUNCT
dpc-1881	337	11	5_9	5_9	NUM
dpc-1881	337	12	.	.	PUNCT
dpc-1881	338	1	pmid	pmid	NOUN
dpc-1881	338	2	:	:	PUNCT
dpc-1881	338	3	26601865	26601865	NUM
dpc-1881	338	4	.	.	PUNCT
dpc-1881	339	1	20	20	NUM
dpc-1881	339	2	.	.	PUNCT
dpc-1881	340	1	hodi	hodi	PROPN
dpc-1881	340	2	fs	fs	PROPN
dpc-1881	340	3	,	,	PUNCT
dpc-1881	340	4	o’day	o’day	NOUN
dpc-1881	340	5	sj	sj	PROPN
dpc-1881	340	6	,	,	PUNCT
dpc-1881	340	7	mcdermott	mcdermott	PROPN
dpc-1881	340	8	df	df	PROPN
dpc-1881	340	9	,	,	PUNCT
dpc-1881	340	10	et	et	PROPN
dpc-1881	340	11	al	al	PROPN
dpc-1881	340	12	.	.	PROPN
dpc-1881	340	13	improved	improved	ADJ
dpc-1881	340	14	survival	survival	NOUN
dpc-1881	340	15	with	with	ADP
dpc-1881	340	16	ipilimumab	ipilimumab	NOUN
dpc-1881	340	17	in	in	ADP
dpc-1881	340	18	patients	patient	NOUN
dpc-1881	340	19	with	with	ADP
dpc-1881	340	20	metastatic	metastatic	ADJ
dpc-1881	340	21	melanoma	melanoma	NOUN
dpc-1881	340	22	.	.	PUNCT
dpc-1881	341	1	n	n	PRON
dpc-1881	341	2	engl	engl	PROPN
dpc-1881	341	3	j	j	PROPN
dpc-1881	341	4	med	med	PROPN
dpc-1881	341	5	.	.	PUNCT
dpc-1881	342	1	2010	2010	NUM
dpc-1881	342	2	;	;	PUNCT
dpc-1881	343	1	363:711–23	363:711–23	NUM
dpc-1881	343	2	.	.	PUNCT
dpc-1881	343	3	doi	doi	NOUN
dpc-1881	343	4	:	:	PUNCT
dpc-1881	343	5	10.1056	10.1056	NUM
dpc-1881	343	6	/	/	SYM
dpc-1881	343	7	nejmoa1003466	nejmoa1003466	NOUN
dpc-1881	343	8	.	.	PUNCT
dpc-1881	344	1	pmid	pmid	NOUN
dpc-1881	344	2	:	:	PUNCT
dpc-1881	344	3	20525992	20525992	NUM
dpc-1881	344	4	.	.	PUNCT
dpc-1881	345	1	21	21	NUM
dpc-1881	345	2	.	.	PUNCT
dpc-1881	346	1	robert	robert	PROPN
dpc-1881	346	2	c	c	PROPN
dpc-1881	346	3	,	,	PUNCT
dpc-1881	346	4	thomas	thomas	PROPN
dpc-1881	346	5	l	l	PROPN
dpc-1881	346	6	,	,	PUNCT
dpc-1881	346	7	bondarenko	bondarenko	PROPN
dpc-1881	346	8	i	i	PRON
dpc-1881	346	9	,	,	PUNCT
dpc-1881	346	10	et	et	PROPN
dpc-1881	346	11	al	al	PROPN
dpc-1881	346	12	.	.	PROPN
dpc-1881	346	13	ipilimumab	ipilimumab	PROPN
dpc-1881	346	14	plus	plus	CCONJ
dpc-1881	346	15	dacarbazine	dacarbazine	NOUN
dpc-1881	346	16	for	for	ADP
dpc-1881	346	17	previously	previously	ADV
dpc-1881	346	18	untreated	untreated	ADJ
dpc-1881	346	19	metastatic	metastatic	ADJ
dpc-1881	346	20	melanoma	melanoma	NOUN
dpc-1881	346	21	.	.	PUNCT
dpc-1881	347	1	n	n	PRON
dpc-1881	347	2	engl	engl	PROPN
dpc-1881	347	3	j	j	PROPN
dpc-1881	347	4	med	med	PROPN
dpc-1881	347	5	.	.	PUNCT
dpc-1881	348	1	2011	2011	NUM
dpc-1881	348	2	;	;	PUNCT
dpc-1881	348	3	364:2517–26	364:2517–26	NUM
dpc-1881	348	4	doi	doi	NOUN
dpc-1881	348	5	:	:	PUNCT
dpc-1881	348	6	10.1056	10.1056	NUM
dpc-1881	348	7	/	/	SYM
dpc-1881	348	8	nejmoa1104621	nejmoa1104621	PROPN
dpc-1881	348	9	.	.	PUNCT
dpc-1881	349	1	pmid	pmid	NOUN
dpc-1881	349	2	:	:	PUNCT
dpc-1881	349	3	21639810	21639810	NUM
dpc-1881	349	4	.	.	PUNCT
dpc-1881	350	1	22	22	NUM
dpc-1881	350	2	.	.	PUNCT
dpc-1881	351	1	schadendorf	schadendorf	PROPN
dpc-1881	351	2	d	d	PROPN
dpc-1881	351	3	,	,	PUNCT
dpc-1881	351	4	hodi	hodi	PROPN
dpc-1881	351	5	fs	fs	PROPN
dpc-1881	351	6	,	,	PUNCT
dpc-1881	351	7	robert	robert	PROPN
dpc-1881	351	8	c	c	PROPN
dpc-1881	351	9	,	,	PUNCT
dpc-1881	351	10	et	et	PROPN
dpc-1881	351	11	al	al	PROPN
dpc-1881	351	12	.	.	PROPN
dpc-1881	351	13	pooled	pool	VERB
dpc-1881	351	14	analysis	analysis	NOUN
dpc-1881	351	15	of	of	ADP
dpc-1881	351	16	long	long	ADJ
dpc-1881	351	17	-	-	PUNCT
dpc-1881	351	18	term	term	NOUN
dpc-1881	351	19	survival	survival	NOUN
dpc-1881	351	20	data	datum	NOUN
dpc-1881	351	21	from	from	ADP
dpc-1881	351	22	phase	phase	NOUN
dpc-1881	351	23	ii	ii	NOUN
dpc-1881	351	24	and	and	CCONJ
dpc-1881	351	25	phase	phase	NOUN
dpc-1881	351	26	iii	iii	NUM
dpc-1881	351	27	trials	trial	NOUN
dpc-1881	351	28	of	of	ADP
dpc-1881	351	29	ipilimumab	ipilimumab	NOUN
dpc-1881	351	30	in	in	ADP
dpc-1881	351	31	unresectable	unresectable	ADJ
dpc-1881	351	32	or	or	CCONJ
dpc-1881	351	33	metastatic	metastatic	ADJ
dpc-1881	351	34	melanoma	melanoma	NOUN
dpc-1881	351	35	.	.	PUNCT
dpc-1881	352	1	j	j	PROPN
dpc-1881	352	2	clin	clin	PROPN
dpc-1881	352	3	oncol	oncol	PROPN
dpc-1881	352	4	.	.	PUNCT
dpc-1881	353	1	2015	2015	NUM
dpc-1881	353	2	;	;	PUNCT
dpc-1881	354	1	33:1889–94	33:1889–94	NUM
dpc-1881	354	2	.	.	PUNCT
dpc-1881	355	1	doi	doi	NOUN
dpc-1881	355	2	:	:	PUNCT
dpc-1881	355	3	10.1200	10.1200	NUM
dpc-1881	355	4	/	/	SYM
dpc-1881	355	5	jco.2014.56.2736	jco.2014.56.2736	PROPN
dpc-1881	355	6	.	.	PUNCT
dpc-1881	356	1	pmid	pmid	NOUN
dpc-1881	356	2	:	:	PUNCT
dpc-1881	356	3	25667295	25667295	NUM
dpc-1881	356	4	.	.	PUNCT
dpc-1881	357	1	23	23	NUM
dpc-1881	357	2	.	.	PUNCT
dpc-1881	358	1	ascierto	ascierto	PROPN
dpc-1881	358	2	pa	pa	PROPN
dpc-1881	358	3	,	,	PUNCT
dpc-1881	358	4	simeone	simeone	PROPN
dpc-1881	358	5	e	e	PROPN
dpc-1881	358	6	,	,	PUNCT
dpc-1881	358	7	sileni	sileni	PROPN
dpc-1881	358	8	vc	vc	PROPN
dpc-1881	358	9	,	,	PUNCT
dpc-1881	358	10	et	et	PROPN
dpc-1881	358	11	al	al	PROPN
dpc-1881	358	12	.	.	PUNCT
dpc-1881	359	1	clinical	clinical	ADJ
dpc-1881	359	2	experience	experience	NOUN
dpc-1881	359	3	with	with	ADP
dpc-1881	359	4	ipilimumab	ipilimumab	NOUN
dpc-1881	359	5	3	3	NUM
dpc-1881	359	6	mg	mg	PROPN
dpc-1881	359	7	/	/	SYM
dpc-1881	359	8	kg	kg	PROPN
dpc-1881	359	9	:	:	PUNCT
dpc-1881	359	10	real	real	ADJ
dpc-1881	359	11	-	-	PUNCT
dpc-1881	359	12	world	world	NOUN
dpc-1881	359	13	efficacy	efficacy	NOUN
dpc-1881	359	14	and	and	CCONJ
dpc-1881	359	15	safety	safety	NOUN
dpc-1881	359	16	data	datum	NOUN
dpc-1881	359	17	from	from	ADP
dpc-1881	359	18	an	an	DET
dpc-1881	359	19	expanded	expand	VERB
dpc-1881	359	20	access	access	NOUN
dpc-1881	359	21	program	program	NOUN
dpc-1881	359	22	cohort	cohort	NOUN
dpc-1881	359	23	.	.	PUNCT
dpc-1881	360	1	j	j	PROPN
dpc-1881	360	2	transl	transl	PROPN
dpc-1881	360	3	med	med	PROPN
dpc-1881	360	4	.	.	PROPN
dpc-1881	360	5	2014	2014	NUM
dpc-1881	360	6	;	;	PUNCT
dpc-1881	360	7	12:116	12:116	NUM
dpc-1881	360	8	.	.	PUNCT
dpc-1881	361	1	doi	doi	NOUN
dpc-1881	361	2	:	:	PUNCT
dpc-1881	361	3	10.1186/1479	10.1186/1479	NUM
dpc-1881	361	4	-	-	SYM
dpc-1881	361	5	5876	5876	NUM
dpc-1881	361	6	-	-	SYM
dpc-1881	361	7	12	12	NUM
dpc-1881	361	8	-	-	PUNCT
dpc-1881	361	9	116	116	NUM
dpc-1881	361	10	.	.	PUNCT
dpc-1881	362	1	pmid	pmid	NOUN
dpc-1881	362	2	:	:	PUNCT
dpc-1881	362	3	24885479	24885479	NUM
dpc-1881	362	4	.	.	PUNCT
dpc-1881	363	1	24	24	NUM
dpc-1881	363	2	.	.	PUNCT
dpc-1881	364	1	queirolo	queirolo	PROPN
dpc-1881	364	2	p	p	X
dpc-1881	364	3	,	,	PUNCT
dpc-1881	364	4	boutros	boutros	PROPN
dpc-1881	364	5	a	a	PRON
dpc-1881	364	6	,	,	PUNCT
dpc-1881	364	7	tanda	tanda	PROPN
dpc-1881	364	8	e	e	PROPN
dpc-1881	364	9	,	,	PUNCT
dpc-1881	364	10	spagnolo	spagnolo	PROPN
dpc-1881	364	11	f	f	PROPN
dpc-1881	364	12	,	,	PUNCT
dpc-1881	364	13	quaglino	quaglino	PROPN
dpc-1881	364	14	p.	p.	NOUN
dpc-1881	364	15	immune	immune	NOUN
dpc-1881	364	16	-	-	PUNCT
dpc-1881	364	17	checkpoint	checkpoint	NOUN
dpc-1881	364	18	inhibitors	inhibitor	NOUN
dpc-1881	364	19	for	for	ADP
dpc-1881	364	20	the	the	DET
dpc-1881	364	21	treatment	treatment	NOUN
dpc-1881	364	22	of	of	ADP
dpc-1881	364	23	metastatic	metastatic	ADJ
dpc-1881	364	24	melanoma	melanoma	NOUN
dpc-1881	364	25	:	:	PUNCT
dpc-1881	364	26	a	a	DET
dpc-1881	364	27	model	model	NOUN
dpc-1881	364	28	of	of	ADP
dpc-1881	364	29	cancer	cancer	NOUN
dpc-1881	364	30	immunotherapy	immunotherapy	NOUN
dpc-1881	364	31	.	.	PUNCT
dpc-1881	365	1	semin	semin	PROPN
dpc-1881	365	2	cancer	cancer	PROPN
dpc-1881	365	3	biol	biol	PROPN
dpc-1881	365	4	.	.	PUNCT
dpc-1881	366	1	2019	2019	NUM
dpc-1881	366	2	;	;	PUNCT
dpc-1881	366	3	59:290	59:290	NUM
dpc-1881	366	4	-	-	SYM
dpc-1881	366	5	297	297	NUM
dpc-1881	366	6	.	.	PUNCT
dpc-1881	366	7	doi:10.1016	doi:10.1016	PROPN
dpc-1881	366	8	/	/	SYM
dpc-1881	366	9	j.semcancer.2019.08.001	j.semcancer.2019.08.001	PROPN
dpc-1881	366	10	.	.	PUNCT
dpc-1881	367	1	pmid	pmid	NOUN
dpc-1881	367	2	:	:	PUNCT
dpc-1881	367	3	31430555	31430555	NUM
dpc-1881	367	4	.	.	PUNCT
dpc-1881	368	1	25	25	NUM
dpc-1881	368	2	.	.	PUNCT
dpc-1881	369	1	robert	robert	PROPN
dpc-1881	369	2	c	c	PROPN
dpc-1881	369	3	,	,	PUNCT
dpc-1881	369	4	long	long	ADV
dpc-1881	369	5	gv	gv	ADP
dpc-1881	369	6	,	,	PUNCT
dpc-1881	369	7	brady	brady	PROPN
dpc-1881	369	8	b	b	PROPN
dpc-1881	369	9	,	,	PUNCT
dpc-1881	369	10	et	et	PROPN
dpc-1881	369	11	al	al	PROPN
dpc-1881	369	12	.	.	PROPN
dpc-1881	369	13	nivolumab	nivolumab	NOUN
dpc-1881	369	14	in	in	ADP
dpc-1881	369	15	previously	previously	ADV
dpc-1881	369	16	untreated	untreated	ADJ
dpc-1881	369	17	melanoma	melanoma	NOUN
dpc-1881	369	18	without	without	ADP
dpc-1881	369	19	braf	braf	NOUN
dpc-1881	369	20	mutation	mutation	NOUN
dpc-1881	369	21	.	.	PUNCT
dpc-1881	370	1	n	n	PROPN
dpc-1881	370	2	engl	engl	PROPN
dpc-1881	370	3	j	j	PROPN
dpc-1881	370	4	med	med	PROPN
dpc-1881	370	5	.	.	PUNCT
dpc-1881	370	6	2014	2014	NUM
dpc-1881	370	7	;	;	PUNCT
dpc-1881	370	8	372:320–30	372:320–30	NUM
dpc-1881	370	9	.	.	PUNCT
dpc-1881	371	1	doi	doi	NOUN
dpc-1881	371	2	:	:	PUNCT
dpc-1881	371	3	10.1056	10.1056	NUM
dpc-1881	371	4	/	/	SYM
dpc-1881	371	5	nejmoa1412082	nejmoa1412082	PROPN
dpc-1881	371	6	.	.	PUNCT
dpc-1881	372	1	pmid	pmid	NOUN
dpc-1881	372	2	:	:	PUNCT
dpc-1881	372	3	25399552	25399552	NUM
dpc-1881	372	4	.	.	PUNCT
dpc-1881	373	1	26	26	NUM
dpc-1881	373	2	.	.	PUNCT
dpc-1881	374	1	robert	robert	PROPN
dpc-1881	374	2	c	c	PROPN
dpc-1881	374	3	,	,	PUNCT
dpc-1881	374	4	long	long	ADV
dpc-1881	374	5	gv	gv	ADP
dpc-1881	374	6	,	,	PUNCT
dpc-1881	374	7	brady	brady	PROPN
dpc-1881	374	8	b	b	PROPN
dpc-1881	374	9	,	,	PUNCT
dpc-1881	374	10	et	et	PROPN
dpc-1881	374	11	al	al	PROPN
dpc-1881	374	12	.	.	PROPN
dpc-1881	374	13	five	five	NUM
dpc-1881	374	14	-	-	PUNCT
dpc-1881	374	15	year	year	NOUN
dpc-1881	374	16	outcomes	outcome	NOUN
dpc-1881	374	17	with	with	ADP
dpc-1881	374	18	nivolumab	nivolumab	NOUN
dpc-1881	374	19	in	in	ADP
dpc-1881	374	20	patients	patient	NOUN
dpc-1881	374	21	with	with	ADP
dpc-1881	374	22	wild	wild	ADJ
dpc-1881	374	23	-	-	PUNCT
dpc-1881	374	24	type	type	NOUN
dpc-1881	374	25	braf	braf	NOUN
dpc-1881	374	26	advanced	advanced	ADJ
dpc-1881	374	27	melanoma	melanoma	NOUN
dpc-1881	374	28	.	.	PUNCT
dpc-1881	375	1	j	j	PROPN
dpc-1881	375	2	clin	clin	PROPN
dpc-1881	375	3	oncol	oncol	PROPN
dpc-1881	375	4	.	.	PUNCT
dpc-1881	376	1	2020	2020	NUM
dpc-1881	376	2	;	;	PUNCT
dpc-1881	376	3	38(33):3937	38(33):3937	NUM
dpc-1881	376	4	-	-	SYM
dpc-1881	376	5	3946	3946	NUM
dpc-1881	376	6	.	.	PUNCT
dpc-1881	377	1	doi	doi	NOUN
dpc-1881	377	2	:	:	PUNCT
dpc-1881	377	3	10.1200/	10.1200/	NUM
dpc-1881	377	4	jco.20.00995	jco.20.00995	PROPN
dpc-1881	377	5	.	.	PUNCT
dpc-1881	378	1	pmid	pmid	NOUN
dpc-1881	378	2	:	:	PUNCT
dpc-1881	378	3	32997575	32997575	NUM
dpc-1881	378	4	.	.	PUNCT
dpc-1881	379	1	27	27	NUM
dpc-1881	379	2	.	.	PUNCT
dpc-1881	380	1	weber	weber	PROPN
dpc-1881	380	2	j	j	PROPN
dpc-1881	380	3	,	,	PUNCT
dpc-1881	380	4	d’angelo	d’angelo	PROPN
dpc-1881	380	5	sp	sp	NOUN
dpc-1881	380	6	,	,	PUNCT
dpc-1881	380	7	minor	minor	ADJ
dpc-1881	380	8	d	d	NOUN
dpc-1881	380	9	,	,	PUNCT
dpc-1881	380	10	et	et	PROPN
dpc-1881	380	11	al	al	PROPN
dpc-1881	380	12	.	.	PROPN
dpc-1881	380	13	nivolumab	nivolumab	X
dpc-1881	380	14	versus	versus	ADP
dpc-1881	380	15	chemotherapy	chemotherapy	NOUN
dpc-1881	380	16	in	in	ADP
dpc-1881	380	17	patients	patient	NOUN
dpc-1881	380	18	with	with	ADP
dpc-1881	380	19	advanced	advanced	ADJ
dpc-1881	380	20	melanoma	melanoma	NOUN
dpc-1881	380	21	who	who	PRON
dpc-1881	380	22	progressed	progress	VERB
dpc-1881	380	23	after	after	ADP
dpc-1881	380	24	anti	anti	ADJ
dpc-1881	380	25	-	-	ADJ
dpc-1881	380	26	ctla-4	ctla-4	NOUN
dpc-1881	380	27	treatment	treatment	NOUN
dpc-1881	380	28	(	(	PUNCT
dpc-1881	380	29	checkmate	checkmate	NOUN
dpc-1881	380	30	037	037	NUM
dpc-1881	380	31	):	):	PUNCT
dpc-1881	380	32	a	a	DET
dpc-1881	380	33	randomised	randomise	VERB
dpc-1881	380	34	,	,	PUNCT
dpc-1881	380	35	controlled	control	VERB
dpc-1881	380	36	,	,	PUNCT
dpc-1881	380	37	open	open	ADJ
dpc-1881	380	38	-	-	PUNCT
dpc-1881	380	39	label	label	NOUN
dpc-1881	380	40	,	,	PUNCT
dpc-1881	380	41	phase	phase	NOUN
dpc-1881	380	42	3	3	NUM
dpc-1881	380	43	trial	trial	NOUN
dpc-1881	380	44	.	.	PUNCT
dpc-1881	381	1	lancet	lancet	PROPN
dpc-1881	381	2	oncol	oncol	PROPN
dpc-1881	381	3	.	.	PUNCT
dpc-1881	382	1	2015	2015	NUM
dpc-1881	382	2	;	;	PUNCT
dpc-1881	382	3	16:375	16:375	NUM
dpc-1881	382	4	–	–	PUNCT
dpc-1881	382	5	84	84	NUM
dpc-1881	382	6	.	.	PUNCT
dpc-1881	383	1	doi	doi	NOUN
dpc-1881	383	2	:	:	PUNCT
dpc-1881	383	3	10.1016	10.1016	NUM
dpc-1881	383	4	/	/	SYM
dpc-1881	383	5	s1470	s1470	PROPN
dpc-1881	383	6	-	-	PUNCT
dpc-1881	383	7	2045(15)70076	2045(15)70076	NUM
dpc-1881	383	8	-	-	PUNCT
dpc-1881	383	9	8	8	NUM
dpc-1881	383	10	.	.	NOUN
dpc-1881	383	11	28	28	NUM
dpc-1881	383	12	.	.	PUNCT
dpc-1881	384	1	larkin	larkin	PROPN
dpc-1881	384	2	j	j	PROPN
dpc-1881	384	3	,	,	PUNCT
dpc-1881	384	4	minor	minor	ADJ
dpc-1881	384	5	d	d	PROPN
dpc-1881	384	6	,	,	PUNCT
dpc-1881	384	7	d’angelo	d’angelo	PROPN
dpc-1881	384	8	s	s	PART
dpc-1881	384	9	,	,	PUNCT
dpc-1881	384	10	et	et	PROPN
dpc-1881	384	11	al	al	PROPN
dpc-1881	384	12	.	.	PUNCT
dpc-1881	385	1	overall	overall	ADJ
dpc-1881	385	2	survival	survival	NOUN
dpc-1881	385	3	in	in	ADP
dpc-1881	385	4	patients	patient	NOUN
dpc-1881	385	5	with	with	ADP
dpc-1881	385	6	advanced	advanced	ADJ
dpc-1881	385	7	melanoma	melanoma	NOUN
dpc-1881	385	8	who	who	PRON
dpc-1881	385	9	received	receive	VERB
dpc-1881	385	10	nivolumab	nivolumab	NOUN
dpc-1881	385	11	versus	versus	ADP
dpc-1881	385	12	investigator	investigator	NOUN
dpc-1881	385	13	’s	’s	PART
dpc-1881	385	14	choice	choice	NOUN
dpc-1881	385	15	chemotherapy	chemotherapy	NOUN
dpc-1881	385	16	in	in	ADP
dpc-1881	385	17	checkmate	checkmate	NOUN
dpc-1881	385	18	037	037	NUM
dpc-1881	385	19	:	:	PUNCT
dpc-1881	385	20	a	a	DET
dpc-1881	385	21	randomized	randomized	ADJ
dpc-1881	385	22	,	,	PUNCT
dpc-1881	385	23	controlled	control	VERB
dpc-1881	385	24	,	,	PUNCT
dpc-1881	385	25	open	open	ADJ
dpc-1881	385	26	-	-	PUNCT
dpc-1881	385	27	label	label	NOUN
dpc-1881	385	28	phase	phase	NOUN
dpc-1881	385	29	iii	iii	NOUN
dpc-1881	385	30	trial	trial	NOUN
dpc-1881	385	31	.	.	PUNCT
dpc-1881	386	1	j	j	PROPN
dpc-1881	386	2	clin	clin	PROPN
dpc-1881	386	3	oncol	oncol	PROPN
dpc-1881	386	4	.	.	PUNCT
dpc-1881	387	1	2018	2018	NUM
dpc-1881	387	2	;	;	PUNCT
dpc-1881	387	3	36(4):383	36(4):383	NUM
dpc-1881	387	4	-	-	SYM
dpc-1881	387	5	390	390	NUM
dpc-1881	387	6	.	.	PUNCT
dpc-1881	388	1	doi	doi	NOUN
dpc-1881	388	2	:	:	PUNCT
dpc-1881	388	3	10.1200	10.1200	NUM
dpc-1881	388	4	/	/	SYM
dpc-1881	388	5	jco.2016.71.8023	jco.2016.71.8023	PROPN
dpc-1881	388	6	.	.	PUNCT
dpc-1881	389	1	pmid	pmid	NOUN
dpc-1881	389	2	:	:	PUNCT
dpc-1881	389	3	28671856	28671856	NUM
dpc-1881	389	4	.	.	PUNCT
dpc-1881	390	1	29	29	NUM
dpc-1881	390	2	.	.	PUNCT
dpc-1881	391	1	robert	robert	PROPN
dpc-1881	391	2	c	c	PROPN
dpc-1881	391	3	,	,	PUNCT
dpc-1881	391	4	schachter	schachter	PROPN
dpc-1881	391	5	j	j	PROPN
dpc-1881	391	6	,	,	PUNCT
dpc-1881	391	7	long	long	ADV
dpc-1881	391	8	gv	gv	ADP
dpc-1881	391	9	,	,	PUNCT
dpc-1881	391	10	et	et	PROPN
dpc-1881	391	11	al	al	PROPN
dpc-1881	391	12	.	.	PROPN
dpc-1881	391	13	pembrolizumab	pembrolizumab	NOUN
dpc-1881	391	14	versus	versus	ADP
dpc-1881	391	15	ipilimumab	ipilimumab	NOUN
dpc-1881	391	16	in	in	ADP
dpc-1881	391	17	advanced	advanced	ADJ
dpc-1881	391	18	melanoma	melanoma	NOUN
dpc-1881	391	19	.	.	PUNCT
dpc-1881	392	1	n	n	PRON
dpc-1881	392	2	engl	engl	PROPN
dpc-1881	392	3	j	j	PROPN
dpc-1881	392	4	med	med	PROPN
dpc-1881	392	5	.	.	PROPN
dpc-1881	392	6	2015	2015	NUM
dpc-1881	392	7	;	;	PUNCT
dpc-1881	392	8	372:2521	372:2521	NUM
dpc-1881	392	9	–	–	PUNCT
dpc-1881	392	10	32	32	NUM
dpc-1881	392	11	.	.	PUNCT
dpc-1881	393	1	doi	doi	NOUN
dpc-1881	393	2	:	:	PUNCT
dpc-1881	393	3	10.1056	10.1056	NUM
dpc-1881	393	4	/	/	SYM
dpc-1881	393	5	nejmoa1503093	nejmoa1503093	PROPN
dpc-1881	393	6	.	.	PUNCT
dpc-1881	394	1	pmid	pmid	NOUN
dpc-1881	394	2	:	:	PUNCT
dpc-1881	394	3	25891173	25891173	NUM
dpc-1881	394	4	.	.	PUNCT
dpc-1881	395	1	30	30	NUM
dpc-1881	395	2	.	.	PUNCT
dpc-1881	396	1	robert	robert	PROPN
dpc-1881	396	2	c	c	PROPN
dpc-1881	396	3	,	,	PUNCT
dpc-1881	396	4	ribas	ribas	PROPN
dpc-1881	396	5	a	a	PRON
dpc-1881	396	6	,	,	PUNCT
dpc-1881	396	7	schachter	schachter	NOUN
dpc-1881	396	8	j	j	PROPN
dpc-1881	396	9	,	,	PUNCT
dpc-1881	396	10	et	et	PROPN
dpc-1881	396	11	al	al	PROPN
dpc-1881	396	12	.	.	PROPN
dpc-1881	396	13	pembrolizumab	pembrolizumab	NOUN
dpc-1881	396	14	versus	versus	ADP
dpc-1881	396	15	ipilimumab	ipilimumab	NOUN
dpc-1881	396	16	in	in	ADP
dpc-1881	396	17	advanced	advanced	ADJ
dpc-1881	396	18	melanoma	melanoma	NOUN
dpc-1881	396	19	(	(	PUNCT
dpc-1881	396	20	keynote-006	keynote-006	ADJ
dpc-1881	396	21	):	):	PUNCT
dpc-1881	396	22	post	post	ADJ
dpc-1881	396	23	-	-	ADJ
dpc-1881	396	24	hoc	hoc	ADJ
dpc-1881	396	25	5	5	NUM
dpc-1881	396	26	-	-	PUNCT
dpc-1881	396	27	year	year	NOUN
dpc-1881	396	28	results	result	NOUN
dpc-1881	396	29	from	from	ADP
dpc-1881	396	30	an	an	DET
dpc-1881	396	31	open	open	ADJ
dpc-1881	396	32	-	-	PUNCT
dpc-1881	396	33	label	label	NOUN
dpc-1881	396	34	,	,	PUNCT
dpc-1881	396	35	multicentre	multicentre	NOUN
dpc-1881	396	36	,	,	PUNCT
dpc-1881	396	37	randomised	randomise	VERB
dpc-1881	396	38	,	,	PUNCT
dpc-1881	396	39	controlled	control	VERB
dpc-1881	396	40	,	,	PUNCT
dpc-1881	396	41	phase	phase	NOUN
dpc-1881	396	42	3	3	NUM
dpc-1881	396	43	study	study	NOUN
dpc-1881	396	44	.	.	PUNCT
dpc-1881	397	1	lancet	lancet	PROPN
dpc-1881	397	2	oncol	oncol	PROPN
dpc-1881	397	3	.	.	PUNCT
dpc-1881	398	1	2019;20(9):1239	2019;20(9):1239	NUM
dpc-1881	398	2	-	-	PUNCT
dpc-1881	398	3	1251	1251	NUM
dpc-1881	398	4	.	.	PUNCT
dpc-1881	399	1	doi	doi	NOUN
dpc-1881	399	2	:	:	PUNCT
dpc-1881	399	3	10.1016	10.1016	NUM
dpc-1881	399	4	/	/	SYM
dpc-1881	399	5	s1470	s1470	PROPN
dpc-1881	399	6	-	-	PUNCT
dpc-1881	399	7	2045(19)30388	2045(19)30388	NUM
dpc-1881	399	8	-	-	PUNCT
dpc-1881	399	9	2	2	NUM
dpc-1881	399	10	.	.	NOUN
dpc-1881	399	11	31	31	NUM
dpc-1881	399	12	.	.	PUNCT
dpc-1881	400	1	ribas	ribas	PROPN
dpc-1881	400	2	a	a	PRON
dpc-1881	400	3	,	,	PUNCT
dpc-1881	400	4	puzanov	puzanov	NOUN
dpc-1881	400	5	i	i	PROPN
dpc-1881	400	6	,	,	PUNCT
dpc-1881	400	7	dummer	dummer	PROPN
dpc-1881	400	8	r	r	PROPN
dpc-1881	400	9	,	,	PUNCT
dpc-1881	400	10	et	et	PROPN
dpc-1881	400	11	al	al	PROPN
dpc-1881	400	12	.	.	PROPN
dpc-1881	400	13	pembrolizumab	pembrolizumab	NOUN
dpc-1881	400	14	versus	versus	ADP
dpc-1881	400	15	investigator	investigator	NOUN
dpc-1881	400	16	-	-	PUNCT
dpc-1881	400	17	choice	choice	NOUN
dpc-1881	400	18	chemotherapy	chemotherapy	NOUN
dpc-1881	400	19	for	for	ADP
dpc-1881	400	20	ipilimumab	ipilimumab	ADJ
dpc-1881	400	21	-	-	PUNCT
dpc-1881	400	22	refractory	refractory	NOUN
dpc-1881	400	23	melanoma	melanoma	NOUN
dpc-1881	400	24	(	(	PUNCT
dpc-1881	400	25	keynote-002	keynote-002	PROPN
dpc-1881	400	26	):	):	PUNCT
dpc-1881	400	27	a	a	DET
dpc-1881	400	28	randomised	randomise	VERB
dpc-1881	400	29	,	,	PUNCT
dpc-1881	400	30	controlled	control	VERB
dpc-1881	400	31	,	,	PUNCT
dpc-1881	400	32	phase	phase	NOUN
dpc-1881	400	33	2	2	NUM
dpc-1881	400	34	trial	trial	NOUN
dpc-1881	400	35	.	.	PUNCT
dpc-1881	401	1	lancet	lancet	PROPN
dpc-1881	401	2	oncol	oncol	PROPN
dpc-1881	401	3	.	.	PUNCT
dpc-1881	402	1	2015	2015	NUM
dpc-1881	402	2	;	;	PUNCT
dpc-1881	403	1	16:908–18	16:908–18	NUM
dpc-1881	403	2	.	.	PUNCT
dpc-1881	404	1	doi	doi	NOUN
dpc-1881	404	2	:	:	PUNCT
dpc-1881	404	3	10.1016	10.1016	NUM
dpc-1881	404	4	/	/	SYM
dpc-1881	404	5	s14702045(15)00083	s14702045(15)00083	PROPN
dpc-1881	404	6	-	-	PUNCT
dpc-1881	404	7	2	2	NUM
dpc-1881	404	8	.	.	NUM
dpc-1881	404	9	32	32	NUM
dpc-1881	404	10	.	.	PUNCT
dpc-1881	405	1	hamid	hamid	PROPN
dpc-1881	405	2	o	o	PROPN
dpc-1881	405	3	,	,	PUNCT
dpc-1881	405	4	puzanov	puzanov	PROPN
dpc-1881	405	5	i	i	PROPN
dpc-1881	405	6	,	,	PUNCT
dpc-1881	405	7	dummer	dummer	PROPN
dpc-1881	405	8	r	r	PROPN
dpc-1881	405	9	,	,	PUNCT
dpc-1881	405	10	et	et	PROPN
dpc-1881	405	11	al	al	PROPN
dpc-1881	405	12	.	.	PROPN
dpc-1881	405	13	final	final	ADJ
dpc-1881	405	14	analysis	analysis	NOUN
dpc-1881	405	15	of	of	ADP
dpc-1881	405	16	a	a	DET
dpc-1881	405	17	randomised	randomised	ADJ
dpc-1881	405	18	trial	trial	NOUN
dpc-1881	405	19	comparing	compare	VERB
dpc-1881	405	20	pembrolizumab	pembrolizumab	NOUN
dpc-1881	405	21	versus	versus	ADP
dpc-1881	405	22	investigator	investigator	NOUN
dpc-1881	405	23	-	-	PUNCT
dpc-1881	405	24	choice	choice	NOUN
dpc-1881	405	25	chemotherapy	chemotherapy	NOUN
dpc-1881	405	26	for	for	ADP
dpc-1881	405	27	ipilimumab	ipilimumab	ADJ
dpc-1881	405	28	-	-	PUNCT
dpc-1881	405	29	refractory	refractory	NOUN
dpc-1881	405	30	advanced	advanced	ADJ
dpc-1881	405	31	melanoma	melanoma	NOUN
dpc-1881	405	32	.	.	PUNCT
dpc-1881	406	1	eur	eur	PROPN
dpc-1881	406	2	j	j	PROPN
dpc-1881	406	3	cancer	cancer	NOUN
dpc-1881	406	4	.	.	PUNCT
dpc-1881	407	1	2017	2017	NUM
dpc-1881	407	2	;	;	PUNCT
dpc-1881	407	3	86:37	86:37	NUM
dpc-1881	407	4	-	-	SYM
dpc-1881	407	5	45	45	NUM
dpc-1881	407	6	.	.	PUNCT
dpc-1881	407	7	doi	doi	PROPN
dpc-1881	407	8	.	.	PUNCT
dpc-1881	408	1	10.1016	10.1016	NUM
dpc-1881	408	2	/	/	SYM
dpc-1881	408	3	j.	j.	PROPN
dpc-1881	408	4	ejca.2017.07.022	ejca.2017.07.022	PROPN
dpc-1881	408	5	.	.	PUNCT
dpc-1881	409	1	pmid	pmid	NOUN
dpc-1881	409	2	:	:	PUNCT
dpc-1881	409	3	28961465	28961465	NUM
dpc-1881	409	4	.	.	PUNCT
dpc-1881	410	1	33	33	NUM
dpc-1881	410	2	.	.	PUNCT
dpc-1881	411	1	hodi	hodi	PROPN
dpc-1881	411	2	fs	fs	PROPN
dpc-1881	411	3	,	,	PUNCT
dpc-1881	411	4	chesney	chesney	PROPN
dpc-1881	411	5	j	j	PROPN
dpc-1881	411	6	,	,	PUNCT
dpc-1881	411	7	pavlick	pavlick	PROPN
dpc-1881	411	8	ac	ac	PROPN
dpc-1881	411	9	,	,	PUNCT
dpc-1881	411	10	et	et	PROPN
dpc-1881	411	11	al	al	PROPN
dpc-1881	411	12	.	.	PROPN
dpc-1881	411	13	combined	combine	VERB
dpc-1881	411	14	nivolumab	nivolumab	NOUN
dpc-1881	411	15	and	and	CCONJ
dpc-1881	411	16	ipilimumab	ipilimumab	VERB
dpc-1881	411	17	versus	versus	ADP
dpc-1881	411	18	ipilimumab	ipilimumab	NOUN
dpc-1881	411	19	alone	alone	ADV
dpc-1881	411	20	in	in	ADP
dpc-1881	411	21	patients	patient	NOUN
dpc-1881	411	22	with	with	ADP
dpc-1881	411	23	advanced	advanced	ADJ
dpc-1881	411	24	melanoma	melanoma	NOUN
dpc-1881	411	25	:	:	PUNCT
dpc-1881	411	26	2	2	NUM
dpc-1881	411	27	-	-	PUNCT
dpc-1881	411	28	year	year	NOUN
dpc-1881	411	29	overall	overall	ADJ
dpc-1881	411	30	survival	survival	NOUN
dpc-1881	411	31	outcomes	outcome	NOUN
dpc-1881	411	32	in	in	ADP
dpc-1881	411	33	a	a	DET
dpc-1881	411	34	multicentre	multicentre	NOUN
dpc-1881	411	35	,	,	PUNCT
dpc-1881	411	36	randomised	randomise	VERB
dpc-1881	411	37	,	,	PUNCT
dpc-1881	411	38	controlled	control	VERB
dpc-1881	411	39	,	,	PUNCT
dpc-1881	411	40	phase	phase	NOUN
dpc-1881	411	41	2	2	NUM
dpc-1881	411	42	trial	trial	NOUN
dpc-1881	411	43	.	.	PUNCT
dpc-1881	412	1	lancet	lancet	PROPN
dpc-1881	412	2	oncol	oncol	PROPN
dpc-1881	412	3	.	.	PUNCT
dpc-1881	413	1	2016	2016	NUM
dpc-1881	413	2	;	;	PUNCT
dpc-1881	413	3	17(11):1558	17(11):1558	NUM
dpc-1881	413	4	-	-	SYM
dpc-1881	413	5	1568	1568	NUM
dpc-1881	413	6	.	.	PUNCT
dpc-1881	414	1	doi	doi	NOUN
dpc-1881	414	2	:	:	PUNCT
dpc-1881	414	3	10.1016	10.1016	NUM
dpc-1881	414	4	/	/	SYM
dpc-1881	414	5	s1470	s1470	PROPN
dpc-1881	414	6	-	-	PUNCT
dpc-1881	414	7	2045(16)30366	2045(16)30366	PROPN
dpc-1881	414	8	-	-	PUNCT
dpc-1881	414	9	7	7	NUM
dpc-1881	414	10	.	.	NOUN
dpc-1881	414	11	34	34	NUM
dpc-1881	414	12	.	.	PUNCT
dpc-1881	415	1	postow	postow	PROPN
dpc-1881	415	2	ma	ma	PROPN
dpc-1881	415	3	,	,	PUNCT
dpc-1881	415	4	chesney	chesney	PROPN
dpc-1881	415	5	j	j	PROPN
dpc-1881	415	6	,	,	PUNCT
dpc-1881	415	7	pavlick	pavlick	PROPN
dpc-1881	415	8	ac	ac	PROPN
dpc-1881	415	9	,	,	PUNCT
dpc-1881	415	10	et	et	PROPN
dpc-1881	415	11	al	al	PROPN
dpc-1881	415	12	.	.	PROPN
dpc-1881	415	13	nivolumab	nivolumab	NOUN
dpc-1881	415	14	and	and	CCONJ
dpc-1881	415	15	ipilimumab	ipilimumab	VERB
dpc-1881	415	16	versus	versus	ADP
dpc-1881	415	17	ipilimumab	ipilimumab	NOUN
dpc-1881	415	18	in	in	ADP
dpc-1881	415	19	untreated	untreated	ADJ
dpc-1881	415	20	melanoma	melanoma	NOUN
dpc-1881	415	21	.	.	PUNCT
dpc-1881	416	1	n	n	PRON
dpc-1881	416	2	engl	engl	PROPN
dpc-1881	416	3	j	j	PROPN
dpc-1881	416	4	med	med	PROPN
dpc-1881	416	5	.	.	PROPN
dpc-1881	416	6	2015	2015	NUM
dpc-1881	416	7	;	;	PUNCT
dpc-1881	417	1	372(21):2006	372(21):2006	PROPN
dpc-1881	417	2	-	-	SYM
dpc-1881	417	3	17	17	NUM
dpc-1881	417	4	.	.	PUNCT
dpc-1881	418	1	doi	doi	NOUN
dpc-1881	418	2	:	:	PUNCT
dpc-1881	418	3	10.1056	10.1056	NUM
dpc-1881	418	4	/	/	SYM
dpc-1881	418	5	nejmoa1414428	nejmoa1414428	PROPN
dpc-1881	418	6	.	.	PUNCT
dpc-1881	419	1	pmid	pmid	NOUN
dpc-1881	419	2	:	:	PUNCT
dpc-1881	419	3	25891304	25891304	NUM
dpc-1881	419	4	.	.	PUNCT
dpc-1881	420	1	35	35	NUM
dpc-1881	420	2	.	.	PUNCT
dpc-1881	421	1	larkin	larkin	PROPN
dpc-1881	421	2	j	j	PROPN
dpc-1881	421	3	,	,	PUNCT
dpc-1881	421	4	chiarion	chiarion	NOUN
dpc-1881	421	5	-	-	PUNCT
dpc-1881	421	6	sileni	sileni	NOUN
dpc-1881	421	7	v	v	NOUN
dpc-1881	421	8	,	,	PUNCT
dpc-1881	421	9	gonzalez	gonzalez	PROPN
dpc-1881	421	10	r	r	PROPN
dpc-1881	421	11	,	,	PUNCT
dpc-1881	421	12	et	et	PROPN
dpc-1881	421	13	al	al	PROPN
dpc-1881	421	14	.	.	PROPN
dpc-1881	422	1	five	five	NUM
dpc-1881	422	2	-	-	PUNCT
dpc-1881	422	3	year	year	NOUN
dpc-1881	422	4	survival	survival	NOUN
dpc-1881	422	5	with	with	ADP
dpc-1881	422	6	combined	combined	ADJ
dpc-1881	422	7	nivolumab	nivolumab	NOUN
dpc-1881	422	8	and	and	CCONJ
dpc-1881	422	9	ipilimumab	ipilimumab	VERB
dpc-1881	422	10	in	in	ADP
dpc-1881	422	11	advanced	advanced	ADJ
dpc-1881	422	12	melanoma	melanoma	NOUN
dpc-1881	422	13	.	.	PUNCT
dpc-1881	423	1	n	n	PRON
dpc-1881	423	2	engl	engl	PROPN
dpc-1881	423	3	j	j	PROPN
dpc-1881	423	4	med	med	PROPN
dpc-1881	423	5	.	.	PROPN
dpc-1881	423	6	2019	2019	NUM
dpc-1881	423	7	;	;	PUNCT
dpc-1881	423	8	381(16):1535	381(16):1535	NUM
dpc-1881	423	9	-	-	SYM
dpc-1881	423	10	1546	1546	NUM
dpc-1881	423	11	.	.	PUNCT
dpc-1881	424	1	doi	doi	NOUN
dpc-1881	424	2	:	:	PUNCT
dpc-1881	424	3	10.1056/	10.1056/	NUM
dpc-1881	424	4	nejmoa1910836	nejmoa1910836	NOUN
dpc-1881	424	5	.	.	PUNCT
dpc-1881	425	1	pmid	pmid	NOUN
dpc-1881	425	2	:	:	PUNCT
dpc-1881	425	3	31562797	31562797	NUM
dpc-1881	425	4	.	.	PUNCT
dpc-1881	426	1	36	36	NUM
dpc-1881	426	2	.	.	X
dpc-1881	426	3	mcdermott	mcdermott	PROPN
dpc-1881	426	4	df	df	PROPN
dpc-1881	426	5	,	,	PUNCT
dpc-1881	426	6	shah	shah	PROPN
dpc-1881	426	7	r	r	NOUN
dpc-1881	426	8	,	,	PUNCT
dpc-1881	426	9	gupte	gupte	NOUN
dpc-1881	426	10	-	-	PUNCT
dpc-1881	426	11	singh	singh	PROPN
dpc-1881	426	12	k	k	PROPN
dpc-1881	426	13	,	,	PUNCT
dpc-1881	426	14	et	et	PROPN
dpc-1881	426	15	al	al	PROPN
dpc-1881	426	16	.	.	PUNCT
dpc-1881	427	1	quality	quality	NOUN
dpc-1881	427	2	-	-	PUNCT
dpc-1881	427	3	adjusted	adjust	VERB
dpc-1881	427	4	survival	survival	NOUN
dpc-1881	427	5	of	of	ADP
dpc-1881	427	6	nivolumab	nivolumab	NOUN
dpc-1881	427	7	plus	plus	CCONJ
dpc-1881	427	8	ipilimumab	ipilimumab	NOUN
dpc-1881	427	9	or	or	CCONJ
dpc-1881	427	10	nivolumab	nivolumab	NOUN
dpc-1881	427	11	alone	alone	ADV
dpc-1881	427	12	versus	versus	ADP
dpc-1881	427	13	ipilimumab	ipilimumab	NOUN
dpc-1881	427	14	alone	alone	ADV
dpc-1881	427	15	among	among	ADP
dpc-1881	427	16	treatment	treatment	NOUN
dpc-1881	427	17	-	-	PUNCT
dpc-1881	427	18	naive	naive	ADJ
dpc-1881	427	19	patients	patient	NOUN
dpc-1881	427	20	with	with	ADP
dpc-1881	427	21	advanced	advanced	ADJ
dpc-1881	427	22	melanoma	melanoma	NOUN
dpc-1881	427	23	:	:	PUNCT
dpc-1881	427	24	a	a	DET
dpc-1881	427	25	quality	quality	NOUN
dpc-1881	427	26	-	-	PUNCT
dpc-1881	427	27	adjusted	adjust	VERB
dpc-1881	427	28	time	time	NOUN
dpc-1881	427	29	without	without	ADP
dpc-1881	427	30	symptoms	symptom	NOUN
dpc-1881	427	31	or	or	CCONJ
dpc-1881	427	32	toxicity	toxicity	NOUN
dpc-1881	427	33	(	(	PUNCT
dpc-1881	427	34	q	q	NOUN
dpc-1881	427	35	-	-	PUNCT
dpc-1881	427	36	twist	twist	NOUN
dpc-1881	427	37	)	)	PUNCT
dpc-1881	427	38	analysis	analysis	NOUN
dpc-1881	427	39	.	.	PUNCT
dpc-1881	428	1	qual	qual	ADJ
dpc-1881	428	2	life	life	NOUN
dpc-1881	428	3	res	re	NOUN
dpc-1881	428	4	.	.	PUNCT
dpc-1881	429	1	2019;28(1):109	2019;28(1):109	PROPN
dpc-1881	429	2	-	-	PUNCT
dpc-1881	429	3	119	119	NUM
dpc-1881	429	4	.	.	PUNCT
dpc-1881	430	1	doi	doi	NOUN
dpc-1881	430	2	:	:	PUNCT
dpc-1881	430	3	10.1007	10.1007	NUM
dpc-1881	430	4	/	/	SYM
dpc-1881	430	5	s11136	s11136	NOUN
dpc-1881	430	6	-	-	PUNCT
dpc-1881	430	7	018	018	NUM
dpc-1881	430	8	-	-	PUNCT
dpc-1881	430	9	1984	1984	NUM
dpc-1881	430	10	-	-	PUNCT
dpc-1881	430	11	3	3	NUM
dpc-1881	430	12	.	.	PUNCT
dpc-1881	431	1	pmid	pmid	NOUN
dpc-1881	431	2	:	:	PUNCT
dpc-1881	431	3	30191365	30191365	NUM
dpc-1881	431	4	.	.	PUNCT
dpc-1881	432	1	37	37	NUM
dpc-1881	432	2	.	.	PUNCT
dpc-1881	433	1	hodi	hodi	PROPN
dpc-1881	433	2	fs	fs	PROPN
dpc-1881	433	3	,	,	PUNCT
dpc-1881	433	4	corless	corless	ADJ
dpc-1881	433	5	cl	cl	NOUN
dpc-1881	433	6	,	,	PUNCT
dpc-1881	433	7	giobbie	giobbie	NOUN
dpc-1881	433	8	-	-	PUNCT
dpc-1881	433	9	hurder	hurder	NOUN
dpc-1881	433	10	a	a	NOUN
dpc-1881	433	11	,	,	PUNCT
dpc-1881	433	12	et	et	PROPN
dpc-1881	433	13	al	al	PROPN
dpc-1881	433	14	.	.	PUNCT
dpc-1881	434	1	imatinib	imatinib	NOUN
dpc-1881	434	2	for	for	ADP
dpc-1881	434	3	melanomas	melanomas	NOUN
dpc-1881	434	4	harboring	harboring	NOUN
dpc-1881	434	5	mutationally	mutationally	ADV
dpc-1881	434	6	activated	activate	VERB
dpc-1881	434	7	or	or	CCONJ
dpc-1881	434	8	amplified	amplify	VERB
dpc-1881	434	9	kit	kit	NOUN
dpc-1881	434	10	arising	arise	VERB
dpc-1881	434	11	on	on	ADP
dpc-1881	434	12	mucosal	mucosal	NOUN
dpc-1881	434	13	,	,	PUNCT
dpc-1881	434	14	acral	acral	ADJ
dpc-1881	434	15	,	,	PUNCT
dpc-1881	434	16	and	and	CCONJ
dpc-1881	434	17	chronically	chronically	ADV
dpc-1881	434	18	sun	sun	NOUN
dpc-1881	434	19	-	-	PUNCT
dpc-1881	434	20	damaged	damage	VERB
dpc-1881	434	21	skin	skin	NOUN
dpc-1881	434	22	.	.	PUNCT
dpc-1881	435	1	j	j	PROPN
dpc-1881	435	2	clin	clin	PROPN
dpc-1881	435	3	oncol	oncol	PROPN
dpc-1881	435	4	.	.	PUNCT
dpc-1881	436	1	2013;31:3182	2013;31:3182	NUM
dpc-1881	436	2	-	-	SYM
dpc-1881	436	3	3190	3190	NUM
dpc-1881	436	4	.	.	PUNCT
dpc-1881	437	1	doi	doi	NOUN
dpc-1881	437	2	:	:	PUNCT
dpc-1881	437	3	10.1200	10.1200	NUM
dpc-1881	437	4	/	/	SYM
dpc-1881	437	5	jco.2012.47.7836	jco.2012.47.7836	PROPN
dpc-1881	437	6	.	.	PUNCT
dpc-1881	438	1	pmid	pmid	NOUN
dpc-1881	438	2	:	:	PUNCT
dpc-1881	438	3	23775962	23775962	NUM
dpc-1881	438	4	.	.	PUNCT
dpc-1881	439	1	38	38	NUM
dpc-1881	439	2	.	.	PUNCT
dpc-1881	440	1	carvajal	carvajal	PROPN
dpc-1881	440	2	rd	rd	PROPN
dpc-1881	440	3	,	,	PUNCT
dpc-1881	440	4	antonescu	antonescu	PROPN
dpc-1881	440	5	cr	cr	PROPN
dpc-1881	440	6	,	,	PUNCT
dpc-1881	440	7	wolchok	wolchok	PROPN
dpc-1881	440	8	jd	jd	PROPN
dpc-1881	440	9	,	,	PUNCT
dpc-1881	440	10	et	et	PROPN
dpc-1881	440	11	al	al	PROPN
dpc-1881	440	12	.	.	PROPN
dpc-1881	440	13	kit	kit	NOUN
dpc-1881	440	14	as	as	ADP
dpc-1881	440	15	a	a	DET
dpc-1881	440	16	therapeutic	therapeutic	ADJ
dpc-1881	440	17	target	target	NOUN
dpc-1881	440	18	in	in	ADP
dpc-1881	440	19	metastatic	metastatic	ADJ
dpc-1881	440	20	melanoma	melanoma	NOUN
dpc-1881	440	21	.	.	PUNCT
dpc-1881	441	1	jama	jama	PROPN
dpc-1881	441	2	.	.	PUNCT
dpc-1881	442	1	2011	2011	NUM
dpc-1881	442	2	;	;	PUNCT
dpc-1881	443	1	305:23272334	305:23272334	X
dpc-1881	443	2	.	.	PUNCT
dpc-1881	443	3	doi	doi	NOUN
dpc-1881	443	4	:	:	PUNCT
dpc-1881	443	5	10.1001	10.1001	NUM
dpc-1881	443	6	/	/	SYM
dpc-1881	443	7	jama.2011.746	jama.2011.746	PROPN
dpc-1881	443	8	.	.	PUNCT
dpc-1881	444	1	pmid	pmid	NOUN
dpc-1881	444	2	:	:	PUNCT
dpc-1881	444	3	21642685	21642685	NUM
dpc-1881	444	4	.	.	PUNCT
dpc-1881	445	1	39	39	NUM
dpc-1881	445	2	.	.	PUNCT
dpc-1881	446	1	guo	guo	PROPN
dpc-1881	446	2	j	j	PROPN
dpc-1881	446	3	,	,	PUNCT
dpc-1881	446	4	si	si	PROPN
dpc-1881	446	5	l	l	PROPN
dpc-1881	446	6	,	,	PUNCT
dpc-1881	446	7	kong	kong	PROPN
dpc-1881	446	8	y	y	PROPN
dpc-1881	446	9	,	,	PUNCT
dpc-1881	446	10	et	et	PROPN
dpc-1881	446	11	al	al	PROPN
dpc-1881	446	12	.	.	PROPN
dpc-1881	446	13	phase	phase	PROPN
dpc-1881	446	14	ii	ii	PROPN
dpc-1881	446	15	,	,	PUNCT
dpc-1881	446	16	open	open	ADJ
dpc-1881	446	17	-	-	PUNCT
dpc-1881	446	18	label	label	NOUN
dpc-1881	446	19	,	,	PUNCT
dpc-1881	446	20	single	single	ADJ
dpc-1881	446	21	-	-	PUNCT
dpc-1881	446	22	arm	arm	NOUN
dpc-1881	446	23	trial	trial	NOUN
dpc-1881	446	24	of	of	ADP
dpc-1881	446	25	imatinib	imatinib	NOUN
dpc-1881	446	26	mesylate	mesylate	VERB
dpc-1881	446	27	in	in	ADP
dpc-1881	446	28	patients	patient	NOUN
dpc-1881	446	29	with	with	ADP
dpc-1881	446	30	metastatic	metastatic	ADJ
dpc-1881	446	31	melanoma	melanoma	NOUN
dpc-1881	446	32	harboring	harbor	VERB
dpc-1881	446	33	c	c	NOUN
dpc-1881	446	34	-	-	PUNCT
dpc-1881	446	35	kit	kit	NOUN
dpc-1881	446	36	mutation	mutation	NOUN
dpc-1881	446	37	or	or	CCONJ
dpc-1881	446	38	amplification	amplification	NOUN
dpc-1881	446	39	.	.	PUNCT
dpc-1881	447	1	j	j	PROPN
dpc-1881	447	2	clin	clin	PROPN
dpc-1881	447	3	oncol	oncol	PROPN
dpc-1881	447	4	.	.	PUNCT
dpc-1881	448	1	2011	2011	NUM
dpc-1881	448	2	;	;	PUNCT
dpc-1881	448	3	29:2904	29:2904	NUM
dpc-1881	448	4	-	-	SYM
dpc-1881	448	5	9	9	NUM
dpc-1881	448	6	.	.	PUNCT
dpc-1881	448	7	doi	doi	NOUN
dpc-1881	448	8	:	:	PUNCT
dpc-1881	448	9	10.1200	10.1200	NUM
dpc-1881	448	10	/	/	SYM
dpc-1881	448	11	jco.2010.33.9275	jco.2010.33.9275	PROPN
dpc-1881	448	12	.	.	PUNCT
dpc-1881	449	1	pmid	pmid	NOUN
dpc-1881	449	2	:	:	PUNCT
dpc-1881	449	3	21690468	21690468	NUM
dpc-1881	449	4	.	.	PUNCT
dpc-1881	450	1	40	40	NUM
dpc-1881	450	2	.	.	PUNCT
dpc-1881	451	1	wei	wei	PROPN
dpc-1881	451	2	x	x	PROPN
dpc-1881	451	3	,	,	PUNCT
dpc-1881	451	4	mao	mao	PROPN
dpc-1881	451	5	l	l	NOUN
dpc-1881	451	6	,	,	PUNCT
dpc-1881	451	7	chi	chi	PROPN
dpc-1881	451	8	z	z	PROPN
dpc-1881	451	9	,	,	PUNCT
dpc-1881	451	10	et	et	PROPN
dpc-1881	451	11	al	al	PROPN
dpc-1881	451	12	.	.	PROPN
dpc-1881	451	13	efficacy	efficacy	NOUN
dpc-1881	451	14	evaluation	evaluation	NOUN
dpc-1881	451	15	of	of	ADP
dpc-1881	451	16	imatinib	imatinib	NOUN
dpc-1881	451	17	for	for	ADP
dpc-1881	451	18	the	the	DET
dpc-1881	451	19	treatment	treatment	NOUN
dpc-1881	451	20	of	of	ADP
dpc-1881	451	21	melanoma	melanoma	NOUN
dpc-1881	451	22	:	:	PUNCT
dpc-1881	451	23	evidence	evidence	NOUN
dpc-1881	451	24	from	from	ADP
dpc-1881	451	25	a	a	DET
dpc-1881	451	26	retrospective	retrospective	ADJ
dpc-1881	451	27	study	study	NOUN
dpc-1881	451	28	.	.	PUNCT
dpc-1881	452	1	oncol	oncol	ADJ
dpc-1881	452	2	res	re	NOUN
dpc-1881	452	3	.	.	PUNCT
dpc-1881	453	1	2019;27(4):495	2019;27(4):495	NUM
dpc-1881	453	2	-	-	PUNCT
dpc-1881	453	3	501	501	NUM
dpc-1881	453	4	.	.	PUNCT
dpc-1881	454	1	doi	doi	NOUN
dpc-1881	454	2	:	:	PUNCT
dpc-1881	454	3	10.3727/096504018x15	10.3727/096504018x15	NUM
dpc-1881	454	4	331163433914	331163433914	NUM
dpc-1881	454	5	.	.	PUNCT
dpc-1881	455	1	pmid	pmid	NOUN
dpc-1881	455	2	:	:	PUNCT
dpc-1881	455	3	30075827	30075827	NUM
dpc-1881	455	4	.	.	PUNCT
dpc-1881	456	1	41	41	NUM
dpc-1881	456	2	.	.	PUNCT
dpc-1881	457	1	guida	guida	PROPN
dpc-1881	457	2	m	m	PROPN
dpc-1881	457	3	,	,	PUNCT
dpc-1881	457	4	bartolomeo	bartolomeo	NOUN
dpc-1881	457	5	n	n	CCONJ
dpc-1881	457	6	,	,	PUNCT
dpc-1881	457	7	quaglino	quaglino	NOUN
dpc-1881	457	8	p	p	X
dpc-1881	457	9	,	,	PUNCT
dpc-1881	457	10	et	et	PROPN
dpc-1881	457	11	al	al	PROPN
dpc-1881	457	12	.	.	PROPN
dpc-1881	458	1	on	on	ADP
dpc-1881	458	2	behalf	behalf	NOUN
dpc-1881	458	3	of	of	ADP
dpc-1881	458	4	the	the	DET
dpc-1881	458	5	italian	italian	ADJ
dpc-1881	458	6	melanoma	melanoma	PROPN
dpc-1881	458	7	intergroup	intergroup	PROPN
dpc-1881	458	8	imi	imi	PROPN
dpc-1881	458	9	study	study	PROPN
dpc-1881	458	10	.	.	PUNCT
dpc-1881	459	1	no	no	DET
dpc-1881	459	2	impact	impact	NOUN
dpc-1881	459	3	of	of	ADP
dpc-1881	459	4	nras	nras	PROPN
dpc-1881	459	5	mutation	mutation	NOUN
dpc-1881	459	6	on	on	ADP
dpc-1881	459	7	features	feature	NOUN
dpc-1881	459	8	of	of	ADP
dpc-1881	459	9	primary	primary	ADJ
dpc-1881	459	10	and	and	CCONJ
dpc-1881	459	11	metastatic	metastatic	ADJ
dpc-1881	459	12	melanoma	melanoma	NOUN
dpc-1881	459	13	or	or	CCONJ
dpc-1881	459	14	on	on	ADP
dpc-1881	459	15	outcomes	outcome	NOUN
dpc-1881	459	16	of	of	ADP
dpc-1881	459	17	checkpoint	checkpoint	NOUN
dpc-1881	459	18	inhibitor	inhibitor	NOUN
dpc-1881	459	19	immunotherapy	immunotherapy	NOUN
dpc-1881	459	20	:	:	PUNCT
dpc-1881	459	21	an	an	DET
dpc-1881	459	22	italian	italian	ADJ
dpc-1881	459	23	melanoma	melanoma	NOUN
dpc-1881	459	24	intergroup	intergroup	NOUN
dpc-1881	459	25	(	(	PUNCT
dpc-1881	459	26	imi	imi	ADJ
dpc-1881	459	27	)	)	PUNCT
dpc-1881	459	28	study	study	NOUN
dpc-1881	459	29	.	.	PUNCT
dpc-1881	460	1	cancers	cancer	NOUN
dpc-1881	460	2	(	(	PUNCT
dpc-1881	460	3	basel	basel	PROPN
dpc-1881	460	4	)	)	PUNCT
dpc-1881	460	5	.	.	PUNCT
dpc-1881	460	6	2021	2021	NUM
dpc-1881	460	7	;	;	PUNCT
dpc-1881	460	8	13(3):475	13(3):475	PROPN
dpc-1881	460	9	.	.	PUNCT
dpc-1881	461	1	doi	doi	NOUN
dpc-1881	461	2	:	:	PUNCT
dpc-1881	461	3	10.3390	10.3390	NUM
dpc-1881	461	4	/	/	SYM
dpc-1881	461	5	cancers13030475	cancers13030475	PROPN
dpc-1881	461	6	.	.	PUNCT
dpc-1881	462	1	pmid	pmid	NOUN
dpc-1881	462	2	:	:	PUNCT
dpc-1881	462	3	33530579	33530579	NUM
dpc-1881	462	4	.	.	PUNCT
dpc-1881	463	1	42	42	NUM
dpc-1881	463	2	.	.	PUNCT
dpc-1881	464	1	dummer	dummer	PROPN
dpc-1881	464	2	r	r	PROPN
dpc-1881	464	3	,	,	PUNCT
dpc-1881	464	4	schadendorf	schadendorf	PROPN
dpc-1881	464	5	d	d	PROPN
dpc-1881	464	6	,	,	PUNCT
dpc-1881	464	7	ascierto	ascierto	PROPN
dpc-1881	464	8	pa	pa	PROPN
dpc-1881	464	9	,	,	PUNCT
dpc-1881	464	10	et	et	PROPN
dpc-1881	464	11	al	al	PROPN
dpc-1881	464	12	.	.	PROPN
dpc-1881	464	13	binimetinib	binimetinib	PROPN
dpc-1881	464	14	versus	versus	ADP
dpc-1881	464	15	dacarbazine	dacarbazine	NOUN
dpc-1881	464	16	in	in	ADP
dpc-1881	464	17	patients	patient	NOUN
dpc-1881	464	18	with	with	ADP
dpc-1881	464	19	advanced	advanced	ADJ
dpc-1881	464	20	nras	nra	NOUN
dpc-1881	464	21	-	-	PUNCT
dpc-1881	464	22	mutant	mutant	ADJ
dpc-1881	464	23	melanoma	melanoma	NOUN
dpc-1881	464	24	(	(	PUNCT
dpc-1881	464	25	nemo	nemo	PROPN
dpc-1881	464	26	):	):	PUNCT
dpc-1881	464	27	a	a	DET
dpc-1881	464	28	multicentre	multicentre	NOUN
dpc-1881	464	29	,	,	PUNCT
dpc-1881	464	30	open	open	ADJ
dpc-1881	464	31	-	-	PUNCT
dpc-1881	464	32	label	label	NOUN
dpc-1881	464	33	,	,	PUNCT
dpc-1881	464	34	randomised	randomise	VERB
dpc-1881	464	35	,	,	PUNCT
dpc-1881	464	36	phase	phase	NOUN
dpc-1881	464	37	3	3	NUM
dpc-1881	464	38	trial	trial	NOUN
dpc-1881	464	39	.	.	PUNCT
dpc-1881	465	1	lancet	lancet	PROPN
dpc-1881	465	2	oncol	oncol	PROPN
dpc-1881	465	3	.	.	PUNCT
dpc-1881	466	1	2017;18(4):435	2017;18(4):435	NUM
dpc-1881	466	2	-	-	SYM
dpc-1881	466	3	445	445	NUM
dpc-1881	466	4	.	.	PUNCT
dpc-1881	467	1	doi	doi	NOUN
dpc-1881	467	2	:	:	PUNCT
dpc-1881	467	3	10.1016	10.1016	NUM
dpc-1881	467	4	/	/	SYM
dpc-1881	467	5	s14702045(17)30180	s14702045(17)30180	NOUN
dpc-1881	467	6	-	-	PUNCT
dpc-1881	467	7	8	8	NUM
dpc-1881	467	8	.	.	NUM
dpc-1881	467	9	43	43	NUM
dpc-1881	467	10	.	.	PUNCT
dpc-1881	468	1	davies	davies	PROPN
dpc-1881	468	2	ma	ma	PROPN
dpc-1881	468	3	,	,	PUNCT
dpc-1881	468	4	liu	liu	PROPN
dpc-1881	468	5	p	p	PROPN
dpc-1881	468	6	,	,	PUNCT
dpc-1881	468	7	mcintyre	mcintyre	PROPN
dpc-1881	468	8	s	s	PROPN
dpc-1881	468	9	,	,	PUNCT
dpc-1881	468	10	et	et	PROPN
dpc-1881	468	11	al	al	PROPN
dpc-1881	468	12	.	.	PUNCT
dpc-1881	469	1	prognostic	prognostic	ADJ
dpc-1881	469	2	factors	factor	NOUN
dpc-1881	469	3	for	for	ADP
dpc-1881	469	4	survival	survival	NOUN
dpc-1881	469	5	in	in	ADP
dpc-1881	469	6	melanoma	melanoma	NOUN
dpc-1881	469	7	patients	patient	NOUN
dpc-1881	469	8	with	with	ADP
dpc-1881	469	9	brain	brain	NOUN
dpc-1881	469	10	metastases	metastasis	NOUN
dpc-1881	469	11	.	.	PUNCT
dpc-1881	470	1	canreview	canreview	NOUN
dpc-1881	470	2	|	|	ADV
dpc-1881	470	3	dermatol	dermatol	ADJ
dpc-1881	470	4	pract	pract	NOUN
dpc-1881	470	5	concept	concept	NOUN
dpc-1881	470	6	.	.	PUNCT
dpc-1881	471	1	2021;11(s1	2021;11(s1	NUM
dpc-1881	471	2	):	):	PUNCT
dpc-1881	471	3	e2021164s	e2021164s	PROPN
dpc-1881	471	4	11	11	NUM
dpc-1881	471	5	cer	cer	NOUN
dpc-1881	471	6	.	.	PUNCT
dpc-1881	472	1	2011;117(8):1687	2011;117(8):1687	NUM
dpc-1881	472	2	-	-	SYM
dpc-1881	472	3	96	96	NUM
dpc-1881	472	4	.	.	PUNCT
dpc-1881	472	5	doi	doi	NOUN
dpc-1881	472	6	:	:	PUNCT
dpc-1881	472	7	10.1002	10.1002	NUM
dpc-1881	472	8	/	/	SYM
dpc-1881	472	9	cncr.25634	cncr.25634	PROPN
dpc-1881	472	10	.	.	PUNCT
dpc-1881	473	1	pmid	pmid	NOUN
dpc-1881	473	2	:	:	PUNCT
dpc-1881	473	3	20960525	20960525	NUM
dpc-1881	473	4	.	.	PUNCT
dpc-1881	474	1	44	44	NUM
dpc-1881	474	2	.	.	PUNCT
dpc-1881	475	1	vecchio	vecchio	PROPN
dpc-1881	475	2	s	s	PROPN
dpc-1881	475	3	,	,	PUNCT
dpc-1881	475	4	spagnolo	spagnolo	PROPN
dpc-1881	475	5	f	f	PROPN
dpc-1881	475	6	,	,	PUNCT
dpc-1881	475	7	merlo	merlo	PROPN
dpc-1881	475	8	df	df	PROPN
dpc-1881	475	9	,	,	PUNCT
dpc-1881	475	10	et	et	PROPN
dpc-1881	475	11	al	al	PROPN
dpc-1881	475	12	.	.	PUNCT
dpc-1881	476	1	the	the	DET
dpc-1881	476	2	treatment	treatment	NOUN
dpc-1881	476	3	of	of	ADP
dpc-1881	476	4	melanoma	melanoma	NOUN
dpc-1881	476	5	brain	brain	NOUN
dpc-1881	476	6	metastases	metastasis	NOUN
dpc-1881	476	7	before	before	ADP
dpc-1881	476	8	the	the	DET
dpc-1881	476	9	advent	advent	NOUN
dpc-1881	476	10	of	of	ADP
dpc-1881	476	11	targeted	target	VERB
dpc-1881	476	12	therapies	therapy	NOUN
dpc-1881	476	13	:	:	PUNCT
dpc-1881	476	14	associations	association	NOUN
dpc-1881	476	15	between	between	ADP
dpc-1881	476	16	therapeutic	therapeutic	ADJ
dpc-1881	476	17	choice	choice	NOUN
dpc-1881	476	18	,	,	PUNCT
dpc-1881	476	19	clinical	clinical	ADJ
dpc-1881	476	20	symptoms	symptom	NOUN
dpc-1881	476	21	and	and	CCONJ
dpc-1881	476	22	outcome	outcome	VERB
dpc-1881	476	23	with	with	ADP
dpc-1881	476	24	survival	survival	NOUN
dpc-1881	476	25	.	.	PUNCT
dpc-1881	477	1	melanoma	melanoma	NOUN
dpc-1881	477	2	res	re	NOUN
dpc-1881	477	3	.	.	PUNCT
dpc-1881	478	1	2014;24(1):61	2014;24(1):61	NUM
dpc-1881	478	2	-	-	SYM
dpc-1881	478	3	7	7	NUM
dpc-1881	478	4	.	.	PUNCT
dpc-1881	478	5	doi	doi	NOUN
dpc-1881	478	6	:	:	PUNCT
dpc-1881	478	7	10.1097	10.1097	NUM
dpc-1881	478	8	/	/	SYM
dpc-1881	478	9	cmr.0000000000000029	cmr.0000000000000029	X
dpc-1881	478	10	.	.	PUNCT
dpc-1881	479	1	pmid	pmid	NOUN
dpc-1881	479	2	:	:	PUNCT
dpc-1881	479	3	24121190	24121190	NUM
dpc-1881	479	4	.	.	PUNCT
dpc-1881	480	1	45	45	NUM
dpc-1881	480	2	.	.	PUNCT
dpc-1881	480	3	becco	becco	PROPN
dpc-1881	481	1	p	p	X
dpc-1881	481	2	,	,	PUNCT
dpc-1881	481	3	gallo	gallo	PROPN
dpc-1881	481	4	s	s	PROPN
dpc-1881	481	5	,	,	PUNCT
dpc-1881	481	6	poletto	poletto	PROPN
dpc-1881	481	7	s	s	PROPN
dpc-1881	481	8	,	,	PUNCT
dpc-1881	481	9	et	et	PROPN
dpc-1881	481	10	al	al	PROPN
dpc-1881	481	11	.	.	PUNCT
dpc-1881	481	12	melanoma	melanoma	PROPN
dpc-1881	481	13	brain	brain	NOUN
dpc-1881	481	14	metastases	metastasis	NOUN
dpc-1881	481	15	in	in	ADP
dpc-1881	481	16	the	the	DET
dpc-1881	481	17	era	era	NOUN
dpc-1881	481	18	of	of	ADP
dpc-1881	481	19	target	target	NOUN
dpc-1881	481	20	therapies	therapy	NOUN
dpc-1881	481	21	:	:	PUNCT
dpc-1881	481	22	an	an	DET
dpc-1881	481	23	overview	overview	NOUN
dpc-1881	481	24	.	.	PUNCT
dpc-1881	482	1	cancers	cancer	NOUN
dpc-1881	482	2	(	(	PUNCT
dpc-1881	482	3	basel	basel	PROPN
dpc-1881	482	4	)	)	PUNCT
dpc-1881	482	5	.	.	PUNCT
dpc-1881	483	1	2020;12(6):1640	2020;12(6):1640	NUM
dpc-1881	483	2	.	.	PUNCT
dpc-1881	483	3	doi	doi	NOUN
dpc-1881	483	4	:	:	PUNCT
dpc-1881	483	5	10.3390	10.3390	NUM
dpc-1881	483	6	/	/	SYM
dpc-1881	483	7	cancers12061640	cancers12061640	NOUN
dpc-1881	483	8	.	.	PUNCT
dpc-1881	484	1	pmid	pmid	NOUN
dpc-1881	484	2	:	:	PUNCT
dpc-1881	484	3	32575838	32575838	NUM
dpc-1881	484	4	.	.	PUNCT
dpc-1881	485	1	46	46	NUM
dpc-1881	485	2	.	.	PUNCT
dpc-1881	485	3	salvati	salvati	PROPN
dpc-1881	485	4	l	l	PROPN
dpc-1881	485	5	,	,	PUNCT
dpc-1881	485	6	mandalà	mandalà	PROPN
dpc-1881	485	7	m	m	PROPN
dpc-1881	485	8	,	,	PUNCT
dpc-1881	485	9	massi	massi	PROPN
dpc-1881	485	10	d.	d.	PROPN
dpc-1881	485	11	melanoma	melanoma	PROPN
dpc-1881	485	12	brain	brain	NOUN
dpc-1881	485	13	metastases	metastasis	NOUN
dpc-1881	485	14	:	:	PUNCT
dpc-1881	485	15	review	review	NOUN
dpc-1881	485	16	of	of	ADP
dpc-1881	485	17	histopathological	histopathological	ADJ
dpc-1881	485	18	features	feature	NOUN
dpc-1881	485	19	and	and	CCONJ
dpc-1881	485	20	immune	immune	ADJ
dpc-1881	485	21	-	-	PUNCT
dpc-1881	485	22	molecular	molecular	ADJ
dpc-1881	485	23	aspects	aspect	NOUN
dpc-1881	485	24	.	.	PUNCT
dpc-1881	486	1	melanoma	melanoma	NOUN
dpc-1881	486	2	manag	manag	NOUN
dpc-1881	486	3	.	.	PUNCT
dpc-1881	487	1	2020;7(2):mmt44	2020;7(2):mmt44	NOUN
dpc-1881	487	2	.	.	PUNCT
dpc-1881	488	1	doi	doi	NOUN
dpc-1881	488	2	:	:	PUNCT
dpc-1881	488	3	10.2217/	10.2217/	NUM
dpc-1881	488	4	mmt-2019	mmt-2019	NOUN
dpc-1881	488	5	-	-	PUNCT
dpc-1881	488	6	0021	0021	NUM
dpc-1881	488	7	.	.	PUNCT
dpc-1881	489	1	47	47	NUM
dpc-1881	489	2	.	.	PUNCT
dpc-1881	490	1	davies	davies	PROPN
dpc-1881	490	2	ma	ma	PROPN
dpc-1881	490	3	,	,	PUNCT
dpc-1881	490	4	saiag	saiag	ADP
dpc-1881	490	5	p	p	X
dpc-1881	490	6	,	,	PUNCT
dpc-1881	490	7	robert	robert	PROPN
dpc-1881	490	8	c	c	PROPN
dpc-1881	490	9	,	,	PUNCT
dpc-1881	490	10	et	et	PROPN
dpc-1881	490	11	al	al	PROPN
dpc-1881	490	12	.	.	PROPN
dpc-1881	490	13	dabrafenib	dabrafenib	NOUN
dpc-1881	490	14	plus	plus	CCONJ
dpc-1881	490	15	trametinib	trametinib	NOUN
dpc-1881	490	16	in	in	ADP
dpc-1881	490	17	patients	patient	NOUN
dpc-1881	490	18	with	with	ADP
dpc-1881	490	19	braf(v600)-mutant	braf(v600)-mutant	ADP
dpc-1881	490	20	melanoma	melanoma	NOUN
dpc-1881	490	21	brain	brain	NOUN
dpc-1881	490	22	metastases	metastasis	NOUN
dpc-1881	490	23	(	(	PUNCT
dpc-1881	490	24	combi	combi	NOUN
dpc-1881	490	25	-	-	PUNCT
dpc-1881	490	26	mb	mb	PROPN
dpc-1881	490	27	):	):	PUNCT
dpc-1881	490	28	a	a	DET
dpc-1881	490	29	multicentre	multicentre	NOUN
dpc-1881	490	30	,	,	PUNCT
dpc-1881	490	31	multicohort	multicohort	NOUN
dpc-1881	490	32	,	,	PUNCT
dpc-1881	490	33	open	open	ADJ
dpc-1881	490	34	-	-	PUNCT
dpc-1881	490	35	label	label	NOUN
dpc-1881	490	36	,	,	PUNCT
dpc-1881	490	37	phase	phase	NOUN
dpc-1881	490	38	2	2	NUM
dpc-1881	490	39	trial	trial	NOUN
dpc-1881	490	40	.	.	PUNCT
dpc-1881	491	1	lancet	lancet	PROPN
dpc-1881	491	2	oncol	oncol	PROPN
dpc-1881	491	3	.	.	PUNCT
dpc-1881	492	1	2017;18(7):863	2017;18(7):863	PROPN
dpc-1881	492	2	-	-	SYM
dpc-1881	492	3	873	873	NUM
dpc-1881	492	4	.	.	PUNCT
dpc-1881	493	1	doi	doi	NOUN
dpc-1881	493	2	:	:	PUNCT
dpc-1881	493	3	10.1016	10.1016	NUM
dpc-1881	493	4	/	/	SYM
dpc-1881	493	5	s14702045(17)30429	s14702045(17)30429	PROPN
dpc-1881	493	6	-	-	PUNCT
dpc-1881	493	7	1	1	NUM
dpc-1881	493	8	.	.	NUM
dpc-1881	493	9	48	48	NUM
dpc-1881	493	10	.	.	PUNCT
dpc-1881	494	1	long	long	ADJ
dpc-1881	494	2	gv	gv	ADP
dpc-1881	494	3	,	,	PUNCT
dpc-1881	494	4	atkinson	atkinson	PROPN
dpc-1881	494	5	v	v	PROPN
dpc-1881	494	6	,	,	PUNCT
dpc-1881	494	7	lo	lo	PROPN
dpc-1881	494	8	s	s	PROPN
dpc-1881	494	9	,	,	PUNCT
dpc-1881	494	10	et	et	PROPN
dpc-1881	494	11	al	al	PROPN
dpc-1881	494	12	.	.	PROPN
dpc-1881	494	13	combination	combination	NOUN
dpc-1881	494	14	nivolumab	nivolumab	NOUN
dpc-1881	494	15	and	and	CCONJ
dpc-1881	494	16	ipilimumab	ipilimumab	NOUN
dpc-1881	494	17	or	or	CCONJ
dpc-1881	494	18	nivolumab	nivolumab	NOUN
dpc-1881	494	19	alone	alone	ADV
dpc-1881	494	20	in	in	ADP
dpc-1881	494	21	melanoma	melanoma	ADJ
dpc-1881	494	22	brain	brain	NOUN
dpc-1881	494	23	metastases	metastasis	NOUN
dpc-1881	494	24	:	:	PUNCT
dpc-1881	494	25	a	a	DET
dpc-1881	494	26	multicentre	multicentre	NOUN
dpc-1881	494	27	randomised	randomise	VERB
dpc-1881	494	28	phase	phase	NOUN
dpc-1881	494	29	2	2	NUM
dpc-1881	494	30	study	study	NOUN
dpc-1881	494	31	.	.	PUNCT
dpc-1881	495	1	lancet	lancet	PROPN
dpc-1881	495	2	oncol	oncol	PROPN
dpc-1881	495	3	.	.	PUNCT
dpc-1881	496	1	2018;19(5):672	2018;19(5):672	NUM
dpc-1881	496	2	-	-	SYM
dpc-1881	496	3	681	681	NUM
dpc-1881	496	4	.	.	PUNCT
dpc-1881	497	1	doi	doi	NOUN
dpc-1881	497	2	:	:	PUNCT
dpc-1881	497	3	10.1016	10.1016	NUM
dpc-1881	497	4	/	/	SYM
dpc-1881	497	5	s1470	s1470	PROPN
dpc-1881	497	6	-	-	PUNCT
dpc-1881	497	7	2045(18)30139	2045(18)30139	NUM
dpc-1881	497	8	-	-	PUNCT
dpc-1881	497	9	6	6	NUM
dpc-1881	497	10	.	.	NOUN
dpc-1881	497	11	49	49	NUM
dpc-1881	497	12	.	.	PUNCT
dpc-1881	498	1	tawbi	tawbi	PROPN
dpc-1881	498	2	ha	ha	INTJ
dpc-1881	498	3	,	,	PUNCT
dpc-1881	498	4	forsyth	forsyth	PROPN
dpc-1881	498	5	pa	pa	PROPN
dpc-1881	498	6	,	,	PUNCT
dpc-1881	498	7	algazi	algazi	PROPN
dpc-1881	498	8	a	a	NOUN
dpc-1881	498	9	,	,	PUNCT
dpc-1881	498	10	et	et	PROPN
dpc-1881	498	11	al	al	PROPN
dpc-1881	498	12	.	.	PROPN
dpc-1881	499	1	combined	combine	VERB
dpc-1881	499	2	nivolumab	nivolumab	NOUN
dpc-1881	499	3	and	and	CCONJ
dpc-1881	499	4	ipilimumab	ipilimumab	VERB
dpc-1881	499	5	in	in	ADP
dpc-1881	499	6	melanoma	melanoma	NOUN
dpc-1881	499	7	metastatic	metastatic	ADJ
dpc-1881	499	8	to	to	ADP
dpc-1881	499	9	the	the	DET
dpc-1881	499	10	brain	brain	NOUN
dpc-1881	499	11	.	.	PUNCT
dpc-1881	500	1	n	n	PROPN
dpc-1881	500	2	engl	engl	PROPN
dpc-1881	500	3	j	j	PROPN
dpc-1881	500	4	med	med	PROPN
dpc-1881	500	5	.	.	PUNCT
dpc-1881	501	1	2018;379(8):722	2018;379(8):722	X
dpc-1881	501	2	-	-	SYM
dpc-1881	501	3	730	730	NUM
dpc-1881	501	4	.	.	PUNCT
dpc-1881	501	5	doi	doi	NOUN
dpc-1881	501	6	:	:	PUNCT
dpc-1881	501	7	10.1056	10.1056	NUM
dpc-1881	501	8	/	/	SYM
dpc-1881	501	9	nejmoa1805453	nejmoa1805453	PROPN
dpc-1881	501	10	.	.	PUNCT
dpc-1881	502	1	pmid	pmid	NOUN
dpc-1881	502	2	:	:	PUNCT
dpc-1881	502	3	30134131	30134131	NUM
dpc-1881	502	4	.	.	PUNCT
dpc-1881	503	1	50	50	NUM
dpc-1881	503	2	.	.	X
dpc-1881	503	3	di	di	PROPN
dpc-1881	503	4	giacomo	giacomo	PROPN
dpc-1881	503	5	am	be	AUX
dpc-1881	503	6	,	,	PUNCT
dpc-1881	503	7	chiarion	chiarion	NOUN
dpc-1881	503	8	sileni	sileni	NOUN
dpc-1881	503	9	v	v	NOUN
dpc-1881	503	10	,	,	PUNCT
dpc-1881	503	11	del	del	PROPN
dpc-1881	503	12	vecchio	vecchio	PROPN
dpc-1881	503	13	m	m	PROPN
dpc-1881	503	14	,	,	PUNCT
dpc-1881	503	15	et	et	PROPN
dpc-1881	503	16	al	al	PROPN
dpc-1881	503	17	.	.	PROPN
dpc-1881	503	18	efficacy	efficacy	NOUN
dpc-1881	503	19	of	of	ADP
dpc-1881	503	20	ipilimumab	ipilimumab	NOUN
dpc-1881	503	21	plus	plus	CCONJ
dpc-1881	503	22	nivolumab	nivolumab	NOUN
dpc-1881	503	23	or	or	CCONJ
dpc-1881	503	24	ipilimumab	ipilimumab	VERB
dpc-1881	503	25	plusfotemustine	plusfotemustine	NOUN
dpc-1881	503	26	vs	vs	ADP
dpc-1881	503	27	fotemustine	fotemustine	NOUN
dpc-1881	503	28	in	in	ADP
dpc-1881	503	29	patients	patient	NOUN
dpc-1881	503	30	with	with	ADP
dpc-1881	503	31	melanomametastatic	melanomametastatic	NOUN
dpc-1881	503	32	to	to	ADP
dpc-1881	503	33	the	the	DET
dpc-1881	503	34	brain	brain	NOUN
dpc-1881	503	35	:	:	PUNCT
dpc-1881	503	36	primary	primary	ADJ
dpc-1881	503	37	analysis	analysis	NOUN
dpc-1881	503	38	of	of	ADP
dpc-1881	503	39	the	the	DET
dpc-1881	503	40	phase	phase	NOUN
dpc-1881	503	41	iii	iii	NUM
dpc-1881	503	42	nibit	nibit	NOUN
dpc-1881	503	43	-	-	PUNCT
dpc-1881	503	44	m2	m2	PROPN
dpc-1881	503	45	trial	trial	NOUN
dpc-1881	503	46	.	.	PUNCT
dpc-1881	503	47	presented	present	VERB
dpc-1881	503	48	at	at	ADP
dpc-1881	503	49	esmo	esmo	NOUN
dpc-1881	503	50	2020	2020	NUM
dpc-1881	503	51	.	.	PUNCT
dpc-1881	504	1	doi	doi	NOUN
dpc-1881	504	2	:	:	PUNCT
dpc-1881	504	3	10.1016	10.1016	NUM
dpc-1881	504	4	/	/	SYM
dpc-1881	504	5	j.annonc.2020.08.1205	j.annonc.2020.08.1205	PROPN
dpc-1881	504	6	.	.	PUNCT
dpc-1881	505	1	51	51	NUM
dpc-1881	505	2	.	.	PUNCT
dpc-1881	506	1	trojaniello	trojaniello	PROPN
dpc-1881	506	2	c	c	PROPN
dpc-1881	506	3	,	,	PUNCT
dpc-1881	506	4	vitale	vitale	PROPN
dpc-1881	506	5	mg	mg	PROPN
dpc-1881	506	6	,	,	PUNCT
dpc-1881	506	7	ascierto	ascierto	PROPN
dpc-1881	506	8	pa	pa	PROPN
dpc-1881	506	9	.	.	PUNCT
dpc-1881	506	10	triplet	triplet	NOUN
dpc-1881	506	11	combination	combination	NOUN
dpc-1881	506	12	of	of	ADP
dpc-1881	506	13	braf	braf	NOUN
dpc-1881	506	14	,	,	PUNCT
dpc-1881	506	15	mek	mek	PROPN
dpc-1881	506	16	and	and	CCONJ
dpc-1881	506	17	pd1	pd1	VERB
dpc-1881	506	18	/	/	SYM
dpc-1881	506	19	pd	pd	NOUN
dpc-1881	506	20	-	-	PUNCT
dpc-1881	506	21	l1	l1	PROPN
dpc-1881	506	22	blockade	blockade	NOUN
dpc-1881	506	23	in	in	ADP
dpc-1881	506	24	melanoma	melanoma	NOUN
dpc-1881	506	25	.	.	PUNCT
dpc-1881	507	1	curr	curr	PROPN
dpc-1881	507	2	opin	opin	NOUN
dpc-1881	507	3	oncol	oncol	ADJ
dpc-1881	507	4	2021	2021	NUM
dpc-1881	507	5	;	;	PUNCT
dpc-1881	507	6	publish	publish	VERB
dpc-1881	507	7	ah	ah	INTJ
dpc-1881	507	8	.	.	PUNCT
dpc-1881	508	1	doi	doi	NOUN
dpc-1881	508	2	:	:	PUNCT
dpc-1881	508	3	10.1097/	10.1097/	NUM
dpc-1881	508	4	cco.0000000000000709.pmid	cco.0000000000000709.pmid	NOUN
dpc-1881	508	5	:	:	PUNCT
dpc-1881	508	6	33399314	33399314	NUM
dpc-1881	508	7	.	.	PUNCT
dpc-1881	509	1	52	52	NUM
dpc-1881	509	2	.	.	PUNCT
dpc-1881	509	3	mandalà	mandalà	PROPN
dpc-1881	509	4	m	m	PROPN
dpc-1881	509	5	,	,	PUNCT
dpc-1881	509	6	massi	massi	PROPN
dpc-1881	509	7	d.	d.	PROPN
dpc-1881	509	8	immunotolerance	immunotolerance	PROPN
dpc-1881	509	9	as	as	ADP
dpc-1881	509	10	a	a	DET
dpc-1881	509	11	mechanism	mechanism	NOUN
dpc-1881	509	12	of	of	ADP
dpc-1881	509	13	resistance	resistance	NOUN
dpc-1881	509	14	to	to	ADP
dpc-1881	509	15	targeted	target	VERB
dpc-1881	509	16	therapies	therapy	NOUN
dpc-1881	509	17	in	in	ADP
dpc-1881	509	18	melanoma	melanoma	NOUN
dpc-1881	509	19	.	.	PUNCT
dpc-1881	510	1	handb	handb	NOUN
dpc-1881	510	2	exp	exp	NOUN
dpc-1881	510	3	pharmacol	pharmacol	NOUN
dpc-1881	510	4	.	.	PUNCT
dpc-1881	511	1	2018	2018	NUM
dpc-1881	511	2	;	;	PUNCT
dpc-1881	511	3	249:129	249:129	PROPN
dpc-1881	511	4	-	-	SYM
dpc-1881	511	5	143	143	PROPN
dpc-1881	511	6	.	.	PUNCT
dpc-1881	512	1	doi	doi	NOUN
dpc-1881	512	2	:	:	PUNCT
dpc-1881	512	3	10.1007/164_2017_5	10.1007/164_2017_5	NUM
dpc-1881	512	4	.	.	PUNCT
dpc-1881	513	1	pmid	pmid	NOUN
dpc-1881	513	2	:	:	PUNCT
dpc-1881	513	3	28238077	28238077	NUM
dpc-1881	513	4	.	.	PUNCT
dpc-1881	514	1	53	53	NUM
dpc-1881	514	2	.	.	PUNCT
dpc-1881	514	3	ferrucci	ferrucci	PROPN
dpc-1881	514	4	pf	pf	PROPN
dpc-1881	514	5	,	,	PUNCT
dpc-1881	514	6	di	di	PROPN
dpc-1881	514	7	giacomo	giacomo	PROPN
dpc-1881	514	8	am	am	PROPN
dpc-1881	514	9	,	,	PUNCT
dpc-1881	514	10	del	del	PROPN
dpc-1881	514	11	vecchio	vecchio	PROPN
dpc-1881	514	12	m	m	PROPN
dpc-1881	514	13	,	,	PUNCT
dpc-1881	514	14	et	et	PROPN
dpc-1881	515	1	al	al	PROPN
dpc-1881	515	2	.	.	PROPN
dpc-1881	515	3	keynote-022	keynote-022	PROPN
dpc-1881	515	4	part	part	NOUN
dpc-1881	515	5	3	3	NUM
dpc-1881	515	6	:	:	PUNCT
dpc-1881	515	7	a	a	DET
dpc-1881	515	8	randomized	randomized	ADJ
dpc-1881	515	9	,	,	PUNCT
dpc-1881	515	10	double	double	ADJ
dpc-1881	515	11	-	-	PUNCT
dpc-1881	515	12	blind	blind	ADJ
dpc-1881	515	13	,	,	PUNCT
dpc-1881	515	14	phase	phase	NOUN
dpc-1881	515	15	2	2	NUM
dpc-1881	515	16	study	study	NOUN
dpc-1881	515	17	of	of	ADP
dpc-1881	515	18	pembrolizumab	pembrolizumab	NOUN
dpc-1881	515	19	,	,	PUNCT
dpc-1881	515	20	dabrafenib	dabrafenib	NOUN
dpc-1881	515	21	,	,	PUNCT
dpc-1881	515	22	and	and	CCONJ
dpc-1881	515	23	trametinib	trametinib	NOUN
dpc-1881	515	24	in	in	ADP
dpc-1881	515	25	braf	braf	NOUN
dpc-1881	515	26	-mutant	-mutant	ADJ
dpc-1881	515	27	melanoma	melanoma	NOUN
dpc-1881	515	28	.	.	PUNCT
dpc-1881	516	1	j	j	PROPN
dpc-1881	516	2	immunother	immunother	PROPN
dpc-1881	516	3	cancer	cancer	NOUN
dpc-1881	516	4	2020;8	2020;8	PROPN
dpc-1881	516	5	:	:	PUNCT
dpc-1881	516	6	e001806	e001806	PROPN
dpc-1881	516	7	.	.	PROPN
dpc-1881	517	1	doi	doi	NOUN
dpc-1881	517	2	:	:	PUNCT
dpc-1881	517	3	10.1136	10.1136	NUM
dpc-1881	517	4	/	/	SYM
dpc-1881	517	5	jitc-2020	jitc-2020	NOUN
dpc-1881	517	6	-	-	NOUN
dpc-1881	517	7	001806	001806	NUM
dpc-1881	517	8	.	.	PUNCT
dpc-1881	518	1	pmid	pmid	NOUN
dpc-1881	518	2	:	:	PUNCT
dpc-1881	518	3	33361337	33361337	NUM
dpc-1881	518	4	.	.	PUNCT
dpc-1881	519	1	54	54	NUM
dpc-1881	519	2	.	.	PUNCT
dpc-1881	519	3	gutzmer	gutzmer	NOUN
dpc-1881	519	4	r	r	NOUN
dpc-1881	519	5	,	,	PUNCT
dpc-1881	519	6	stroyakovskiy	stroyakovskiy	NOUN
dpc-1881	519	7	d	d	PROPN
dpc-1881	519	8	,	,	PUNCT
dpc-1881	519	9	gogas	gogas	NOUN
dpc-1881	519	10	h	h	NOUN
dpc-1881	519	11	,	,	PUNCT
dpc-1881	519	12	et	et	PROPN
dpc-1881	519	13	al	al	PROPN
dpc-1881	519	14	.	.	PROPN
dpc-1881	519	15	atezolizumab	atezolizumab	PROPN
dpc-1881	519	16	,	,	PUNCT
dpc-1881	519	17	vemurafenib	vemurafenib	NOUN
dpc-1881	519	18	,	,	PUNCT
dpc-1881	519	19	and	and	CCONJ
dpc-1881	519	20	cobimetinib	cobimetinib	NOUN
dpc-1881	519	21	as	as	ADP
dpc-1881	519	22	first	first	ADJ
dpc-1881	519	23	-	-	PUNCT
dpc-1881	519	24	line	line	NOUN
dpc-1881	519	25	treatment	treatment	NOUN
dpc-1881	519	26	for	for	ADP
dpc-1881	519	27	unresectable	unresectable	ADJ
dpc-1881	519	28	advanced	advanced	ADJ
dpc-1881	519	29	braf(v600	braf(v600	NOUN
dpc-1881	519	30	)	)	PUNCT
dpc-1881	519	31	mutation	mutation	NOUN
dpc-1881	519	32	-	-	PUNCT
dpc-1881	519	33	positive	positive	ADJ
dpc-1881	519	34	melanoma	melanoma	NOUN
dpc-1881	519	35	(	(	PUNCT
dpc-1881	519	36	imspire150	imspire150	PROPN
dpc-1881	519	37	):	):	PUNCT
dpc-1881	519	38	primary	primary	ADJ
dpc-1881	519	39	analysis	analysis	NOUN
dpc-1881	519	40	of	of	ADP
dpc-1881	519	41	the	the	DET
dpc-1881	519	42	randomised	randomised	ADJ
dpc-1881	519	43	,	,	PUNCT
dpc-1881	519	44	double	double	ADJ
dpc-1881	519	45	-	-	PUNCT
dpc-1881	519	46	blind	blind	ADJ
dpc-1881	519	47	,	,	PUNCT
dpc-1881	519	48	placebo	placebo	NOUN
dpc-1881	519	49	-	-	PUNCT
dpc-1881	519	50	controlled	control	VERB
dpc-1881	519	51	,	,	PUNCT
dpc-1881	519	52	phase	phase	NOUN
dpc-1881	519	53	3	3	NUM
dpc-1881	519	54	trial	trial	NOUN
dpc-1881	519	55	.	.	PUNCT
dpc-1881	520	1	lancet	lancet	PROPN
dpc-1881	520	2	.	.	PUNCT
dpc-1881	521	1	2020	2020	NUM
dpc-1881	521	2	jun	jun	PROPN
dpc-1881	521	3	13;395(10240):18351844	13;395(10240):18351844	NUM
dpc-1881	521	4	.	.	PUNCT
dpc-1881	521	5	doi	doi	PROPN
dpc-1881	521	6	:	:	PUNCT
dpc-1881	521	7	10.1016	10.1016	NUM
dpc-1881	521	8	/	/	SYM
dpc-1881	521	9	s0140	s0140	PROPN
dpc-1881	521	10	-	-	PUNCT
dpc-1881	521	11	6736(20)30934	6736(20)30934	NOUN
dpc-1881	521	12	-	-	PUNCT
dpc-1881	521	13	x.	x.	NOUN
dpc-1881	521	14	55	55	NUM
dpc-1881	521	15	.	.	PUNCT
dpc-1881	522	1	nathan	nathan	PROPN
dpc-1881	522	2	p	p	PROPN
dpc-1881	522	3	,	,	PUNCT
dpc-1881	522	4	dummer	dummer	PROPN
dpc-1881	522	5	r	r	PROPN
dpc-1881	522	6	,	,	PUNCT
dpc-1881	522	7	long	long	ADV
dpc-1881	522	8	gv	gv	ADP
dpc-1881	522	9	,	,	PUNCT
dpc-1881	522	10	et	et	PROPN
dpc-1881	522	11	al	al	PROPN
dpc-1881	522	12	.	.	PUNCT
dpc-1881	523	1	lba43	lba43	PROPN
dpc-1881	523	2	spartalizumab	spartalizumab	PROPN
dpc-1881	523	3	plus	plus	CCONJ
dpc-1881	523	4	dabrafenib	dabrafenib	NOUN
dpc-1881	523	5	and	and	CCONJ
dpc-1881	523	6	trametinib	trametinib	NOUN
dpc-1881	523	7	(	(	PUNCT
dpc-1881	523	8	sparta	sparta	NOUN
dpc-1881	523	9	-	-	PUNCT
dpc-1881	523	10	dabtram	dabtram	NOUN
dpc-1881	523	11	)	)	PUNCT
dpc-1881	523	12	in	in	ADP
dpc-1881	523	13	patients	patient	NOUN
dpc-1881	523	14	(	(	PUNCT
dpc-1881	523	15	pts	pt	NOUN
dpc-1881	523	16	)	)	PUNCT
dpc-1881	523	17	with	with	ADP
dpc-1881	523	18	previously	previously	ADV
dpc-1881	523	19	untreated	untreate	VERB
dpc-1881	523	20	braf	braf	NOUN
dpc-1881	523	21	v600	v600	PROPN
dpc-1881	523	22	–	–	PUNCT
dpc-1881	523	23	mutant	mutant	NOUN
dpc-1881	523	24	unresectable	unresectable	ADJ
dpc-1881	523	25	or	or	CCONJ
dpc-1881	523	26	metastatic	metastatic	ADJ
dpc-1881	523	27	melanoma	melanoma	NOUN
dpc-1881	523	28	:	:	PUNCT
dpc-1881	523	29	results	result	NOUN
dpc-1881	523	30	from	from	ADP
dpc-1881	523	31	the	the	DET
dpc-1881	523	32	randomized	randomized	ADJ
dpc-1881	523	33	part	part	NOUN
dpc-1881	523	34	3	3	NUM
dpc-1881	523	35	of	of	ADP
dpc-1881	523	36	the	the	DET
dpc-1881	523	37	phase	phase	NOUN
dpc-1881	523	38	iii	iii	NUM
dpc-1881	523	39	combi	combi	PROPN
dpc-1881	523	40	-	-	PUNCT
dpc-1881	523	41	i	i	PROPN
dpc-1881	523	42	trial	trial	NOUN
dpc-1881	523	43	.	.	PUNCT
dpc-1881	524	1	ann	ann	PROPN
dpc-1881	524	2	oncol	oncol	PROPN
dpc-1881	524	3	2020	2020	NUM
dpc-1881	524	4	.	.	PUNCT
dpc-1881	525	1	doi:10.1016	doi:10.1016	PROPN
dpc-1881	525	2	/	/	SYM
dpc-1881	525	3	j.	j.	PROPN
dpc-1881	525	4	annonc.2020.08.2273	annonc.2020.08.2273	PROPN
dpc-1881	525	5	.	.	PROPN
dpc-1881	526	1	56	56	NUM
dpc-1881	526	2	.	.	X
dpc-1881	527	1	aiom	aiom	ADJ
dpc-1881	527	2	(	(	PUNCT
dpc-1881	527	3	associazione	associazione	PROPN
dpc-1881	527	4	italiana	italiana	PROPN
dpc-1881	527	5	di	di	PROPN
dpc-1881	527	6	oncologia	oncologia	PROPN
dpc-1881	527	7	medica	medica	PROPN
dpc-1881	527	8	)	)	PUNCT
dpc-1881	527	9	melanoma	melanoma	NOUN
dpc-1881	527	10	guidelines	guideline	NOUN
dpc-1881	527	11	.	.	PUNCT
dpc-1881	528	1	www.aiom.it	www.aiom.it	PROPN
dpc-1881	528	2	57	57	NUM
dpc-1881	528	3	.	.	PUNCT
dpc-1881	529	1	seth	seth	PROPN
dpc-1881	529	2	r	r	PROPN
dpc-1881	529	3	,	,	PUNCT
dpc-1881	529	4	messersmith	messersmith	ADJ
dpc-1881	529	5	h	h	PROPN
dpc-1881	529	6	,	,	PUNCT
dpc-1881	529	7	kaur	kaur	PROPN
dpc-1881	529	8	v	v	PROPN
dpc-1881	529	9	,	,	PUNCT
dpc-1881	529	10	et	et	PROPN
dpc-1881	529	11	al	al	PROPN
dpc-1881	529	12	.	.	PUNCT
dpc-1881	530	1	systemic	systemic	ADJ
dpc-1881	530	2	therapy	therapy	NOUN
dpc-1881	530	3	for	for	ADP
dpc-1881	530	4	melanoma	melanoma	NOUN
dpc-1881	530	5	:	:	PUNCT
dpc-1881	530	6	asco	asco	PROPN
dpc-1881	530	7	guideline	guideline	NOUN
dpc-1881	530	8	.	.	PUNCT
dpc-1881	531	1	j	j	PROPN
dpc-1881	531	2	clin	clin	PROPN
dpc-1881	531	3	oncol	oncol	PROPN
dpc-1881	531	4	.	.	PUNCT
dpc-1881	532	1	2020	2020	NUM
dpc-1881	532	2	;	;	PUNCT
dpc-1881	532	3	38(33):3947	38(33):3947	NUM
dpc-1881	532	4	-	-	SYM
dpc-1881	532	5	3970	3970	NUM
dpc-1881	532	6	.	.	PUNCT
dpc-1881	533	1	doi	doi	NOUN
dpc-1881	533	2	:	:	PUNCT
dpc-1881	533	3	10.1200	10.1200	NUM
dpc-1881	533	4	/	/	SYM
dpc-1881	533	5	jco.20.00198	jco.20.00198	NOUN
dpc-1881	533	6	.	.	PUNCT
dpc-1881	534	1	pmid	pmid	NOUN
dpc-1881	534	2	:	:	PUNCT
dpc-1881	534	3	32228358	32228358	NUM
dpc-1881	534	4	.	.	PUNCT
dpc-1881	535	1	1	1	NUM
dpc-1881	535	2	-	-	PUNCT
dpc-1881	535	3	indice	indice	NOUN
dpc-1881	535	4	6	6	NUM
dpc-1881	535	5	-	-	SYM
dpc-1881	535	6	1881	1881	NUM